NEW COMPOUND

Abstract: This invention relates to new polypeptide compounds represented by general formula (I), wherein R<1>, R<2>, R<3> and R<4> are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on beta -1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases including <u>Pneumocystis</u> <u>carinii</u> infection (e.g. <u>Pneumocystis</u> <u>carinii</u> pneumonia) in a human being or an animal.

Description: DESCRIPTION NEW COMPOUND TECHNICAL FIELD The present invention relates to new polypeptide compound and a salt thereof which are useful as a medicament. BACKGROUND ART In U.S. Pat. No. 5,376,634 and WO 96/11210, there are disclosed the polypeptide compound and a pharmaceutically acceptable salt thereof, which have antimicrobial activities (especially antifungal activity) . DISCLOSURE OF INVENTION The present invention relates to new polypeptide compound and a salt thereof. More particularly, it relates to new polypeptide compound and a salt thereof, which have antimicrobial activities [especially, antifungal activities, in which the fungi may include Asperσillus. Cryptococcus. Candida, Mucor, Actinomyces, Histoplasma, Dermatophyte, Malassezia, Fusarium and the like. ] , inhibitory activity on β-1, 3-glucan synthase, and further which are expected to be useful for the prophylactic and/or therapeutic treatment of Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal, to a process for preparation thereof, to a pharmaceutical composition comprising the same, and to a methods for the prophylactic and/or therapeutic treatment of infectious disease including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal . The object polypeptide compounds of the present invention are new and can be represented by the following general formula [I]: R 1 [I] Wherein R 1 is hydrogen; arylamino (lower) alkanoyl which may have one or more suitable substituent (s) ; aroyl substituted with heterocyclic group which may have one or more suitable substituent (s) ; aroyl substituted with aryl having higher alkyl; aroyl substituted with aryl having lower alkyl; aryl (C2~Cg) alkanoyl substituted with aryl having lower alkyl; lower alkanoyl substituted with unsaturated condensed heterocyclic group which may have one or more suitable substituent (s) ; lower alkanoyl substituted with pyridyl which may have one or more suitable substituent (s) ; a ino protective group; heptylnaphthoyl ; hexylnaphthoyl ; aroyl substituted with heterocyclic carbamoyl which may have one or more suitable substituent (s) ; lower alkanoyl substituted with cyclo (lower) alkyl which may have one or more suitable substituent (s) ; lower alkanoyl substituted with thienyl having heterocyclic group which may have one or more suitable substituent (s) ; or lower alkenoyl substituted with heterocyclic group which may have one or more suitable substituent (s) , R^ is hydrogen or hydroxy, R 3 is hydroxy, hydroxysulfonyloxy or lower alkoxy, and R4 is hydroxy or lower alkoxy, or a salt thereof. The new polypeptide compound [I] and a salt thereof can be prepared by the process as illustrated in the following reaction schemes. Process 1 O RJ -OH [ III ] H 3 C^ s NH. or its reactive derivative ■ N — O a the carboxy group or a salt thereof or its reactive derivative at the amino group or a salt thereof OH O ,- HO NH H,C -NH — R. -N =0 Process 2 HO OH Reduction OH HO V= 0 HN OH / -^ °=< CH 3 OH O [la] a salt thereof Process 3 HO OH o • ^ -N Reduction R J OH HO Q NH H^C -N y The starting compound [II] and [IV], or a salt thereof can be prepared by the process as illustrated in the following reaction schemes. Process A RI-OH [III] or its reactive derivative at the carboxy group or a salt thereof at the amino group or a salt thereof HO OH Process B Hydrolysis or at the sulfonic acid group or a salt thereof HO OH H0 [ IVb ] or a salt thereof Process C HO OH Alkylation or its reactive derivative at the hydroxy group or a salt thereof HO OH O HO > NH H,C- -NH, ' or a salt thereof 10 wherein R 2 , R 3 and R 4 are as defined above, R g is arylamino (lower) alkanoyl which may have one or more suitable substituent (s) ; aroyl substituted with heterocyclic group which may have one or more suitable substituent (s) ; aroyl substituted with aryl having higher alkyl; aroyl substituted with aryl having lower alkyl; aryl (C2~Cg) alkanoyl substituted with aryl having lower alkyl; lower alkanoyl substituted with unsaturated condensed heterocyclic group which may have one or more suitable substituent (s) ; lower alkanoyl substituted with pyridyl which may have one or more suitable substituent (s) ; a ino protective group; heptylnaphthoyl ; hexylnaphthoyl ; aroyl substituted with heterocyclic carbamoyl which may have one or more suitable substituent (s) ; lower alkanoyl substituted with cyclo (lower) alkyl which may have one or more suitable substituent (s) ; lower alkanoyl substituted with thienyl having heterocyclic group which may have one or more suitable substituent (s) ; or lower alkenoyl substituted with heterocyclic group which may have one or more suitable substituent (s) , R is lower alkoxy, and R is hydroxy or lower alkoxy. Suitable salt of the new polypeptide compound [I] is a pharmaceutically acceptable and conventional non-toxic salt, and may include a salt with a base or an acid addition salt 11 such as a salt with an inorganic base, for example, an alkali metal salt (e.g., sodium salt, potassium salt, etc.), an alkaline earth metal salt (e.g., calcium salt, magnesium salt, etc.), an ammonium salt; a salt with an organic base, for example, an organic amine salt (e.g., triethylamine salt, diisopropylethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'- dibenzylethylenediamine salt, etc.); an inorganic acid addition salt (e.g., hydrochloride, hydrobromide, sulfate, phosphate, etc.); an organic carboxylic sulfonic acid addition salt (e.g., formate, acetate, trifluoroacetate, maleate, tartrate, fumarate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.); a salt with a basic or acidic amino acid (e.g., arginine, aspartic acid, glutamic acid, etc.). Suitable examples and illustration of the various definitions in the above and subsequent descriptions of the present specification, which the present invention intends to include within the scope thereof, are explained in detail as follows : The term "lower" is used to intend a group having 1 to 6 carbon atom(s), unless otherwise provided. The term "higher" is used to intend a group having 7 to 20 carbon atoms, unless otherwise provided. Suitable example of "one or more" may be the number of 1 to 6, in which the preferred one may be the number of 1 to 3. Suitable example of "lower alkanoyl" may include straight or branched one such as formyl, acetyl, 2-methylacetyl, 2, 2-dimethylacetyl, propionyl, butyryl, isobutyryl, pentanoyl, 2, 2-dimethylpropionyl, hexanoyl, and the like. 12 Suitable example of "suitable substituent (s) " in the R 1 and R^ may include higher alkoxy, aryl which has one or more higher alkoxy, higher alkyl, lower alkyl, aryl which has one or more lower alkoxy, heterocyclic group which may have one or more higher alkoxy, aryl which has one or more cyclo (lower) alkyl, aryl which has one or more lower alkoxy (higher) alkoxy, aryl which has one or more heterocyclic groups, cyclo (lower) alkyl which has one or more cyclo (lower) alkyl, aryl substituted with aryl which may have one or more lower alkoxy, aryl substituted with aryl which may have one more higher alkoxy, aryl substituted with aryl which may have one or more lower alkoxy having heterocyclic group, aryl which has one or more lower alkoxy (lower) alkoxy, heterocyclic group which may have one or more higher alkyl, aryl substituted with aryl which may have one or more aryloxy (lower) alkoxy, aryl substituted with aryl which may have one or more lower alkenyloxy, aryl substituted with aryl which may have one or more lower alkoxy (higher) alkoxy, aryl substituted with aryl which may have one or more heterocyclic (lower) alkoxy, aryl which has one or more aryloxy (lower) alkoxy, heterocyclic group which may have one or more heterocyclic groups, aryl which has one or more cyclo (lower) alkyloxy, aryl which has one or more heterocyclic groups having lower alkoxy, aryl which has one or more heterocyclic groups having cyclo (lower) alkyloxy, aryl which has one or more heterocyclic groups having aryl (lower) alkyloxy, aryl which has one or more heterocyclic groups having cyclo (lower) alkyl, aryl which has one or more heterocyclic groups having aryl, heterocyclic group which may have one or more aryl having lower alkoxy, heterocyclic group which may have one or more aryl having higher alkoxy (lower) alkyl, heterocyclic group which may have one or more aryl having lower alkoxy (lower) alkoxy, heterocyclic group which may have one or more aryl having cyclo (lower) alkyl, heterocyclic group which 13 may have one or more aryl having heterocyclic group, heterocyclic group which may have one or more aryl substituted with heterocyclic (lower) alkyl having aryl, heterocyclic group which may have one or more heterocyclic groups having aryl, aryl substituted with aryl which may have one or more cyclo (lower) alkyloxy, aryl substituted with aryl which may have one or more lower alkoxy (lower) alkyl, aryl substituted with aryl which may have one or more lower alkoxy (lower) alkoxy, aryl substituted with aryl which may have one or more lower alkoxy (lower) alkoxy (lower) alkyl, aryl substituted with aryl which may have one or more lower alkoxy (lower) alkoxy (lower) alkoxy, aryl substituted with aryl which may have one or more heterocyclic groups, aryl which has one or more cyclo (lower) alkyloxy, aryl which has one or more lower alkoxy (higher) alkylthio, aryl which has one or more lower alkoxy having heterocyclic group, cyclo (lower) alkyl which may have one or more lower alkyl, cyclo (lower) alkyl-which may have one or more aryl, aryl, and the like. Suitable example of "lower alkoxy" may include straight or branched one such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, pentyloxy, tert-pentyloxy, neo-pentyloxy, hexyloxy, isohexyloxy and the like, in which the preferred one may be methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy and isohexyloxy. Suitable example of "higher alkoxy" may include straight or branched one such as heptyloxy, octyloxy, 3, 5-dimethyloctyloxy, 3, 7-dimethyloctyloxy, nonyloxy, decyloxy, undecyloxy, dodecyloxy, tridecyloxy, tetradecyloxy, hexadecyloxy, heptadecyloxy, octadecyloxy, nonadecyloxy, icosyloxy, and the like, in which the preferred one may be (C-y-C-^) alkoxy, and the more preferred one may be heptyloxy and octyloxy. Suitable example of "lower alkyl" may include straight or branched one having 1 to 6 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, 14 tert-butyl, pentyl, tert-pentyl, neo-pentyl, hexyl, isohexyl and the like, in which the preferred one may be methyl, pentyl, hexyl and isohexyl . Suitable example of "higher alkyl" may include straight or branched one having 7 to 20 carbon atoms, such as heptyl, octyl, 3, 5-dimethyloctyl, 3, 7-dimethyloctyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, icosyl, and the like, in which the preferred one may be (C -C-L4 ) alkyl, and the more preferred one may be heptyl, octyl, nonyl and decyl. Suitable example of "aryl" and "ar" moiety may include phenyl which may have lower alkyl (e.g., phenyl, mesityl, xylyl, tolyl, etc.), naphthyl, anthryl, indanyl, and the like, in which the preferred one may be phenyl and naphthyl, and this "aryl" and "ar" moiety may have halogen or lower alkoxy. Suitable example of "aroyl" may include benzoyl, toluoyl, naphthoyl, anthrylcarbonyl, and the like, in which the preferred one may be benzoyl and naphthoyl, and this "aroyl" may have lower alkyl. Suitable example of "heterocyclic group" and "heterocyclic" moiety may include unsaturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, dihydropyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1, 2, -triazolyl, 1H- 1, 2, 3-triazolyl, 2H-1, 2, 3-triazolyl, etc.), tetrazolyl (e.g., lH-tetrazolyl, 2H-tetrazolyl, etc.), etc.; saturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s) , for example, pyrrolidinyl, imidazolidinyl, piperidyl, piperazinyl, etc.; unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s), for example, indolyl, isoindolyl, 15 indolinyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, etc.; unsaturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1, 2, 4-oxadiazolyl, 1,3,4- oxadiazolyl, 1, 2, 5-oxadiazolyl, etc.), etc.; saturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s) , for example, morpholinyl, sydnonyl, morpholino, etc.; unsaturated condensed heterocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, benzoxazolyl, benzoxadiazolyl, etc.; unsaturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolyl, isothiazolyl, thiadiazolyl (e.g., 1, 2, 3-thiadiazolyl, 1, 2, 4-thiadiazolyl, 1, 3, 4-thiadiazolyl, 1, 2, 5-thiadiazolyl, etc.), dihydrothiazinyl, etc.; saturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s) , for example thiazolidinyl, thiomorpholinyl, thiomorpholino, etc.; unsaturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing 1 or 2 sulfur atom(s), for example, thienyl, dihydrodithiinyl, dihydrodithionyl, etc.; unsaturated condensed heterocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, benzothiazolyl, benzothiadiazolyl, imidazothiadiazolyl, etc. ; unsaturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing an oxygen atom, for example, furyl, etc.; 16 saturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing an oxygen atom, for example, tetrahydrofuran, tetrahydropyran, etc.; unsaturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing an oxygen atom and 1 or 2 sulfur atom(s), for example, dihydrooxathiinyl, etc; unsaturated condensed heterocyclic group containing 1 or 2 sulfur atom(s), for example benzothienyl, benzodithiinyl, etc ; unsaturated condensed heterocyclic group containing an oxygen atom and 1 or 2 sulfur atom(s), for example, benzoxathiinyl, etc; and the like and this "heterocyclic group" and "heterocyclic" moiety may have lower alkyl or cyclo (lower) alkyl . Suitable example of "lower alkenyloxy" may include vinyloxy, 1- (or 2-) propenyloxy, 1- (or 2- or 3-) butenyloxy, l-(or 2- or 3- or 4-) pentenyloxy, l-(or 2- or 3- or 4- or 5-) hexenyloxy, and the like, in which the preferred one may be (C2 _ Cg) alkenyloxy, and the most preferred one may be 2-propenyloxy. Suitable example of "cyclo (lower) alkyl" may include cyclopropyl, cylclobutyl, cyclopentyl, cyclohexyl, and the like, in which the preferred one may be cyclo (C^ j -Cg) alkyl, and the most preferred one may be cyclohexyl and this "cyclo (lower) alkyl" may have lower alkyl. Suitable "amino protective group" may include acyl group as explained below, a conventional protective group such as ar (lower) alkyl which may have 1 to 3 suitable substituent (s) (e.g. benzyl, phenethyl, 1-phenylethyl, benzhydryl, trityl, etc), [5- (lower) alkyl-2-oxo-l, 3-dioxol-4-yl] (lower) alkyl [e.g. (5-methyl-2-oxo-l, 3-dioxol-4-yl) methyl, etc] or the like; and the like. Suitable "acyl group" and "acyl" may include aliphatic acyl, aromatic acyl, arylaliphatic acyl and heterocyclic- aliphatic acyl derived from carboxylic acid, carbonic acid. 17 carbamic acid, sulfonic acid, and the like. Suitable example of said "acyl group" may be illustrated as follows. Aliphatic acyl such as lower or higher alkanoyl (e.g., formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2, 2-dimethylpropanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl, heptadecanoyl, octadecanoyl, nonadecanoyl, icosanoyl, etc.); lower or higher alkoxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, t-pentyloxycarbonyl, heptyloxycarbonyl, etc); lower or higher alkylsulfonyl (e.g., methylsulfonyl, ethylsulfonyl, etc); lower or higher alkoxysulfonyl (e.g., methoxysulfonyl, ethoxysulfonyl, etc.); or the like; Aromatic acyl such as aroyl (e.g., benzoyl, toluoyl, naphthoyl, etc); ar (lower) alkanoyl [e.g., phenyl (C^-Cg) alkanoyl (e.g., phenylacetyl, phenylpropanoyl, phenylbutanoyl, phenylisobutanoyl, phenylpentanoyl, phenylhexanoyl, etc), naphthyl (C^-Cg) alkanoyl (e.g., naphthylacetyl, naphthylpropanoyl, naphthylbutanoyl, etc), etc.]; ar (lower) alkenoyl [e.g., phenyl (C 3 -Cg) alkenoyl (e.g., phenylpropenoyl, phenylbutenoyl, phenylmethacryloyl, phenylpentenoyl, phenylhexenoyl, etc.), naphthyl (C3~Cg) alkenoyl (e.g., naphthylpropenoyl, naphthylbutenoyl, etc. ) , etc. ] ; ar (lower) alkoxycarbonyl [e.g., phenyl (C- j _-Cg) alkoxycarbonyl (e.g., benzyloxycarbonyl, etc.), fluorenyl (C-^-Cg) alkoxycarbonyl (e.g., fluorenylmethyloxycarbonyl, etc.), etc.]; aryloxycarbonyl (e.g., phenoxycarbonyl, naphthyloxycarbonyl, etc. ) ; aryloxy (lower) alkanoyl (e.g., phenoxyacetyl, phenoxypropionyl, etc.); arylcarbamoyl (e.g., phenylcarbamoyl, etc.); arylthiocarbamoyl (e.g., phenylthiocarbamoyl, etc.); arylglyoxyloyl (e.g., phenylglyoxyloyl, naphthylglyoxyloyl, etc ) ; arylsulfonyl which may have 1 to 4 lower alkyl (e.g., phenylsulfonyl, p-tolylsulfonyl, etc.); or the like; Heterocyclic acyl such as heterocycliccarbonyl; heterocyclic (lower) alkanoyl (e.g., heterocyclicacetyl, heterocyclicpropanoyl, heterocyclicbutanoyl, heterocyclicpentanoyl, heterocyclichexanoyl, etc); heterocyclic (lower) alkenoyl (e.g., heterocyclicpropenoyl, heterocyclicbutenoyl, heterocyclicpentenoyl, heterocyclichexenoyl, etc); heterocyclicglyoxyloyl; or the like; in which suitable "heterocyclic" moiety in the terms "heterocycliccarbonyl", "heterocyclic (lower) alkanoyl", heterocyclic (lower) alkenoyl" and "heterocyclicglyoxyloyl" can be referred to aforementioned "heterocyclic" moiety, in which the preferred one may be ar (lower) alkoxycarbonyl, and the more preferred one may be phenyl (C^-C^) alkoxycarbonyl and fluorenyl (C -C4) alkoxycarbonyl, and the most preferred one may be benzyloxycarbonyl and fluorenylmethyloxycarbonyl . Suitable example of "arylamino" moiety in the term of "arylamino (lower) alkanoyl which may have one or more suitable substituent (s) " may be phenylamino, mesitylamino, tolylamino, naphthylamino, anthrylamino, and the like, in which the preferred one may be naphthylamino. Suitable example of "lower alkanoyl" moiety in the term of "arylamino (lower) alkanoyl which may have one or more suitable substituent (s) " can be referred to aforementioned "lower alkanoyl", in which the preferred one may be for yl. Suitable example of "suitable substituent (s) " moiety in the term of "arylamino (lower) alkanoyl which may have one or 19 more suitable substituent (s) " can be referred to aforementioned "suitable substituent (s) ", in which the preferred one may be higher alkoxy, and the most preferred one may be heptyloxy. Suitable example of "arylamino (lower) alkanoyl which may have one or more suitable substituent (s) " may be naphthylaminocarbonyl having higher alkoxy, in which the preferred one may be naphthylaminocarbonyl having heptyloxy. Suitable example of "aroyl" moiety in the term of "aroyl substituted with heterocyclic group which may have one or more suitable substituent (s) " can be referred to aforementioned "aroyl", in which the preferred one may be benzoyl. Suitable example of "heterocyclic group" moiety in the term of "aroyl substituted with heterocyclic group which may have one or more suitable substituent (s) " can be referred to aforementioned "heterocyclic group", in which the preferred one may be saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) , unsaturated 3 to 8-membered heteromonocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), unsaturated 3 to 8-membered heteromonocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom (s) and unsaturated condensed heterocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s) and the more preferred one may be piperazinyl, thiadiazolyl, oxadiazolyl, imidazothiadiazolyl and isoxazolyl . Suitable example of "suitable substituent (s) " moiety in the term of "aroyl substituted with heterocyclic group which may have one or more suitable substituent (s) " can be referred to aforementioned "suitable substituent (s) ", in which the preferred one may be aryl which has one or more higher alkoxy, aryl which has one or more lower alkoxy, aryl which has one or more cyclo (lower) alkyl, aryl which has one or more lower alkoxy (higher) alkoxy, aryl which has one or more heterocyclic 20 groups, cyclo (lower) alkyl which may have one or more cyclo (lower) alkyl, aryl substituted with aryl which may have one or more lower alkoxy, aryl substituted with aryl which may have one or more higher alkoxy, aryl substituted with aryl which may have one or more lower alkoxy having heterocyclic group, aryl which has one or more lower alkox (lower) alkoxy, heterocyclic group which may have one or more higher alkyl, aryl substituted with aryl which may have one or more aryloxy (lower) alkoxy, aryl substituted with aryl which may have one or more lower alkenyloxy, aryl substituted with aryl which may have one or more lower alkoxy (higher) alkoxy, aryl substituted with aryl which has one or more heterocyclic (lower) alkoxy, in which heterocyclic group may have one or more lower alkyl, aryl which has one or more aryloxy (lower) alkoxy, heterocyclic group which may have one or more heterocyclic groups, aryl which has one or more cyclo (lower) alkyloxy, aryl which has one or more heterocyclic groups having lower alkoxy, aryl which has one or more heterocyclic groups having cyclo (lower) alkyloxy, aryl which has one or more heterocyclic groups having aryl (lower) alkyloxy, aryl which has one or more heterocyclic groups having cyclo (lower) alkyl, aryl which has one or more heterocyclic groups having aryl, heterocyclic group which may have one or more aryl having lower alkoxy, heterocyclic group which may have one or more aryl having higher alkoxy (lower) alkyl, heterocyclic group which may have one or more aryl having lower alkoxy ( lower) alkoxy, heterocyclic group which may have one or more aryl having cyclo (lower) alkyl, heterocyclic group which may have one or more aryl having heterocyclic group, heterocyclic group which may have one or more aryl substituted with heterocyclic (lower) alkyl having aryl, heterocyclic group which may have one or more heterocyclic groups having aryl, aryl substituted with aryl which may have one or more cyclo (lower) alkyloxy, aryl substituted with aryl which may have one or more lower alkoxy (lower) alkyl, aryl substituted 21 with aryl which may have one or more lower alkoxy (lower) alkoxy, aryl substituted with aryl which may have one or more lower alkoxy (lower) alkoxy (lower) alkyl, aryl substituted with aryl which may have one or more lower alkoxy (lower) alkoxy (lower) alkoxy, aryl substituted with aryl which may have one or more heterocyclic groups, aryl which has one or more cyclo (lower) alkyloxy, aryl which has one or more lower alkoxy (higher) alkylthio, aryl which has one or more lower alkoxy having heterocyclic group, cyclo (lower) alkyl which may have one or more lower alkyl, cyclo (lower) alkyl which may have one or more aryl, aryl, in which the preferred one may be phenyl having (C 7 -C 14 ) alkoxy, phenyl having (C4- Cg) alkoxy, phenyl having cyclo (C4~Cg) alkyl, phenyl having ( c l~ c 4) alkoxy (C--C- j ^) alkoxy, phenyl having saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s), cyclo (C 4 -Cg) alkyl having cyclo (C ~Cg) alkyl, phenyl substituted with phenyl having (C-^-Cg) alkoxy, phenyl - substituted with phenyl having (C7-C-L4) alkoxy, phenyl substituted with phenyl which has (C-L-C4) alkoxy having saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s), phenyl having (0^-04) alkoxy (C4- Cg) alkoxy, unsaturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) having (C-y-C-^) alkyl, phenyl substituted with phenyl having phenyloxy (C1-C4 ) alkoxy, phenyl substituted with phenyl having (C 3 -Cg) alkenyloxy, phenyl substituted with phenyl having (C-L-C ) alkoxy (C7- C14) alkoxy, phenyl substituted with phenyl which has (C ] _- C4) alkoxy having saturated 3 to 8-membered heteromonocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s) having 1 to 4 (C -C ) alkyl, phenyl having phenyloxy- ( c l~ c ) alkoxy, phenyl having (C-L-C4) alkoxy (C7-C-L4) alkoxy, unsaturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) having saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s), phenyl having cyclo (C4~Cg) alkyloxy, phenyl which has 22 saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom (s) having (C ] _-C4 ) alkoxy, phenyl which has saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) having cyclo (C4~C ) alkyloxy, phenyl which has saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) having phenyl { -^- ^ ) - alkyloxy, phenyl which has saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) having cyclo (C ~Cg) alkyl, phenyl which has saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) substituted with cyclo (C4~C ) alkyl having di (C-L-C ) alkyl, phenyl which has saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) substituted with cyclo (C ~Cg) alkyl having (0^-04) alkyl, phenyl which has saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) substituted with (C1-C4) alkoxy and phenyl having halogen, phenyl which has saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) substituted with phenyl, phenyl which has unsaturated 3 to 8-membered heteromonocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s) substituted with phenyl having (C^-Cg) alkoxy, unsaturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) which has phenyl having (C-^-Cg) alkoxy, unsaturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) which has phenyl having (C7-C-L4)- alkoxy (C^-Cg) alkyl, saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) which has phenyl having (C4~C ) alkyl, unsaturated 3 to 8- membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) which has phenyl having saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s), unsaturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) which has phenyl substituted with (C ] _-Cg) alkyl having saturated 3 to 8-membered 23 heteromonocyclic group containing 1 to 4 nitrogen atom(s) having phenyl, unsaturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) which has saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom (s) having phenyl, phenyl substituted with phenyl which has cyclo (C4~C ) alkyloxy, phenyl substituted with phenyl which has (C^-Cg) alkoxy (C ] _-Cg) alkyl, phenyl substituted with phenyl which has (C^-Cg) alkoxy (C^-Cg) alkoxy, phenyl substituted with phenyl which has (C^-Cg) alkoxy (C^- Cg) alkoxy (C^-Cg) alkyl, phenyl substituted with phenyl which has (C^-Cg) alkoxy (C ] _-Cg) alkoxy (C^-Cg) alkoxy, phenyl substituted with phenyl which has saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) having cyclo (C4~Cg) alkyl, phenyl substituted with phenyl which has saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) substituted with cyclo (C 4 -Cg) alkyl having di (C-L-C ) alkyl, phenyl which has cyclo (C4~Cg) alkyloxy, phenyl which has (C- j _-Cg) alkoxy (C7- C-L4) alkylthio, phenyl which has (C ] _-Cg) alkoxy having saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) , phenyl which has (C^-Cg) alkoxy having saturated 3 to 8-membered heteromonocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s) , phenyl which has (C-^-Cg) alkoxy having saturated 3 to 8-membered heteromonocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s) having di (0^-04) alkyl, phenyl which has (C^-Cg) alkoxy having saturated 3 to 8-membered heteromonocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), cyclo (C4~C ) alkyl which has (C ] _- Cg) alkyl, cyclo (C4~Cg) alkyl which has phenyl, indanyl, phenyl substituted with saturated 3 to 8-membered heteromonocyclic group containing 1 or 2 oxgen atom ( s ) and 1 to 3 nitrogen atom ( s ) , phenyl substituted with saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) having (C-^-Cg) alkyl, phenyl substituted with saturated 3 to 24 8-membered heteromonocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom (s) having di (C-L-C ) alkyl, and phenyl substituted with saturated 3 to 8-membered heteromonocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom ( s ) , and the most preferred one may be phenyl having octyloxy, phenyl having hexyloxy, phenyl having cyclohexyl, phenyl having piperidyl, cyclohexyl having cyclohexyl, phenyl having methoxyoctyloxy, phenyl having methoxyheptyloxy, phenyl having butoxy, phenyl having pentyloxy, phenyl substituted with phenyl having methoxy, phenyl substituted with phenyl having propyloxy, phenyl substituted with phenyl having butoxy, phenyl substituted with phenyl having pentyloxy, phenyl substituted with phenyl having hexyloxy, phenyl substituted with phenyl having heptyloxy, phenyl substituted with phenyl which has propyloxy having piperidyl, phenyl having methoxyhexyloxy, isoxazolyl having decyloxy, phenyl substituted with phenyl having phenyloxypropyloxy, phenyl substituted with phenyl having propenyloxy, phenyl substituted with phenyl having phenyloxybutoxy, phenyl substituted with phenyl having methoxyoctyloxy, phenyl substituted with phenyl which has propoxy having dimethyl, phenyl having phenyloxypropoxy, phenyl having phenyloxybutoxy, phenyl having phenyloxypentyloxy, phenyl having methoxypentyloxy, phenyl having methoxyheptyloxy, pyridyl having piperidyl, phenyl having cyclohexyloxy, phenyl which has piperidyl having propoxy, phenyl which has piperidyl having cyclohexyl, phenyl which has piperidyl having phenymethoxy, phenyl which has piperazinyl having cyclohexyl, phenyl which has piperazinyl substituted with cyclohexyl having dimethyl, phenyl which has piperazinyl substituted with cyclohexyl having methyl, phenyl which has piperidyl substituted with methoxy and chlorophenyl, phenyl which has piperidyl substituted with phenyl, phenyl which has piperazinyl substituted with phenyl, phenyl which has thiadiazolyl substituted with pentyloxyphenyl, pyrazolyl 25 which has hexyloxyphenyl, pyrazolyl which has heptyloxymethylphenyl, piperazinyl which has phenyl having cyclohexyl, pyrazolyl which has phenyl having piperidyl, pyrazolyl which has phenyl having pyrrolidinyl, pyrazolyl which has phenyl substituted with piperazinylmethyl having phenyl, pyridyl which has piperidyl having phenyl, phenyl substituted with phenyl which has cyclohexyloxy, phenyl substituted with phenyl which has ethoxymethyl, phenyl substituted with phenyl which has ethoxypropoxy, phenyl substituted with phenyl which has ethoxyethoxy, phenyl substituted with phenyl which has methoxypropoxy, phenyl substituted with phenyl which has methoxyethoxy, phenyl substituted with phenyl which has methoxypentyloxy, phenyl substituted with phenyl which has methoxyethoxymethyl, phenyl substituted with phenyl which has methoxyethoxyethoxy, phenyl substituted with phenyl which has piperazinyl having cyclohexyl, phenyl substituted with phenyl which has morpholinyl having dimethyl, phenyl which has cyclohexyloxy, phenyl which has methoxyheptylthio, phenyl which has piperidinobutoxy, phenyl which has piperidinopentyloxy, phenyl which has piperidinohexyloxy, phenyl which has morpholinopentyloxy, phenyl which has morpholinopentyloxy having dimethyl, phenyl which has morpholinohexyloxy having dimethyl, phenyl which has thiomorpholinopentyloxy, cyclohexyl which has pentyl, cyclohexyl which has phenyl, indanyl, phenyl having piperidyl, phenyl having morpholinyl, phenyl having thiomorpholino, phenyl substituted with phenyl having methoxybutoxy, phenyl substituted with piperazinyl having ethyl, and phenyl substituted with morpholinyl having dimethyl. Suitable example of "aroyl substituted with heterocyclic group which may have one or more suitable substituent (s) " may be benzoyl substituted with piperazinyl which has phenyl having octyloxy, benzoyl substituted with piperazinyl which has phenyl having hexyloxy, benzoyl substituted with 26 thiadiazolyl which has phenyl having hexyloxy, benzoyl substituted with oxadiazolyl which has phenyl having hexyloxy, benzoyl substituted with piperazinyl which has phenyl having cyclohexyl, benzoyl substituted with thiadiazolyl which has phenyl having methoxyoctyloxy, benzoyl substituted with thiadiazolyl which has phenyl having piperidyl, benzoyl substituted with piperazinyl which has cyclohexyl having cyclohexyl, benzoyl substituted with piperazinyl which has phenyl having methoxyoctyloxy, benzoyl substituted with piperazinyl which has phenyl having methoxyheptyloxy, benzoyl substituted with imidazothiadiazolyl which has phenyl having butyloxy, benzoyl substituted with imidazothiadiazolyl which has phenyl having pentyloxy, benzoyl substituted with oxadiazolyl which has phenyl substituted with phenyl having methoxy, benzoyl substituted with oxadiazolyl which has phenyl substituted with phenyl having propyloxy, benzoyl substituted with oxadiazolyl which has phenyl substituted with phenyl having butyloxy, benzoyl substituted with oxadiazolyl which has phenyl substituted with phenyl having pentyloxy, benzoyl substituted with oxadiazolyl which has phenyl substituted with phenyl having hexyloxy, benzoyl substituted with oxadiazolyl which has phenyl substituted with phenyl having heptyloxy, benzoyl substituted with oxadiazolyl which has phenyl substituted with phenyl which has propyloxy having piperidyl, benzoyl substituted with thiadiazolyl which has phenyl having methoxyhexyloxy, benzoyl substituted with oxadiazolyl which has pyrazolyl having decyl, benzoyl substituted with thiadiazolyl which has pyrazolyl having decyl, benzoyl substituted with oxadiazolyl which has phenyl substituted with phenyl having phenyloxypropyloxy, benzoyl substituted with oxadiazolyl which has phenyl substituted with phenyl having propenyloxy, benzoyl substituted with thiadiazolyl which has phenyl having methoxyhexyloxy, benzoyl substituted with oxadiazolyl which has phenyl substituted with phenyl having phenyloxybutyloxy, benzoyl substituted with oxadiazolyl which 27 has phenyl substituted with phenyl having methoxyoctyloxy, benzoyl substituted with oxadiazolyl which has phenyl substituted with phenyl which has propyloxy having dimethylmorpholinyl, benzoyl substituted with thiadiazolyl which has phenyl having phenyloxybutyloxy, benzoyl substituted with thiadiazolyl which has phenyl having phenyloxypentyloxy, benzoyl substituted with thiadiazolyl which has phenyl having phenyloxypropyloxy, benzoyl substituted with thiadiazolyl which has phenyl having methoxypentyloxy, benzoyl substituted with thiadiazolyl which has phenyl having methoxyheptyloxy, benzoyl substituted with thiadiazolyl which has pyridyl having piperidyl, benzoyl substituted with imidazothiadiazolyl which has phenyl having pentyloxy, benzoyl substituted with imidazothiadiazolyl which has phenyl having cyclohexyloxy, benzoyl substituted with isoxazolyl which has phenyl having pentyloxy, benzoyl substituted with thiadiazolyl having phenyl which has piperidyl having propoxy, benzoyl substituted with thiadiazolyl having phenyl which has piperidyl having cyclohexyloxy, benzoyl substituted with thiadiazolyl having phenyl which has piperidyl having phenylmethoxy, benzoyl substituted with imidazothiadiazolyl having phenyl which has piperazinyl having cyclohexyl, benzoyl substituted with thiadiazolyl having phenyl which has piperazinyl substituted with cyclohexyl having dimethyl, benzoyl substituted with thiadiazolyl having phenyl which has piperazinyl having cyclohexyl, benzoyl substituted with thiadiazolyl having phenyl which has piperazinyl substituted with cyclohexyl having methyl, benzoyl substituted with thiadiazolyl having phenyl which has piperidyl substituted with methoxy and chlorophenyl, benzoyl substituted with thiadiazolyl having phenyl which has piperidyl substituted with phenyl, benzoyl substituted with thiadiazolyl having phenyl which has piperazinyl substituted with phenyl, benzoyl substituted with thiadiazolyl having phenyl which has thiadiazolyl substituted 28 with pentyloxyphenyl, benzoyl substituted with thiadiazolyl having pyrazolyl which has hexyloxyphenyl, benzoyl substituted with thiadiazolyl having pyrazolyl which has heptyloxymethylphenyl, benzoyl substituted with piperidyl having piperazinyl which has phenyl having cyclohexyl, benzoyl substituted with thiadiazolyl having pyrazolyl which has phenyl having piperidyl, benzoyl substituted with thiadiazolyl having pyrazolyl which has phenyl having pyrrolidinyl, benzoyl substituted with thiadiazolyl having pyrazolyl which has phenyl substituted with piperazinylmethyl having phenyl, benzoyl substituted with thiadiazolyl having pyridyl which has piperidyl having phenyl, benzoyl substituted with thiadiazolyl having phenyl substituted with phenyl which has cyclohexyloxy, benzoyl substituted with thiadiazolyl having phenyl substituted with phenyl which has ethoxymethyl, benzoyl substituted with thiadiazolyl having phenyl substituted with phenyl which has ethoxypropoxy, benzoyl substituted with thiadiazolyl having phenyl substituted with phenyl which has ethoxyethoxy, benzoyl substituted with thiadiazolyl having phenyl substituted with phenyl which has methoxypropoxy, benzoyl substituted with thiadiazolyl having phenyl substituted with phenyl which has methoxyethoxy, benzoyl substituted with piperazinyl having phenyl substituted with phenyl which has methoxypentyloxy, benzoyl substituted with thiadiazolyl having phenyl substituted with phenyl which has methoxyethoxymethyl, benzoyl substituted with thiadiazolyl having phenyl substituted with phenyl which has methoxyethoxyethoxy, benzoyl substituted with thiadiazolyl having phenyl substituted with phenyl which has piperazinyl having cyclohexyl, benzoyl substituted with thiadiazolyl having phenyl substituted with phenyl which has morpholinyl having dimethyl, benzoyl substituted with oxadiazolyl which has phenyl having cyclohexyloxy, benzoyl substituted with thiadiazolyl which has phenyl having cyclohexyloxy, benzoyl substituted with piperazinyl which has 29 phenyl having cyclohexyloxy, benzoyl substituted with piperazinyl which has phenyl having methoxyheptylthio, benzoyl substituted with imidazothiadiazolyl which has phenyl having piperidinobutoxy, benzoyl substituted with imidazothiadiazolyl which has phenyl having piperidinopentyloxy, benzoyl substituted with imidazothiadiazolyl which has phenyl having piperidinohexyloxy, benzoyl substituted with imidazothiadiazolyl which has phenyl having morpholinopentyloxy, benzoyl substituted with imidazothiadiazolyl having phenyl which has morpholinopentyloxy having dimethyl, benzoyl substituted with imidazothiadiazolyl having phenyl which has morpholinohexyloxy having dimethyl, benzoyl substituted with imidazothiadiazolyl having phenyl which has thiomorpholinopentyloxy, benzoyl substituted with piperazinyl which has cyclohexyl having pentyl, benzoyl substituted with piperazinyl which has cyclohexyl having phenyl, benzoyl substituted with piperazinyl which has indanyl, benzoyl substituted with imidazothiadiazolyl having phenyl which has piperazinyl having ethyl, benzoyl substituted with imidazothiadiazolyl which has phenyl having butoxy, benzoyl substituted with imidazothiadiazolyl which has phenyl having methoxypentyloxy, benzoyl substituted with piperazinyl which has phenyl having cyclohexyl, dimethylbenzoyl substituted with thiadiazolyl which has phenyl having methoxyhexyloxy, naphthoyl substituted with oxadiazolyl having phenyl substituted with phenyl having butoxy, naphthoyl substituted with thiadiazolyl which has phenyl having methoxyhexyloxy, benzoyl substituted with thiazolyl which has phenyl having pentyloxy, benzoyl substituted with thiazolyl which has phenyl having hexyloxy, benzoyl substituted with thiazolyl which has phenyl having heptyloxy, benzoyl substituted with thiazolyl having phenyl substituted with phenyl having propoxy, benzoyl substituted with imidazothiadiazolyl which has phenyl having 30 methoxyhexyloxy, benzoyl substituted with imidazothiadiazolyl which has phenyl having methoxyheptyloxy, benzoyl substituted with imidazothiadiazolyl which has phenyl having methoxyoctyloxy, benzoyl substituted with imidazothiadiazolyl which has phenyl having morpholino, benzoyl substituted with imidazothiadiazolyl which has phenyl having dimethylmorpholino, benzoyl substituted with imidazothiadiazolyl which has phenyl having thiomorpholino, benzoyl substituted with imidazothiadiazolyl which has phenyl having pentyloxy, benzoyl substituted with imidazothiadiazolyl which has phenyl having hexyloxy, benzoyl substituted with thiadiazolyl which has phenyl having cyclohexyl, benzoyl substituted with oxadiazolyl which has phenyl having cyclohexyl, benzoyl substituted with thiadiazolyl which has phenyl substituted with phenyl having propoxy, benzoyl substituted with thiadiazolyl which has phenyl substituted with phenyl having ethoxy, benzoyl substituted with thiadiazolyl which has phenyl substituted with phenyl having methoxybutoxy, and benzoyl substituted with thiadiazolyl which has phenyl substituted with phenyl having butoxy. Suitable example of "aroyl" moiety in the term of "aroyl substituted with aryl having higher alkyl" can be referred to aforementioned "aroyl", in which the preferred one may be benzoyl . Suitable example of "aryl" moiety in the term of "aroyl substituted with aryl having higher alkyl" can be referred to aforementioned "aryl", in which the preferred one may be phenyl. Suitable example of "higher alkyl" moiety in the term of "aroyl substituted with aryl having higher alkyl" can be referred to aforementioned "higher alkyl", in which the preferred one may be (C -C ) alkyl, and the more preferred one may be heptyl. 31 Suitable example of "aroyl substituted with aryl having higher alkyl" may be benzoyl substituted with phenyl having (C7-C-L4) alkyl, in which the preferred one may be benzoyl substituted with phenyl having heptyl. Suitable example of "aroyl" moiety in the term of "aroyl substituted with aryl having lower alkyl" can be referred to aforementioned "aroyl", in which the preferred one may be benzoyl . Suitable example of "aryl" moiety in the term of "aroyl substituted with aryl having lower alkyl" can be referred to aforementioned "aryl", in which the preferred one may be phenyl . Suitable example of "lower alkyl" moiety in the term of "aroyl substituted with aryl having lower alkyl" can be referred to aforementioned "lower alkyl", in which the preferred one may be (C4~Cg) alkyl, and the more preferred one may be hexyl . Suitable example of "aroyl substituted with aryl having lower alkyl" may be benzoyl substituted with phenyl having (C4~C ) alkyl, in which the preferred one may be benzoyl substituted with phenyl having hexyl. Suitable example of "aryl" moiety in the term of "aryl (C2~Cg) alkanoyl substituted with aryl having lower alkyl" can be referred to aforementioned "aryl", in which the preferred one may be phenyl. Suitable example of " (C2~Cg) alkanoyl" moiety in the term of "aryl (C2~Cg) alkanoyl substituted with aryl having lower alkyl" maybe acetyl, propionyl, butyryl, etc., in which the preferred one may be (C2-C ) alkanoyl, and the more preferred one may be propionyl . Suitable example of "lower alkyl" moiety in the term of "aryl (C2~C ) alkanoyl substituted with aryl having lower alkyl" can be referred to aforementioned "lower alkyl", in 32 which the preferred one may be (C 4 -Cg) alkyl, and the more preferred one may be pentyl. Suitable example of "aryl (C 2 -Cg) alkanoyl substituted with aryl having lower alkyl" may be phenylpropionyl substituted with phenyl having pentyl. Suitable example of "lower alkanoyl" moiety in the term of "lower alkanoyl substituted with unsaturated condensed heterocyclic group which may have one or more suitable substituent (s) " can be referred to aforementioned "lower alkanoyl", in which the preferred one may be (C-L-C3) alkanoyl, and the more preferred one may be formyl . Suitable example of "unsaturated condensed heterocyclic group" moiety in the term of "lower alkanoyl substituted with unsaturated condensed heterocyclic group which may have one or more suitable substituent (s) " can be referred to aforementioned "heterocyclic group", in which the preferred one may be unsaturated condensed heterocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s) , and the more preferred one may be benzoxazolyl . Suitable example of "suitable substituent (s) " moiety in the term of "lower alkanoyl substituted with unsaturated condensed heterocyclic group which may have one or more suitable substituent (s) " may be heterocyclic group which may have one or more higher alkoxy and aryl which may have one or more lower alkoxy, in which the preferred one may be unsaturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) having (C7-C 4) alkoxy and phenyl having (C 4 -Cg) alkoxy, and the more preferred one may be pyridyl having octyloxy and phenyl having hexyloxy. Suitable example of "lower alkanoyl substituted with unsaturated condensed heterocyclic group which may have one or more suitable substituent (s) " may be benzoxazolylcarbonyl which has pyridyl having (C7-C-L ) alkoxy and benzoxazolylcarbonyl which has phenyl having (C 4 -Cg) alkoxy, 33 in which the preferred one may be benzoxazolylcarbonyl which has pyridyl having octyloxy and benzoxazolylcarbonyl which has phenyl having hexyloxy. Suitable example of "lower alkanoyl" moiety in the term of "lower alkanoyl substituted with pyridyl which may have one or more suitable substituent (s) " can be referred to aforementioned "lower alkanoyl", in which the preferred one may be (C -C 3 ) alkanoyl, and the more preferred one may be formyl . Suitable example of "suitable substituent (s) " moiety in the term of "lower alkanoyl substituted with pyridyl which may have one or more suitable substituent (s) " can be referred to aforementioned "suitable substituent (s) " , in which the preferred one may be higher alkoxy, and the more preferred one may be (C -C1 ) alkoxy, and the most preferred one may be heptyloxy and octyloxy. Suitable example of "lower alkanoyl substituted with pyridyl which may have one or more suitable substituent (s) " may be pyridylcarbonyl having (C7-C-L4 ) alkoxy, in which the preferred one may be pyridylcarbonyl having octyloxy and pyridylcarbonyl having heptyloxy. Suitable example of "aroyl" moiety in the term of "aroyl substituted with heterocyclic carbamoyl which may have one or more suitable substituent (s) " can be referred to aforementioned "aroyl", in which the preferred one may be benzoyl . Suitable example of "heterocyclic" moiety in the term of "aroyl substituted with heterocyclic carbamoyl which may have one or more suitable substituent (s) " can be referred to aforementioned "heterocyclic" moiety, in which the preferred one may be unsaturated 3 to 8-membered heteromonocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), and the more preferred one may be thiadiazolyl. 34 Suitable example of "suitable substituent (s) " moiety in the term of "aroyl substituted with heterocyclic carbamoyl which may have one or more suitable substituent (s) " can be referred to aforementioned "suitable substituent (s) ", in which the preferred one may be phenyl having (C- j _-Cg) alkoxy, and the more preferred one may be phenyl having pentyloxy. Suitable example of "aroyl substituted with heterocyclic carbamoyl which may have one or more suitable substituent (s) " may be benzoyl substituted with thiadiazolyl carbamoyl which has phenyl having pentyloxy. Suitable example of "lower alkanoyl" moiety in the term of "lower alkanoyl substituted with cyclo (lower) alkyl which may have one or more suitable substituent (s) " can be referred to aforementioned "lower alkanoyl", in which the preferred one may be formyl . Suitable example of "cyclo (lower) alkyl" moiety "in the term of "lower alkanoyl substituted with cyclo (lower) alkyl which may have one or more suitable substituent (s) " can be referred to aforementioned "cyclo (lower) alkyl", in which the preferred one may be cyclohexyl. Suitable example of "suitable substituent (s) " moiety in the term of "lower alkanoyl substituted with cyclo (lower) alkyl which may have one or more suitable substituent (s) " can be referred to aforementioned "suitable substituent (s) ", in which the preferred one may be heterocyclic group which may have one or more aryl having lower alkoxy (lower) alkoxy, and the more preferred one may be thiadiazolyl which has phenyl having methoxyhexyloxy. Suitable example of "lower alkanoyl" moiety in the term of "lower alkanoyl substituted with thienyl having heterocyclic group which may have one or more suitable substituent (s) " can be referred to aforementioned "lower alkanoyl", in which the preferred one may be formyl. 35 Suitable example of " heterocyclic group " moiety in the term of "lower alkanoyl substituted with thienyl having heterocyclic group which may have one or more suitable substituent (s) " can be referred to aforementioned "heterocyclic group", in which the preferred one may be unsaturated 3 to 8-membered heteromonocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s) , and the more preferred one may be oxadiazolyl. Suitable example of "suitable substituent (s) " moiety in the term of "lower alkanoyl substituted with thienyl having heterocyclic group which may have one or more suitable substituent (s) " can be referred to aforementioned "suitable substituent (s) " , in which the preferred one may be aryl substituted with aryl which may have one or more lower alkoxy, and the more preferred one may be phenyl substituted with phenyl having pentyloxy. Suitable example of "lower alkenoyl" moiety in the term of "lower alkenoyl substituted with heterocyclic group which may have one or more suitable substituent (s) " may be acryloyl, butenoyl, pentenoyl, hexenoyl, 2, 4-hexendienoyl, and the like, in which the preferred one may be 2, 4-hexenedienoyl . Suitable example of "heterocyclic group" moiety in the term of "lower alkenoyl substituted with heterocyclic group which may have one or more suitable substituent (s) " can be referred to aforementioned "heterocyclic group" moiety, in which the preferred one may be unsaturated 3 to 8-membered heteromonocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), and the more preferred one may be thiadiazolyl. Suitable example of "suitable substituent (s) " moiety in the term of "lower alkenoyl substituted with heterocyclic group which may have one or more suitable substituent (s) " can be referred to aforementioned "suitable substituent (s) ", in which the preferred one may be aryl having lower 36 alkoxy (lower) alkoxy, and the more preferred one may be phenyl having methoxyhexyloxy. The processes for preparing the object polypeptide compound [I] and the starting compound [II] or a salt thereof of the present invention are explained in detail in the following. Process 1 The object polypeptide compound [la] or a salt thereof can be prepared by reacting the compound [lb] or its reactive derivative at the amino group or a salt thereof with the compound [III] or its reactive derivative at the carboxy group or a salt thereof. Suitable reactive derivative at the carboxy group of the compound [III] may include an acid halide, an acid anhydride, an activated amide, an activated ester, and the like. Suitable examples of the reactive derivatives may be an acid chloride; an acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid [e.g., dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.], dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, sulfuric acid, sulfonic acid [e.g., methanesulfonic acid, etc.], aliphatic carboxylic acid [e.g., acetic acid, propionic acid, butyric acid, isobutyric acid, pivaric acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid, etc.]; or aromatic carboxylic acid [e.g., benzoic acid, etc.]; a symmetrical acid anhydride; an activated amide with imidazole, 4-substituted imidazole, dimethylpyrazole, triazole, tetrazole or 1-hydroxy-lH-benzotriazole; or an activated ester [e.g., cyanomethyl ester, methoxymethyl ester, + dimethyliminomethyl [ (CH 3 ) 2 =CH-] ester, vinyl ester, propargyl ester, p-nitrophenyl ester, 2, 4-dinitrophenyl ester, 37 trichlorophenyl ester, pentachloropentyl ester, mesylphenyl ester, phenylazophenyl ester, phenyl thioester, p-nitrophenyl thioester, p-cresyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolyl thioester, etc.], or an ester with a N-hydroxy compound [e.g. N,N-dimethylhydroxylamine, l-hydroxy-2- ( 1H) -pyridone, N- hydroxysuccinimide, N-hydroxyphthalimide, 1-hydroxy-lH- benzotriazole, etc.], and the like. These reactive derivatives can optionally be selected from them according to the mind of the compound [III] to be used. Suitable salts of the compound [III] and its reactive derivative can be referred to the ones as exemplified for the object polypeptide compound [I]. The reaction is usually carried out in a conventional solvent such as water, alcohol [e . g. , methanol, ethanol, etc.], acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction. These conventional solvent may also be used in a mixture with water. In this reaction, when the compound [III] is used in a free acid form or its salt form, the reaction is preferably carried out in the presence of a conventional condensing agent such as N,N' -dicyclohexylcarbodiimide; N-cyclohexyl-N' -morpholinoethylcarbodiimide; N-cyclohexyl-N' - (4-diethylaminocyclohexyl) carbodiimide; N,N' -diethylcarbodiimide; N,N' -diisopropylcarbodiimide; N-ethyl-N'- (3-dimethylaminopropyl) carbodiimide; N,N-carbonylbis- (2-methylimidazole) ; pentamethyleneketene-N-cyclohexylimine; diphenylketene-N-cyclohexylimine, ethoxyacetylene; l-alkoxy-2-chloroethylene; trialkyl phosphite; ethyl polyphosphate; isopropyl polyphosphate; phosphorus oxychloride (phosphoryl chloride) ; phosphorus trichloride; thionyl chloride; oxalyl chloride; 38 lower alkyl haloformate [e.g., ethyl chloroformate, isopropyl chloroformate, etc.]; triphenylphosphine; 2-ethyl-7-hydroxybenzisoxazolium salt; 2-ethyl-5- (m-sulfophenyl) isoxazolium hydroxide intramolecular salt; 1- (p-chlorobenzenesulfonyloxy) -6-chloro-lH-benzotriazole; so-called Vilsmeier reagent prepared by the reaction of N,N-dimethylformamide with thionyl chloride, phosgene, trichloromethyl chloroformate, phosphorous oxychloride, methanesulfonyl chloride, etc.; or the like. The reaction may also be carried out in the presence of an inorganic or organic base such as an alkali metal carbonate, alkali metal bicarbonate, tri (lower) alkyla ine, pyridine, di (lower) alkylaminopyridine (e.g., 4-dimethylaminopyridine, etc.), N- (lower) alkylmorpholine, N,N- di (lower) alkylbenzylamine, or the like. The reaction temperature is not critical, and the reaction is usually carried out under cooling to warming. Process 2 The object compound [I a ] or a salt thereof can be prepared by reducing a compound [II] or a salt thereof. Suitable salts of the compounds [I a ] and [II] may be the same as those exemplified for the compound [I] . The reaction can be carried out in a conventional manner, namely, chemical reduction or catalytic reduction. Suitable reducing agents to be used in chemical reduction are a combination of metal [e.g. tin, zinc, iron, etc.] or metallic compound [e.g. chromium chloride, chromium acetate, etc.] and an organic or inorganic acid [e.g. formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, hydride transfer reagent such as aluminum hydride compound (e.g. lithium aluminum hydride, lithium hydridotri-t-butoxyaluminate, etc.), borohydride compound (e.g. sodium borohydride, sodium cyanoborohydride, etc.) or the like etc.]. Suitable catalysts to be used in catalytic reduction are 39 conventional ones such as platinum catalyst [e.g. platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.], palladium catalyst [e.g., spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc], nickel catalyst [e.g. reduced nickel, nickel oxide, Raney nickel, etc.], cobalt catalyst [e.g. reduced cobalt, Raney cobalt, etc.], iron catalyst [e.g. reduced iron, Raney iron, etc.], copper catalyst [e.g. reduced copper, Raney copper, Ullman copper, etc.] or the like. The reaction of this process is usually carried out in a solvent such as water, alcohol [e.g. methanol, ethanol, propanol, etc], acetic acid, diethyl ether, dioxane, tetrahydrofuran, methylene chloride, etc. or a mixture thereof. The reaction is preferably carried out under somewhat milder conditions such as under cooling to warming. It is included within the scope of the present invention that "hydroxy" in R 2 may be reduced to "hydrogen" during the reaction. Process 3 The object compound [lb] or a salt thereof can be prepared by reducing the starting compound [IV] or a salt thereof to reduction reaction. This reaction can be carried out in substantially the same manner as Process 2 , and therefore the reaction mode and reaction conditions [e.g. solvent, reaction temperature, etc. ] of this reaction are to be referred to those as explained in Process 2. Process A The object compound [II] or a salt thereof can be prepared by reacting the starting compound [IV] or its reactive derivative at the a ino group or a salt thereof with the compound [III] or its reactive derivative at the carboxy group 40 or a salt thereof. This reaction can be carried out in substantially the same manner as Process 1 , and therefore the reaction mode and reaction conditions [e.g. solvent, reaction temperature, etc. ] of this reaction are to be referred to those as explained in Process 1. Process B The compound [IVb] or a salt thereof can be prepared by subjecting the compound [IVa] or its reactive derivative at the sulfonic acid group or a salt thereof to hydrolysis reaction of the sulfonic acid group. The hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid. Suitable base may include an inorganic base and an organic base such as an alkali metal [e.g., sodium, potassium, etc], an alkaline earth metal [e.g., magnesium, calcium, etc.], the hydroxide or carbonate or hydrogencarbonate thereof, trialkylamine [e.g. trimethylamine, triethylamine, etc.], picoline, 1, 5-diazabicyclo [4.3.0] -non-5-ene, or the like. Suitable acid may include an organic acid [e.g., formic acid, acetic acid, propionoc acid, trichloroacetic acid, trifluoroacetic acid, etc], and an inorganic acid [e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, etc.]. The elimination using Lewis acid such as trihaloacetic acid [e.g., trichloroacetic acid, trifluoroacetic acid , etc.], or the like preferably carried out in the presence of cation trapping agent [e.g., anisole, phenol, etc]. The reaction is usually carried out in a conventional solvent such as water, alcohol [e.g. methanol, ethanol, isopropyl alcohol, etc.], tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene dichloride, chloroform, N,N- dimethylformamide, N,N-dimethylacetamide or any other organic solvent which do not adversely affect the reaction, or the mixture thereof. 41 The reaction temperature is not critical and the reaction is usually carried out under cooling to warming. The starting compound [IVa] is known compound. It can be prepared by fermentation and synthetic processes disclosed in EP 0462531 A2. Process C The compound [IVc] or a salt thereof can be prepared by subjecting the compound [IVb] or its reactive derivative at the hydroxy group or a salt thereof with the diazo compound [e.g., diazomethane, phenyldiazomethane, diphenyldiazomethane, trimethylsilyldiazomethane, β- diazopropionic acid etc.] or a salt thereof to alkylation reaction of the hydroxy group. This reaction is usually carried out in the solvent such as water, alcohol [e.g. methanol, ethanol, etc.], benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether, acetonitrile or any other solvents which do not adversely affect the reaction, or the mixture thereof. The reaction temperature is not critical and the reaction is usually carried out under cooling to heating. The reaction may be usually carried out in the presence of an acid including Lewis acid. Suitable acid may include an organic acid [e.g., formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc], and an inorganic acid [e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, zinc halide (e.g., zinc chloride, zinc bromide, etc.), etc.] and the like. The reaction may be also carried out in the presence of an inorganic or an organic base such as an alkali metal [e.g., sodium, potassium, etc], an alkali metal hydroxide [e.g., sodium hydroxide, potassium hydroxide, etc.], an alkali metal hydrogencarbonate [e.g., sodium hydrogencarbonate, potassium hydrogencarbonate, etc.], alkaline metal carbonate [e.g., 42 sodium carbonate, potassium carbonate, etc.], tri (lower) alkylamine [e.g. trimethylamine, triethylamine, diisopropylethylamine, etc.], alkali metal hydride [e.g., sodium hydride, etc], alkali metal (lower) alkoxide [e.g., sodium methoxide, sodium ethoxide, etc.], pyridine, lutidine, picoline, dimethylaminopyridine, N- (lower) alkylmorpholine, N,N-di (lower) alkylbenzylamine, N,N-di (lower) alkylaniline or the like. When the base, the acid and/or the starting compound are in liquid, they can be used also as a solvent. The compounds obtained by the above Processes 1 to 3. and Processes A to C_ can be isolated and purified by a conventional method such as pulverization, recrystallization, column-chromatography, high-performance liquid chromatography (HPLC) , reprecipitation, desalting resin column chromatography, or the like. The compounds obtained by the above Processes 1 to 3. and Processes A to C_ may be obtained as its hydrate, and its hydrate is included within the scope of present invention. It is to be noted that each of the object compound (I) may include one or more stereoisomer such as optical isomer(s) and geometrical isomer(s) due to asymmetric carbon atom(s) and double bond(s) and all such isomers and the mixture thereof are included within the scope of the present invention. The object compound (I) or a salt thereof includes solvated compound [e.g., enclosure compound (e.g., hydrate, etc.) ] The object compound (I) or a salt thereof includes both its crystal form and non-crystal form. It should be understood that the compounds in the present invention may include the prodrug form. The patent applications and publications cited herein are incorporated by reference. This application is based on application No. PP1728/98 43 and application No. PP3138/98 filed in Australia, the content of which is incorporated hereinto by reference. Biological property of the polypeptide compound rτi of the present invention In order to show the usefulness of the polypeptide compound [I] of the present invention, the biological data of the representative compound is explained in the following. Test (Antimicrobial activity) : In vitro antimicrobial activity of the object compound of Example 12 disclosed later was determined by microdilution method as described below. Test Method : The antifungal susceptibility assays were performed by the microdilution method according to M27-A guidelines recommended by the National Committee for Clinical Laboratory Standards (NCCLS) to determine the MICs of the compounds. RPMI1640 medium with L-glutamine, without sodium bicarbonate, and buffered with 165 mM morpholinepropanesulfonic acid buffer (pH 7.0) was used as a test medium. Inoculum suspension of 10° CFU/ml were prepared by a hemocytometric procedure, and diluted to obtain an inoculum size of approximately 0.5 X 10 3 to 2.5 X 10 3 CFU/ml. Microplates were incubated at 35°C and readings were taken when good growth in the growth control . The MICs were defined as the lowest concentrations at which no visible growth was observed. Test Result : MIC (μg/ml) Test compound The object compound Test organism of Example 12 Candida albicans FP-633 0.0625 From the test result, it is realized that the object 44 polypeptide compound [I] of the present invention has an antimicrobial activity (especially, antifungal activity) . The pharmaceutical composition of the present invention can be used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form, which contains the object polypeptide compound [I] or a pharmaceutically acceptable salt thereof, as an active ingredient in admixture with an organic or inorganic carrier or excipient which is suitable for rectal; pulmonary (nasal or buccal inhalation) ; ocular; external (topical) ; oral administration; parenteral (including subcutaneous, intravenous and intramuscular) administrations; insufflation (including aerosols from metered dose inhalator) ; nebulizer; or dry powder inhalator. The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers in a solid form such as granules, tablets, dragees, pellets, troches, capsules, or suppositories; creams; ointments; aerosols; powders for insufflation; in a liquid form such as solutions, emulsions, or suspensions for injection; ingestion; eye drops; and any other form suitable for use. And, if necessary, there may be included in the above preparation auxiliary substance such as stabilizing, thickening, wetting, emulsifying and coloring agents; perfumes or buffer; or any other commonly may be used as additives. The object polypeptide compound [I] or a pharmaceutically acceptable salt thereof is/are included in the pharmaceutical composition in an amount sufficient to produce the desired antimicrobial effect upon the process or condition of diseases . For applying the composition to human, it is preferable to apply it by intravenous, intramuscular, pulmonary, oral administration, or insufflation. While the dosage of therapeutically effective amount of the object polypeptide 45 compound [I] varies from and also depends upon the age and condition of each individual patient to be treated, in the case of intravenous administration, a daily dose of 0.01-20 mg of the object polypeptide compound [I] per kg weight of human being in the case of intramuscular administration, a daily dose of 0.1-20 mg of the object polypeptide compound [I] per kg weight of human being, in case of oral administration, a daily dose of 0.5-50 mg of the object polypeptide compound [I] per kg weight of human being is generally given for treating or preventing infectious diseases. Especially in case of the treatment of prevention of Pneumocystis carinii infection, the followings are to be noted. For administration by inhalation, the compounds of the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized as powders which may be formulated and the powder compositions may be inhaled with the aid of an insufflation powder inhaler device. The preferred delivery system for inhalation is a metered dose inhalation aerosol, which may be formulated as a suspension or solution of compound in suitable propellants such as fluorocarbons or hydrocarbons. Because of desirability to directly treat lung and bronchi, aerosol administration is a preferred method of administration. Insufflation is also a desirable method, especially where infection may have spread to ears and other body cavities. Alternatively, parenteral administration may be employed using drip intravenous administration. The following Preparations and Examples are given for the purpose of illustrating the present invention in more detail. Preparation 1 A solution of 4-hydroxybenzoic acid methyl ester (100 g) and 1, 6-dibromohexane (481 g) in N,N-dimethylformamide (500 46 ml) was treated with potassium carbonate (109 g) then heated at 60°C for 2 hours. After cooling, the mixture was diluted with ethyl acetate (3 L) and washed with water (7 x 1 L) . The organic layer was dried over magnesium sulfate, filtered, and evaporated to give a crude oil. Hexane (~100 ml) was added and the resulting precipitate removed by filtration and discarded and the filtrate loaded onto a silica gel column (2 kg). Elution with hexane, followed by 9:1 hexane-ethyl acetate and 8:1 hexane-ethyl acetate afforded methyl 4- (6- bromo-n-hexyloxy) benzoate (186 g) as a white solid. NMR (CDC1 3 , δ) : 1.46-1.55 (4H, m) , 1.78-1.97 (4H, m) , 3.38-3.46 (2H, m) , 3.88 (3H, s), 4.01 (2H, t, J=6.3Hz), 6.90 (2H, d, J=8.9Hz), 7.98 (2H, d, J=8.9Hz) MASS (m/z) : 315, 317 (M + ) The following compound was obtained in a manner similar to that of Preparation 1. Preparation 2 Methyl 4- (7-bromo-n-heptyloxy) benzoate NMR (DMSO-dg, δ) : 1.2-1.6 (6H, m) , 1.6-2.0 (4H, m) , 3.53 (2H, t, J=6.7Hz), 3.81 (3H, s) , 4.04 (2H, t, J=6.4Hz), 7.03 (2H, d, J=8.9Hz), 7.90 (2H, d, J=8.9Hz) MASS (m/z) : 329 (M+l), 331 (M+3) Preparation 3 A solution of methyl 4- (6-bromo-n-hexyloxy) benzoate (186 g) in methanol (1 L) was treated with 28% sodium methoxide in methanol (340 ml) and the solution refluxed for 2 hours . After cooling, the stirred solution was adjusted to pH 2 with lM-hydrochloric acid then extracted with ethyl acetate. The organic layer was washed with water, dried over magnesium sulfate, filtered and evaporated to give a crude oil. This oil was purified on a silica gel column (2 kg, 9:1 hexane- ethyl acetate elution) to give methyl 4- (6-methoxy-n- hexyloxy) benzoate (127 g) as an oil. 47 NMR (CDC1 3 , δ) : 1.37-1.68 (6H, m) , 1.74-1.88 (2H, m) , 3.33 (3H, s), 3.39 (2H, t, J=6.3Hz), 3.88 (3H, s) , 4.01 (2H, t, J=6.4Hz), 6.90 (2H, d, J=8.9Hz), 7.97 (2H, d, J=8.9Hz) The following compound was obtained in a manner similar to that of Preparation 3. Preparation 4 Methyl 4- (7-methoxy-n-heptyloxy) benzoate NMR (DMSO-dg, δ) : 1.2-1.6 (8H, m) , 1.6-1.9 (2H, m) , 3.21 (3H, s), 3.29 (2H, t, J=6.4Hz), 3.81 (3H, s), 4.04 (2H, t, J=6.5Hz), 7.03 (2H, d, J=8.9Hz), 7.90 (2H, d, J=8.9Hz) MASS (m/z) : 281 (M+l) Preparation 5 A solution of methyl 4- ( 6-methoxy-n-hexyloxy) benzoate (17.05 g) in 1 : 1 tetrahydrofuran-methanol (300 ml) was treated with hydrazine monohydrate (66 ml) and refluxed for 15 hours then cooled to room temperature. The reaction mixture was poured into water and the resulting precipitate collected by filtration, washed thoroughly with water then dried under hi-vacuum at 50°C to give 4- ( 6-methoxy-n- hexyloxy) benzohydrazide (15.63 g) as a white solid. NMR (DMSO-dg, δ) : 1.29-1.58 (6H, m) , 1.65-1.78 (2H, m) , 3.21 (3H, s) , 3.30 (2H, t, J=6.4Hz), 4.00 (2H, t, J=6.4Hz), 4.40 (2H, s) , 6.96 (2H, d, J=8.8Hz), 7.78 (2H, d, J=8.8Hz), 9.59 (1H, s) MASS (m/z) : 267 (M+l) The following compound was obtained in a manner similar to that of Preparation 5. Preparation 6 4- (7-Methoxy-n-heptyloxy) benzohydrazide NMR (DMSO-dg, δ) : 1.2-1.6 (8H, m) , 1.6-1.9 (2H, m) , 3.21 (3H, s), 3.30 (2H, t, J=6.4Hz), 4.00 (2H, t, J=6.4Hz), 4.40 (2H, s) , 6.96 (2H, d, J=8.7Hz), 7.78 (2H, d, J=8.9Hz), 9.59 (1H, s) 48 MASS (m/z) : 281 (M+l) Preparation 7 A mixture of 4- ( 6-methoxy-n-hexyloxy) benzohydrazide (106.82 g) and pyridine (162 ml) in tetrahydrofuran (1 L) at 0°-5°C was treated portionwise with 4-methoxycarbonylbenzoyl chloride (83.75 g) over 30 minutes. After a further 1 hour at 0°-5°C, and 2 hours at room temperature, tic indicated complete reaction and the reaction mixture was poured into water (7 L) . The resulting precipitate was collected by filtration, washed thoroughly with water, and dried under hi-vacuum at 50°C to give N- [4- ( 6-methoxy-n-hexyloxy) - benzoyl] -N 1 - (4-methoxycarbonylbenzoyl) hydrazine (171.9 g) as a white solid. NMR (DMSO-dg, δ) : 1.40-1.80 (8H, m) , 3.22 (3H, s) , 3.31 (2H, t, J=6.4Hz), 3.90 (3H, s), 4.05 (2H, t, J=6.3Hz), 7.04 (2H, d, J=8.8Hz), 7.90 (2H, d, J=8.8Hz), 8.03 (2H, d, J=8.6Hz), 8.10 (2H, d, J=8.6Hz), 10.41 (1H, s), 10.64 (1H, s) The following compound was obtained in a manner similar to that of Preparation 7. Preparation 8 N- [4- (7-Methoxy-n-heptyloxy) benzoyl] -N' - (4-methoxycarbonylbenzoyl ) hydrazine NMR (DMSO-dg, δ) : 1.2-1.6 (8H, m) , 1.6-1.9 (2H, m) , 3.21 (3H, s), 3.30 (2H, t, J=6.4Hz), 3.90 (3H, s) , 4.05 (2H, t, J=6.4Hz), 7.04 (2H, d, J=8.8Hz), 7.90 (2H, d, J=8.8Hz), 8.03 (2H, d, J=8.6Hz), 8.10 (2H, d, J=8.6Hz), 10.42 (1H, s) , 10.63 (1H, s) MASS (m/z) : 443 (M+l) Preparation 9 A mixture of N- [4- ( 6-methoxy-n-hexyloxy) benzoyl] -N 1 - (4-methoxycarbonylbenzoyl) hydrazine (193.4 g) and phosphorus pentasulfide (113.34 g) in tetrahydrofuran (2.5 L) was heated to reflux for 1 hour then cooled to room temperature and poured into water (7 L) . The resulting precipitate was collected by 49 filtration, washed thoroughly with water then partially dried. The solid was added to 1 : 1 CH 3 CN-H 2 0 (200 ml), stirred then filtered. This procedure was repeated a further 2 times, and the resulting yellow powder washed thoroughly with acetonitrile (500 ml x 5) then dried under hi-vacuum at 50°C to give methyl 4- [5- [4- ( 6-methoxy-n-hexyloxy) phenyl] - 1, 3, 4-thiadiazol-2-yl]benzoate (179.6 g) as a yellow powder . NMR (CDC1 3 , δ) : 1.40-1.87 (8H, m) , 3.34 (3H, s) , 3.40 (2H, t, J=6.2Hz), 3.96 (3H, s), 4.03 (2H, t, J=6.5Hz), 6.99 (2H, d, J=8.8Hz), 7.95 (2H, d, J=8.8Hz), 8.07 (2H, d, J=8.5Hz), 8.16 (2H, d, J=8.5Hz) The following compound was obtained in a manner similar to that of Preparation 9. Preparation 10 Methyl 4- [5- [4- (7-methoxy-n-heptyloxy) phenyl] -1, 3, 4- thiadiazol-2-yl] benzoate NMR (CDCI3, δ) : 1.3-2.0 (10H, m) , 3.34 (3H, s) , 3.38 (2H, t, J=6.4Hz), 3.96 (3H, s), 4.03 (2H, t, J=6.5Hz), 6.99 (2H, d, J=8.8Hz), 7.95 (2H, d, J=8.8Hz), 8.07 (2H, d, J=8.4Hz), 8.43 (2H, d, J=8.4Hz) MASS (m/z) : 441 (M+l) Preparation 11 A mixture of methyl 4- [5- [4- ( 6-methoxy-n-hexyloxy) - phenyl] -1, 3, 4-thiadiazol-2-yl]benzoate (179.6 g) , sodium hydroxide (25.3 g) , water (250 ml), methanol (1 L) , and tetrahydrofuran (750 ml) was heated under refluxing for 1 hour then cooled to room temperature and poured into water (7 L) . The pH of the stirred mixture was adjusted to 2.0 with 6N- hydrochloric acid and the precipitate collected by filtration, washed thoroughly with water, followed by acetonitrile, then dried under hi-vacuum at 50°C to give 4- [5- [4- (6-methoxy- n-hexyloxy) phenyl] -1, 3, 4-thiadiazol-2-yl]benzoic acid (167 g) as a yellow powder. NMR (DMSO-dg, δ) : 1.27-1.85 (8H, m) , 3.22 (3H, s) , 3.32 (2H, t, J=6.4Hz), 4.06 (2H, t, J=6.3Hz), 7.12 50 (2H, d, J=8.8Hz), 7.97 (2H, d, J=8.7Hz), 8.12 (4H, s) , 13.28 (1H, br s) The following compound was obtained in a manner similar to that of Preparation 11. Preparation 12 4- [5- [4- (7-Methoxy-n-heptyloxy) phenyl] -1,3,4- thiadiazol-2-yl]benzoic acid IR (KBr) : 2939.0, 2867.6, 2642.0, 1712.5, 1604.5, 1440.6, 1402.0, 1253.5 cm -1 MASS (m/z) : 427 (M+l) Preparation 13 A mixture of 4- [5- [4- ( 6-methoxy-n-hexyloxy) phenyl] - 1, 3, 4-thiadiazol-2-yl]benzoic acid (50 g) , 1-hydroxybenzotriazole (18 g) and l-ethyl-3- (3 ' - dimethylaminopropyl) carbodiimide, hydrochloride (34.86 g) in methylene chloride (1 L) was stirred for 16 hours at room temperature then evaporated under reduced pressure and dried for 1 hour under hi-vacuum. Water (1 L) was added to the residue and the resulting precipitate collected by filtration, washed with water (1 L x 5) , acetonitrile (1 L x 5) , isopropyl ether (250 ml x 2) , then dried under hi-vacuum to give 4- [5- [4- (6-methoxy-n-hexyloxy) phenyl] -1,3, 4-thiadiazol-2- yl]benzoic acid benzotriazol-1-yl ester (56.92 g) as a yellow powder. IR (KBr) : 1778 cm -1 NMR (CDC1 3 , δ) : 1.44-1.89 (8H, m) , 3.35 (3H, s) , 3.40 (2H, t, J=6.2Hz), 4.05 (2H, t, J=6.4Hz), 7.01 (2H, d, J=8.8Hz), 7.43-7.63 (3H, m) , 7.98 (2H, d, J=8.8Hz), 8.13 (1H, d, J=8.2Hz), 8.24 (2H, d, J=8.5Hz), 8.41 (2H, d, J=8.5Hz) The following compounds [Preparations 14 and 15.] were obtained in a manner similar to that of Preparation 13. Preparation 14 4- [5- [4- (7-Methoxy-n-heptyloxy) phenyl] -1, 3, 4- thiadiazol-2-yl]benzoic acid benzotriazol-1-yl ester 51 IR (KBr) : 3446.2, 2937.1, 2865.7, 1778.0, 1602.6, 1253.5 cm -1 NMR (CDC1 3 , δ) : 1.3-2.0 (10H, m) , 3.34 (3H, s) , 3.39 (2H, t, J=6.4Hz), 4.03 (2H, t, J=6.5Hz), 7.01 (2H, d, J=8.8Hz), 7.4-7.7 (3H, m) , 7.98 (2H, d, J=8.8Hz), 8.13 (1H, d, J=8.2Hz), 8.24 (2H, d, J=8.7Hz), 8.41 (2H, d, J=8.7Hz) MASS (m/z) : 544 (M+l) Preparation 15 4- [5- (4-Pentyloxyphenyl) isoxazol-3-yl] benzoic acid benzotriazol-1-yl ester Preparation 16 To 3-hydroxybenzoic acid methyl ester (25 g) and potassium carbonate (25 g) in N, N-dimethylformamide (300 ml) were added 1-bromopentane (25 ml) and the mixture was stirred for 7 hours at 80°C . The reaction mixture was added to a mixture of water and ethyl acetate. The organic layer was taken and dried over magnesium sulfate. The magnesium sulfate was filtered off and the filtrate was evaporated under reduced pressure to give 3-amyloxybenzoic acid methyl ester (35 g) . IR (KBr) : 2954, 2870, 1724, 1587 cm -1 NMR (CDC1 3 , δ) : 0.94 (3H, t, J=7.0Hz), 1.43 (4H, m) , 1.80 (2H, m) , 3.91 (3H, s) , 3.99 (2H, t, J=6.6Hz), 7.09 (1H, ddd, J=7.8, 1.7 and 1.7Hz), 7.32 (1H, t, J=7.8Hz), 7.55 (1H, dd, J=l .7 and 1.1Hz) , 7.61 (1H, ddd, J=7.8, 1.7 and 1.1Hz) MASS (m/z) : 223 (M+l) Preparati n 17 To 3-amyloxybenzoic acid methyl ester (35 g) in methanol (200 ml) was added lN-sodium hydroxide aqueous solution (200 ml) and the mixture was stirred for 2 days at room temperature. Hydroxy chloride (20 ml) was added to the reaction mixture. The precipitate was filtered and washed with water, acetonitrile and diisopropyl ether to give 3-amyloxybenzoic acid (30 mg) . 52 IR (KBr) : 2954, 2848, 2570, 1691, 1600, 1591 cm -1 NMR (DMSO-dg, δ) : 0.90 (3H, t, J=7.0Hz), 1.40 (4H, m) , 1.73 (2H, m) , 4.00 (2H, t, J=6.6Hz), 7.17 (1H, ddd, J=7.7, 2.6 and 1.2Hz), 7.39 (1H, t, J=7.7Hz), 7.42 (1H, dd, J=1.5 and 1.2Hz) , 7.52 (1H, ddd, 3=1 . 1 , 1.5 and 1.2Hz) MASS (m/z) : 209 (M+l) Preparation 18 To a solution of 1-hydroxybenzotriazole (24 g) and 3- amyloxybenzoic acid (29.5 g) in dichloromethane (500 ml) was added l-ethyl-3- (3 ' -dimethylaminopropyl) carbodiimide hydrochloride (WSCD-HC1) (41 g) and the mixture was stirred for 5 hours at ambient temperature. The reaction mixture was added to water. The organic layer was taken and dried over magnesium sulfate. Magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to give 3-amyloxybenzoic acid benzotriazol-1-yl ester (42 g) . IR (KBr) : 2956, 2935, 2869, 1788, 1600 cm -1 NMR (CDC1 3 , δ) : 0.95 (3H, t, J=7.0Hz), 1.45 (4H, m) , 1.84 (2H, m) , 4.05 (2H, t, J=6.5Hz), 7.30 (1H, d, J=9.4Hz), 7.43-7.56 (4H, ) , 7.74 (1H, t, J=2.0Hz), 8.10 (1H, d, J=8.5Hz), 8.53 (1H, d, J=8.5Hz) MASS (m/z) : 326 (M+l) Preparation 19 To a solution of 4-n-butyloxybenzoic acid benzotriazol-1-yl ester (15 g) in N,N-dimethylformamide (100 ml) was added thiosemicarbazide (5.27 g) and the mixture was stirred for 12 hours at ambient temperature. The reaction mixture was pulverized with diisopropyl ether. The precipitate was collected by filtration to give l-(4-n- butyloxybenzoyl) thiosemicarbazide (11.51 g) . NMR (DMSO-dg, δ) : 0.93 (3H, t, J=7.0Hz), 1.2-1.5 (2H, m) , 1.6-1.8 (2H, m) , 4.02 (2H, t, J=6.5Hz) , 6.98 (2H, d, J=8.8Hz), 7.56 (1H, s) , 7.83 (1H, s) , 7.84 (2H, d, J=8.8Hz), 9.26 (1H, s) , 10.21 (1H, s) 53 The following compound was obtained in a manner similar to that of Preparation 19. Preparation 20 1- (3-Amyloxybenzoyl) thiosemicarbazide NMR (DMSO-dg, δ) : 0.90 (3H, t, J=6.8Hz), 1.39 (4H, m) , 1.73 (2H, m) , 4.01 (2H, t, J=6.4Hz), 7.10 (1H, d, J=8.0Hz) , 7.30-8.00 (5H, m) , 9.33 (1H, s) , 10.34 (1H, s), 8.53 (1H, d, J=8.5Hz) MASS (m/z) : 282 (M+l) Preparation 21 To a slurry of 1- (4-n-butyloxybenzoyl) thiosemicarbazide (20 g) in toluene (213.3 ml) at 40°C, was added dropwise over 30 minutes, methanesulfonic acid (6.92 ml) . The mixture was stirred under refluxing for 12 hours. After cooling to 10°C, the sulfonate salt was filtered and dried. The salt was placed in water, the solution was adjusted to pH 9 with IN sodium hydroxide and extracted with ethyl acetate . The organic layer was separated, washed with brine, dried over magnesium sulfate and evaporated under reduced pressure to give 2-amino-5- (4-n-butyloxyphenyl) -1,3, 4-thiadiazole (4.314 g) . NMR (CDC1 3 , δ) : 0.94 (3H, t, J=7.0Hz), 1.2-1.6 (2H, m) , 1.6-1.9 (2H, m) , 4.01 (2H, t, J=6.5Hz) , 7.00 (2H, d, J=8.8Hz), 7.28 (2H, s), 7.66 (2H, d, J=8.8Hz) The following compound was obtained in a manner similar to that of Preparation 21. Preparation 22 2-Amino-5- (3-amyloxyphenyl) -1, 3, 4-thiadiazole IR (KBr) : 3291.9, 3114.5, 2952.5, 1610.3 cm "1 NMR (DMSO-dg, δ) : 0.90 (3H, t, J=7.0Hz), 1.39 (4H, m) , 1.73 (2H, m) , 4.01 (2H, t, J=6.5Hz), 7.00 (1H, d, J=8.5Hz), 7.25-7.42 (5H, m) MASS (m/z) : 264 (M+l) Preparation 23 To a suspension of 2-amino-5- (4-n-butyloxyphenyl) - 1, 3, 4-thiadiazole (1.5 g) in ethanol (30 ml) was added ethyl 54 4-bromoacetylbenzoate (1.86 g) and the mixture was stirred under refluxing for 1.5 hours. The reaction mixture was pulverized with ethyl acetate. The precipitate was filtered and dried. To a suspension of the powder in xylene (15 ml) was added trifluoroacetic acid (3 ml) and the mixture was stirred under refluxing for 3 hours. The reaction mixture was pulverized with diisopropyl ether. The precipitate was filtered and dried to give 4- [2- (4-butyloxyphenyl) imidazo- [2, 1-b] [1, 3, 4] thiadiazol-6-yl]benzoic acid ethyl ester trifluoroacetic acid salt (2.15 g) . IR (KBr) : 1714.4, 1602.6, 1278.6, 1255.4, 1178.3 cm -1 The following compound was obtained in a manner similar to that of Preparation 23 Preparation 24 4- [2- (3-Amyloxyphenyl) imidazo [2, 1- b] [1, 3, 4] thiadiazol-6-yl]benzoic acid ethyl ester trifluoroacetic acid salt IR (KBr) : 2869.6, 1704.8, 1573.6, 1278.6 cm -1 MASS (m/z) : 436 (M+l) Preparation 25 To a solution of 4- [2- (4-butyloxyphenyl) imidazo [2, 1-b] - [1, 3, 4] thiadiazol-6-yl]benzoic acid ethyl ester trifluoroacetic acid salt (2.05 g) in the mixture of methanol (41 ml) and tetrahydrofuran (20.5 ml) was added 2N NaOH aq. (19.1 ml) and refluxed for 17 hours. The reaction mixture was adjusted to pH 1-2 with IN HCl and the resulting precipitate was collected by filtration to give 4- [2- (4- butyloxyphenyl) imidazo [2, 1-b] [1,3,4] thiadiazol-6- yl]benzoic acid (1.544 g) . The following compound was obtained in a manner similar to that of Preparation 25. Preparation 26 4- [2- (3-Amyloxyphenyl) imidazo [2, 1-b] [1,3,4]- thiadiazol-6-yl]benzoic acid 55 IR (KBr) : 2935.1, 2867.6, 1685.5, 1608.3, 1484.9, 1288.2 cm -1 NMR (DMSO-dg, δ) : 0.91 (3H, t, J=7.0Hz), 1.39 (4H, m) , 1.75 (2H, m) , 4.07 (2H, t, J=6.5Hz), 7.19 (1H, ) , 7.42-7.49 (3H, m) , 8.00 (4H, s) , 8.89 (1H, s) MASS (m/z) : 408 (M+l) The Starting Compound used and the Object Compounds (27) to (30) obtained in the following Preparations 27 to 3JD are given in the table as below, in which the formula of the starting compound is in the upper column and the formula of the object compounds (27) to (30) are in the lower column, respectively. 56 Preparation Formula No. HO OH 27 HO OH 0 0 57 Preparation Formula No. HO OH 28 HO OH 0 0 58 Preparation Formula No. HO OH 29 HO OH JO ; θ<lK ,eH - 2 ) 3 CH ; H3C~ -( 7 ^ Naθ 3 S 59 Preparation Formula No. HO OH 30 HO OH H 10O 0 4 i-N _>-0 ( CH 2 ) 4 CH3 60 Preparation 27 To a solution of Starting Compound (1 g) in tetrahydrofuran (10 ml) and pH 6.86 standard buffer solution (prepared by Nacalai Tesque, Inc.) (10 ml) was added dropwise with stirring to benzyloxycarbonyl chloride (0.15 ml) in an ice-bath. The solution was then stirred for 2 hours. The reaction mixture was acidified with dilute hydrogen chloride, and evaporated under reduced pressure. The residue was dissolved in water, and subjected to column chromatography on ion exchange resin (DOWEX-50WX4 (Trademark: prepared by Dow Chemical) ) eluting with water. The fractions containing the object compound were combined, and subjected to column chromatography on ODS (YMC-gel ODS-AM-S-50 (Trademark: prepared by Yamamura Chemical Lab.)) eluting with 5% acetonitrile aqueous solution. The fractions containing the object compound were combined, and evaporated under reduced pressure to remove acetonitrile. The residue was lyophilized to give Object Compound (27) (0.78 g) . IR (KBr) : 3462, 3336, 1668, 1539, 1265 cm -1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.6Hz), 1.05 (3H, d, J=5.8Hz), 1.78-5.53 (35H, m) , 6.71-8.84 (16H, m) MASS (m/z) : 1068.90 (M-Na + ) Preparation 28 To a solution of Starting Compound (54.4 g) and ethyldiisopropylamine (35 ml) in N,N-dimethylformamide (230 ml) was added 9-fluorenylmethyl chloroformate (15.8 g) at room temperature. The solution was stirred for 5 hours at the same temperature. Ethyl acetate (1.5 L) was added to the reaction mixture and the mixture was stirred for 30 minutes . The powder was collected by filtration to give crude material (94.3 g) . The crude material was purified by column chromatography on DOWEX and on ODS to give Object Compound (28) (52.6 g) . NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.8Hz), 1.03 (3H, d, J=5.6Hz), 1.60-2.00 (3H, m) , 2.05-2.49 (4H, m) , 3.18 (1H, t, J=ll.lHz), 61 3.60-4.48 (17H, m) , 4.68-5.36 (10H, m) , 5.35 (1H, d, J=5.9Hz), 6.73 (1H, d, J=8.2Hz), 6.82 (1H, dd, J=8.2 and 1.6Hz), 6.84 (1H, m) , 6.97 (1H, m) , 7.04 (1H, d, J=1.6Hz), 7.27-7.46 (6H, m) , 7.74-7.78 (3H, m) , 7.89 (2H, d, J=7.2Hz), 8.06 (2H, t, J=7.2Hz), 8.77 (1H, s) Preparation 29 To a solution of 1-hydroxybenzotriazole (216 mg) and 4- [2- (4-butyloxyphenyl) imidazo [2, 1-b] [1,3,4] thiadiazol-6- yl]benzoic acid (420 mg) in N, N-dimethylformamide (20 ml) was added l-ethyl-3- (3 ' -dimethylaminopropyl) carbodiimide hydrochloride (245 mg) and the mixture was stirred for 2 hours at ambient temperature . Then to the reaction mixture was added Starting Compound (1 g) and diisopropylethylamine (0.279 ml) and the mixture was stirred for 5 hours at ambient temperature. The reaction mixture was pulverized with ethyl acetate. The precipitate was collected by filtration and dried over under reduced pressure. The powder was added to water and subjected to ion-exchange column chromatography on DOWEX-50WX4 and eluted with water. The fractions containing the Object Compound were combined and subjected to column chromatography on ODS (YMC-gel ODS-AM S-50) and eluted with 25-30% acetonitrile aq. The fractions containing the Object Compound were combined and evaporated under reduced pressure to remove acetonitrile. The residue was lyophilized to give Object Compound (29) (891 mg) . NMR (DMSO-dg, δ) : 0.94 (3H, t, J=7.2Hz), 0.96 (3H, d, J=7.1Hz), 1.11 (3H, d, J=5.5Hz), 1.3-1.6 (2H, m) , 1.6-2.1 (5H, m) , 2.1-2.7 (4H, m) , 3.25 (1H, m) , 3.6-4.5 (16H, m) , 4.7-5.3 (10H, m) , 5.53 (1H, d, J=5.8Hz), 6.73 (1H, d, J=8.2Hz), 6.82 (1H, d,=8.2Hz), 6.86 (1H, s), 7.05 (1H, s) , 7.14 (2H, d, J=8.9Hz), 7.2-7.5 (3H, m) , 7.90 (2H, d, J=8.9Hz), 7.9-8.0 (4H, m) , 8.10 (1H, d, J=7.7Hz), 8.30 (1H, d, J=6.8Hz), 8.70 (1H, d, J=6.8Hz), 8.86 (1H, s) 62 MASS (m/ z ) : 1356 (M+Na + ) The following compound was obtained in a manner similar to that of Preparation 29. Preparation 30 IR (KBr) : 3359, 1673.9, 1648.8, 1257.4 cm -1 NMR (DMSO-dg, δ) : 0.91 (3H, t, J=7.1Hz), 0.96 (3H, d, J=6.7Hz), 1.09 (3H, d, J=5.9Hz), 1.3-1.5 (4H, m) , 1.6-2.7 (9H, m) , 3.19 (1H, m) , 3.6-4.6 (15H, m) , 4.7-5.3 (11H, m) , 5.53 (1H, d, J=5.9Hz), 6.73 (1H, d, J=8.3Hz), 6.83 (1H, d, J=8.3Hz), 6.88 (1H, s), 7.06 (1H, s), 7.14 (2H, d, J=8.9Hz), 7.2-7.4 (3H, m) , 7.90 (2H, d, J=8.9Hz), 7.97 (4H, m) , 8.08 (1H, d, J=6Hz) , 8.31 (1H, d, J=5Hz) , 8.76 (1H, d, J=5Hz), 8.85 (1H, s) , 8.86 (1H, s) MASS (m/z) : 1325 (M+Na + ) Elemental Analysis Calcd. for C57H 7 oN 11 0 2 2S2Na- 8H 0 : C 45.87, H 5.81, N 10.32 Found : C 46.04, H 5.77, N 10.28 Preparation 31 A solution of 4- (4 ' -hydroxyphenyl) benzoic acid (25.6 g) in 10% hydrochloric acid-methanol was stirred for 3 days at room temperature. Then the solvent was evaporated in vacuo and the residue was triturated with toluene-ethyl acetate (20:1) to afford methyl 4- (4 ' -hydroxyphenyl) benzoate (26.5 g) . NMR (CDC1 3 , δ) : 3.94 (3H, s) , 6.93 (2H, d, J=8.4Hz), 7.27 (1H, s), 7.53 (2H, d, J=8.6Hz), 7.60 (2H, d, J=8.4Hz), 8.08 (2H, d, J=8.4Hz) MASS (m/z) : 229 (M + +l) Preparation 32 A solution of 4- (4 ' -hydroxyphenyl) benzoic acid (4.98 g) , methyliodide (5 ml), and sodium carbonate (7.19 g) in N,N- dimethy1formamide (50 ml) was stirred for 17 hours at room temperature. The reaction mixture was partitioned between ethyl acetate and water. The aqueous layer was extracted with 63 ethyl acetate. The combined organic layer was washed with water and brine. After dried over magnesium sulfate, the solution was evaporated in vacuo . The residue was triturated with n-hexane to afford methyl 4- (4 ' -methoxyphenyl) benzoate (5.45 g) . IR (KBr) : 1718 cm -1 NMR (CDC1 3 , δ) : 3.86 (3H, s), 3.93 (3H, s) , 7.00 (2H, d, J=8.8Hz), 7.57 (2H, d, J=8.8Hz), 7.61 (2H, d, J=8.6Hz), 8.07 (2H, d, J=8.6Hz) MASS (m/z) : 243 (M + +l) Preparation 33 A mixture of methyl 4- [5- [4 ' - [4"- [3- (piperizin-1-yl) - propyloxy] phenyl] phenyl] -1,3, 4-oxadiazol-2-yl] benzoate (1.13 g) , IN sodium hydroxide aqueous solution (3.5 ml), methanol (5 ml) and tetrahydrofuran (5 ml) was refluxed for 17 hours. The mixture was cooled down to room temperature and evaporated in vacuo. To the residue was added IN hydrochloric acid aqueous solution. The powder was obtained by filtration to give 4- [5- [4 ' - [4"- [3- (piperizin-1-yl) - propyloxy] phenyl] phenyl] -1, 3, 4-oxadiazol-2-yl] benzoic acid hydrochloric acid salt (1.01 g) . IR (KBr) : 3431, 2943, 2877, 2694, 2640, 2571, 2543, 1699 cm "1 NMR (DMSO-dg, δ) : 1.56 (2H, m) , 1.78 (4H, m) , 2.19 (2H, m) , 3.17 (6H, m) , 4.14 (2H, t, J=7.0Hz), 7.09 (2H, d, J=8.8Hz), 7.77 (2H, d, J=8.8Hz), 7.92 (2H, d, J=8.6Hz), 8.17 (2H, d, J=8.6Hz), 8.20 (2H, d, J=8.5Hz), 8.27 (2H, d, J=8.5Hz) MASS (m/z) : 484 (M + +l) free Preparation 34 A solution of methyl pyrazole-4-carboxylate (10 g) in N,N-dimethylformamide (100 ml) was treated with potassium carbonate (10.95 g) and 1-bromodecane (19.31 g) and the mixture was stirred for 16 hours at room temperature. Ethyl acetate was added and the solution was washed with water (6x), dried 64 over magnesium sulfate and the evaporated residue was purified by silica gel chromatography (5:1 hexane-ethyl acetate elution) to give methyl l-decylpyrazole-4-carboxylate (19.4 g) as a white solid. NMR (CDC1 3 , δ) : 0.84-0.90 (3H, m) , 1.25 (14H, br s), 1.83-1.90 (2H, m) , 3.82 (3H, s) , 4.15 (2H, t, J=7Hz) , 7.87 (1H, s), 7.90 (1H, s) MASS (m/z) : 267 (M + ) Preparation 35 A solution of methyl 4- (4 ' -hydroxyphenyl) benzoate (2 g) in N,N-dimethylformamide (20 ml) was treated with potassium carbonate (1.21 g) and 3-phenoxypropylbromide (2.07 g) was stirred for 15 hours at room temperature and 4 hours at 85°C. After cooling, the reaction was quenched with water and the precipitate was collected, washed thoroughly with water and dried to give methyl 4- [4 ' - (3-phenoxypropyloxy) phenyl] - benzoate (2.6 g) . NMR (DMSO-dg, δ) : 2.14-2.26 (2H, m) , 3.87 (3H, s), 4.12-4.29 (4H, m) , 6.89-6.98 (3H, m) , 7.08 (2H, d, J=8.8Hz), 7.25-7.33 (2H, m) , 7.70 (2H, d, J=8.8Hz), 7.78 (2H, d, J=8.5Hz), 8.00 (2H, d, J=8.4Hz) MASS (m/z) : 363 (M + ) Preparation 36 A solution of methyl 4- (4 ' -hydroxyphenyl) benzoate (5 g) in N,N-dimethylformamide (50 ml) was treated with potassium carbonate (6.06 g) and allyl bromide (2.46 ml), then heated at 60°C for 3 hours. After cooling, the reaction mixture was poured into ice-water (~200 ml) and the resulting precipitate was collected by filtration, washed with water, then isopropyl ether, then dried to give methyl 4-[4'- (allyloxy) phenyl] benzoate (5.55 g) as a solid. mp : 148-149°C NMR (CDCI3, δ) : 3.93 (3H, s) , 4.29-4.61 (2H, m) , 5.28- 5.49 (2H, m) , 5.99-6.18 (1H, m) , 7.00 (2H, d, J=8.8Hz), 7.56 (2H, d, J=8.8Hz), 7.61 (2H, d, 65 J=8 . 5Hz ) , 8 . 07 ( 2H, d, J=8 . 5Hz ) MASS (m/z) : 269 (M + ) Preparation 37 A solution of 4- (4 ' -hydroxyphenyl) benzoic acid (4 g) and IN sodium hydroxide (41 ml) in dimethyl sulfoxide (40 ml) was heated for 30 minutes at 85°C, then treated with 4-phenoxybutyl bromide (6.42 g) and heating continued for 8 hours. After cooling, the reaction was poured into water and adjusted to pH 2 and the resulting precipitate was collected, washed with water, and dried to give 4-[4'-(4- phenoxybutyloxy) phenyl] benzoic acid (6.7 g) . IR (KBr) : 1683.6, 1594.8, 1535.1 cm "1 NMR (DMSO-dg, δ) : 1.89 (4H, br s), 3.34 (1H, br s) , 4.04-4.10 (4H, m) , 6.91-6.95 (3H, m) , 7.05 (2H, d, J=7.9Hz) , 7.24-7.30 (2H, m) , 7.66-7.76 (4H, m) , 7.98 (2H, d, J=7.8Hz) Preparation 38 A mixture of 4- [4 '- (4-phenoxybutyloxy) phenyl] benzoic acid (5 g) , 1-hydroxybenzotriazole (2.24 g) and l-ethyl-3- (3 ' -dimethylaminopropyl) carbodiimide hydrochloride (3.97 g) in N,N-dimethylformamide (70 ml) was stirred for 18 hours at room temperature, then treated with tert-butylcarbazate (2.19 g) and the mixture was stirred for further 4 hours at ambient temperature. Water was added and the precipitate was collected, washed with water, and dried to give N-(tert- butoxycarbonyl) -N'- [4- [4 ' - (4- phenoxybutyloxy) phenyl] benzoyl] hydrazine (6 g) as a solid. IR (KBr) : 1650.8, 1492.6, 1290.1, 1249.6 cm -1 NMR (DMSO-dg, δ) : 1.44 (9H, br s) , 1.90 (4H, br s) , 4.04-4.10 (4H, m) , 6.88-6.96 (3H, ) , 7.05 (2H, d, J=8.7Hz), 7.24-7.32 (2H, m) , 7.69 (2H, d, J=8.8Hz), 7.75 (2H, d, J=8.5Hz), 7.92 (2H, d, J=8.2Hz), 8.91 (1H, s), 10.21 (1H, s) Preparation 39 A solution of N- (tert-butoxycarbonyl) -N' - [4- [4 ' - (4- 66 phenoxybutyloxy) phenyl] benzoyl] hydrazine (6 g) in trifluoroacetic acid (40 ml) was stirred for 2 hours at room temperature, then evaporated under reduced pressure, dissolved in water, then adjusted to pH 8 with saturated sodium hydrogen carbonate solution. The precipitate was collected, washed with water, and dried to give 4- [4 '-(4- phenoxybutyloxy) phenyl ] benzoylhydrazine (5 g). IR (KBr) : 3282.3, 1604.5 cm -1 NMR (DMSO-dg, δ) : 1.89 (4H, br s) , 4.04-4.09 (4H, m) , 4.55 (2H, br) , 6.83-6.96 (3H, m) , 7.04 (2H, d, J=8.6Hz) , 7.24-7.28 (2H, m) , 7.64-7.72 (4H, m) , 7.88 (2H, d, J=8.3Hz), 9.79 (1H, s) MASS (m/z) : 377 (M + ) Preparation 40 A solution of 4-methoxycarbonylbenzoylhydrazine (432 mg) in tetrahydrofuran (15 ml)-pyridine (5 ml) was treated with 4- [4 ' - (8-methoxy-n-octyloxy) phenyl] benzoic acid benzotriazol-1-yl ester (1.054 g) and the mixture was stirred for 72 hours at room temperature, then water (~100 ml) was added to the reaction mixture and the precipitate was collected, washed with water and dried to give N- [4- [4 '- (8-methoxy-n- octyloxy) phenyl] benzoyl] -N' - (4-methoxycarbonylbenzoyl) hydrazine (1.10 g) . IR (KBr) : 3220.5, 2933.2, 2856.1, 1724.0, 1679.7, 1654.6 cm "1 NMR (DMSO-dg, δ) : 1.20-1.60 (10H, m) , 1.60-1.80 (2H, m) , 3.21 (3H, s), 3.21-3.33 (2H, m) , 3.90 (3H, s) , 4.02 (2H, t, J=6.9Hz), 7.05 (2H, d, J=8.7Hz), 7.70 (2H, d, J=8.6Hz), 7.79 (2H, d, J=8.3Hz), 7.99 (2H, d, J=8.3Hz), 8.04 (2H, d, J=8.5Hz), 8.11 (2H, d, J=8.5Hz), 10.60 (1H, s) , 10.70 (1H, s) MASS (m/z) : 533 (M + ) Preparation 41 A suspension of N- (4-methoxybenzoyl) -N' - (4- methoxycarbonylbenzoyl) hydrazine (10 g) and di-phosphorus 67 pentasulfide (6.77 g) in tetrahydrofuran (100 ml) was refluxed for 3 hours. The reaction mixture was cooled, poured into water (300 ml) , stirred for 30 minutes and extracted with dichloromethane (1500 ml) and methanol (300 ml). The organic layer was washed with water and brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was triturated with acetonitrile. The solid was collected by filtration and dried under reduced pressure to give methyl 4- [5- (4-methoxyphenyl) -1, 3, 4- thiadiazol-2-yl]benzoate (8.15 g) . IR (KBr) : 2952.5, 2840.6, 1714.4, 1606.4, 1278.6, 1251.6 cm "1 NMR (CDC1 3 , δ) : 3.89 (3H, s) , 3.96 (3H, s) , 7.01 (2H, d, J=8.9Hz), 7.97 (2H, d, J=8.9Hz), 8.07 (2H, d, J=8.7Hz), 8.16 (2H, d, J=8.7Hz) MASS (m/z) : 327 (M + +l) Preparation 42 To a solution of borontribromide (2.0M in dichloromethane, 103 ml) was added dropwise methyl 4- [5- (4-methoxyphenyl) - 1, 3, 4-thiadiazol-2-yl]benzoate (6.75 g) and dichloromethane (100 ml) at -78 °C. The reaction mixture was allowed to warm to room temperature, and the mixture was stirred overnight. The reaction mixture was poured into ice-water (1000 ml) . The precipitate was collected by filtration, washed with water and dried under reduced pressure at 60 °C to give a mixture of methyl 4- [5- (4-hydroxyphenyl) -1, 3, -thiadiazol-2-yl]benzoate and 4- [5- (4-hydroxyphenyl) -1, 3, 4-thiadiazol-2-yl]benzoic acid (6.56 g) , that was used crude in the next reaction. Preparation 43 To a suspension of a mixture of methyl 4- [5- (4- hydroxyphenyl) -1, 3, 4-thiadiazol-2-yl]benzoate and 4- [5- (4- hydroxyphenyl) -1, 3, 4-thiadiazol-2-yl]benzoic acid (600 mg), potassium carbonate (531 mg) and N,N-dimethylformamide (3 ml) was added 4-phenoxybutylbromide (880 mg) and the mixture was stirred at 100°C (bath temperature) for 2 hours. After cooling, 68 the mixture was added to 0. IN hydrochloric acid (100 ml) . The resulting precipitate was collected by filtration and washed with water. To this material was added tetrahydrofuran (20 ml) , ethanol (20 ml) and 10% sodium hydroxide aqueous solution (1.39 ml) . The mixture was refluxed for 2 hours. After cooling, the reaction mixture was diluted with water (100 ml), adjusted to pH 1.8 with IN hydrochloric acid, then extracted with a mixture of dichloromethane (1000 ml), tetrahydrofuran (200 ml) and methanol (200 ml) . The organic layer was washed with brine and dried over magnesium sulfate. The solvents were removed under reduced pressure and the residue was triturated with acetonitrile. The solid was collected by filtration and dried to give 4- [5- [4- (4-phenoxybutyloxy) phenyl] -1, 3, 4- thiadiazol-2-yl]benzoic acid (685 mg) . IR (KBr) : 3371.0, 2674.8, 2547.5, 1685.5, 1604.5, 1249.6 cm "1 Preparation 44 To a suspension of a mixture of methyl 4- [5- (4- hydroxyphenyl) -1, 3, 4-thiadiazol-2-yl]benzoate and 4- [5- (4- hydroxyphenyl) -1, 3, 4-thiadiazol-2-yl]benzoic acid (2.0 g) , potassium carbonate (14.6 g) and N, N-dimethylformamide (15 ml) was added 1, 5-dibromopentane (10 ml) and the mixture was stirred at 100°C (bath temperature) for 1.5 hours. The resulting mixture was neutralized by 0. IN hydrochloric acid and extracted with dichloromethane. The organic layer was washed with brine and dried over magnesium sulfate. The solvents were removed under reduced pressure and the residue was triturated with n-hexane. The solid was collected by filtration and dried. To this compound was added phenol (1.43 g) , potassium carbonate (2.10 g) and N, N-dimethylformamide (30 ml), and the mixture was stirred at 100°C (bath temperature) for 20 hours. After cooling, the reaction mixture was poured into saturated sodium hydrogen carbonate aqueous solution. The resulting precipitate was collected by filtration, washed with water. To this compound was added tetrahydrofuran (20 69 ml) , ethanol (20 ml) and 10% sodium hydroxide aqueous solution (2.6 ml) . The mixture was refluxed for 1.5 hours. The reaction mixture was diluted with water, acidified with IN hydrochloric acid (10 ml) . The resulting precipitate was collected by filtration, washed with water, dried under reduced pressure to give 4- [5- [4- (5-phenoxy-n- pentyloxy) phenyl] -1, 3, 4-thiadiazol-2-yl]benzoic acid (2.47 g) , that was used crude in the next reaction. MASS (m/z) : 461 (M + +l) Preparation 45 To a suspension of a mixture of methyl 4- [5- (4- hydroxyphenyl) -1, 3, -thiadiazol-2-yl] benzoate and 4- [5- (4- hydroxyphenyl) -1, 3, 4-thiadiazol-2-yl] benzoic acid (3.12 g) , potassium carbonate (22.07 g) and N, N-dimethylformamide (15 ml) was added 1, 5-dibromopentane (15 ml) and the mixture was stirred at 100°C (bath temperature) for 5 hours . The resulting mixture was neutralized by 0. IN hydrochloric acid and extracted with dichloromethane. The organic layer was washed with brine and dried over magnesium sulfate . The solvents were removed under reduced pressure and the residue was triturated with n-hexane . The solid was collected by filtration and dried to give a crude powder (3.71 g) . To the crude powder (2.11 g) was added methanol (10 ml) and sodium methoxide (28% in methanol) (10 ml), and refluxed for 2 hours. Then to the reaction mixture was added sodium methoxide (28% in methanol) (5ml) and refluxed for 1.5 hours . After cooling, the reaction mixture was added to water and tetrahydrofuran, stirred overnight and adjusted to pH 2 with 4N hydrochloric acid. The resulting precipitate was collected by filtration, washed with acetonitrile and dried under reduced pressure to give 4- [5- [4- (5-methoxy-n-pentyloxy) phenyl] -1, 3, 4-thiadiazol-2- yl]benzoic acid (1.34 g) . IR (KBr) : 2940.9, 2865.7, 2663.2, 2549.4, 1685.5, 1604.5, 1432.9, 1413.6, 1292.1, 1253.5 cm "1 70 NMR (DMSO-dg, δ) : 1.3-1.7 (4H, m) , 1.7-2.0 (2H, m) , 3.23 (3H, s), 3.36 (2H, m) , 4.07 (2H, t, J=6.4Hz) , 7.13 (2H, d, J=8.8Hz), 7.97 (2H, d, J=8.8Hz) , 8.12 (4H, s) MASS (m/z) : 399 (M + +l) Preparation 46 To a solution of piperidine (2.98 g) and methyl 6- chloronicotinate (5.00 g) in N, N-dimethylformamide (75ml) was added potassium carbonate (12.08 g) . The mixture was stirred at 100°C for 3 hours. After cooling to ambient temperature, to the reaction mixture was added water (100 ml) and then the mixture was stirred for 15 minutes at ambient temperature . The resulting precipitates were filtered, washed with water, and dried to give methyl 6- ( 1-piperidyl) nicotinate (5.55 g) , as a white solid. IR (KBr) : 2941, 2850, 1701, 1608, 1552, 1508, 1435, 1415 cm "1 NMR (CDC1 3 , δ) : 1.5-1.8 (6H, m) , 3.6-3.7 (4H, m) , 3.86 (3H, s), 6.57 (1H, d, J=9.1Hz), 7.98 (1H, dd, J=9.1 and 2.4Hz), 8.78 (1H, d, J=2.0Hz) MASS (m/z) : 221 (M + +l) Preparation 47 To a solution of methyl 6- (1-piperidyl) nicotinate (5.00 g) in a mixed solvent of ethanol (25 ml) and tetrahydrofuran (10 ml) was added hydrazine monohydrate (11.0 ml). The solution was refluxed for 6 hours, during which period additional hydrazine monohydrate (11.0 ml) was added to the mixture. After cooling to ambient temperature, the reaction mixture was added to water (100 ml) and then stirred for 20 minutes at ambient temperature. The resulting precipitates were filtered, washed with water, and dried to give 6-(l- piperidyl) nicotinoylhydrazine (3.44 g) , as a white solid. IR (KBr) : 3300, 2931, 2846, 1649, 1608, 1554, 1502, 1417, 1348, 1242 cm -1 NMR (CDCI3, δ) : 1.5-1.8 (6H, m) , 3.4-3.8 (6H, m) , 6.61 71 ( 1H, d, J=8 . 9Hz ) , 7 . 51 ( 1H, br s ) , 7 . 85 ( 1H, dd, J=9 . 0 and 2 . 5Hz ) , 8 . 54 ( 1H, d, J=2 . 0Hz ) MASS (m/z) : 221 (M++1) Preparation 48 To a solution of N- [ 6- (1-piperidyl) nicotinoyl] -N 1 - (4- methoxycarbonylbenzoyl) hydrazine (2.00 g) in pyridine (40 ml) was added phosphorus pentasulfide (1.74 g) . The mixture was refluxed for 4 hours. After cooling to ambient temperature, the reaction mixture was poured into cold water (150 ml) and the mixture was adjusted to pH 11 with IN sodium hydroxide aqueous solution and the mixture was stirred for 30 minutes at ambient temperature. The resulting precipitates were filtered, washed with water and dried to give methyl 4- [5- [ 6- (1-piperidyl) pyridin-3-yl] -1, 3, 4-thiadiazol-2- yl]benzoate (1.59 g) , as a yellow solid. IR (KBr) : 2933, 2848, 1720, 1604, 1433, 1279, 1109 cm "1 NMR (CDC1 3 , δ) : 1.6-1.8 (6H, m) , 3.6-3.8 (4H, m) , 3.96 (3H, s) , 6.73 (1H, d, J=9.1Hz) , 8.06 (2H, d, J=8.7Hz) , 8.14 (1H, dd, J=9.2 and2.9Hz) , 8.16 (2H, d, J=8.6Hz) , 8.70 (1H, d, J=2.2Hz) MASS (m/z) : 381 (M + +l) Preparation 49 To a refluxing suspension of methyl 4-[5-[2-(l- piperidyl ) pyridin-5-yl] -1,3, 4-thiadiazol-2-yl] benzoate (1.50 g) in a mixed solvent of tetrahydrofuran (75 ml) and ethanol (15 ml) was added dropwise 10% sodium hydroxide aqueous solution (3.15 ml) . The mixture was refluxed for 1.5 hours and cooled to ambient temperature. To the reaction mixture was added water (100 ml) and the pH was adjusted to 1 with IN hydrochloric acid (15 ml) . The mixture was stirred for 30 minutes at ambient temperature and the resulting precipitates were filtered, washed with water and dried to give 4- [5- [6- ( 1-piperidyl ) pyridin-3-yl] -1,3, 4-thiadiazol-2- yl]benzoic acid hydrochloride (1.36 g) , as a yellow solid. 72 IR (KBr) : 3479, 2935, 2854, 1695, 1605, 1431, 1281, 1250 cm -1 NMR (DMSO-dg, δ) : 1.5-1.7 (6H, m) , 3.6-3.7 (4H, m) , 6.99 (1H, d, J=9.1Hz) , 8.08 (1H, dd, J=9.1 and2.5Hz) , 8.11 (4H, s), 8.71 (1H, d, J=2.4Hz) MASS (m/z) : 367 (M + +l) (free) Preparation 50 To a suspension of 4- [5- [ 6- ( 1-piperidyl) pyridin-3-yl] - 1, 3, 4-thiadiazol-2-yl]benzoic acid hydrochloride (1.20 g) in methylene chloride (60 ml) was added triethylamine (0.57 ml) and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (1.43 g) . The mixture was stirred for 6 hours at ambient temperature. To the reaction mixture was added water and the organic layer was separated, washed with aqueous sodium hydrogen carbonate solution and saturated sodium chloride solution, and dried over magnesium sulfate, and concentrated in vacuo. Diisopropyl ether was added to the residue and the precipitates were filtered, washed with the same solvent, and dried to give 4-[5-[6-(l- piperidyl) pyridin-3-yl] -1, 3, 4-thiadiazol-2-yl] benzoic acid benzotriazol-1-yl ester (1.18 g) , as a yellow solid. IR (KBr) : 2931, 2854, 1778, 1600, 1547, 1512, 1431, 1358, 1242, 993 cm "1 NMR (CDC1 3 , δ) : 1.6-1.8 (6H, m) , 3.6-3.8 (4H, m) , 6.75 (1H, d, J=9.1Hz), 7.4-7.7 (3H, m) , 8.13 (1H, d, J=8.2Hz), 8.16 (1H, dd, J=9.1 and 2.5Hz) , 8.24 (2H, d, J=8.6Hz), 8.40 (2H, d, J=8.6Hz), 8.72 (1H, d, J=2.3Hz) MASS (m/z) : 484 (M + +l) Preparation 51 A solution of methyl 4- (4 ' -hydroxyphenyl) benzoate (2.02 g) , n-butylbromide (3 ml) and sodium carbonate (3.6 g) in N, N-dimethylformamide was stirred for 17 hours at 80°C. The reaction mixture was cooled to room temperature and partitioned between ethyl acetate and water. The aqueous 73 layer was extracted with ethyl acetate. The combined organic layer was washed with water and brine. After dried over magnesium sulfate, the solution was evaporated in vacuo. The residue was triturated with n-hexane to afford methyl 4- (4 ' -butyloxyphenyl) benzoate (2.45 g) . IR (KBr) : 2956, 2935, 2873, 1722 cm "1 NMR (DMSO-dg, δ) : 0.94 (3H, d, J=7.3Hz), 1.45 (2H, qt, J=7.3 and 6.9Hz), 1.70 (2H, tt, J=6.9 and 6.9Hz), 4.03 (2H, t, J=6.9Hz), 7.04 (2H, d, J=8.8Hz), 7.68 (2H, d, J=8.8Hz), 7.78 (2H, d, J=8.5Hz), 8.00 (2H, d, J=8.5Hz) MASS (m/z) : 285 (M + +l) The following compounds [Preparations 52 to 5_4 were obtained in a manner similar to that of Preparation 51. Preparation 52 Methyl 4- ( 4 ' -n-pentyloxyphenyl) benzoate IR (KBr) : 2958, 2935, 2866, 1722 cm "1 NMR (DMSO-dg, δ) : 0.91 (3H, t, J=7.0Hz), 1.39 (4H, m) , 1.74 (2H, m) , 3.87 (3H, s) , 4.02 (2H, t, J=6.4Hz), 7.04 (2H, t, J=8.8Hz), 7.69 (2H, d, J=8.8Hz), 7.78 (2H, d, J=8.5Hz), 8.00 (2H, d, J=8.5Hz) MASS (m/z) : 299 (M + +l) Prep a ion 53 Methyl 4- ( 4 ' -n-hexyloxyphenyl ) benzoate IR (KBr) : 2954, 2933, 2866, 1724 cm "1 NMR (DMSO-dg, δ) : 0.87 (3H, m) , 1.20-1.87 (8H, m) , 3.87 (3H, s), 4.02 (2H, m) , 7.04 (2H, d, J=8.7Hz), 7.68 (2H, d, J=8.7Hz), 7.78 (2H, d, J=8.4Hz), 8.00 (2H, d, J=8.4Hz) MASS (m/z) : 313 (M + +l) Preparation 54 Methyl 4- ( 4 ' -n-heptyloxyphenyl ) benzoate IR (KBr) : 2956, 2931, 2856, 1724 cm "1 NMR (DMSO-dg, δ) : 0.86 (3H, m) , 1.20-1.80 (10H, m) , 3.87 (3H, s) , 4.05 (2H, m) , 7.04 (2H, d, J=8.7Hz), 74 7 . 69 ( 2H, d, J=8 . 7Hz ) , 7 . 78 ( 2H, d, J=8 . 5Hz ) , 8 . 00 ( 2H, d, J=8 . 5Hz ) MASS (m/z) : 327 (M + +l) Preparation 55 A solution of methyl 4- [4 '-(3- bromopropoxy) phenyl] benzoate (1.5 g) , potassium carbonate (1.2 g) and cis-2, 6-dimethylmorpholine (990.6 mg) in N,N- dimethylformamide was stirred for 15 hours at room temperature, then diluted with ethyl acetate and washed with water (5x) , dried over magnesium sulfate, evaporated, then purified by silica gel chromatography (20:1 dichloromethane-ethanol elution) to give methyl 4- [4 ' - [3- (2, 6- dimethylmorpholino) propoxy] phenyl] benzoate (755 mg) . NMR (CDC1 3 , δ) : 1.18 (6H, d, J=6.3Hz), 1.70-1.90 (2H, m) , 2.00-2.14 (2H, m) , 2.50-2.65 (2H, m) , 2.82 (2H, d, J=llHz) , 3.74 (2H, br s) , 3.93 (3H, s) , 4.08 (2H, t, J=6.2Hz), 6.98 (2H, d, J=8.7Hz), 7.56 ("2H, d, J=8.7Hz), 7.61 (2H, d, J=8.3Hz), 8.08 (2H, d, J=8.3Hz) MASS (m/z) : 384 (M + ) The following compound was obtained in a manner similar to that of Preparation 55. Preparation 56 Methyl 4- [4 ' - [3- (piperizin-1-yl) propyloxy] phenyl] - benzoate IR (KBr) : 2933, 2852, 2771, 1718 cm "1 NMR (CDC1 3 , δ) : 1.47 (2H, m) , 1.64 (4H, m) , 2.04 (2H, tt, J=6.3 and 6.3Hz), 2.51 (6H, m) , 3.93 (3H, s) , 4.07 (2H, t, J=6.3Hz), 6.98 (2H, d, J=8.8Hz), 7.56 (2H, d, J=8.8Hz), 7.61 (2H, d, J=8.6Hz), 8.07 (2H, d, J=8.6Hz) MASS (m/z) : 354 (M + +l) Preparation 57 A mixture of N- [4- (4 ' -allyloxyphenyl) benzoyl] -N' - (4- methoxycarbonylbenzoyl) hydrazine (1.5 g) and phosphorus 75 oxychloride (15 ml) was heated to reflux for 6 hours, then cooled to room temperature and poured into ice-water, stirred for ~2 hours then filtered. The resulting solid was washed thoroughly with water and dried at 50 °C under vacuum to give methyl 4- [5- [4 ' - [4"-allyloxyphenyl] phenyl] -1, 3, 4- oxadiazol-2-yl]benzoate as a solid. IR (KBr) : 1720.2, 1650.8, 1284.4, 1255.4 cm "1 NMR (DMSO-dg, δ) : 3.98 (3H, s) , 4.61 (2H, d, J=5.3Hz), 5.30-5.50 (2H, m) , 6.03-6.17 (1H, m) , 7.04 (2H, d, J=8.8Hz), 7.61 (2H, d, J=8.8Hz), 7.74 (2H, d, J=8.5Hz), 8.20 (2H, d, J=8.5Hz), 8.23 (4H, s) MASS (m/z) : 413 (M + ) The following compounds [Preparations 58 to jό_8] were obtained in a manner similar to that of Preparation 57. Preparation 58 Methyl 4- [5- [4'- (4 "-methoxyphenyl) phenyl] -1, 3, 4- oxadiazol-2-yl] benzoate IR (KBr) : 1716 cm "1 NMR (CDC1 3 , δ) : 3.88 (3H, s) , 3.98 (3H, s) , 7.02 (2H, d, J=8.8Hz), 7.61 (2H, d, J=8.8Hz) MASS (m/z) : 387 (M + +l) Preparation 59 Methyl 4- [5- [4'- (4"-butyloxyphenyl) phenyl] -1, 3, 4- oxadiazol-2-yl] benzoate IR (KBr) : 2956, 2933, 2871, 1720 cm "1 NMR (CDC1 3 , δ) : 1.00 (3H, t, J=7.3Hz), 1.54 (2H, qt, J=7.3 and 7.0Hz), 1.82 (2H, tt, J=7.0 and 7.0Hz), 3.98 (3H, s), 4.03 (2H, t, J=7.0Hz), 7.00 (2H, d, J=8.7Hz), 7.60 (2H, d, J=8.7Hz), 7.73 (2H, d, J=8.4Hz), 8.22 (6H, ) MASS (m/z) : 429 (M + +l) Preparation 60 Methyl 4- [5- [4 '- ( 4 "-n-pentyloxyphenyl) phenyl] -1, 3, 4- oxadiazol-2-yl] benzoate IR (KBr) : 2956, 2931, 2870, 1720 cm "1 76 NMR (CDCI3, δ) : 0.995 (3H, t, J=7.0Hz) , 1.43 (4H, ) , 1.83 (2H, tt, J=7.0Hz) , 3.98 (3H, s), 4.02 (2H, t, J=7.0Hz), 7.00 (2H, d, J=8.7Hz), 7.60 (2H, d, J=8.7Hz), 7.73 (2H, d, J=8.4Hz), 8.23 (2H, m) MASS (m/z) : 443 (M + +l) Preparation 61 Methyl 4- [5- [4 '- ( "-n-hexyloxyphenyl) phenyl] -1, 3, 4- oxadiazol-2-yl] benzoate IR (KBr) : 2954, 2933, 2870, 1722 cm "1 NMR (CDCI3, δ) : 0.92 (3H, t, J=6.7Hz), 1.39 (6H, m) , 1.82 (2H, tt, J=6.9Hz), 3.98 (3H, s), 4.02 (2H, t, J=6.5Hz), 7.00 (2H, d, J=8.6Hz), 7.60 (2H, d, J=8.6Hz), 7.73 (2H, d, J=8.3Hz), 8.22 (6H, m) MASS (m/z) : 457 (M + +l) Preparation 62 Methyl 4- [5- [4'- (4"-n-heptyloxyphenyl) phenyl] -1, 3, 4- oxadiazol-2-yl] benzoate IR (KBr) : 2954, 2931, 2856, 1722 cm "1 NMR (CDCI3, δ) : 0.90 (3H, br) , 1.20-2.00 (10H, br) , 3.98 (3H, s), 4.02 (2H, br) , 7.00 (2H, d, J=7.6Hz), 7.59 (2H, d, J=7.6Hz), 7.73 (2H, d, J=6.8Hz), 8.20 (6H, m) MASS (m/z) : 471 (M + +l) Preparation 63 Methyl 4- [5- [ ' - [4"- [3- (piperizin-1- yl) propyloxy] phenyl] phenyl] -1,3, 4-oxadiazol-2-yl] benzoate IR (KBr) : 2931, 2852, 2804, 2769, 1720 cm "1 NMR (CDC1 3 , δ) : 1.51 (2H, m) , 1.74 (4H, m) , 2.14 (2H, m) , 2.64 (6H, m) , 3.98 (3H, s) , 4.10 (2H, t, J=6.2Hz) , 7.00 (2H, d, J=8.8Hz), 7.60 (2H, d, J=8.7Hz), 7.73 (2H, d, J=8.20Hz), 8.20 (2H, d, J=8.5Hz), 8.23 (4H, s) MASS (m/z) : 498 (M + +l) Preparation 64 Methyl 4- [5- (l-n-decylpyrazol-4-yl) -1, 3, 4-oxadiazol- 77 2-yl] benzoate NMR (CDC1 3 , δ) : 0.84-0.91 (3H, m) , 1.26-1.32 (14H, m) , 1.80-2.00 (2H, m) , 3.97 (3H, s) , 4.21 (2H, t, J=7.1Hz), 7.26 (IH, s) , 8.09 (IH, s), 8.26 (4H, s) MASS (m/z) : 411 (M + ) Preparation 65 Methyl 4- [5- [4 ' - [4"- (3-phenoxypropyloxy) - phenyl] phenyl] -1, 3, 4-oxadiazol-2-yl] benzoate IR (KBr) : 1718.3, 1600.6, 1490.7, 1280.5, 1245.8 cm "1 NMR (CDC1 3 , δ) : 2.26-2.35 (2H, m) , 3.98 (3H, s) , 4.16-4.27 (4H, m) , 6.91-7.05 (5H, m) , 7.26-7.33 (2H, m) , 7.60 (2H, d, J=8.7Hz), 7.73 (2H, d, J=8.4Hz), 8.20 (2H, d, J=8.4Hz) , 8.23 (4H, s) MASS (m/z) : 507 (M + ) Preparation 66 Methyl 4- [5- [4 ' - [4"- (4-phenoxybutyloxy) - phenyl] phenyl] -1, 3, 4-oxadiazol-2-yl] benzoate IR (KBr) : 1720.2, 1602.6 cm "1 NMR (CDC1 3 , δ) : 2.02 (4H, br s), 3.93 (3H, s) , 3.97- 4.06 (4H, m) , 6.83-7.04 (6H, m) , 7.26-7.33 (IH, m) , 7.60 (2H, d, J=8.7Hz), 7.89 (2H, d, J=8.7Hz), 8.18-8.23 (6H, m) MASS (m/z) : 521 (M + ) Preparation 67 Methyl 4- [5- [4 '- [4"- ( 8-methoxy-n-octyloxy) phenyl] - phenyl] -1, 3, 4-oxadiazol-2-yl] benzoate IR (KBr) : 1720.2 cm "1 NMR (CDC1 3 , δ) : 1.20-1.95 (12H, m) , 3.34 (3H, s) , 3.38 (2H, t, J=7Hz), 3.98 (3H, s) , 4.02 (2H, t, J=6.5Hz), 7.00 (2H, d, J=8.7Hz), 7.59 (2H, d, J=8.7Hz), 7.73 (2H, d, J=8.5Hz), 8.19 (2H, d, J=8.5Hz), 8.22 (4H, s) MASS (m/z) : 515 (M + ) Preparation 68 78 Methyl 4- [5- [4 ' - [4"- [3- (2, 6-dimethylmorphino) - propyloxy] phenyl] phenyl] -1, 3, 4-oxadiazol-2-yl]benzoate NMR (CDC1 3 , δ) : 1.26 (6H, d, J=6.3Hz), 2.32-2.60 (4H, m) , 3.15-3.30 (2H, m) , 3.43 (2H, d, J=ll.lHz), 3.98 (3H, s), 4.10-4.20 (2H, m) , 4.30-4.50 (2H, m) , 6.98 (2H, d, J=8.7Hz), 7.61 (2H, d, J=8.8Hz), 7.73 (2H, d, J=8.5Hz), 8.20 (2H, d, J=8.5Hz), 8.23 (4H, s) MASS (m/z) : 528 (M + ) The following compound was obtained in a manner similar to that of Preparation 9. Preparation 69 Methyl 4- [5- (l-n-decylpyrazol-4-yl) -1, 3, 4-thiadiazol- 2-yl]benzoate NMR (DMSO-dg, δ) : 0.84 (3H, br s) , 1.23 (14H, br s) , 1.70-1.90 (2H, m) , 3.90 (3H, s) , 4.15-4.23 (2H, m) , 8.09 (IH, s), 8.13 (4H, s), 8.58 (IH, s) MASS (m/z) : 427 (M + ) The following compound was obtained in a manner similar to that of Preparation 1. Preparation 70 Methyl 4- [4 ' - (3-bromopropyloxy) phenyl] benzoate NMR (DMSO-dg, δ) : 2.22-2.32 (2H, m) , 3.69 (2H, t, J=6.6Hz), 3.87 (3H, s) , 4.15 (2H, t, J=6Hz) , 7.08 (2H, d, J=8.8Hz), 7.71 (2H, d, J=8.7Hz), 7.79 (2H, d, J=8.5Hz), 8.01 (2H, d, J=8.4Hz) The following compound was obtained in a manner similar to that of Preparation 19. Preparation 71 1- (4-Cyclohexyloxybenzoyl) -3-thiosemicarbazide NMR (DMSO-dg, δ) : 1.32 (6H, m) , 1.71 (2H, m) , 1.91 (2H, m) , 4.45 (IH, ) , 7.00 (2H, d, J=8.8Hz), 7.57 (2H, s), 7.84 (2H, d, J=8.7Hz), 9.27 (IH, s) , 10.21 (IH, s) MASS (m/z) : 294 (M + +l) The following compound was obtained in a manner similar 79 to that of Preparation 21. Preparation 72 2-Amino-5- (4-cyclohexyloxyphenyl) -1, 3, 4-thiadiazole IR (KBr) : 3272.6, 3114.5, 2937.1, 2856.1, 1604.5, 1519.6, 1465.6 cm "1 NMR (DMSO-dg, δ) : 1.17-1.48 (6H, m) , 1.73 (2H, m) , 1.92 (2H, m) , 4.40 (IH, ) , 7.00 (2H, d, J=8.8Hz), 7.27 (2H, s), 7.64 (2H, d, J=8.8Hz) MASS (m/z) : 276 (M + +l) The following compound was obtained in a manner similar to that of Preparation 23. Preparation 73 4- [2- (4-Cyclohexyloxyphenyl) imidazo [2, 1-b] [1,3,4]- thiadiazol-6-yl] benzoic acid ethyl ester trifluoroacetate IR (KBr) : 2931.3, 2861.8, 1714.4, 1702.8, 1502.3, 1280.5, 1257.4 cm "1 MASS (m/z) : 448 (M + +l) The following compound was obtained in a manner similar to that of Preparation 25. Preparation 74 4- [2- (4-Cyclohexyloxyphenyl) imidazo [2, 1-b] [1,3,4]- thiadiazol-6-yl] benzoic acid IR (KBr) : 2931.3, 1679.7, 1606.4, 1473.3, 1421.3, 1290.1, 1249.6 cm "1 NMR (DMSO-dg, δ) : 1.43 (6H, m) , 1.74 (2H, m) , 1.94 (2H, m) , 4.50 (IH, m) , 7.14 (2H, d, J=8.8Hz), 7.88 (2H, d, J=8.8Hz), 8.00 (4H, s) , 8.86 (IH, s) MASS (m/z) : 420 (M + +l) The following compounds [Preparations 75 to j3_4 were obtained in a manner similar to that of Preparation 5. Preparation 75 4- (4' -Methoxyphenyl )benzoylhydrazine IR (KBr) : 3292, 3205, 1655, 1622 cm "1 NMR (CDC1 3 , δ) : 1.59 (2H, br) , 3.86 (3H, s) , 6.99 (2H, d, J=7.9Hz), 7.38 (IH, br), 7.55 (2H, d, 80 J=7 . 9Hz ) , 7 . 62 ( 2H, d, J=7 . 3Hz ) , 7 . 79 ( 2H, d, J=7 . 3Hz ) MASS (m/z) : 243 (M + +l) Preparation 76 4- ( 4 ' -Butyloxyphenyl ) benzoylhydrazine IR (KBr) : 3340, 3277, 3194, 2956, 2918, 2870, 1655, 1610 cm "1 NMR (CDC1 3 , δ) : 0.99 (3H, t, J=7.3Hz), 1.53 (4H, m) , 1.80 (2H, tt, J=6.4 and 6.4Hz) , 4.02 (2H, t, J=6.4Hz), 6.98 (2H, d, J=8.8Hz), 7.38 (IH, s), 7.54 (2H, d, J=8.8Hz), 7.62 (2H, d, J=8.4Hz), 7.79 (2H, d, J=8.4Hz) MASS (m/z) : 285 (M + +l) Preparation 77 4- (4 ' -n-Pentyloxyphenyl) benzoylhydrazine IR (KBr) : 3288, 3205, 3059, 2958, 2937, 2868, 1655, 1622, 1601 cm "1 NMR (CDCI3, δ) : 0.94 (3H, t, J=6.8Hz), 1.44 (4H, m) , 1.60 (2H, br) , 1.82 (2H, m) , 4.00 (2H, t, J=6.8Hz), 6.98 (2H, t, J=8.5Hz), 7.38 (IH, br) , 7.54 (2H, d, J=8.5Hz), 7.62 (2H, d, J=8.1Hz), 7.79 (2H, d, J=8.1Hz) MASS (m/z) : 299 (M + +l) Preparation 78 4- ( 4 ' -n-Hexyloxyphenyl ) benzoylhydrazine IR (KBr) : 3288, 3207, 3057, 2954, 2935, 2868, 1655, 1626, 1606 cm "1 NMR (CDCI3, δ) : 0.91 (3H, m) , 1.36 (6H, ) , 1.81 (2H, ) , 4.01 (2H, m) , 6.98 (2H, d, J=8.0Hz), 7.20 (IH, br), 7.54 (2H, d, J=8.0Hz), 7.62 (2H, d, J=7.9Hz), 7.78 (2H, d, J=7.9Hz) MASS (m/z) : 313 (M + +l) Preparation 79 4- (4 ' -n-Heptyloxyphenyl) benzoylhydrazine IR (KBr) : 3286, 3205, 3061, 2956, 2931, 2856, 1654, 81 1623, 1608 cm -1 NMR (CDC1 3 , δ) : 0.90 (3H, m) , 1.32 (8H, m) , 1.81 (2H, m) , 4.00 (2H, m) , 6.98 (2H, d, J=8.4Hz), 7.40 (IH, br), 7.52 (2H, d, J=8.4Hz), 7.64 (2H, d, J=8.4Hz), 7.77 (2H, d, J=8.4Hz) MASS (m/z) : 327 (M + +l) Preparation 80 4- [4 ' - [3- (Piperazin-1-yl) propyloxy] phenyl] - benzoylhydrazine IR (KBr) : 3275, 3105, 3041, 2956, 2933, 2870, 2852, 2814, 2767, 1643 cm -1 NMR (CDCI3, δ) : 1.47 (2H, m) , 1.63 (4H, m) , 2.03 (2H, tt, J=6.3Hz), 2.50 (6H, m) , 4.06 (2H, t, J=6.3Hz), 6.98 (2H, d, J=8.8Hz), 7.41 (IH, s) , 7.54 (2H, d, J=8.8Hz), 7.62 (2H, d, J=8.5Hz), 7.79 (2H, d, J=8.5Hz) MASS (m/z) : 354 (M + +l) Preparation 81 l-n-Decyl-4-pyrazolylcarbonylhydrazine NMR (DMSO-dg, δ) : 0.82-0.95 (3H, m) , 1.22 (14H, br s) , 1.62-1.81 (2H, m) , 4.08 (2H, t, J=6.9Hz), 4.29 (2H, d, J=4Hz), 7.82 (IH, s) , 8.12 (IH, s) , 9.28 (IH, br s) MASS (m/z) : 267 (M + ) Preparation 82 4- [ 4 ' - ( 3-Phenoxypropyloxy) phenyl ] benzoylhydrazine NMR (DMSO-dg, δ) : 2.16-2.26 (2H, m) , 4.11-4.23 (4H, m) , 4.54 (2H, s), 6.89-6.98 (3H, m) , 7.06 (2H, d, J=8.8Hz), 7.25-7.33 (2H, m) , 7.67 (2H, d, J=8.7Hz), 7.70 (2H, d, J=8.4Hz), 7.89 (2H, d, J=8.4Hz), 9.79 (IH, s) MASS (m/z) : 363 (M + ) Preparation 83 4- [4 ' -Allyloxyphenyl] benzoylhydrazine NMR (DMSO-dg, δ) : 4.51 (2H, s) , 4.60-4.65 (2H, m) , 82 5.25-5.47 (2H, m) , 5.98-6.17 (IH, m) , 7.06 (2H, d, J=8.8Hz) , 7.67 (2H, d, J=8.8Hz), 7.70 (2H, d, J=8.4Hz) , 7.89 (2H, d, J=8.4Hz) , 9.80 (IH, s) MASS (m/z) : 269 (M + ) Preparation 84 4- [4 ' - [3- (2, 6-Dimethylmorpholino) propyloxy] phenyl] - benzoylhydrazine NMR (DMSO-dg, δ) : 1.04 (6H, d, J=6.3Hz), 1.58 (2H, t, J=10.6Hz), 1.86-1.92 (2H, m) , 2.40 (2H, t, J=7Hz) , 2.75 (2H, d, J=10.2Hz), 3.51-3.58 (2H, m) , 4.05 (2H, t, J=6.2Hz), 4.50 (2H, s) , 7.02 (2H, d, J=8.8Hz), 7.64-7.71 (4H, m) , 7.88 (2H, d, J=8.4Hz), 9.79 (IH, s) MASS (m/z) : 384 (M + ) The following compounds [Preparations 85 to 9_6] were obtained in a manner similar to that of Preparation 7. Preparation 85 1- [ 4- ( 4 ' -Methoxyphenyl ) benzoyl ] -2- (4-methoxycarbonylbenzoyl) hydrazine IR (KBr) : 3228, 2956, 2840, 1720, 1680, 1655 cm "1 NMR (DMSO-d 6 , δ) : 3.82 (3H, s) , 3.90 (3H, s) , 7.06 (2H, d, J=8.8Hz), 7.72 (2H, d, J=8.8Hz), 7.79 (2H, d, J=8.5Hz), 8.00 (2H, d, J=8.5Hz), 8.05 (2H, d, J-8.7HZ), 8.11 (2H, d, J=8.7Hz), 10.60 (IH, s) , 10.72 (IH, s) MASS (m/z) : 405 (M + +l) Preparation 86 1- [4- (4 '-Butyloxyphenyl) benzoyl] -2- (4- methoxycarbonylbenzoyl ) hydrazine IR (KBr) : 3242, 3088, 3028, 2956, 2933, 2872, 1724, 1682, 1655, 1605 cm "1 NMR (DMSO-dg, δ) : 0.95 (3H, t, J=7.3Hz), 1.45 (2H, qt, J=7.3 and 6.4Hz), 1.73 (2H, tt, J=6.4 and 6.4Hz), 3.91 (3H, s), 4.03 (2H, t, J=6.4Hz), 7.05 (2H, d, J=8.8Hz), 7.70 (2H, d, J=8.8Hz), 7.90 (2H, d, 83 J=8.4Hz), 8.00 (2H, d, J=8.4Hz), 8.05 (2H, d, J=8.4Hz) , 8.05 (2H, d, J=8.7Hz), 8.11 (2H, d, J=8.7Hz) , 10.60 (IH, s) , 10.72 (IH, s) MASS (m/z) : 447 (M + +l) Preparation 87 1- [4- (4 '-Pentyloxyphenyl) benzoyl] -2- (4- methoxycarbonylbenzoyl ) hydrazine IR (KBr) : 3226, 3030, 2958, 2931, 2870, 1724, 1680, 1655, 1605 cm "1 NMR (DMSO-dg, δ) : 0.91 (3H, t, J=6.7Hz), 1.40 (4H, m) , 1.74 (2H, m) , 3.90 (3H, s) , 4.03 (2H, t, J=6.5Hz), 7.05 (2H, d, J=8.6Hz), 7.70 (2H, d, J=8.6Hz), 7.78 (2H, d, J=8.3Hz), 8.00 (2H, d, J=8.3Hz), 8.07 (2H, d, J=8.6Hz), 8.09 (2H, d, J=8.6Hz), 10.60 (IH, s) , 10.72 (IH, s) MASS (m/z) : 461 (M + +l) Preparation 88 1- [4- (4 ' -n-Hexyloxyphenyl) benzoyl] -2- (4- methoxycarbonylbenzoyl ) hydrazine IR (KBr) : 3242, 3219, 3091, 3028, 2956, 2933, 2866, 1724, 1680, 1655, 1605 cm "1 NMR (DMSO-dg, δ) : 0.89 (3H, t, J=6.2Hz), 1.35 (6H, m) , 1.74 (2H, m) , 3.90 (3H, s) , 4.03 (2H, t, J=6.9Hz), 7.05 (2H, d, J=8.7Hz), 7.70 (2H, d, J=8.7Hz), 7.79 (2H, d, J=8.3Hz), 8.00 (2H, d, J=8.3Hz), 8.06 (2H, d, J=8.6Hz), 8.10 (2H, d, J=8.6Hz), 10.60 (IH, s) , 10.72 (IH, s) MASS (m/z) : 475 (M + +l) Preparation 89 1- [4- (4 '-n-Heptyloxyphenyl) benzoyl] -2- (4- methoxycarbonylbenzoyl ) hydrazine IR (KBr) : 3219, 3091, 3029, 2956, 2931, 2856, 1722, 1679, 1652, 1604 cm "1 NMR (DMSO-dg, δ) ■ : 0.88 (3H, br) , 1.29 (8H, br) , 1.75 (2H, br) , 3.90 (3H, s) , 4.02 (2H, br) , 7.03 (2H, d, 84 J=8.4Hz), 7.70 (2H, d, J=8.4Hz), 7.80 (2H, d, J=8.8Hz), 8.00 (2H, d, J=8.8Hz), 8.45 (2H, br) MASS (m/z) : 489 (M + +l) Preparation 90 1- [4- [4 '- [3- (Piperidin-1-yl) propyloxy] phenyl] - benzoyl ] -2- (4-methoxycarbonylbenzoyl ) hydrazine IR (KBr) : 3061, 3026, 2933, 2852, 2805, 2771, 2391, 1724 cm "1 NMR (DMSO-dg, δ) : 1.49 (6H, m) , 1.88 (2H, tt, J=6.2 and 6.2Hz), 2.36 (6H, m) , 3.90 (3H, s) , 4.06 (2H, t, J=6.2Hz), 7.05 (2H, d, J=8.7Hz), 7.70 (2H, d, J=8.7Hz), 7.78 (2H, d, J=8.4Hz), 8.00 (2H, d, J=8.4Hz), 8.05 (2H, d, J=8.5Hz), 8.11 (2H, d, J=8.5Hz), 10.6 (IH, s) MASS (m/z) : 516 (M + +l) Preparation 91 N- (4-Methoxycarbonylbenzoyl) -N' - (l-n-decyl-4- pyrazolylcarbonyl ) hydrazine NMR (DMSO-dg, δ) : 0.82-0.89 (3H, m) , 1.24 (14H, br s) , 1.70-1.90 (2H, m) , 3.90 (3H, s) , 4.14 (2H, t, J=7Hz) , 7.95 (IH, s), 8.02 (2H, d, J=8.5Hz), 8.10 (2H, d, J=8.5Hz), 8.28 (IH, s) , 10.18 (IH, s) , 10.50 (IH, s) MASS (m/z) : 429 (M + ) Preparation 92 N- [4- [4 ' - (3-Phenoxypropyloxy) phenyl] benzoyl] -N 1 - (4- methoxycarbonylbenzoyl ) hydrazine IR (KBr) : 3210.9, 1724.0, 1650.8, 1602.6, 1560.1, 1523.5, 1502.3, 1469.5, 1432.9, 1284.4, 1247.7 cm "1 NMR (DMSO-dg, δ) : 2.18-2.24 (2H, m) , 3.90 (3H, s) , 4.13-4.21 (4H, m) , 6.95-6.99 (3H, m) , 7.09 (2H, d, J=7.9Hz), 7.25-7.33 (2H, m) , 7.69-7.81 (4H, m) , 7.98-8.09 (6H, m) , 10.61 (IH, s) , 10.73 (IH, s) MASS (m/z) : 525 (M + ) 85 Preparation 93 N- [4- (4 '-Allyloxyphenyl) benzoyl] -N 1 - (4- methoxycarbonylbenzoyl ) hydrazine IR (KBr) : 3228.3, 3023.8, 1724.0, 1679.7, 1654.6, 1604.5, 1554.3, 1513.8, 1492.6, 1434.8 cm "1 NMR (DMSO-dg, δ) : 3.90 (3H, s) , 4.64 (2H, d, J=5.1Hz), 5.26-5.47 (2H, ) , 5.98-6.17 (IH, m) , 7.08 (2H, d, J=8.7Hz), 7.72 (2H, d, J=8.7Hz), 7.80 (2H, d, J=8.4Hz), 8.00 (2H, d, J=8.5Hz), 8.05 (2H, d, J=8.6Hz), 8.11 (2H, d, J=8.6Hz), 10.60 (IH, s) , 10.72 (IH, s) MASS (m/z) : 431 (M + ) Preparation 94 N- [4- [4 '- (4-Phenoxybutyloxy) phenyl] benzoyl] -N 1 - (4- methoxycarbonylbenzoyl) hydrazine IR (KBr) : 3228.3, 1724.0, 1679.7, 1654.6, 1602.6 cm "1 NMR (DMSO-dg, δ) : 1.90 (4H, br s) , 3.90 (3H, s) , 4.05-4.11 (4H, m) , 6.88-6.96 (3H, m) , 7.05-7.09 (2H, ) , 7.25-7.28 (2H, m) , 7.69-8.09 (10H, m) , 10.60 (IH, s), 10.72 (IH, s) Preparation 95 N- [4- [4 ' - [3- (2, 6-Dimethylmorpholino) propyloxy] - phenyl] benzoyl] -N'- (4-methoxycarbonylbenzoyl) hydrazine IR (KBr) : 1720.2, 1681.6, 1645.0, 1604.5 cm "1 NMR (DMSO-dg, δ) : 1.05 (6H, d, J=6.3Hz), 1.53-1.64 (2H, m) , 1.87-1.93 (2H, m) , 2.41 (2H, t, J=7.1Hz), 2.76 (2H, d, J=10.4Hz), 3.52-3.59 (2H, m) , 3.90 (3H, s), 4.00-4.10 (2H, m) , 7.05 (2H, d, J=8.7Hz), 7.71 (2H, d, J=8.7Hz), 7.79 (2H, d, J=8.4Hz), 8.00 (2H, d, J=8.6Hz), 8.02-8.13 (4H, m) , 10.60 (IH, s) , 10.72 (IH, s) MASS (m/z) : 546 (M + ) Preparation 96 N- [6- (1-Piperidyl) nicotinoyl] -N 1 - (4-methoxycarbonyl- 86 benzoyl ) hydrazine IR (KBr) : 3240, 2933, 2852, 1724, 1686, 1643, 1603, 1547, 1497, 1437 cm "1 NMR (DMSO-dg, δ) : 1.4-1.7 (6H, m) , 3.6-3.7 (4H, m) , 3.90 (3H, s), 6.92 (IH, d, J=9.0Hz), 7.9-8.2 (5H, m) , 8.65 (IH, s) , 10.34 (IH, s), 10.62 (IH, s) MASS (m/z) : 383 (M++1) The following compounds [Preparations 97 to 1081 were obtained in a manner similar to that of Preparation 11. Preparation 97 4- [5- [4 '- [4"- (8-Methoxy-n-octyloxy) phenyl] phenyl] - 1, 3, 4-oxadiazol-2-yl]benzoic acid NMR (DMSO-dg, δ) : 1.20-1.60 (10H, m) , 1.60-1.80 (2H, m) , 3.21 (3H, s) , 3.25-3.50 (3H, m) , 3.90-4.10 (2H, m) , 6.95-7.10 (2H, m) , 7.50-7.80 (4H, ) , 7.80-8.00 (2H, m) , 8.10-8.30 (4H, m) MASS (m/z) : 501 (M + ) Preparation 98 4- [5- [4 ' - (4 "-Methoxyphenyl) phenyl] -1,3, 4-oxadiazol-2- yl] benzoic acid IR (KBr) : 2960, 2904, 2839, 2675, 2543, 1684, 1604 cm "1 NMR (DMSO-dg, δ) : 3.83 (3H, s) , 7.08 (2H, d, J=8.5Hz), 7.91 (2H, d, J=8.5Hz), 8.17 (2H, d, J=8.5Hz), 8.20 (2H, d, J=8.5Hz), 8.28 (2H, d, J=8.5Hz) MASS (m/z) : 373 (M + +l) Preparation 99 4- [5- [4 ' - (4"-Butyloxyphenyl) phenyl] -1, 3, 4-oxadiazol- 2-yl]benzoic acid IR (KBr) : 2958, 2935, 2871, 1687 cm "1 NMR (DMSO-dg, δ) : 0.95 (3H, t, J=7.3Hz), 1.46 (2H, qt, J=7.3 and 7.5Hz), 1.73 (2H, tt, J=7.5 and 6.3Hz), 4.04 (2H, t, J=6.3Hz), 7.07 (2H, d, J=8.9Hz), 7.75 (2H, d, J=8.9Hz), 7.91 (2H, d, J=8.4Hz), 8.16 (2H, d, J=8.3Hz), 8.20 (2H, d, J=8.3Hz), 8.28 (2H, d. J=8.4Hz) MASS (m/z) : 415 (M + +l) Preparation 100 4- [5- [4 ' - ( 4 "-Pentyloxyphenyl) phenyl] -1, 3, 4-oxadiazol- 2-yl]benzoic acid IR (KBr) : 2958, 2933, 2865, 2673, 2546, 1685 cm -1 NMR (DMSO-dg, δ) : 0.91 (3H, t, J=7.0Hz), 1.40 (4H, m) , 1.75 (2H, tt, J=6.6 and 6.6Hz), 4.04 (2H, t, J=6.6Hz), 7.07 (3H, d, J=8.8Hz), 7.74 (2H, d, J=8.8Hz), 7.91 (2H, d, J=8.5Hz), 8.15 (2H, d, J=8.4Hz), 8.20 (2H, d, J=8.1Hz), 8.27 (2H, d, J=8.5Hz) MASS (m/z) : 429 (M + +l) Preparation 101 4- [5- [4 '- ( 4 "-Hexyloxyphenyl) phenyl] -1, 3, 4-oxadiazol- 2-yl]benzoic acid IR (KBr) : 2954, 2933, 2864, 2675, 2546, 1686 cm "1 NMR (DMSO-dg, δ) : 0.89 (3H, t, J=6.8Hz), 1.30 (6H, m) , 1.74 (2H, tt, J=7.7 and 6.4Hz) , 4.04 (2H, t, J=6.4Hz), 7.07 (2H, d, J=8.8Hz), 7.74 (2H, d, J=8.8Hz), 7.91 (2H, d, J=8.0Hz), 8.16 (2H, d, J=8.6Hz), 8.20 (2H, d, J=8.0Hz), 8.27 (2H, d, J=8.6Hz) MASS (m/z) : 433 (M + +l) Preparation 102 4- [5- [4'- ( 4 "-n-Heptyloxyphenyl) phenyl] -1,3,4- oxadiazol-2-yl]benzoic acid IR (KBr) : 2956, 2931, 2856, 2671, 2545, 1686 cm "1 MASS (m/z) : 457 (M + +l) Preparation 103 4- [5- (l-n-Decylpyrazol-4-yl) -1, 3, 4-oxadiazol-2-yl] - benzoic acid NMR (DMSO-dg, δ) : 0.75-0.95 (3H, m) , 1.23 (14H, br s) , 1.83 (2H, br s) , 3.33 (IH, br s, C0 2 H) , 4.22 (2H, t, J=6.8Hz), 8.14 (IH, s) , 8.17 (4H, s) , 8.65 (IH, s) 88 MASS (m/z) : 397 (M + ) Preparation 104 4- [5- [l-n-Decylpyrazol-4-yl] -1, 3, 4-thiadiazol-2-yl] - benzoic acid NMR (DMSO-dg, δ) : 0.80-0.90 (3H, m) , 1.23 (14H, br s), 1.70-1.90 (2H, m) , 3.34 (IH, br s) , 4.19 (2H, t, J=6.9Hz), 8.08 (IH, s) , 8.10 (4H, s) , 8.58 (IH, s) Preparation 105 4- [5- [4 '- [4"- (3-Phenoxypropyloxy) phenyl] phenyl] - 1, 3, 4-oxadiazol-2-yl] benzoic acid IR (KBr) : 1685.5, 1602.6, 1548.6, 1490.7, 1469.5, 1429.0, 1400.1, 1290.1, 1249.6 cm "1 NMR (DMSO-dg, δ) : 2.18-2.24 (2H, m) , 4.13-4.25 (4H, m) , 6.90-6.99 (3H, m) , 7.11 (2H, d, J=8.8Hz), 7.26-7.33 (2H, m) , 7.75 (2H, d, J=8.7Hz), 7.91 (2H, d, J=8.5Hz) , 8.15-8.30 (6H, m) , 13.20-13.60 (IH, br) MASS (m/z) : 493 (M + ) Preparati n 106 4- [5- [4 '- [4 "-Allyloxyphenyl] phenyl] -1, 3, 4-oxadiazol- 2-yl]benzoic acid IR (KBr) : 1685.5, 1652.7, 1604.5, 1577.5, 1548.6, 1488.8, 1429.0, 1288.2, 1253.5, 823.5 cm "1 NMR (DMSO-dg, δ) : 4.65 (2H, d, J=5Hz) , 5.27-5.48 (2H, ) , 5.99-6.15 (IH, ) , 7.10 (2H, d, J=8.7Hz), 7.75 (2H, d, J=8.6Hz), 7.91 (2H, d, J=8.3Hz), 8.15-8.30 (6H, m) , 12.38 (IH, br s) MASS (m/z) : 399 (M + ) Preparation 107 4- [5- [4'- [4"- (4-Phenoxybutyloxy) phenyl] phenyl ]-l, 3,4- oxadiazol-2-yl]benzoic acid IR (KBr) : 1733.7, 1697.1, 1650.8, 1602.6 cm "1 NMR (DMSO-dg, δ) : 1.91 (4H, br s), 3.33 (IH, br s) , 4.05-4.12 (4H, m) , 6.88-6.96 (2H, m) , 7.07-7.11 (2H, m) , 7.25-7.28 (2H, m) , 7.66-8.00 (5H, m) , 8.14-8.36 (6H, m) 89 Preparation 108 4- [ 5- [ 4 ' - [ 4 "- [ 3- (2 , 6-Dimethylmorpholino ) propyloxy] - phenyl] phenyl] -1, 3, 4-oxadiazol-2-yl] benzoic acid MASS (m/z) : 514 (M + ) The following compounds [Preparations 109 to 1231 were obtained in a manner similar to that of Preparation 13. Preparation 109 4- [5- [4'- ( 4 "-Methoxyphenyl) phenyl] -1, 3, 4-oxadiazol-2- yl]benzoic acid benzotriazol-1-yl ester IR (KBr) : 1782 cm "1 NMR (CDC1 3 , δ) : 3.89 (3H, s) , 7.03 (2H, d, J=8.7Hz), 7.53 (3H, m) , 7.62 (2H, d, J=8.7Hz), 7.76 (2H, d, J=8.4Hz), 8.13 (IH, d, J=8.2Hz), 8.23 (2H, d, J=8.4Hz), 8.41 (2H, d, J=8.4Hz), 8.48 (2H, d, J=8.7Hz) MASS (m/z) : 490 (M + +l) Preparation 110 4- [5- [4 ' - (4 "-Butyloxyphenyl) phenyl] -1, 3, -oxadiazol- 2-yl] benzoic acid benzotriazol-1-yl ester IR (KBr) : 2956, 2933, 2872, 1776 cm "1 NMR (CDCI3, δ) : 1.00 (3H, t, J=7.3Hz), 1.52 (2H, qt, J=7.3 and 6.4Hz), 1.79 (2H, tt, J=6.4 and 6.4Hz), 4.04 (2H, t, J=6.4Hz), 7.02 (2H, d, J=8.7Hz), 7.45-7.57 (3H, m) , 7.61 (2H, d, J=8.7Hz), 7.76 (2H, d, J=8.4Hz), 8.14 (IH, d, J=8.2Hz), 8.22 (2H, d, J=8.4Hz), 8.40 (2H, d, J=8.7Hz), 8.47 (2H, d, J=8.7Hz) MASS (m/z) : 532 (M + +l) Preparation 111 4- [ 5- [ 4 * - ( 4"-n-Pentyloxyphenyl ) phenyl ] -1, 3, 4- oxadiazol-2-yl] benzoic acid benzotriazol-1-yl ester IR (KBr) : 2956, 2935, 2868, 1779 cm "1 NMR (CDCI3, δ) : 0.95 (3H, t, J=6.9Hz), 1.44 (4H, m) , 1.77 (2H, ) , 4.03 (2H, t, J=6.5Hz), 7.02 (2H, d, J=8.7Hz), 7.45-7.57 (3H, m) , 7.60 (2H, d, J=8.7Hz), 90 7.75 (2H, d, J=8.4Hz), 8.14 (IH, d, J=8.2Hz), 8.22 (2H, d, J=8.4Hz), 8.22 (2H, d, J=8.4Hz) , 8.40 (2H, d, J=8.7Hz), 8.47 (2H, d, J=8.7Hz) MASS (m/z) : 546 (M + +l) Preparati n 112 4- [5- [4 '- ( 4 "-n-Hexyloxyphenyl) phenyl] -1, 3, 4- oxadiazol-2-yl]benzoic acid benzotriazol-1-yl ester IR (KBr) : 2953, 2931, 2866, 1776 cm "1 NMR (CDC1 3 , δ) : 0.92 (3H, t, J=6.7Hz), 1.36-1.49 (6H, m) , 1.82 (2H, m) , 4.03 (2H, t, J=6.5Hz), 7.02 (2H, d, J=8.8Hz), 7.45-7.57 (3H, ) , 7.61 (2H, d, J=8.8Hz), 7.76 (2H, d, J=8.4Hz), 8.14 (2H, d, J=8.2Hz), 8.22 (2H, d, J=8.4Hz), 8.41 (2H, d, J=8.8Hz), 8.48 (2H, d, J=8.8Hz) MASS (m/z) : 560 (M + +l) Preparation 113 4- [5- [4 '- ( 4 "-n-Heptyloxyphenyl) phenyl] -1, 3, 4- oxadiazol-2-yl] benzoic acid benzotriazol-1-yl ester IR (KBr) : 2954, 2929, 2856, 1776 cm "1 NMR (CDCI3, δ) : 0.91 (3H, m) , 1.34 (8H, m) , 1.75 (2H, m) , 4.03 (2H, t, J=6.5Hz), 7.02 (2H, t, J=8.7Hz), 7.47-7.57 (3H, m) , 7.61 (2H, d, J=8.7Hz), 7.76 (2H, d, J=8.3Hz), 8.14 (IH, d, J=8.2Hz), 8.22 (2H, d, J=8.3Hz), 8.41 (2H, d, J=8.5Hz), 8.48 (2H, d, J-8.5HZ) MASS (m/z) : 574 (M + +l) Preparation 114 4- [5- (l-n-Decylpyrazol-4-yl) -1,3, 4-oxadiazol-2-yl] - benzoic acid benzotriazol-1-yl ester IR (KBr) : 1783.8, 1623.8, 1234.2, 989.3 cm -1 NMR (CDCI3, δ) : 0.84-0.91 (3H, m) , 1.26-1.34 (14H, m) , 1.80-2.00 (2H, m) , 4.23 (2H, t, J=7.1Hz), 7.44-7.63 (3H, m) , 8.11-8.15 (3H, m) , 8.35 (2H, d, J=8.7Hz), 8.45 (2H, d, J=8.7Hz) MASS (m/z) : 514 (M + ) 91 Preparation 115 4- [5- (l-n-Decylpyrazol-4-yl) -1, 3, 4-thiadiazol-2-yl] - benzoic acid benzotriazol-1-yl ester IR (KBr) : 1776.1, 1575.6, 1234.2, 983.5 cm "1 NMR (CDC1 3 , δ) : 0.84-0.91 (3H, m) , 1.26-1.34 (14H, m) , 1.94 (2H, br s) , 4.21 (2H, t, J=7.1Hz), 7.43-7.63 (3H, m) , 7.99 (IH, s), 8.09 (IH, s) , 8.10-8.15 (IH, m) , 8.22 (2H, d, J=8.5Hz), 8.40 (2H, d, J=8.5Hz) MASS (m/z) : 530 (M + ) Preparation 116 4- [5- [4 '- [4"- (3-Phenoxypropyloxy) phenyl] phenyl] - 1, 3, 4-oxadiazol-2-yl]benzoic acid benzotriazol-1-yl ester IR (KBr) : 1778.0, 1602.6, 1490.7, 1471.4, 1238.1 cm "1 NMR (CDCI3, δ) : 2.27-2.34 (2H, m) , 4.16-4.26 (4H, m) , 6.91-7.05 (5H, m) , 7.26-7.33 (2H, m) , 7.44-7.62 (5H, ) , 7.74 (2H, d, J=7.9Hz), 8.13 (IH, d, J=β.5Hz), 8.21 (2H, d, J=7.9Hz), 8.37-8.48 (4H, m) MASS (m/z) : 610 (M + ) preparation 117 4- [ 5- [ 4 ' - [ 4 "-Allyloxyphenyl ] phenyl ] -1 , 3, 4-oxadiazol- 2-yl]benzoic acid benzotriazol-1-yl ester IR (KBr) : 1776.1, 1602.6, 1488.9, 1232.3 cm "1 NMR (CDCI3, δ) : 4.61 (2H, d, J=5.2Hz), 5.30-5.50 (2H, m) , 6.00-6.19 (IH, m) , 7.04 (2H, d, J=8.7Hz), 7.44-7.63 (4H, ) , 7.75 (2H, d, J=8.4Hz), 8.11-8.30 (4H, m) , 8.38-8.49 (4H, m) MASS (m/z) : 516 (M + ) Preparation 118 4-[5-[4'-[4"- (4-Phenoxybutyloxy) phenyl] phenyl] -1, 3, 4- oxadiazol-2-yl]benzoic acid benzotriazol-1-yl ester IR (KBr) : 1776.1 cm "1 NMR (CDCI3, δ) : 2.02 (4H, br s) , 4.06-4.11 (4H, m) , 6.83-7.04 (5H, m) , 7.26-7.33 (IH, m) , 7.48-7.63 (6H, m) , 7.76 (2H, d, J=8.4Hz), 8.14 (IH, d, J=8.2Hz), 92 8 . 22 ( 2H, d, J=8 . 3Hz ) , 8 . 41 ( 2H, d, J=8 . 7Hz ) , 8 . 48 ( 2H, d, J=8 . 7Hz ) MASS (m/z) : 624 (M + ) Preparation 119 4- [ 5- [ * - [ "- ( 8-Methoxy-n-octyloxy) phenyl ] phenyl ] - 1, 3, 4-oxadiazol-2-yl]benzoic acid benzotriazol-1-yl ester IR (KBr) : 2931.3, 2856.1, 1776.1 cm "1 NMR (CDC1 3 , δ) : 1.30-1.70 (10H, m) , 1.70-1.90 (2H, m) , 3.34 (3H, s), 3.38 (2H, t, J=6.4Hz), 4.02 (2H, t, J=6.5Hz), 7.02 (2H, d, J=8.7Hz), 7.45-7.63 (5H, m) , 7.76 (2H, d, J=8.5Hz), 8.12-8.31 (3H, m) , 8.41 (2H, d, J=8.8Hz), 8.48 (2H, d, J=8.8Hz) MASS (m/z) : 618 (M + ) Preparation 120 4- [5- [4 ' - (4-Phenoxybutyloxy) phenyl] -1, 3, 4-thiadiazol- 2-yl]benzoic acid benzotriazol-1-yl ester IR (KBr) : 3058.5, 2956.3, 2873.4, 1778.0, 1602.6, 1236.1 cm "1 NMR (CDCI3, δ) : 2.0-2.1 (4H, m) , 4.0-4.2 (4H, m) , 6.9-7.0 (3H, m) , 7.03 (2H, d, J=8.8Hz), 7.3-7.4 (2H, m) , 7.4-7.6 (3H, ) , 7.99 (2H, d, J=8.8Hz) , 8.13 (IH, d, J=8.2Hz), 8.25 (2H, d, J=8.6Hz), 8.42 (2H, d, J=8.6Hz) MASS (m/z) : 564 (M + +l) Preparat n 121 4- [5- [4 '- (5-Phenoxy-n-pentyloxy) phenyl ]-l, 3, 4- thiadiazol-2-yl]benzoic acid benzotriazol-1-yl ester IR (KBr) : 2946.7, 2871.5, 1785.8, 1600.6, 1255.4, 1234.2 cm "1 NMR (CDCI3, δ) : 1.5-2.1 (6H, m) , 3.9-4.2 (4H, m) , 6.8-7.1 (5H, m) , 7.2-7.4 (2H, m) , 7.4-7.7 (3H, m) , 7.98 (2H, d, J=8.8Hz), 8.13 (IH, d, J=8.2Hz), 8.25 (2H, d, J=8.6Hz), 8.41 (2H, d, J=8.6Hz) MASS (m/z) : 578 (M + +l) Preparation 122 93 4- [5- [4 ' - (5-Methoxy-n-pentyloxy) phenyl] -1,3,4- thiadiazol-2-yl]benzoic acid benzotriazol-1-yl ester NMR (CDC1 3 , δ) : 1.5-2.1 (6H, m) , 3.54 (3H, s), 3.43 (2H, t, J=6.1Hz), 4.06 (2H, t, J=6.3Hz), 7.02 (2H, d, J=8.8Hz), 7.4-7.7 (3H, m) , 7.98 (2H, d, J=8.8Hz), 8.13 (IH, d, J=8.2Hz), 8.25 (2H, d, J=8.5Hz), 8.41 (2H, d, J=8.5Hz) MASS (m/z) : 516 (M + +l) Preparation 123 4-Cyclohexyloxybenzoic acid benzotriazol-1-yl ester IR (KBr) : 2939, 2854.1, 1776.1, 1602.6, 1508.1 cm "1 NMR (CDCI3, δ) : 1.25-1.67 (6H, m) , 1.85 (2H, m) , 2.01 (2H, m) , 4.43 (IH, m) , 7.03 (2H, d, J=7.0Hz), 7.38-7.54 (3H, m) , 8.08 (IH, d, J=8.2Hz), 8.19 (2H, d, J=7.0Hz) MASS (m/z) : 338 (M + +l) Preparation 124 To a solution of 4-methoxybenzoic acid benzotriazol-1-yl ester (80 g) in N, N-dimethylformamide (700 ml) was added thiosemicarbazide (28 g) and the mixture was stirred for 23 hours at ambient temperature. The reaction mixture was pulverized with diisopropyl ether. The precipitate was collected by filtration to give 1- (4-methoxybenzoyl) -3- thiosemicarbazide (57 g) . Preparation 125 To a slurry of 1- (4-methoxybenzoyl) -3-thiosemicarbazide (57 g) in toluene (300 ml) , was added methanesulfonic acid (25 ml) dropwise over 30 minutes at 40°C. The mixture was stirred under refluxing for 24 hours. After cooling to 10°C, the sulfonate salt was filtered and dried. The salt was placed in water, and the solution was adjusted to pH 9 with IN sodium hydroxide and extracted with ethyl acetate. The organic layer was separated, washed with brine, dried over magnesium sulfate and evaporated under reduced pressure to give 2-amino-5- (4-methoxyphenyl) -1, 3, 4-thiadiazole (31.1 g) . 94 IR (KBr) : 3251, 3114.5, 1610.3, 1525 cm "1 NMR (DMSO-dg, δ) : 3.80 (3H, s) , 7.00 (2H, d, J=8.5Hz), 7.28 (2H, s), 7.69 (2H, d, J=8.5Hz) MASS (m/z) : 208 (M+H + ) Preparation 126 A mixture of 4-bromobenzenethiol (6 g) , 1,7- dibromoheptane (16.37 g) , and potassium carbonate (8.77 g) in dimethylformamide (30 ml) was stirred at room temperature for 5.5 hours . The reaction mixture was pulverized with water and extracted with ethyl acetate. The organic layer was separated, washed with brine, dried over magnesium sulfate and evaporated under reduced pressure to give l-bromo-4- (7- bromoheptylthio) benzene (7.62 g) . IR (KBr) : 1465.6, 1089.6, 800.3 cm "1 NMR (CDC1 3 , δ) : 1.37-1.88 (10H, m) , 2.89 (2H, t, J=7.2Hz) , 3.40 (2H, t, J=6.8Hz), 7.14-7.21 (2H, m) , 7.36-7.43 (2H, m) Preparation 127 To a solution of l-bromo-4- (7-bromoheptylthio) benzene (5 g) in methanol (25 ml) was added 28% sodium methylate in methanol (7.9 g) and the mixture was stirred under refluxing for 2 hours . The reaction mixture was evaporated under reduced pressure. The residue was adjusted to pH 2 with dilute HCl aq. and extracted with ethyl acetate. The organic layer was separated, washed with brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with n- hexane/ethyl acetate (50:1) to give l-bromo-4- (7- methoxyheptylthio) benzene (3.59 g) . IR (KBr) : 1471.4, 1118.5, 1093.4 cm "1 NMR (CDCI3, δ) : 1.30-1.67 (10H, m) , 2.88 (2H, t, J=7.3Hz) , 3.33 (3H, s), 3.36 (2H, t, J=6.2Hz), 7.13-7.20 (2H, m) , 7.35-7.42 (2H, m) MASS (m/z) : 317.1 95 Preparation 128 To a solution of 4- (4-chlorophenyl) -4-hydroxypiperidine (5.0 g) in dichloromethane (50 ml) was added di-tert-butyl dicarbonate (5.7 g) . After stirring for 5 hours at room temperature, the solvent was evaporated in vacuo and the residue was poured into a mixture of ethyl acetate and water. The organic layer was successively washed with brine and dried over magnesium sulfate. The solvent was evaporated in vacuo and the residue was purified by column chromatography on silica gel eluting with a mixture of hexane and ethyl acetate (3:1) . The eluted fractions containing the desired product were collected and evaporated in vacuo to give 1-tert- butoxycarbonyl-4- (4-chlorophenyl) -4-hydroxypiperidine (7.58 g) . IR (Film) : 2976, 2926, 1668 cm" 1 NMR (CDC1 3 , δ) : 1.47 (9H, s) , 1.6-1.8 (3H, m) , 1.9-2.1 (2H, m) , 3.1-3.3 (2H, m) , 3.9-4.1 (2H, m) , T.2-7.5 (4H, m) (+) APCI MS : 212 (M+H)+-101 Preparation 129 To a solution of l-tert-butoxycarbonyl-4- (4- chlorophenyl) -4-hydroxypiperidine (1.0 g) in N,N-dimethyl formamide (10 ml) was added sodium hydride (0.14 g) under ice cooling. Then the reaction mixture was stirred for 30 minutes at room temperature and for 2 hours at 60°C. To the reaction mixture was added iodomethane (4.0ml) at 60°C. After stirring for 6 hours at 60 °C, the reaction mixture was poured into a mixture of ethyl acetate and water. The organic layer was successively washed with brine and dried over magnesium sulfate. The solvent was evaporated in vacuo and the residue was purified by column chromatography on silica gel eluting with a mixture of hexane and ethyl acetate (10:1) . The eluted fractions containing the desired product were collected and evaporated in vacuo to give l-tert-butoxycarbonyl-4- (4- chlorophenyl) -4-methoxypiperidine (0.75 g) . 96 IR (Film) : 2976, 2935, 1680 cm "1 NMR (CDC1 3 , δ) : 1.47 (9H, s) , 1.7-2.1 (4H, m) , 2.97 (3H, s), 3.0-3.3 (2H, m) , 3.9-4.1 (2H, m) , 7.2-7.4 (4H, ) (+) APCI MS : 226 (M+H)+-101 Preparation 130 To a solution of 2-indanol (4 g) and triethylamine (5.8 ml) in dichloromethane (40 ml) was added dropwise with stirring methanesulfonylchloride (2.8 ml) in an ice-bath. The mixture was then stirred for 1.5 hours . The reaction mixture was added to a mixture of water and dichloromethane. The organic layer was taken and dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was concentrated under reduced pressure to give methanesulfonic acid indan- 2-yl ester (6.29 g) . IR (KBr) : 3029.6, 1328.7, 1162.9 cm" 1 NMR (CDCI3, δ) : 3.02 (3H, s) , 3.19-3.44 (4H, m) , 5.48-5.58 (IH, m) , 7.18-7.28 (4H, m) MASS (m/z) : 119.2 (M-OMs+1) preparation 131 To a solution of 4- (5-amino-l, 3, 4-thiadiazol-2- yl)benzoic acid methyl ester trifluoroacetic acid salt (8 g) in water was added IN sodium hydroxide and the mixture was adjusted to pH 8. The precipitate was collected by filtration to give 4- (5-amino-l, 3, 4-thiadiazol-2-yl) benzoic acid (5.05 g ) . Preparation 132 A mixture of 1- (4-nitrophenyl) -lH-pyrazol-4-carboxylic acid methyl ester (19.44 g) , Fe powder, NH4CI, methanol and H 2 0 was heated for 30 minutes at 80°C and 3 hours at 100°C. The reaction mixture was concentrated by evaporation, added into dichloromethane, and was filtered. The filtrate was extracted with water, dried over magnesium sulfate and concentrated by evaporation to give 1- (4-aminophenyl) -1H- pyrazol-4-carboxylic acid methyl ester (9.84 g) . 97 IR (KBr) : 1701, 1521, 1248 cm -1 NMR (CDC1 3 , δ) : 3.86 (2H, brs) , 3.90 (3H, s),6.75 (2H, d, J=8.8Hz), 7.45 (2H, d, J=8.8Hz), 8.05 (IH, s) , 8.26 (lH,s) MASS (m/z ) : 218 (M + +1 ) Prepa ration 1 33 A mixture of 1- ( 4-formylphenyl ) -lH-pyrazol-4-carboxylic acid methyl ester (1.00 g) , methanol (10 ml) and tetrahydrofuran (25 ml) was treated with sodium borohydride at 0°C. After 15 minutes, the mixture was diluted with ethyl acetate and washed with water. The organic layer was dried over magnesium sulfate, filtered, and concentrated by evaporation to give 1- (4-hydroxymethylphenyl) -lH-pyrazol- 4-carboxylic acid methyl ester (1.04 g) . IR (KBr) : 1724, 1558, 1521, 1443, 1392, 1255 cm" 1 NMR (CDCI3, δ) : 3.88 (3H, s), 4.76 (2H, s) , 7.48 (2H, d, J=8.7Hz), 7.69 (2H, d, J=8.7Hz), 8.10 (IH, s) , 8.41 (lH,s) MASS (m/z) : 233(M + +1) Preparation 134 A solution of 1- (4-formylphenyl) -lH-pyrazol-4- carboxylic acid methyl ester (5.0 g) in dichloromethane (100 ml) was treated with 3-chloroperbenzoic acid for 5 minutes at room temperature. The solution was heated at 50°C for 4 hours, during which period additional 3-chloroperbenzoic acid (1.87 g) was added. After concentration, methanol (150 ml) and potassium carbonate (9.00 g) were added to the residue, and the mixture was stirred for 14 hours at ambient temperature. The reaction mixture was poured into water, adjusted to pH 8 with IN HCl and the resulting precipitate was collected by filtration to give 1- (4-hydroxyphenyl) -lH-pyrazol-4- carboxylic acid methyl ester (0.51 g) . IR (KBr) : 1718, 1691, 1554, 1523, 1250 cm" 1 NMR (CDCI3, δ) : 3.87 (3H, s) , 6.92 (2H, d, J=9.0Hz), 7.55 (2H, d, J=9.0Hz), 8.07 (IH, s) , 8.30 (lH,s) 98 MASS (m/z) : 219(M + +1) Preparation 135 A solution of 4- (4-hydroxypiperidin-l-yl) benzoic acid ethyl ester (5.4 g) , silver oxide (5.31 g) and 3- bromocyclohexene (3.24 ml) in tetrahydrofuran (52 ml) was stirred for 1 day at room temperature. The reaction mixture was filtered off, and the filtrate was concentrated by evaporation under reduced pressure. To the residue was added ethyl acetate, and the resulting precipitate was collected by filtration and dried. The residue was purified by silica gel chromatography (3:2 hexane-ethyl acetate elution) to give 4- [4- (2-cyclohexenyloxy)piperidin-l-yl]benzoic acid ethyl ester (3.84 g) . NMR (CDC1 3 , δ) : 1.36 (3H, t, J=7.1Hz), 1.40-2.15 (10H, m) , 3.00-3.20 (2H, m) , 3.50-3.75 (3H, m) , 3.90-4.05 (IH, m) , 4.32 (2H, q, J=7.1Hz), 5.60-5.90 (2H, m) , 6.86 (2H, d, J=9.1Hz), 7.90 (2H, d, J=9.1Hz) APCI MASS : 330(M++1) Preparation 136 To a solution of 4- [4- (2-cyclohexenyloxy) piperidin-1- yl]benzoic acid ethyl ester (3.82 g) in methanol (80 ml) was added 10% palladium on carbon (1.0 g) , and hydrogen gas at atmosphere pressure for 5 hours. The reaction mixture was filtered, and the filtrate was concentrated by evaporation under reduced pressure to give 4- (4-cyclohexyloxypiperidin-l- yl) enzoic acid ethyl ester (2.38 g) . NMR (CDCI3, δ) : 1.10-1.32 (4H, ) , 1.36 (3H, t, J=7.1Hz), 1.40-2.00 (9H, m) , 2.90-3.15 (2H, m) , 3.20-3.45 (IH, m) , 3.50-3.75 (3H, m) , 4.32 (2H, q, J=7.1Hz), 6.86 (2H, dd, J-2.2 and 9.1Hz), 7.85-8.00 (2H, m) APCI MASS (positive) : 332.3(M++1) Preparation 137 To a suspension of 4- [2- (4-methoxyphenyl) imidazo [2, 1- b] [1, 3, 4] thiadiazol-6-yl]benzoic acid ethyl ester trifluoroacetic acid salt (1.0 g) in dichloromethane (10 ml) 99 was added borone tribromide (1.0M solution in dichloromethane) (8.0 ml) at 0°C and the mixture was stirred at ambient temperature for 1 week. The reaction mixture was pulverized with cold water. The precipitate was collected by filtration and dried to give 4- [2- (4-hydroxyphenyl) imidazo- [2, 1-b] [1, 3, 4] thiadiazol-6-yl]benzoic acid (893 mg) . IR (KBr) : 3209, 1689.3, 1604.5, 1484.9 cm "1 NMR (DMSO-dg, δ) : 6.97 (2H, d, J=8.5Hz), 7.81 (2H, d, J=8.5Hz), 8.00 (4H, s), 8.84 (lH,s) MASS (m/z) : 338 (M+H + ) Preparation 138 To a solution of 5- (4-pentyloxyphenyl) -1, 3, 4- thiadiazol-2-yl-amine (20 g) in pyridine (200 ml) was added 4-methoxycarbonylbenzoylchloride (15 g) and the mixture was stirred at ambient temperature for 2 hours. The reaction mixture was pulverized with water. The precipitate was collected by filtration and dried to give N-[5-(4- - pentyloxyphenyl) -1, 3, 4-thiadiazol-2-yl] terephthalamic acid methyl ester (30.3 g) . IR (KBr) : 2946, 2863, 1724, 1670, 1604, 1538, 1521, 1457, 1317, 1276, 1249, 1174, 1106 cm "1 NMR (DMSO-dg, δ) : 0.91 (3H, t, J=7.0Hz), 1.2-1.5 (4H, m) , 1.6-1.9 (2H, m) , 3.90 (3H, s) , 4.05 (2H, t, J=6.5Hz), 7.09 (2H, d, J=8.8Hz), 7.91 (2H, d, J=8.8Hz), 8.12 (2H, d, J=8.4Hz), 8.25 (2H, d, J=8.4Hz) , MASS (m/z) : 426(M+H + ) Preparation 139 To a solution of N-tert-butoxycarbonyl-4-piperidinone (3.3 g) and 1- (4-cyclohexylphenyl) piperazine (4.0 g) in dichloromethane (20 ml) was added titanium (IV) isopropoxide (8 ml) and the mixture was stirred at ambient temperature for 2 hours. Then, to the reaction mixture was added ethanol (20 ml) and sodium cyanoborohydride (1 g) in several portions, the reaction mixture was stirred at ambient temperature for 2 hours . 100 The reaction mixture was pulverized with water. The precipitate was filtered off and the filtrate was extracted with dichloromethane. The organic layer was taken and dried over magnesium sulfate. Magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure and chromatographed (Silica gel 60 (Trademark : prepared by Merck) ) eluting with hexane/ethyl acetate to afford 1- tert-butoxycarbonyl-4- [4- (4-cyclohexylphenyl) piperazin-1- yl]piperidine (1.35 g) . NMR (CDC1 3 , δ) : 1.3-1.6 (6H, m) , 1.45 (9H, s) , 1.6-2.0 (8H, m) , 2.3-2.6 (2H, ) , 2.6-3.0 (6H, ) , 3.0-3.3 (4H, m) , 4.17 (2H, d, J=13Hz) , 6.86 (2H, d, J=8.7Hz), 7.11 (2H, d, J=8.7Hz) MASS (m/z) : 428(M+H + ) reparation 140 To a solution of 4- [4- [4- (4- cyclohexylphenyl) piperazin-1-yl] piperidin-1- yl]benzonitrile (1.95 g) in acetic acid (10 ml) was added concentrated hydrogen chloride (20 ml) and the mixture was stirred at 120°C for 10 hours. The reaction mixture was added to water and the resulting precipitate was collected by filtration to give 4- [4- [4- (4-cyclohexylphenyl) piperazin- l-yl]piperidin-l-yl]benzoic acid (959 mg) . IR (KBr) : 3400, 2927, 2620, 2514, 1714, 1608, 1513, 1452, 1274, 1226, 1182, 1010 cm -1 NMR (DMSO-dg, δ) : 1.2-1.5 (5H, ) , 1.6-1.9 (7H, ) , 2.2 (2H, m) , 2.4 (IH, m) , 2.84 (2H, t, J=8.5Hz), 3.20 (4H, d, J=8.5Hz), 3.4-3.8 (5H, m) , 4.08 (2H, d, J=12.5Hz), 6.93 (2H, d, J=8.8Hz), 7.03 (2H, d, J=8.8Hz), 7.12 (2H, d, J=8.8Hz), 7.78 (2H, d, J=8.8Hz), 11.13 (IH, s) MASS (m/z) : 448(M+H + ) Preparation 141 Amixture of 1- (4-formylphenyl) -lH-pyrazol-4-carboxylic acid methyl ester (5.0 g), 1-phenyl piperazine (4.21 g), acetic 101 acid (3.7 ml), sodium cyanoborohydride (1.55 g), methanol (110 ml), tetrahydrofuran (75 ml) and dichloromethane (20 ml) was stirred for 15 minutes at 0°C and for 14 hours at ambient temperature. The reaction mixture was poured into saturated NaHC03 aqueous solution and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, filtered, and evaporated. The residue was purified by silica gel chromatography (1:1 hexane-ethyl acetate elution) and recrystallized from diisopropyl ether and acetone to give 1- [4- (4-phenylpiperazin-l-yl-methyl) phenyl] -lH-pyrazol-4- carboxylic acid methyl ester (3.90 g) . IR (KBr) : 1702, 1600, 1560, 1271 cm "1 NMR (DMSO-dg, δ) : 2.4-2.6 (4H, m) , 3.14 (3H, t, J=4.8Hz), 3.58 (2H, s), 3.81 (3H, s) , 6.76 (IH, t, J=7.2Hz), 6.91 (2H, d, J=7.8Hz), 7.20 (2H, t, J=7.8Hz), 7.48 (2H, t, J=8.6Hz), 7.90 (2H, d, J=8.6Hz), 8.15 (IH, s), 9.11 (IH, s) MASS (m/z) : 377(M++1) Preparation 142 To an ice-cooled solution of methyl 4- (4- hydroxyphenyl) benzoate (3.00 g) and N- phenyltrifluoromethanesulfonide (4.84 g) in tetrahydrofuran (60 ml) was added triethylamine (1.98 ml), then the solution was stirred at this temperature for 1 hour and at ambient temperature for further 18 hours. Water (200 ml) was added to the reaction mixture and the mixture was extracted with methylene chloride. The organic layer was dried over magnesium sulfate, filtered and evaporated to give a crude oil . This oil was purified on a silica gel column chromatography eluting successively with the following solvents: (1)2.5% ethyl acetate in n-hexane, (2)5% ethyl acetate in n-hexane. The fractions containing the object compound were concentrated to give methyl 4- (4-trifluoro ethanesulfonyloxyphenyl) - benzoate (5.30 g) as a white solid. IR (KBr) : 1713, 1691, 1606, 1522, 1495, 1420 cm "1 102 NMR ( CDCI3 , δ ) : 3 . 95 ( 3H, s ) , 7 . 31-7 . 46 ( 2H, m) , 7 . 56-7 . 75 ( 4H, m) , 8 . 08- 8 . 20 ( 2H, m) MASS (m/z) : 361(M + +1) Preparation 143 To a suspension of 4-piperazin-l-yl-benzoic acid ethyl ester dihydrochloride (1 g) and potassium bicarbonate (1.57 g) in acetonitrile (10 ml) was added methanesulfonic acid indane-2-yl ester (0.69 g) and the mixture was stirred under refluxing for 8 hours. The reaction mixture was pulverized with water. The precipitate was collected by filtration and dried over under reduced pressure. The powder was purified by column chromatography on silica gel using methanol/dichloromethane (50:1) as the eluent to give 4- (4-indan-2-yl-piperazin-l-yl)benzoic acid ethyl ester (0.38 g) . IR (KBr) : 1697.1, 1606.4, 1349.9, 1238.1 cm" 1 NMR (CDCI3, δ) : 1.37 (3H, t, J=7.1Hz), 2.67-2.72 (4H, m) , 2.88-3.40 (9H, m) , 4.33 (2H, q, J=7.1Hz), 6.85-6.90 (2H, m) , 7.12-7.23 (4H, m) , 7.91-7.96 (2H, m) MASS (m/z) : 351.3 (M+l) Preparati n 44 To a solution of 2-amino-4' -bromoacetophenone hydrochloride (5.0 g) , 4-heptyloxybenzoic acid (4.72 g) and 1-hydroxybenzotriazole (2.7 g) in dichloromethane (50 ml) was added l-ethyl-3- (3' -dimethylaminopropyl) carbodiimide (WSCD) (3.65 ml) and the mixture was stirred for 3 hours at ambient temperature. The reaction mixture was diluted with dichloromethane (200 ml) , and washed with water, IN hydrochloric acid, saturated sodium hydrogen carbonate aqueous solution and brine. The organic layer was dried over magnesium sulfate. Magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure. The solids were slurried in ethyl acetate and collected by filtration to give 2- (4-heptyloxybenzoylamino) -4' - 103 bromoacetophenone (6.73 g) . IR (KBr) : 3318.9, 2937.1, 2858.0, 1699.0, 1639.2, 1556.3, 1508.1, 1255.4 cm "1 NMR (CDC1 3 , δ) : 0.80-1.10 (3H, m) , 1.20-1.60 (8H, m) , 1.75-1.95 (2H, m) , 4.01 (2H, t, J=6.5Hz), 4.91 (2H, d, J=4.2Hz), 6.94 (2H, d, J=8.8Hz), 7.14 (IH, brs) , 7.67 (2H, d, J=8.6Hz), 7.83 (2H, d, J=8.8Hz), 7.90 (2H, d, J=8.6Hz) APCI-MS (m/z) : 432, 434 Preparation 145 A solution of 2- (4-heptyloxyphenyl) -5- (4- bromophenyl) thiazole (2.06 g) in dry tetrahydrofuran (60 ml) was cooled to -60°C, and a solution of n-butyllithium (1.56M in n-hexane, 4.05 ml) was added slowly to maintain the reaction temperature at -60°C. After stirring for 1 hour, dry-ice (4 g) was added. The reaction mixture was allowed to warm to room temperature over 30 minutes . To the reaction mixture was added water (20ml) and 0.5N hydrochloric acid (80ml), then extracted with dichloromethane (700 ml) . The organic layer was washed with brine, and dried over magnesium sulfate. Magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure. The solids were slurried in acetonitrile and collected by filtration to give 4- [5- (4- heptyloxyphenyl) thiazol-2-yl]benzoic acid (1.68 g) . IR (KBr) : 2929.3, 2856.1, 2674.8, 2549.4, 1683.6, 1604.5, 1432.9, 1297.9, 1253.5 cm "1 NMR (DMSO-dg, δ) : 0.70-1.00 (3H, ) , 1.10-1.60 (8H, m) , 1.60-1.90 (2H, m) , 4.04 (2H, t, J=6.4Hz), 7.07 (2H, d, J=8.7Hz), 7.83 (2H, d, J=8.2Hz), 7.91 (2H, d, J=8.7Hz), 8.00 (2H, d, J=8.2Hz), 8.39 (IH, s) APCI-MS (m/z) : 396 The following compound was obtained in a manner similar to that of Preparation 19. Preparation 146 N- [4- [5- (4-Pentyloxyphenyl) -1, 3, 4-thiadiazol-2- 104 yl ] benzoyl ] -N' - (4-methoxycarbonylbenzoyl ) hydrazine NMR (DMSO-dg, δ) : 0.91 (3H, t, J=6.9Hz), 1.28-1.52 (4H, m) , 1.68-1.86 (2H, ) , 3.91 (3H, s) , 4.08 (2H, t, J=6.5Hz), 7.14 (2H, d, J=8.8Hz), 7.98 (2H, d, J=8.8Hz), 8.01-8.24 (8H, ) , 10.82 (2H, s) MASS (m/z) : 545 (M + +l) Preparation 147 To a solution of l-tert-butoxycarbonyl-4- (4- chlorophenyl) -4-methoxypiperidine (0.72 g) in ethyl acetate (10 ml) was added 4N HCl in ethyl acetate (5.5 ml) . After stirring for 6.7 hours, the reaction mixture was poured into a mixture of ethyl acetate and water, followed by alkalification of the solution to pH 12. The organic layer was successively washed with water and brine and dried over magnesium sulfate . The solvent was evaporated in vacuo to give 4- (4-chlorophenyl) -4-methoxypiperidine (0.39 g) . IR (Film) : 2943, 2827, 1541 cm "1 NMR (CDC1 3 , δ) : 1.7-2.1 (4H, m) , 2.17 (IH, s) , 2.9-3.2 (7H, m) , 7.33 (4H, s) The following compound was obtained in a manner similar to that of Preparation 147. Preparation 148 1- [ - ( 5-Methoxypentyloxy) biphenyl-4-yl ] piperazine dihydrochloride IR (KBr) : 2940.9, 2508.9, 1498.4, 1249.6 cm "1 NMR (CDCI3, δ) : 1.51-1.83 (6H, m) , 3.34 (3H, s) , 3.40 (2H, t, J=6.2Hz), 3.93 (2H, t, J=6.4Hz), 4.00-4.40 (8H, m) , 6.84-6.89 (2H, ) , 7.36-7.40 (2H, ) , 7.58-7.62 (2H, ) , 7.87-7.92 (2H, m) , 9.90-10.15 (IH, m) MASS (m/z) : 355 (M+l) Preparation 149 To a solution of 4-hydroxyacetophenone (10 g) and pyridinium hydrobromide perbromide (23.5 g) in acetic acid (80 105 ml) was added hydrogenbromide (30% in acetic acid solution) (40 ml) and the mixture was stirred overnight at ambient temperature. The reaction mixture was added to ice water and extracted with ethyl acetate. The organic layer was taken and dried over magnesium sulfate. Magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to afford 2-bromo-l- (4-hydroxyphenyl) ethanone (1.72 g) . NMR (CDC1 3 , δ) : 4.40 (2H, s), 5.78 (IH, s) , 6.92 (2H, d, J=8.8Hz), 7.94 (2H, d, J=8.8Hz) MASS (m/z) : 217 (M+H + ) The following compound was obtained in a manner similar to that of Preparation 149. Preparation 150 2-Bromo-l- (4-pentyloxyphenyl) ethanone NMR (CDCI3, δ) : 0.94 (3H, t, J=6.8Hz), 1.3-1.5 (4H, m) , 1.82 (2H, q, J=6.8Hz), 4.03 (2H, t, J=6.8Hz), 4.40 (2H, s), 6.94 (2H, d, J=9.0Hz), 7.96 (2H, d, J=9.0Hz) MASS (m/z) : 287 (M+H + ) Preparation 151 A solution of 1- (4-aminophenyl) -lH-pyrazol-4-carboxylic acid methyl ester (3.0 g) in N, N-dimethylformamide (30 ml) was treated with potassium carbonate (5.72 g), sodium iodide (4.14 g) and 1, 5-dibromopentane, and the mixture was stirred for 20 hours at room temperature and 6 hours at 80°C, during which period additional N, N-dimethylformamide (20 ml), 1.5- dibromopentane (1.14 g) and potassium carbonate (0.95 g) were added. The reaction mixture was cooled to room temperature and poured into water. The precipitate was collected by filtration, dried over under reduced pressure. The residue was purified by silica gel chromatography (dichloromethane elution) to give 1- (4-piperidylphenyl) -lH-pyrazol-4- carboxylic acid methyl ester (1.34 g) . IR (KBr) : 1720, 1521, 1248 cm "1 NMR (CDCI3, δ) : 1.5-1.8 (6H, m) , 3.21 (4H, t, J=5.3Hz), 3.86 (3H, s) , 6.98 (2H, d, J=9.1Hz), 7.53 (2H, d. 106 J=9 . 1Hz ) , 8 . 06 ( IH, s ) , 8 . 29 ( IH, s ) MASS (m/ z ) : 286 (M + +l ) The following compound was obtained in a manner similar to that of Preparation 151. Preparation 152 1- (4-Pyrrolidinylphenyl) -lH-pyrazol-4-carboxylic acid methyl ester IR (KBr) : 1720, 1541, 1525, 1246 cm "1 NMR (CDC1 3 , δ) : 2.0-2.1 (4H, m) , 3.2-3.4 (4H, m) , 3.86 (3H, s), 6.59 (2H, dd, J=6.9 and 2.1Hz) , 7.49 (2H, dd, J=6.9 and 2.1Hz), 8.05 (IH, s) , 8.25 (IH, s) MASS (m/z) : 294 (M + +23) Preparation 153 To a suspension of cyclohexane-l-4-dicarboxylic acid monomethyl ester (1.57 g) in thionyl chloride (3.14 ml) was added N, N-dimethylformamide (2 drops) and the mixture was stirred under refluxing for 1 hour. The reaction mixture was concentrated by evaporation under reduced pressure to give 4-chlorocarbonylcyclohexane carboxylic acid methyl ester (1.78 g) . NMR (CDCI3, δ) : 1.38-1.64 (4H, ) , 2.09-2.32 (5H, m) , 2.64-2.77 (IH, m) , 3.68 (3H, s) Preparation 154 Thionyl chloride (8.47 ml) was added dropwise to methanol (54 ml) at 10°C. To the solution was added trans-1,4- cyclohexane dicarboxylic acid (4 g) and the mixture was stirred for 24 hours at ambient temperature. The reaction mixture was evaporated under reduced pressure to give cyclohexane-1, 4- dicarboxylic acid dimethyl ester (4.68 g) . IR (KBr) : 1729.8, 1195.6 cm "1 NMR (CDCI3, δ) : 1.34-2.15 (8H, m) , 2.23-2.34 (2H, m) , 3.67 (6H, s) MASS (m/z) : 201 (M+l) The following compounds [Preparations 155 to 1571 were obtained in a manner similar to that of Preparation 154. 107 Preparation 155 2, 5-Dimethyl-terephthalic acid dimethyl ester IR (KBr) : 1722.1, 1261.2, 1101.2 cm -1 NMR (CDC1 3 , δ) : 2.57 (6H, s) , 3.91 (6H, s) , 7.76 (2H, s) MASS (m/z) : 223 (M+l) Preparation 156 2, 4-Hexendioic acid dimethyl ester IR (KBr) : 1702.8, 1612.2, 1249.6 cm "1 NMR (CDCI3, δ) : 3.71 (6H, s) , 6.49 (2H, dd, J=3.1 and 11.5Hz), 7.40 (2H, dd, J=3.1 and 11.5Hz) MASS (m/z) : 171 (M+l) Preparation 157 Naphthalene-1, 4-dicarboxylic acid dimethyl ester NMR (CDCI3, δ) : 4.03 (6H, s) , 7.65 (2H, q, J=3.3Hz), 8.09 (2H, s), 8.83 (2H, q, J=3.3Hz) MASS (m/z) : 245 (M+l) The following compounds [Preparations 158 to 1621 were obtained in a manner similar to that of Preparation 153. Preparation 158 5-Chlorocarbonylthiophene-2-carboxylic acid methyl ester IR (KBr) : 1724.0, 1666.2, 1251.6 cm "1 NMR (CDCI3, δ) : 3.86 (3H, s) , 7.73-7.87 (2H, m) preparation 159 4-Chlorocarbonyl-2, 5-dimethylbenzoic acid methyl ester IR (KBr) : 1756.8, 1718.3, 1220.7 cm" 1 NMR (CDCI3, δ) : 2.54 (3H, s) , 2.60 (3H, s) , 3.93 (3H, s), 7.78 (IH, s), 8.03 (IH, s) preparation 160 5-Chlorocarbonyl-2, 4-pentenoic acid methyl ester IR (KBr) : 1745.3, 1714.4, 1243.9 cm -1 NMR (CDCI3, δ) : 3.70 (3H, s) , 6.29-6.64 (2H, m) , 7.24-7.64 (2H, m) 108 Preparation 161 4-Chlorocarbonylnaphtalene-l-carboxylic acid methyl ester IR (KBr) : 1762.6, 1724.0, 1257.4 cm "1 NMR (CDC1 3 , δ) : 3.98 (3H, s) , 7.68-7.77 (2H, m) , 8.14 (2H, s), 8.66-8.82 (2H, m) Preparation 162 6-Chlorocarbonylnaphtalene-2-carboxylic acid methyl ester IR (KBr) : 1743.3, 1714.4, 1290.1 cm "1 NMR (CDCI3, δ) : 3.94 (3H, s) , 8.04-8.08 (2H, ) , 8.21-8.27 (2H, m) , 8.68-8.71 (2H, m) Preparation 163 To a solution of 4-piperidin-l-yl-benzonitrile (3 g) and thiosemicarbazide (1.8 g) in toluene (30 ml) was added trifluoroacetic acid (20 ml) and the mixture was stirred at 60°C for 6 hours. The reaction mixture was placed in water, the solution was adjusted to pH 9 with IN sodium hydroxide and the precipitate was collected by filtration to give 5- (4- piperidin-1-yl-phenyl) - [1, 3, 4] thiadiazol-2-yl-amine (3.58 g ) . IR (KBr) : 2933, 2838, 1604, 1502, 1463, 1386, 1349 1245, 1126, 1043, 821 cm "1 NMR (DMSO-dg, δ) : 1.57 (6H, m) , 3.24 (4H, m) , 6.96 (2H, d, J=8.8Hz), 7.19 (2H, s) , 7.54 (2H, d, J=8.8Hz) MASS (m/z) : 261 (M+H + ) The following compounds [Preparations 164 to 1691 were obtained in a manner similar to that of Preparation 163. Preparation 164 5- (4-Morpholinylphenyl) -[1,3,4] thiadiazol-2-yl-amine IR (KBr) : 3274, 3106, 1604, 1508, 1465, 1378, 1324, 1267, 1238, 1122 cm -1 NMR (DMSO-dg, δ) : 3.19 (4H, t, J=4.8Hz), 3.74 (4H, t, J=4.8Hz), 7.00 (2H, d, J=8.8Hz), 7.22 (2H, s) , 7.59 (2H, d, J=8.8Hz) 109 MASS (m/z) : 263 (M+H + ) Preparati n 165 5- [4- (cis-2, 6-Dimethylmorpholin-4-yl) phenyl] - [1, 3, 4] thiadiazol-2-yl-amine IR (KBr) : 3272, 3106, 1608, 1525, 1469, 1376, 1346, 1245, 1176, 1145, 1081 cm" 1 NMR (DMSO-dg, δ) : 1.16 (6H, d, J=6.2Hz), 2.31 (2H, t, J=11.5Hz), 3.6-3.8 (4H, m) , 7.00 (2H, d, J=8.8Hz), 7.21 (2H, s), 7.58 (2H, d, J=8.8Hz) MASS (m/z) : 291 (M+H + ) Preparation 166 5- (4-Thiomorpholinophenyl) -[1,3,4] thiadiazol-2-yl- amine IR (KBr) : 3340, 3270, 3129, 1604, 1506, 1467, 1384, 1295, 1230, 1195 cm "1 NMR (DMSO-dg, δ) : 2.64 (4H, t, J=5.0Hz), 3.66 (4H, t, J=5.0Hz), 6.97 (2H, d, J=8.8Hz), 7.21 (2H, s) , 7.57 (2H, d, J=8.8Hz), MASS (m/z) : 279 (M+H + ) Preparation 167 5- [4- (4-Ethylpiperazinylphenyl) ] - [1, 3, ] thiadiazol-2- yl-amine IR (KBr) : 3278, 3120, 2967, 2829, 1685, 1608, 1517, 1467, 1388, 1240, 1203, 1130 crn -1 NMR (DMSO-dg, δ) : 1.04 (3H, t, J=7.2Hz), 2.41 (2H, q, J=7.2Hz), 2.51 (4H, m) , 3.23 (4H, m) , 6.99 (2H, d, J=8.8Hz), 7.21 (2H, s) , 7.57 (2H, d, J=8.8Hz) MASS (m/z) : 290 (M+H + ) Preparation 168 5- [4- (4-Cyclohexylpiperazinylphenyl) ] - [1, 3, 4] thiadiazol-2-yl-amine IR (KBr) : 3016, 2950, 2865, 1743, 1672, 1606, 1513, 1456, 1430, 1402, 1201, 1133 cm -1 NMR (DMSO-dg, δ) : 1.0-1.6 (5H, m) , 1.63 (IH, d, J=10Hz) , 1.85 (2H, d, J=10Hz) , 2.09 (2H, d, J=10Hz) , 2.8- 110 3 . 3 ( 5H, m) , 3 . 55 ( 2H, m) , 3 . 99 ( 2H, d, J=10Hz ) , 7 . 09 ( 2H, d, J=8 . 8Hz ) , 7 . 65 ( 2H, d, J=8 . 8Hz ) MASS (m/ z ) : 344 (M+H + ) Preparation 169 4- (5-Amino- [1, 3, 4] thiadiazol-2-yl) benzoic acid methyl ester trifluoroacetic acid salt IR (KBr) : 3004, 2746, 1726, 1675, 1645, 1608, 1436, 1284, 1211, 1186, 1137, 1112 cm "1 NMR (DMSO-dg, δ) : 3.88 (3H, s) , 7.19 (2H, s), 7.90 (2H, d, J=8.5Hz), 8.04 (2H, d, J=8.5Hz) MASS (m/z) : 236 (M+H + ) Preparation 170 To a mixture of 4-methoxycarbonylphenylboronic acid (2.01 g) and l-bromo-4-ethoxymethylbenzene (2.00 g) in a mixed solvent of ethylene glycol dimethyl ether (20 ml) and 2M aqueous sodium carbonate solution (6 ml) was added tetrakis (triphenylphosphine) palladium (0) (0.54 g) . The mixture was heated at 80°C for 5 hours. After cooling to room temperature, water (150 ml) was added to the reaction mixture and the resulting precipitate was collected by filtration, washed thoroughly with water and dried to give a crude solid. This solid was purified by column chromatography on silica gel (60 g) eluting successively with the following solvents: (1) n-hexane : ethyl acetate=50 : 1, (2) n-hexane : ethyl acetate=10: 1. The fractions containing the object compound were concentrated and dried to give methyl 4-(4'- ethoxymethylphenyl) benzoate as a white solid (1.85 g) . NMR (CDC1 3 , δ) : 1.27 (3H, t, J=7.0Hz), 3.58 (2H, q, J=7.0Hz), 3.94 (3H, m) , 4.56 (2H, s) , 7.44 (2H, d, J=8.7Hz), 7.54-7.61 (4H, ) , 8.04-8.15 (2H, m) The following compound was obtained in a manner similar to that of Preparation 170. Preparation 171 Methyl 4- [4' - (2-methoxyethoxymethyl) phenyl] benzoate NMR (CDCI3, δ) : 3.41 (3H, m) , 3.55-3.70 (4H, m) , 3.94 111 (3H, s), 4.63 (2H, s) , 7.45 (2H, d, J=8.3Hz), 7.56-7.74 (4H, m) , 8.07-8.20 (2H, m) MASS (m/z) : 301 (M + +l) Preparation 172 To an ice-cooled solution of 4-bromobenzyl bromide (3.00 g) and 2-methoxyethanol (1.04 ml) in tetrahydrofuran (30 ml) was added sodium hydride (60%) (0.58 g) in a stream of nitrogen. The mixture was stirred at this temperature for 15 minutes and at room temperature for further 4 hours. To the mixture was added water (1 ml) under ice-cooling. The reaction mixture was diluted with ethyl acetate and washed successively with water and saturated sodium chloride solution. The organic layer was dried over magnesium sulfate, filtered and evaporated to give l-bromo-4- (2-methoxyethoxymethyl) benzene (3.10 g) as a pale yellow oil. NMR (DMSO-dg, δ) : 3.25 (3H, m) , 3.43-3.60 (2H, ) , 4.46 (2H, s), 7.28 (2H, d, J=8.5Hz), 7.49-7.60 t4H, m) The following compounds [Preparations 173 to 1751 were obtained in a manner similar to that of Preparation 172. Preparation 173 Ethyl 4- (4-propoxypiperidin-l-yl) benzoate NMR (DMSO-dg, δ) : 0.87 (3H, t, J=7.4Hz), 1.28 (3H, t, J=7.1Hz), 1.36-1.60 (4H, m) , 1.80-1.98 (2H, m) , 3.00-3.20 (2H, m) , 3.39 (2H, t, J=6.5Hz), 3.41-3.76 (3H, m) , 4.23 (2H, q, J=7.1Hz), 6.97 (2H, d, J=9.1Hz), 7.76 (2H, d, J=9.0Hz) MASS (m/z) : 292 (M + +l) Preparation 174 Ethyl 4- (4-benzyloxypiperidin-l-yl) benzoate NMR (DMSO-dg, δ) : 1.28 (3H, t, J=7.1Hz), 1.45-1.66 (2H, m) , 1.85-2.02 (2H, m) , 3.00-3.21 (2H, m) , 3.55-3.78 (3H, m) , 4.23 (2H, q, J=7.1Hz), 4.55 (2H, s) , 6.98 (2H, d, J=9.1Hz), 7.23-7.43 (5H, m) , 7.76 (2H, d, J=9.0Hz) MASS (m/z) : 340 (M + +l) 112 Preparation 175 1- (4-Heptyloxymethylphenyl) -lH-pyrazol-4-carboxylic acid methyl ester IR (KBr) : 1703, 1558, 1265 cm "1 NMR (DMSO-dg, δ) : 0.85 (3H, m) , 1.1-1.6 (10H, m) , 3.44 (2H, t, J=6.4Hz), 3.81 (3H, s) , 4.49 (2H, s) , 7.45 (2H, d, J=8.5Hz), 7.91 (2H, d, J=8.5Hz), 8.15 (IH, s) , 9.11 (IH, s) MASS (m/z) : 331 (M + +l) Preparation 176 To a solution of methyl 4- (4-hydroxyphenyl) benzoate (3.00 g) and cyclohexanol (1.58 g) in tetrahydrofuran (60 ml) was added dropwise diethyl azodicarboxylate (2.48 ml) at 0-10°C under nitrogen atmosphere, and the mixture was stirred at ambient temperature for 4 hours. After concentration, to the residue was added ethyl acetate (50 ml) and n-hexane (10 ml), and the resulting precipitate was removed by filtration and discarded. To the filtrate was added silica gel (12 g) and the mixture was evaporated. The residue was purified by column chromatography on silica gel (80 g) eluting with a mixed solvent of 5% ethyl acetate in n-hexane to give methyl 4- (4-cyclohexyloxyphenyl) benzoate (1.79 g) as a white solid. IR (KBr) : 1720, 1603, 1525, 1495, 1437 cm "1 NMR (CDC1 3 , δ) : 1.22-1.66 (6H, m) , 1.72-1.90 (2H, m) , 1.95-2.10 (2H, ) , 3.93 (3H, s) , 4.22-4.37 (IH, m) , 6.89-7.03 (2H, m) , 7.47-7.76 (4H, m) , 8.00-8.13 (2H, m) MASS (m/z) : 311 (M + +l) The following compound was obtained in a manner similar to that of Preparation 176. Preparation 177 4-Cyclohexyloxybenzoic acid methyl ester NMR (CDCI3, δ) : 1.20-2.10 (10H, m) , 3.88 (3H, s) , 4.20-4.40 (IH, m) , 6.85-6.95 (2H, m) , 7.90-8.00 (2H, m) 113 APCI MASS (positive) : 235.2 (M + +l) Preparation 178 To an ice-cooled solution of ethyl 4- (piperazin-1- yl)benzoate (2.00 g) and 4-methylcyclohexanone (1.05 ml) in a mixed solvent of methanol (40 ml) and acetic acid (1.47 ml) was added sodium cyanoborohydride (0.59 g) in a stream of nitrogen. The mixture was stirred at this temperature for 1 hour and at room temperature for 17 hours. The reaction mixture was quenched with saturated aqueous sodium hydrogen carbonate solution and the resulting precipitate was collected by filtration, washed thoroughly with water and dried to give a mixture of cis and trans products. This mixture was separated by column chromatography on silica gel eluting with a mixed solvent of methylene chloride-methanol (from 0% to 2% gradient solution) to give ethyl 4-[4-(cis-4- methylcyclohexyl) piperazin-1-yl] benzoate (0.80 g) as a pale green solid and ethyl 4- [4- (trans-4- methylcyclohexyl) piperazin-1-yl] benzoate (0.64 g) as a pale green solid. Trans-product was confirmed by X-ray crystal analysis. Ethyl 4- [4- (cis-4-methylcyclohexyl) piperazin-1- yl] benzoate IR (KBr) : 1697, 1608, 1520, 1446 cm "1 NMR (DMSO-Dg, δ) : 0.89 (3H, d, J=6.8Hz), 1.28 (3H, t, J=7.1Hz), 1.23-1.52 (6H, ) , 1.52-1.76 (3H, m) , 2.07-2.25 (IH, m) , 2.47-2.63 (4H, m) , 3.20-3.40 (4H, m) , 4.23 (2H, q, J=7.1Hz), 6.96 (2H, d, J=9.1Hz), 7.78 (2H, d, J=8.9Hz) MASS (m/z) : 331 (M + +l) Ethyl 4- [4- (trans-4-methylcyclohexyl) piperazin-1- yl]benzoate IR (KBr) : 1709, 1608, 1518, 1444 cm "1 NMR (DMSO-Dg, δ) : 0.85 (3H, d, J=6.8Hz), 0.80-1.02 (2H, m) , 1.28 (3H, t, J=7.1Hz), 1.09-1.56 (3H, m) , 1.56-1.88 (4H, m) , 2.08-2.34 (IH, m) , 2.50-2.67 (4H, 114 m) , 3 . 18-3 . 34 ( 4H, m) , 4 . 23 ( 2H, q, J=7 . 1Hz ) , 6 . 95 ( 2H, d, J=9 . 1Hz ) , 7 . 77 ( 2H, d, J=8 . 9Hz ) MASS (m/ z ) : 331 (M + + l ) The following compound was obtained in a manner similar to that of Preparation 178. Preparation 179 Ethyl 4- [4- (4, 4-dimethylcyclohexyl) piperazin-1- yl]benzoate NMR (CDC1 3 , δ) : 0.91 (6H, s) , 1.07-1.55 (6H, m) , 1.36 (3H, t, J=7.1Hz) ,1.64-1.82 (2H, m) , 2.10-2.30 (IH, ) , 2.72 (4H, t, J=5.1Hz), 3.33 (4H, t, J=5.1Hz), 4.32 (2H, q, J=7.1Hz), 6.86 (2H, d, J=9.1Hz), 7.87-7.99 (2H, m) MASS (m/z) : 345 (M + +l) Preparation 180 To a mixture of cesium carbonate (1.90 g), palladium (II) acetate (46.7 mg) and 2, 2 ' -bis (diphenylphosphino) -1, 1' - binaphthyl (194 mg) in toluene (3.3 ml) was successively added a solution of cis-2, 6-dimethyl morpholine (0.58 g) in toluene (5 ml) and methyl 4- (4-trifluoromethanesulfonyloxyphenyl) - benzoate (1.50 g) in a stream of nitrogen. The mixture was stirred at ambient temperature for 30 minutes and refluxed for further 6 hours. After cooling to room temperature, water was added to the reaction mixture and the mixture was extracted with methylene chloride. The organic layer was washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate, filtered and concentrated in vacuo. The residue was pulverized with acetonitrile and collected by filtration to give methyl 4- [4- (cis-2, 6-dimethylmorpholino- phenyl) ] benzoate (525 mg) as a pale yellow solid. IR (KBr) : 1720, 1603, 1497, 1446 cm "1 NMR (CDCI3, δ) : 1.28 (6H, d, J=6.3Hz), 2.46 (IH, d, J=10.6Hz), 2.49 (IH, d, J=10.6Hz), 3.46-3.62 (2H, m) , 3.72-3.94 (2H, m) , 3.93 (3H, s) , 6.98 (2H, d, J=8.9Hz), 7.51-7.70 (4H, m) , 8.02-8.14 (2H, m) 115 MASS (m/ z ) : 326 (M + + l ) The following compound was obtained in a manner similar to that of Preparation 180. Preparation 181 Methyl 4- [4- (4-cyclohexylpiperazin-l- yl) phenyl] benzoate IR (KBr) : 2929, 2852, 2829, 1714, 1603, 1529, 1498, 1439 cm -1 NMR (CDC1 3 , δ) : 1.00-1.41 (5H, m) , 1.51-2.05 (5H, m) , 2.24-2.43 (IH, m) , 2.69-2.84 (4H, m) , 3.22-3.36 (4H, m) , 3.93 (3H, s) , 7.00 (2H, d, J=8.9Hz), 7.48-7.68 (4H, ) , 8.00-8.12 (2H, m) MASS (m/z) : 379 (M + +l) Preparation 182 To a suspension of 2-amino-5- (4-methoxyphenyl) -1, 3, 4- thiadiazole (7.2 g) in ethanol (50 ml) was added ethyl 4- bromoacetylbenzoate (11.3 g) and the mixture was stirred under refluxing for 2.5 hours. The reaction mixture was pulverized with ethyl acetate. The precipitate was collected by filtration and dried. To a suspension of the powder in xylene (50 ml) was added trifluoroacetic acid (5 ml) and the mixture was stirred under refluxing for 3.5 hours. The reaction mixture was pulverized with diisopropyl ether. The precipitate was collected by filtration and dried to give 4- [2- (4-methoxyphenyl) imidazo [2, 1-b] [1,3, 4] thiadiazol-6- yljbenzoic acid ethyl ester trifluoroacetic acid salt (13.7 g). IR (KBr) : 2360.4, 1746.3, 1604.5, 1483.0 cm "1 MASS (m/z) : 380 ( (M-TFA) +H + ) The following compounds [Preparations 183 to 1901 were obtained in a manner similar to that of Preparation 182. Preparation 183 4- [2- (4-Piperidin-l-yl-phenyl) imidazo [2, 1- b] [1, 3, ] thiadiazol-6-yl]benzoic acid ethyl ester trifluoroacetic acid salt 11 6 IR (KBr) : 2940, 2584, 2474, 1702, 1608, 1523, 1471, 1409, 1367, 1280 cm "1 MASS (m/z) : 433 ( (M-TFA) +H + ) Preparation 184 4- [2- (4-Morpholin-4-yl-phenyl) imidazo [2, 1- b] [1, 3, 4] thiadiazol-6-yl]benzoic acid ethyl ester trifluoroacetic acid salt IR (KBr) : 2669, 1706, 1606, 1473, 1274, 1236, 1176, 1118, 1020, 929 cm "1 MASS (m/z) : 435 ( (M-TFA) +H + ) Preparation 185 4- [2- (cis-2, 6-Dimethylmorpholin-4-yl- phenyl) imidazo [2, 1-b] [ 1, 3, 4] thiadiazol-6-yl] benzoic acid ethyl ester trifluoroacetic acid salt IR (KBr) : 2979, 1710, 1606, 1473, 1371, 1278, 1241, 1176, 1106 cm "1 MASS (m/z) : 463 ( (M-TFA) +H + ) Preparation 186 4- [2- (4-Thiomorpholin-4-yl-phenyl) imidazo [2, 1- b] [1, 3, 4] thiadiazol-6-yl]benzoic acid ethyl ester trifluoroacetic acid salt IR (KBr) : 2979, 1708, 1604, 1504, 1471, 1274, 1193, 1105 cm "1 MASS (m/z) : 451 ((M-TFA)+H + ) Preparation 187 4- [2- [4- (4-Ethylpiperazin-l-yl) phenyl] imidazo [2, 1- b] [1, 3, 4] thiadiazol-6-yl]benzoic acid ethyl ester trifluoroacetic acid salt IR (KBr) : 2983, 2931, 2674, 2605, 1702, 1606, 1471, 1405, 1282, 1241, 1201 cm "1 NMR (DMSO-dg, δ) : 1.23-1.38 ( 6H, m) , 3.30-3.23 (6H, m) , 3.61 (2H, d, J=8.2Hz), 4.12 (2H, d, J=8.2Hz), 4.33 (2H, q, J=7.2Hz), 7.20 (2H, d, J=8.8Hz), 7.85 (2H, d, J=8.8Hz), 8.02 (4H, s), 8.86 (IH, s) MASS (m/z) : 462 ( (M-TFA) +H + ) 117 Preparation 188 4- [2- [4- (4-Cyclohexylpiperazin-l- yl) phenyl] imidazo [2, 1-b] [1,3,4] thiadiazol-6-yl] benzoic acid ethyl ester trifluoroacetic acid salt IR (KBr) : 2935, 2586, 1708, 1604, 1571, 1488, 1409, 1367, 1278, 1199, 1106 cm "1 MASS (m/z) : 516 ( (M-TFA) +H + ) Preparation 189 4- [ 6- (4-Hydroxyphenyl) imidazo [2,1- b] [1, 3, 4] thiadiazol-2-yl] benzoic acid methyl ester trifluoroacetic acid salt IR (KBr) : 3214, 3027, 1720, 1629, 1610, 1513, 1434, 1284, 1187, 1112 cm "1 NMR (DMSO-dg, δ) : 3.91 (3H, s) , 7.72 (2H, d, J=8.5Hz), 7.91 (2H, d, J=8.5Hz), 8.12 (4H, s) , 8.61 (IH, s) MASS (m/z) : 352 ( (M-TFA) +H + ) Preparation 190 4- [ 6- (4-Pentyloxyphenyl) imidazo [2,1- b] [1, 3, 4] thiadiazol-2-yl]benzoic acid methyl ester trifluoroacetic acid salt IR (KBr) : 2952, 2869, 1720, 1612, 1494, 1471, 1436, 1405, 1280, 1251, 1182, 1110 cm "1 MASS (m/z) : 422 ((M-TFA)+H + ) Preparation 191 A solution of methyl 4- [4- (4- bromobutoxy) phenyl] benzoate (1.40 g) in methanol (14ml) was treated with 28% sodium methoxide in methanol (14 ml) and the solution was refluxed for 5 hours. After cooling to room temperature, the reaction mixture was poured into cold 1N- hydrochloric acid (110 ml) and the resulting precipitate was collected by filtration, washed thoroughly with water and dried to give a white solid. To a mixture of this solid in methanol (20 ml) was added concentrated sulfuric acid (0.5ml) and refluxed for 4 hours. After cooling to room temperature, the reaction mixture was poured into cold water and the 118 resulting precipitate was collected by filtration, washed thoroughly with water and dried to give methyl 4- [4- (4- methoxybutoxy) phenyl] benzoate (1.16 g) as a white solid. IR (KBr) : 2949, 2873, 1720, 1603, 1529, 1498, 1439 cm "1 NMR (DMSO-dg, δ) : 1.54-1.85 (4H, m) , 3.24 (3H, s) , 3.38 (2H, t, J=6.2Hz), 3.87 (3H, s) , 4.04 (2H, t, J=6.1Hz), 7.05 (2H, t, J=8.8Hz), 7.69 (2H, d, J=8.7Hz), 7.78 (2H, d, J=8.4Hz), 8.00 (2H, d, J=8.4Hz) MASS (m/z) : 315 (M + +l) The following compounds [Preparations 192 to 1941 were obtained in a manner similar to that of Preparation 191. Preparation 192 Methyl 4- [4' - (3-methoxypropoxy) phenyl] benzoate IR (KBr) : 2953, 2875, 1724, 1603, 1529, 1495, 1435cm "1 NMR (DMSO-dg, δ) : 1.96 (2H, m) , 3.26 (3H, s) , 3.49 (2H, t, J=6.3Hz), 3.87 (3H, s) , 4.08 (2H, t, J=6.4Hz), 6.98-7.14 (2H, m) , 7.64-7.86 (4H, m) , 7.96-8.10 (2H, m) MASS (m/z) : 301 (M + +l) Preparation 193 l-Bromo-4-ethoxymethylbenzene NMR (DMSO-dg, δ) : 1.15 (3H, t, J=7.0Hz), 3.47 (2H, q, J=7.0Hz), 4.42 (2H, s) , 7.28 (2H, d, J=8.5Hz), 7.46-7.61 (2H, ) Preparation 194 Methyl 4- [4- (3-ethoxypropoxy) phenyl] benzoate NMR (DMSO-dg, δ) : 1.11 (3H, t, J=7.0Hz), 1.96 (2H, m) , 3.43 (2H, q, J=7.0Hz), 3.52 (2H, t, J=6.3Hz), 3.87 (3H, s), 4.08 (2H, t, J=6.3Hz), 7.06 (2H, d, J=8.8Hz), 7.70 (2H, d, J=8.8Hz), 7.78 (2H, d, J=8.5Hz), 8.00 (2H, d, J=8.5Hz) MASS (m/z) : 315 (M + +l) Preparation 195 To a suspension of 4- [2- (4-hydroxyphenyl) imidazo [2, 1- b] [1, 3, 4] thiadiazol-6-yl]benzoic acid ethyl ester (500 mg) 119 and potassium carbonate (2 g) in N, N-dimethylformamide (25ml) was added 1, 4-dibromobutane (1 ml) and the mixture was stirred at room temperature for 22 hours. The reaction mixture was pulverized with ethyl acetate. The precipitate was collected by filtration and dried. To a suspension of the powder in N, N-dimethylformamide (25 ml) was added piperidine (2ml) and the mixture was stirred at room temperature for 21 hours. The reaction mixture was pulverized with water. The precipitate was collected by filtration, washed with water, acetonitrile and diisopropyl ether and dried to give 4- [2- [4- (4- piperidin-1-yl-butyloxy) phenyl] imidazo [2,1- b] [1, 3, 4] thiadiazol-6-yl]benzoic acid ethyl ester (479 mg) . IR (KBr) : 2933.2, 1708.6, 1608.3, 1471.4, 1274.7, 1176.4, 1101.2 cm "1 MASS (m/z) : 505 (M+H + ) The following compounds [Preparations 196 to 201] were obtained in a manner similar to that of Preparation -195. Preparation 196 4- [2- [4- (5-Piperidin-l-yl- pentyloxy) phenyl] imidazo [2, 1-b] [1, 3, 4] thiadiazol-6- yl]benzoic acid ethyl ester IR (KBr) : 2935, 1708, 1608, 1471, 1274, 1176, 1101cm "1 MASS (m/z) : 519 (M+H + ) Preparation 197 4- [2- [4- (6-Piperidin-l-yl- hexyloxy) phenyl] imidazo [2, 1-b] [1,3,4] thiadiazol-6- yl] benzoic acid ethyl ester IR (KBr) : 2933, 1710, 1608, 1471, 1274, 1176, 1103 cm "1 MASS (m/z) : 533 (M+H + ) Preparation 198 4- [2- [4- (5-Morpholin-4-yl- pentyloxy) phenyl] imidazo [2, 1-b] [1,3,4] thiadiazol-6- yl] benzoic acid ethyl ester IR (KBr) : 2940, 1708, 1608, 1471, 1276, 1176 1116cm -1 120 MASS (m/z) : 521 (M+H + ) Preparation 199 4- [2- [4- [5- (cis-2, 6-Dimethylmorpholin-4- yl) pentyloxy] phenyl] imidazo [2, 1-b] [1,3,4] thiadiazol-6- yl] benzoic acid ethyl ester IR (KBr) : 2937, 1708, 1608, 1471, 1409, 1369, 1307, 1278, 1176 cm "1 MASS (m/z) : 549 (M+H + ) Preparation 2 QQ 4- [2- [4- [6- (cis-2, 6-Dimethylmorpholin-4- yl) hexyloxy] phenyl] imidazo [2, 1-b] [1,3,4] thiadiazol-6- yl] benzoic acid ethyl ester IR (KBr) : 2937, 1710, 1606, 1544, 1471, 1403, 1305, 1270, 1257, 1176 cm "1 MASS (m/z) : 563 (M+H + ) Preparation 201 4- [2- [4- (5-Thiomorpholin-4-yl- pentyloxy) phenyl] imidazo [2, 1-b] [1,3,4] thiadiazol-6- yl]benzoic acid ethyl ester IR (KBr) : 2939, 1706, 1608, 1471, 1274, 1176, 1108 cm "1 MASS (m/z) : 537 (M+H + ) Preparation 202 To a suspension of 4- [2- (4-hydroxyphenyl) imidazo [2, 1- b] [1, 3, 4] thiadiazol-6-yl]benzoic acid ethyl ester (1 g) and potassium carbonate (4 g) in N, N-dimethylformamide (50 ml) was added 1, 5-dibromopentane (2 ml) and the mixture was stirred at room temperature for 6 hours. The reaction mixture was pulverized with ethyl acetate. The precipitate was collected by filtration, washed with water and methanol. To a suspension of the powder in methanol (10 ml) was added sodium methylate (28% in methanol) (20 ml) and the mixture was stirred at 80°C for 19 hours . The reaction mixture was pulverized with water . The precipitate was collected by filtration, washed with water, methanol and diisopropyl ether and dried to give 4- [2- [4- (5-methoxypentyloxy) phenyl] imidazo [2, 1- 121 b] [1,3,4] thiadiazol-6-yl]benzoic acid methyl ester (479 mg) . MASS (m/z) : 452 (M+H + ) The following compounds [Preparations 203 to 2051 were obtained in a manner similar to that of Preparation 202. Preparation 203 4- [2- [4- (6-Methoxyhexyloxy) phenyl] imidazo [2,1- b] [1, 3, 4] thiadiazol-6-yl]benzoic acid methyl ester IR (KBr) : 2935, 2861, 1712, 1608, 1591, 1533, 1471, 1417, 1305, 1259, 1178, 1116 cm "1 MASS (m/z) : 466 (M+H + ) Preparation 204 4- [2- [4- (7-Methoxyheptyloxy) phenyl] imidazo [2, 1- b] [1, 3, 4] thiadiazol-6-yl]benzoic acid methyl ester IR (KBr) : 2933, 2858, 1714, 1608, 1591, 1533, 1469, 1419, 1305, 1259, 1178, 1112 cm "1 MASS (m/z) : 480 (M+H + ) Preparation 205 4- [2- [4- (8-Methoxyoctyloxy) phenyl] imidazo [2, 1- b] [1, 3, 4] thiadiazol-6-yl]benzoic acid methyl ester IR (KBr) : 2931, 2856, 1712, 1610, 1591, 1533, 1471, 1419, 1305, 1259, 1178, 1112 cm "1 MASS (m/z) : 494 (M+H + ) Preparation 206 A mixture of piperazin-1-carboxylic acid tert-butyl ester (0.64 g) , 4-bromo-4' - (5-methoxypentyloxy) biphenyl (1 g) , tris (dibenzylideneacetone) (chloroform) dipalladium(O) (59 mg) , (S) - (-) -2, 2' -bis (diphenylphosphino) -1, 1' - binaphthyl (0.12 g) and sodium tert-butoxide (0.55 g) in toluene (10 ml) was stirred for 54 hours at 90°C. The reaction mixture was added to a mixture of water and ethyl acetate. The organic layer was taken and dried over magnesium sulfate. The magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to give 4-[4'-(5- methoxypentyloxy) biphenyl-4-yl] piperazin-1-carboxylic acid tert-butyl ester (1.19 g) . 122 IR (KBr) : 1691.3, 1504.2, 1232.3 cm "1 NMR (CDC1 3 , δ) : 1.49 (9H, s) , 1.49-1.90 (6H, m) , 3.14-3.19 (4H, m) , 3.34 (3H, s) , 3.41 (2H, t, J=6.2Hz), 3.57-3.62 (4H, m) , 3.99 (2H, t, J=6.4Hz), 6.91-6.99 (4H, m) , 7.44-7.49 (4H, ) MASS (m/z) : 455 (M+l) The following compound was obtained in a manner similar to that of Preparatio 206. Preparation 207 4- [4- [4- (7-Methoxyheptylthio) phenyl] piperazin-1- yl]benzoic acid IR (KBr) : 1681.6, 1585.2, 1423.2, 1230.4 cm "1 NMR (DMSO-dg, δ) : 1.20-1.55 (10H, m) , 2.80 (2H, t, J=6.7Hz), 3.20 (3H, s) , 3.24-3.43 (10H, m) , 6.82-6.86 (2H, ) , 6.94-6.98 (2H, m) , 7.23-7.27 (2H, m) , 7.69-7.73 (2H, m) MASS (m/z) : 443.2 (M+l) Preparation 208 l-tert-Butoxycarbonyl-4- [4- (4- cyclohexylphenyl)piperazin-l-yl]piperidine (3.3 g) and trifluoroacetic acid (10 ml) were mixed and the mixture was stirred at ambient temperature for 1 hour. The solution was placed in water, adjusted to pH 8 with IN sodium hydroxide and extracted with ethyl acetate. The organic layer was separated, washed with brine, dried over magnesium sulfate and evaporated under reduced pressure to give l-(4- cyclohexylphenyl) -4-piperidylpiperazine (3.83 g) . Preparation 209 To a suspension of 4- [2- (4-hydroxyphenyl) imidazo [2, 1- b] [1, 3, 4] thiadiazol-6-yl]benzoic acid (4.0 g) in ethanol (50 ml) was added sulfuric acid (1.0 ml) and the mixture was stirred at 80°C for 9 hours. The reaction mixture was pulverized with water. The precipitate was collected by filtration, washed with water, acetonitrile and diisopropyl ether and dried to give 4- [2- (4- 123 hydroxyphenyl) imidazo [2, 1-b] [1,3,4] thiadiazol-6- yl]benzoic acid ethyl ester (2.09 g) . IR (KBr) : 3215, 1679.7, 1608.3, 1473.3, 1288.2 cm "1 NMR (DMSO-dg, δ) : 1.34 (3H, t, J=7.1Hz), 4.32 (2H, q, J=7.1Hz), 6.96 (2H, d, J=8.5Hz), 7.89 (2H, d, J=8.5Hz), 8.02 (4H, s) , 8.84 (IH, s) , 10.40 (IH, s) MASS (m/z) : 366 (M+H + ) The following compound was obtained in a manner similar to that of Preparation 209. Preparation 210 4-Cyclohexylbenzoic acid methyl ester NMR (CDC1 3 , δ) : 1.10-1.55 (5H, m) , 1.65-1.95 (5H, m) , 2.45-2.65 (IH, m) , 3.89 (3H, s) , 7.26 (2H, d, J=8.2Hz), 7.95 (2H, d, J=8.2Hz) APCI MASS: 219 (M + +l) The Object Compounds (211) to (457) obtained in- the following Preparations 211 to 457 are given in the tables as below. 124 Preparation No. Formula 211 g -^ ^o -o 212 Λ ~"0Me o N V'' N IN "0 * ^ A^^S^] f ^ N « -£ /^\ ^O(CH 2 ) 6 CH 3 213 214 g X ) 215 g ^o-κ o 216 g ^ -w c > 125 Preparation No. Formula N-N 217 Ko' Λ \ / 218 N K ) 219 δ^ ^o 220 221 N \ == / N "°^ / — N N " ~ S(C H 2 ) 7 OC H 3 222 - 0(CH 2 ) 6 OCH 3 126 Preparation No. Formula 223 tt s ,== 224 s^ _ ° (CH2)6 ° CH3 0(CH 2 ) 6 θCH 3 225 226 227 0(CH 2 ) 6 OCH 3 228 127 Preparation No. Formula OMe 229 OEt 230 o Λ ,OMe "cr o' 231 - OMe 232 233 234 OMe 128 Preparation No. Formula OMe 235 O ,N- N* N, -o 236 / 237 0(CH 2 ) 6 CH 3 238 K) 239 /=\ 240 129 Preparation No. Formula N- -O n C 6 H 13 241 / N-N 242 ! NV{K7- N -^ 243 244 g -^ ^ - ; 245 g^ >o> ^ 246 g**OX> N N 130 Preparation No. Formula 247 yy yyyc-o- 248 Cl 249 W^O ^N O )" 250 g ^ κκx 251 252 g - ^ κ> 131 Preparation No. Formula 253 g- >o o^ 254 C0 2 Me 255 ^ "" θ 2 Me 256 NC O ~ 257 NC O ^ 258 NC O ~N \ 259 NC- ~ 132 Preparation No. Formula 260 NC ~ N \ N"Et 261 EtOOC— <{ h — N \ — OH 262 Etooc O ^N 0^} 263 EtOOC— ^ — N N— ^ EtOOC— i — N — OH 264 265 Meooc "0 ^N 0 ~ 266 E,OOC - - N N^ 133 Preparation No. Formula EtOOC 267 Cl 268 ™ \ r ~ NC- ~N ^ :» > NC— N- 269 270 °' /=\ EtO % ^ f ~ 271 MeQ 2 C 272 273 Me0 2 C— (' (' ^— O 134 Preparation No. Formula ,o Me0 7 C OMe 274 ,OEt 275 MeO,C O' ,OMe 276 Me0 2 C N 277 .J v -0(CH 2 ) 3 CH 3 "N 278 MeO j C _/ = 279 Et0 2 C- ~ \— < χ ~{ >—0(CH 2 ) 5 CH3 N' =\ .0 '.v. (CH 2 ) 6 CH 3 H 9 NHN 280 O 135 Preparation No. Formula 281 H 2 N™^ >N→ 0^ N G N→ Q 0 282 o 283 H 2 NHN ^j N - " ° nC6Hl3 0 284 H 2 NHN C N -0 ^ o 285 H2NHN 0G- N O O 0 286 H2NHN Y 0 "N OO 287 H2NHN γ 0O ° } 136 Preparation No. Formula 288 0 o 289 H2NHN ^O ~ _N C N 0 0 290 H 2 NHN ^ ^~ N \ — "( / O 291 H 2 NHN' " ^^ ~ N \ / °^^\ O 292 0 293 137 Preparation No. Formula 294 H,NHN - κ o 295 H 2 NHN O 296 H 2 NHN' O 297 H,NHN O Me 298 H2NHN ,O O 299 138 Preparation No. Formula O 300 /~ H 2 NHN I N -* >* \ / o 301 H 2 NHN-^^ V-N Nl ( -*- O 302 H 2 NHN O 303 Me H 2 NHN o^ O' O ,0. 304 H2NHN "OMe O 305 H 2 NHN' O ^^ OEt 139 Preparation No. Formula O 306 ,OEt H 2 NHN' O 307 H 2 NHN -or OMe O 308 ,OMe H 2 NHN OMe 309 H,NHN' -N 310 "(CH 2 ) 6 CH 3 O 311 MeO H H N N-N K3 O O 140 Preparation No. Formula O 312 0 0 313 " ^γ 0Hγ0 β -O-O o 314 0 0 O 315 " ^ l γ 0 H γo O-O 0 316 0 o 0 317 0 0 141 Preparation No. Formula O 318 MeO H H O O O O o 319 MeO >'- JL N " N O 320 H /—\ -N- ■ N \ / O O D O 321 O "" oG Z 0 " O O 322 MeO' 323 o o o \ r > — i — i Me 142 Preparation No. Formula O 324 o ^ Y oO-^ 0 -^) O _ o O 325 MeO a 326 8 N- H N O O ° — O O ϊ 327 8 ,OMe N- HN 328 O O O O 329 ~^> x o 143 Preparation No. Formula 330 M γ"- δ γ"0 N N O O 331 Oγ O"^ o0- "O" — O o ° ϊ 332 MeO^ g-g OEt O O ^Λ)^ ,OMe 333 Λ o _ o o 334 MeO' O O O 335 MeO 144 Preparation No. Formula 336 0 0 337 0 0 338 0 ° ° Meo - jL - y ^ B-g^ τ _/ ° 339 Cl 340 / \ HN-NH /=\ H 3 C0 2 C— ( ^ ^-^ -0(CH 2 ) 6 OCH 3 00 ^ — ' 341 H J C0 2 C-ζ^7 → O^ ^ O<CHΛCH! 145 Preparation No. Formula H.C β — ^ HN-NH "^ 342 H 3 C0 2 C \ = r /-yj-™^ 0 ™ ! H 3 C0 2 C. HN-NH / === \ 343 00 HN-NH / == \ /^V H 3 C0 2 C— ( )— f~\_/ \_f ~0(Cn2)2CH 344 345 S^ ~ /— 0(CH 2 ) 6 OCH 3 00 346 0(CH 2 ) 6 CH 3 O 347 N N ,= MeO O H -O 146 Preparation No. Formula 348 349 ^Ό J -Ό^O 350 0"C fi H 6 π π 351 H.COoC ^ <\ — 0(CH 2 ) 6 OCH 3 352 H 3 C0 2 C 0(CH 2 ) 6 OCH 3 353 H 3 C0 2 C 0(CH 2 ) 6 OCH 3 147 Preparation No. Formula H 3 C0 2 C 354 0(CH 2 ) 6 OCH 3 355 Br- N ^ r 0(CH 2 ) 6 CH 3 356 MeOOC— 357 MeOOC - N-N ,== N-N -_ 358 359 MeOOC N-N 148 Preparation No. Formula 360 MeOOC - H Q^S^Q^S^Q ^0(CH2)4CH3 N— N N— N 361 Me00C_ 0 N- s yN^ h O N" 362 ooc -0 N- s γNO ~ y} 'o ^ / 363 N-N 364 Meooc -0\ N-- s rN "N ~ °--^ 365 Meooc -O^s → Q^ N C^O 149 Preparation No. Formula N-N 366 MeOOC- // w ,OMe -o' 367 Me00C→ 0γ N-yN → 00 368 MeOOC ^XC N N N-NO" 369 MeOOC → C N s -NO^ N N ""0^ 370 MeOOC II N-N 371 N-N 150 Preparation No. Formula 372 373 Mε00C→ _/ N- s N _/ ° 374 j^ N— s γ N\J-\_f-° ' 375 Me00C ^ t- s N^-λ _/ OEt N OMe 376 N-N MeOOC OMe 377 N-N 151 Preparation No. Formula 378 MeOOC -O' OEt // N-N OEt 379 N—N 380 /=\ MeOOC- -O' OMe \ If N—N 381 ,OMe MQθOC Λ ^ N-γN \ ^ - '& 382 383 0(CH 2 ) 6 CH 3 H00C→ 152 Preparation No. Formula HOOC 384 N MD N-N HOOC 385 N-N HOOC 386 j - O n ' C ή 6H n l 3 N-N =\ N-N ,=. 387 HOOC— ( V\ / io \ / Ό HOOC 388 N-N ,= N-N . 4 / -=. 389 MeOOC— - 153 Preparation No. Formula 390 MeOOC -O- -OKD 391 MeOOC yyD y N-N /= \ ,=. 392 H.COC -CM 0(CH 2 ) 4 CH 3 XT v -v — H 3 C0 2 C 393 __ N-N / =, 394 HOOC OV^ OM 395 HOOC 154 Preparation No. Formula 396 « >CK M> 397 H∞ O ζ K <X > 398 H< *M> O-°-0 399 "--O^ OO / ess \ / s \ / = / SSB / — / — \ 400 Hooc→ ^_MD^ N N - -) • 2HC1 401 HOOC^Q^ S -^^ S - ^ 0(CH 2 ) 4 CH 3 N ' N-N ' N-N ^— J 155 Preparation No. Formula HOOC- -N N 402 N \_/ -o 2HC1 403 H∞c " C)- N C^ 0 ' HCl 404 HOOC HOOC- 405 \ N-N r \ o r ~^ r ~ \ Me -N v_/ > s Me •2HC1 406 HOOC HCl HOOC 407 156 Preparation No. Formula HOOC 408 HCl 409 410 HOOC 411 2HC1 412 2HC1 HOOC 413 * 2HC1 157 Preparation No. Formula 414 415 ^ > N-N 416 - C ^ 417 418 HOOC- V S >-( /)— (v h-QT )Et N-N OEt 419 158 Preparation No. Formula 420 OMe 421 HOOC 422 HOOC-f 423 .HCl 424 HCl 425 HOOC -0(CH 2 ) 6 OCH 3 159 Preparation No. Formula N-N 426 H0 2 C Λ ■ 0(CH 2 ) 4 CH 3 427 HO w CH, HO,C. N-N 428 /V ^, S H )— 0(CH 2 ) 6 OCH 3 H0 2 C 429 HO,C 430 0(CH 2 ) 6 0CH 3 431 HO MD^ S ^O<CH2)" hi CD O o - &> CO CO co CO CO CO O hj © oo σ, π CO to • r+ H- o 13 O o hj CD •0 o n so so en 00 161 Preparation No. Formula 438 Hθ2C→ Q^ ^ 0(CH2)5θMe 439 Hθ2C→ Q" → ^sM ^ o<cHAθMe 440 Hθ2C~ ~ C^sM ^o(cH2),oMe 441 H02C~ O^ → O _0lCHΛ0Me 442 " XK D 443 - (XKX> 162 Preparation No. Formula 444 - iK ^ 445 » κχκx 446 « C0~CK> 447 * >χ>> o 448 H0 2 C^Q-^^ ^O«CH 2 ) 3 CH 3 449 H<v - -( VO →)(αwi11 163 Preparation No. Formula H0 2 C- ^" ^HQ ^ O(CH Λ CH 3 450 451 H ° 2C~ ^ ^° <CH * CH] 0 N-N == 452 ^ΛHJ "o,CHιlA uo 2 c ^^ ^ 453 H 3 C0 2 C— V-C0 2 H H 3 C 454 H 3 C0 2 C— ^ V- C0 2 H CH 3 455 H 3 C0 2 C^^^ C ° 2H H 3 C0 2 C— \-C0 2 H 456 457 164 The following compounds [Preparations 211 to 2531 were obtained in a manner similar to that of Preparation 18. Preparation 211 NMR (CDC1 3 , δ) : 1.10-1.45 (6H, m) , 1.45-2.10 (8H, m) , 3.0-3.80 (6H, m) , 6.97 (2H, d, J=9.0Hz), 7.40-7.65 (3H, m) , 7.90 (2H, d, J=8.9Hz) , 8.13 (2H, d, J=8.2Hz) , 8.18 (2H, d, J=8.7Hz), 8.39 (2H, d, J=8.6Hz) APCI MASS : 581 (M + ) Preparation 212 IR (KBr) : 3008, 2935, 1792, 1770, 1600 cm "1 NMR (CDCI3, δ) : 3.97 (3H, s) , 7.07 (2H, d, J=8.5Hz), 7.43-7.56 (3H, m) , 8.10 (IH, d, J=8.5Hz), 8.23 (2H, d, J=8.5Hz) MASS (m/z) : 270 (M+H + ) Preparation 213 IR (KBr) : 1776, 1234, 1095 cm-1 NMR (CDCI3, δ) : 0.89 (3H, m) , 1.1-2.0 (10H, m) , 3.52 (2H, t, J=6.6Hz), 4.57 (2H, s) , 7.4-7.6 (4H, ) , 7.75 (2H, d, J=8.5Hz), 8.14 (2H, d, J=8.1Hz), 8.22 (IH, s), 8.26 (2H, d, J=8.7Hz), 8.43 (2H, d, J=8.7Hz), 8.59 (IH, s) MASS (m/z) : 594 (M + +l) Preparation 214 NMR (CDCI3, δ) : 1.20-1.60 (5H, m) , 1.70-2.05 (5H, m) , 2.50-2.75 (IH, m) , 7.25-8.50 (12H, m) ESI MASS (positive) : 502.3 (M + +Na) Preparation 215 NMR (CDCI3, δ) : 1.10-2.20 (10H, m) , 4.30-4.50 (IH, m) , 7.04 (2H, d, J=9.1Hz), 7.40-8.50 (10H, m) APCI MASS (positive) : 518.3 (M + +Na) Preparation 216 NMR (CDCI3+CD3OD, δ) : 1.70-2.15 (4H, m) , 2.70-2.90 (IH, m) , 2.90-3.20 (2H, m) , 4.00-4.15 (2H, m) , 7.08 (2H, d, J=9.1Hz), 7.10-7.40 (5H, m) , 7.40-7.70 (3H, ) , 7.90-8.55 (7H, m) 165 APCI MASS : 543 (M + +l) Preparation 217 NMR (CDCI3+CD3OD, δ) : 1.70-2.10 (4H, m) , 2.60-3.15 (3H, m) , 3.90-4.15 (2H, m) , 6.90-7.15 (2H, m) , 7.15-7.40 (6H, m) , 7.40-8.45 (9H, m) Preparation 218 NMR (CDCI3, δ) : 1.20-2.15 (10H, m) , 4.25-4.50 (IH, m) , 7.05 (2H, d, J=6.9Hz), 7.35-7.65 (3H, m) , 8.00-8.50 (7H, m) APCI MASS (positive) : 502.2 (M + +Na) Preparation 219 NMR (CDCI3, δ) : 1.15-2.00 (10H, m) , 2.45-2.75 (IH, m) , 7.30-8.50 (12H, ) APCI MASS (positive) : 466.2 (M + +l) Preparation 220 IR (KBr) : 2978, 2937, 2873, 1772, 1599, 1498, 1439 cm "1 NMR (CDCI3, δ) : 1.27 (3H, t, J=7.0Hz), 3.65 (2H, q, J=7.0Hz), 3.84 (2H, t, J=4.8Hz), 4.20 (2H, t, J=4.8Hz), 7.05 (2H, d, J=8.8Hz), 7.40-7.66 (5H, m) , 7.60 (2H, d, J=8.8Hz) ,7.72 (2H, d, J=8.4Hz), 8.07-8.17 (IH, m) , 8.28 (2H, d, J=8.6Hz), 8.43 (2H, d, J=8.7Hz) MASS (m/z) : 564 (M + +l) Preparation 221 IR (KBr) : 1778.0, 1600.6, 1230.4, 1182.2 cm -1 NMR (CDCI3, δ) : 1.10-1.74 (10H, m) , 2.82 (2H, t, J=7.2Hz) , 3.33 (3H, s), 3.33-3.65 (10H, m) , 6.88-7.02 (4H, m) , 7.32-7.58 (5H, m) , 8.07-8.18 (3H, m) Preparation 222 IR (KBr) : 1810.8, 1600.6, 1257.4, 1178.3 cm "1 NMR (DMSO-d 6 , δ) : 1.30-2.40 (18H, m) , 3.21 (3H, s) , 3.28-3.35 (2H, m) , 4.05 (2H, t, J=6.6Hz), 7.05-7.10 (2H, m) , 7.40-8.18 (6H, m) MASS (m/z) : 536 (M+l) 166 Preparation 223 IR (KBr) : 1776.1, 1677.8, 1251.6, 1197.6 cm -1 NMR (DMSO-d 6 , δ) : 0.91 (3H, t, J=6.9Hz), 1.23-1.55 (4H, m) , 1.60-1.90 (2H, m) , 4.00-4.10 (2H, m) , 7.03-7.09 (2H, m) , 7.39-8.17 (12H, m) MASS (m/z) : 552 Preparation 224 IR (KBr) : 1795.4, 1606.4, 1442.5, 1259.3, 1220.7 cm -1 NMR (DMSO-d 6 , δ) : 1.44-1.95 (8H, m) , 2.71 (3H, s), 2.75 (3H, s), 3.35 (3H, s) , 3.40 (2H, t, J=6.4Hz), 4.05 (2H, t, J=6.4Hz), 7.02 (2H, d, J=8.8Hz), 7.43-7.64 (3H, m) , 7.84 (IH, s) , 7.96-8.15 (3H, m) , 8.34 (IH, s) MASS (m/z) : 558 (M+l) Preparation 225 IR (KBr) : 1697.1, 1604.5, 1251.6 cm -1 NMR (CDC1 3 , δ) : 1.40-2.00 (8H, m) , 3.35 (3H, s) , 3.40 (2H, t, J=6.4Hz), 4.04 (2H, t, J=6.4Hz), 6.97-7.02 (2H, m) , 7.20-8.07 (9H, m) , 8.50-8.54 (IH, m) MASS (m/z) : 506 (M+l) Preparation 226 IR (KBr) : 1778.0, 1602.6, 1238.1 cm "1 NMR (CDCI3, δ) : 1.07 (3H, t, J=7.4Hz), 1.77-1.94 (2H, m) , 4.00 (2H, t, J=6.6Hz), 7.00-7.05 (2H, m) , 7.46-9.56 (16H, m) MASS (m/z) : 568 (M+l) Preparation 227 IR (KBr) : 1778.0, 1604.5, 1257.4, 1172.5 cm "1 NMR (CDCI3, δ) : 1.40-1.90 (8H, m) , 3.35 (3H, s) , 3.41 (2H, t, J=6.3Hz), 4.05 (2H, t, J=6.3Hz), 7.00-7.04 (2H, m) , 7.44-9.04 (12H, m) MASS (m/z) : 580 (M+l) 1 67 Preparation 228 IR (KBr) : 2956, 2933, 2872, 1776, 1601, 1500, 1438 cm "1 NMR (CDC1 3 , δ) : 1.00 (3H, t, J=7.3Hz), 1.40-1.96 (4H, m) , 4.04 (2H, t, J=6.5Hz) , 7.02 (2H, d, J=8.7Hz) , 7.36-7.66 (5H, m) , 7.73 (2H, d, J=8.4Hz), 8.00-8.21 (3H, m) , 8.28 (2H, d, J=8.6Hz) , 8.44 (2H, d, J=8.7Hz) MASS (m/z) : 548 (M + +l) Preparation 229 IR (KBr) : 2870, 1778, 1649, 1601, 1529, 1500, 1471, 1439 cm -1 NMR (CDCI3, δ) : 1.70-2.00 (4H, m) , 3.37 (3H, s), 3.47 (2H, t, J=6.1Hz), 4.06 (2H, t, J=6.1Hz), 7.01 (2H, d, J=8.7Hz), 7.42-7.68 (3H, m) , 7.60 (2H, d, J=8.8Hz), 7.72 (2H, d, J=8.5Hz) , 8.06-8.20 (IH, m) , 8.28 (2H, d, J=8.7Hz), 8.43 (2H, d, J=8.6Hz) MASS (m/z) : 578 (M + +l) Preparation 230 NMR (CDCI3, δ) : 1.29 (3H, t, J=7.0 Hz), 3.60 (2H, q, J=7.0Hz), 4.58 (2H, s), 7.40-7.64 (5H, m) , 7.65 (2H,d, J=8.2Hz), 7.76 (2H, d, J=8.4Hz), 8.09-8.20 (3H, m) , 8.29 (2H, d, J=8.7Hz) , 8.44 (2H, d, J=8.7Hz) MASS (m/z) : 534 (M + +l) Preparation 231 IR (KBr) : 2978, 2937, 2873, 1772, 1599, 1498, 1439 cm "1 NMR (CDCI3, δ) : 3.42 (3H, m) , 3.55-3.74 (4H, m) , 4.65 (2H, s), 7.43-7.63 (5H, m) , 7.65 (2H, d, J=8.2Hz), 7.76 (2H, d, J=8.5Hz), 8.08-8.17 (3H, ) , 8.28 (2H, d, J=8.7Hz), 8.43 (2H, d, J=8.6Hz) MASS (m/z) : 564 (M + +l) Preparation 232 NMR (CDCI3, δ) : 3.41 (3H, s) , 3.54-3.68 (2H, m) ,3.68-3.80 (2H, m) , 3.90 (2H, t, J=4.9Hz) , 4.22 (2H, t, J=4.9Hz) , 7.04 (2H, d, J=8.8Hz), 7.44-7.68 (3H, m) , 7.55 (2H, 1 68 d, J=9.1Hz), 7.72 (2H, d, J=8.5Hz), 8.05-8.20 (3H, m) , 8.27 (2H, d, J=8.6Hz), 8.43 (2H, d, J=8.7Hz) MASS (m/z) : 594 (M + +l) Preparation 233 IR (KBr) : 2976, 2868, 1778, 1601, 1527, 1500, 1471, 1439 cm "1 NMR (CDC1 3 , δ) : 1.22 (3H, t, J=7.0Hz), 2.10 (2H, m) , 3.52 (2H, q, J=7.0Hz), 3.63 (2H, t, J=6.2Hz), 4.14 (2H, t, J=6.5Hz), 7.03 (2H, d, J=8.8Hz), 7.42-7.66 (5H, m) , 7.72 (2H, d, J=8.5Hz), 8.04-8.20 (IH, m) , 8.10 (2H, d, J=8.4Hz), 8.28 (2H, d, J=8.6Hz), 8.43 (2H, d, J=8.6Hz) Preparation 234 IR (KBr) : 2926, 2877, 1768, 1601, 1527, 1500, 1439, 1417 cm -1 NMR (CDCI3, δ) : 2.09 (2H, m) , 3.38 (3H, s) , 3.59 (2H, t, J=6.1Hz), 4.13 (2H, t, J=6.3Hz), 7.03 (2H, d, J=8.8Hz), 7.44-7.66 (5H, m) , 7.72 (2H, d, J=8.5Hz), 8.08-8.18 (3H, m) , 8.28 (2H, d, J=8.7Hz), 8.44 (2H, d, J=8.7Hz) MASS (m/z) : 564 (M + +l) Preparation 235 IR (KBr) : 1776, 1655, 1601, 1529, 1498, 1439 cm "1 NMR (CDCI3, δ) : 3.49 (3H, s) , 3.80 (2H, m) , 4.20 (2H, m) , 7.05 (2H, d, J=8.8Hz), 7.40-7.64 (4H, m) , 7.72 (2H, d, J=8.4Hz), 7.98-8.18 (4H, m) , 8.28 (2H, d, J=8.6Hz), 8.44 (2H, d, J=8.7Hz) MASS (m/z) : 550 (M + +l) Preparation 236 IR (KBr) : 1776, 1603, 1527, 1497, 1439 cm "1 NMR (CDCI3, δ) : 1.19-2.14 (10H, ) , 4.23-4.40 (IH, m) , 7.02 (2H, d, J=8.8Hz), 7.41-7.67 (5H, m) , 7.72 (2H, d, J=8.5Hz), 8.02-8.21 (3H, m) , 8.28 (2H, d, J=8.7Hz), 8.43 (2H, d, J=8.7Hz) MASS (m/z) : 574 (M + +l) 1 69 Preparation 237 IR (KBr) : 2929.3, 2856.1, 1774.2, 1602.6, 1253.5 cm " -'- NMR (CDC1 3 , δ) : 0.80-1.10 (3H, m) , 1 10-1.60 (8H, m) , 1.60-2.00 (2H, m) , 4.03 (2H, t, J=6.5Hz), 6.98 (2H, d, J=8.8Hz), 7.40-7.70 (3H, m) , 7.81 (2H, d, J=8.5Hz), 7.93 (2H, d, J=8.8Hz), 8.12 (2H, d, J=8.1Hz), 8.17 (IH, s), 8.31 (2H, d, J=8.5Hz) APCI MASS (m/z) : 513 Preparation 238 IR (KBr) : 1776, 1603, 1524, 1441, 1414 cm "1 NMR (CDC1 3 , δ) : 1.03-1.43 (5H, m) , 1.54-2.14 (5H, m) , 2.24-2.50 (IH, m) , 2.65-2.86 (4H, m) , 3.23-3.47 (4H, m) , 6.98 (2H, d, J=8.7Hz), 7.41-7.68 (3H, m) , 7.92 (2H, d, J=8.5Hz), 8.13 (IH, d, J=8.2Hz) , 8.24 (2H, d, J=8.2Hz), 8.40 (2H, d, J=8.2Hz) MASS (m/z) : 566 (M + +l) Preparation 239 IR (KBr) : 1772, 1574, 1234 cm "1 NMR (CDCI3, δ) : 2.6-2.75 (4H, m) , 3.2-3.3 (4H, m) , 3.65 (2H, s), 6.8-7.0 (3H, m) , 7.1-7.3 (2H, m) , 7.4-7.6 (4H, m) , 7.74 (2H, d, J=8.5Hz), 8.14 (2H, d, J=8.1Hz), 8.21 (IH, s) , 8.26 (2H, d, J=8.6Hz), 8.43 (2H, d, J=8.6Hz), 8.59 (IH, s) MASS (m/z) : 640 (M + +l) Preparation 240 IR (KBr) : 1780, 1520, 1236, 982 cm "1 NMR (CDCI3, δ) : 1.5-1.8 (6H, m) , 3.42 (4H, t, J=5.6Hz), 7.02 (2H, d, J=9.1Hz), 7.4-7.7 (5H, m) , 8.14 (2H, d, J=10.5Hz), 8.25 (2H, d, J=8.6Hz), 8.42 (2H, d, J=8.6Hz), 8.47 (IH, s) MASS (m/z) : 549 (M + +l) Preparation 241 IR (KBr) : 1776, 1571, 1252 cm "1 NMR (CDCI3, δ) : 0.8-1.0 (3H, m) , 1.2-1.8 (8H, m) , 170 4.02 (2H, t, J=6.5Hz), 7.01 (2H, d, J=9.0Hz), 7.4-7.7 (5H, m) , 8.1-8.3 (4H, m) , 8.43 (2H, d, J=8.6Hz), 8.51 (IH, s) Preparation 242 IR (KBr) : 2927, 2854, 1599, 1531, 1498, 1444 cm "1 MASS (m/z) : 642 (M + +l) Preparation 243 IR (KBr) : 1782, 1597, 1533, 1502, 1444, 1421 cm "1 NMR (CDC1 3 , δ) : 1.30 (6H, d, J=6.3Hz), 2.40-2.58 (2H, m) , 3.49-3.63 (2H, ) , 3.72-3.94 (2H, m) , 7.01 (2H, d, J=8.8Hz), 7.42-7.65 (5H, m) , 7.73 (2H, d, J=8.5Hz), 8.09 (2H, d, J=8.6Hz), 8.14 (IH, d, J=8.4Hz), 8.28 (2H, d, J=8.6Hz), 8.44 (2H, d, J=8.6Hz) MASS (m/z) : 589 (M + +l) Preparation 244 IR (KBr) : 1778, 1603, 1441, 1414 cm "1 NMR (CDCI3, δ) : 0.92 (6H, s) , 1.10-1.84 (8H, m) , 2.16-2.35 (IH, m) , 2.68-2.87 (4H, m) , 3.30-3.46 (4H, m) , 6.98 (2H, d, J=9.0Hz), 7.40-7.65 (3H, m) , 7.93 (2H, d, J=8.8Hz), 8.13 (IH, d, J=8.1Hz), 8.25 (2H, d, J=8.7Hz), 8.40 (2H, d, J=8.6Hz) MASS (m/z) : 594 (M + +l) Preparation 245 IR (KBr) : 1784, 1603, 1520, 1441, 1414 cm "1 NMR (CDCI3, δ) : 1.66-2.14 (4H, m) , 3.07-3.28 (2H, m) , 3.56-3.84 (3H, m) , 4.60 (2H, s) , 6.98 (2H, d, J=9.0Hz), 7.23-7.67 (8H, m) , 7.91 (2H, d, J=8.9Hz), 8.13 (IH, d, J=8.2Hz), 8.23 (2H, d, J=8.6Hz), 8.40 (2H, d, J=8.6Hz) MASS (m/z) : 589 (M + +l) Preparation 246 IR (KBr) : 1780, 1603, 1522, 1441, 1414 cm "1 NMR (CDCI3, δ) : 0.95 (3H, d, J=6.9Hz), 1.37-2.15 (9H, m) , 2.25-2.44 (IH, m) , 2.68-2.92 171 (4H, m) , 3.27-3.50 (4H, m) , 6.98 (2H, d, J=9.0Hz), 7.37-7.67 (3H, m) , 7.93 (2H, d, J=8.9Hz), 8.08-8.18 (IH, m) , 8.24 (2H, d, J=8.6Hz), 8.40 (2H, d, J=8.6Hz) Preparation 247 IR (KBr) : 1778, 1603, 1524, 1441, 1414 cm "1 NMR (CDC1 3 , δ) : 0.90 (3H, d, J=6.4Hz), 0.90-1.13 (2H, m) , 1.13-2.05 (7H, m) , 2.20-2.48 (IH, m),2.62-2.90 (4H, m) , 3.23-3.53 (4H, m) , 6.97 (2H, d,J=9.0Hz), 7.38-7.66 (3H, m) , 7.92 (2H, d, J=8.8Hz), 8.06-8.17 (IH, m) , 8.24 (2H, d, J=8.6Hz) , 8.40 (2H, d, J=8.7Hz) Preparation 248 IR (Nujol) : 1782, 1603 cm "1 NMR (CDCI3, δ) : 1.9-2.3 (4H, m) , 3.03 (3H, s), 3.2-3.5 (2H, m) , 3.6-3.9 (2H, m) , 7.03 (2H, d, J=8.9Hz) , 7.36 (4H, s) , 7.4-7.7 (3H, m) , 7.93 (2H, d, J=8.9Hz) , 8.13 (IH, d, J=8.2Hz) (+)APCI MASS : 623 (M+H) + Preparation 249 IR (KBr) : 2923, 2848, 2823, 1766, 1602, 1515, 1450, 1378, 1259, 1222, 1186, 1153, 1089, 1014, 971 cm -1 NMR (CDCI3, δ) : 1.2-1.5 (5H, m) , 1.6-1.9 (7H, m) , 2.07 (2H, m) , 2.43 (IH, m) , 2.6-2.9 (5H, ) , 3.02 (2H, t, J=8.5Hz), 3.26 (4H, m) , 4.07 (2H, d, J=13Hz) , 6.8-7.1 (4H, m) , 7.12 (2H, d, J=8.6Hz) , 7.3-7.6 (3H, m) , 8.0-8.2 (3H, m) MASS (m/z) : 462 (M+H + ) Preparation 250 IR (KBr) : 1780, 1682, 1655, 1601, 1549, 1498, 1429 cm "1 NMR (CDCI3, δ) : 1.62-1.95 (2H, m) , 2.01 (2H, m) , 2.70-3.18 (3H, m) , 4.64 (2H, m) , 6.80 (IH, d, J=9.1Hz), 7.18-7.40 (5H, m) , 7.40-7.65 (3H, m) , 8.00-8.25 (2H, m) , 8.25 (2H, d, J=8.6Hz), 8.41 (2H, d, J=8.6Hz), 8.76 (IH, d, J=2.3Hz) MASS (m/z) : 560 (M + +l) 172 Preparation 251 IR (KBr) : 1781.9, 1602.6, 1228.4 cm "1 NMR (CDC1 3 , δ) : 1.54-1.87 (6H, m) , 3.35 (3H, s) , 3.38-3.68 (10H,m), 4.00 (2H, t, J=6.4Hz), 6.93-7.05 (6H, m) , 7.39-7.53 (7H, ) , 8.08-8.18 (3H, m) Preparation 252 IR (KBr) : 1776.1, 1600.6, 1232.3 cm "1 NMR (CDC13, δ) : 2.73-2.78 (4H, m) , 2.93-3.73 (9H, ) , 6.94-6.98 (2H, m) , 7.14-7.58 (7H, m) , 8.07-8.15 (3H, m) MASS (m/z) : 440 (M+l) Preparation 253 IR (KBr) : 1778, 1599, 1576, 1527, 1498, 1473, 1439 cm "1 NMR (CDCI3, δ) : 1.47 (3H, t, J=7.0Hz), 4.11 (2H, q, J=7.0Hz), 7.02 (2H, d, J=8.9Hz), 7.42-7.80 (7H, m) , 8.10-8.56 (7H, m) MASS (m/z) : 520 (M + +l) The following compounds [Preparations 254 to 2701 were obtained in a manner similar to that of Preparation 46. Preparation 254 IR (KBr) : 1702.2, 1702.8 cm "1 NMR (DMSO-d 6 , δ) : 3.83 (3H, s) , 8.06 (2H, d, J=8.7Hz), 8.20 (2H, d, J=8.7Hz), 8.24 (IH, s) , 9.31 (IH, s), 10.04 (IH, s) MASS (m/z) : 231 (M + +l) Preparation 255 IR (KBr) : 1722, 1562, 1514, 1346, 1279 cm "1 NMR (CDCI3, δ) : 3.90 (3H, s) , 7.92 (2H, d, J=9.2Hz), 8.16 (IH, s), 8.38 (2H, d, J=9.2Hz), 8.86 (IH, s) MASS (m/z) : 246 (M + +l) Preparation 256 IR (KBr) : 2937, 2856, 2819, 2213, 1608, 1517, 1448, 1384, 1349, 1247, 1224, 1180, 1122 cm "1 NMR (CDCI3, δ) : 1.66 (6H, m) , 3.32 (4H, t, J=5.0Hz), 6.83 (2H, d, J=9.1Hz), 7.46 (2H, d, J=9.1Hz) 173 MASS (m/z) : 187 (M+H + ) Preparation 257 NMR (CDC1 3 , δ) : 3.28 (4H, t, J=4.9Hz), 3.85 (2H, d, J=4.9Hz), 6.87 (2H, d, J=9.0Hz), 7.52 (2H, d, J=9.0Hz) MASS (m/z) : 189 (M+H + ) Preparation 258 NMR (CDCI3, δ) : 1.27 (6H, d, J=6.2Hz), 2.52 (2H, t, J=11.5Hz), 3.57 (2H, dd, J=2.2 and J=12.7Hz), 3.6-3.9 (2H, m) , 6.85 (2H, d, J=9.0Hz), 7.50 (2H, d, J=9.0Hz) MASS (m/z) : 217 (M+H + ) Preparation 259 NMR (CDCI3, δ) : 2.69 (2H, t, J=5.1Hz), 3.77 (2H, t, J=5.1Hz), 6.81 (2H, d, J=9.0Hz), 7.49 (2H, d, J=9.0Hz) MASS (m/z) : 205 (M+H + ) Preparation 260 NMR (CDCI3, δ) : 1.13 (3H, t, J=7.2Hz), 2.47 (2H, q, J=7.2Hz), 2.58 (4H, t, J=5.1Hz), 3.35 (4H, t, J=5.1Hz), 7.22 (2H, d, J=8.8Hz), 7.49 (2H, d, J=8.8Hz) MASS (m/z) : 216 (M+H + ) Preparation 261 NMR (CDCI3, δ) : 1.36 (3H, t, J=7.1Hz), 1.55-1.75 (2H, ) , 1.80-2.10 (4H, m) , 3.00-3.15 (2H, m) , 3.60-4.00 (3H, m) , 4.31 (2H, q, J=7.1Hz), 6.82 (2H, d, J=9.1Hz), 7.90 (2H, d, J=9.1Hz) APCI MASS (positive) : 250.3 (M + +l) Preparation 262 NMR (CDCI3, δ) : 1.37 (3H, t, J=7.1Hz), 1.60-2.10 (4H, m) , 2.55-2.80 (IH, m) , 2.95 (2H, dt, J=3.1Hz, J=12.3Hz) , 3.90-4.05 (2H, m) , 4.32 (2H, q, J=7.1Hz) , 6.90 (2H, d, J=9.1Hz), 7.10-7.35 (4H, m) , 7.93 (2H, d, J=9.1Hz) 174 APCI MASS : 310.3 (M + +l) Preparation 263 NMR (DMSO-d 6 , δ) : 1.29 (3H, t, J=7.1Hz), 3.21-3.34 (4H, m) , 3.40-3.53 (4H, m) , 4.24 (2H, q, J=7.1Hz), 6.81 (IH, t, J=7.2Hz), 7.00 (2H, d, J=7.9Hz), 7.05 (2H, d, J=9.0Hz), 7.25 (2H, t, J=7.9Hz), 7.81 (2H, d, J=8.9Hz) MASS (m/z) : 311 (M + +l) Preparation 264 NMR (DMSO-d 6 , δ) : 1.28 (3H, t, J=7.1Hz), 1.26-1.54 (2H, m) , 1.64-1.90 (2H, m) , 2.90-3.16 (2H, m) , 3.58-3.84 (3H, m) , 4.23 (2H, q, J=7.1Hz) , 4.75 (IH, brs) , 6.95 (2H, d, J=9.1Hz), 7.76 (2H, d, J=9.0Hz) MASS (m/z) : 250 (M + +l) Preparation 265 IR (KBr) : 2939, 2843, 1703, 1601, 1552, 1497, 1439, 1414 cm "1 NMR (DMSO-d 6 , δ) : 1.59 (2H, m) , 1.87 (2H, m) , 2.78-3.15 (3H, m) , 3.79 (3H, s) , 4.62 (2H, m) , 6.92 (IH, d, J=9.1Hz), 7.21 (5H, m) , 7.94 (IH, dd, J=9.1 and 2.3Hz), 8.65 (IH, d, J=2.3Hz) MASS (m/z) : 297 (M + +l) Preparation 266 IR (KBr) : 1707, 1610, 1516, 1444 cm -1 NMR (DMSO-d 6 , δ) : 1.04-1.30 (5H, m) , 1.28 (3H, t, J=7.1Hz), 1.47-1.86 (5H, m) , 2.16-2.34 (IH, m) , 2.52-2.64 (4H, m) , 3.19-3.34 (4H, m),4.23 (2H, q, J=7.1Hz), 6.95 (2H, d, J=9.0Hz), 7.77 (2H, d, J=8.9Hz) MASS (m/z) : 317 (M + +l) Preparation 267 IR (Nujol) : 1699, 1606 cm "1 NMR (CDC1 3 , δ) : 1.37 (3H, t, J=7.1Hz), 1.9-2.2 (4H, m) , 3.01 (3H, s), 3.2-3.4 (2H, m) , 3.6-3.8 (2H, m) , 4.33 (2H, q, J=7.1Hz) 175 ( + ) APCI MASS : 374 (M+H) + Preparation 268 IR (KBr) : 2927, 2850, 2212, 1602, 1517, 1442, 1394, 1253, 1178, 1143, 927, 823 cm "1 NMR (CDC1 3 , δ) : 1.2 (5H, m) , 1.65 (IH, m) , 1.85 (4H, m) , 2.30 (lH,m), 2.70 (4H, t, J=5.1Hz), 3.32 (4H, t, J=5.1Hz), 6.85 (2H, d, J=9.0Hz), 7.48 (2H, d, J=9.0Hz) MASS (m/z) : 270 (M+H + ) Preparation 269 Preparation 270 IR (KBr) : 1708.6, 1288.2, 1230.4 cm -1 NMR (CDCI3, δ) : 1.38 (3H, t, J=7.1Hz), 1.50-1.87 (6H, m) , 3.34 (3H, s) , 3.37-3.53 (10H, m) , 4.00 (2H, t,J=6.4Hz), 4.34 (2H, q, J=7.1Hz), 6.90-7.04 (6H, m), 7.45-7.51 (4H, m) , 7.94-7.98 (2H, m) MASS (m/z) : 503 (M+l) The following compounds [Preparations 271 to 2791 were obtained in a manner similar to that of Preparation 16. Preparation 271 IR (KBr) : 1724, 1558, 1521, 1257 cm -1 NMR (CDCI3, δ) : 0.91 (3H, t, J=6.9Hz), 1.3-1.9 (8H, m) , 3.87 (3H, s), 3.99 (2H, t, J=6.5Hz), 6.98 (2H, d, J=9.0Hz), 7.58 (2H, d, J=9.0Hz), 8.30 (IH, s) , 8.53 (IH, s) MASS (m/z) : 303 (M + +l) Preparation 272 NMR (CDCI3, δ) : 1.44 (3H, t, J=7.0Hz), 4.08 (2H, qt, J=7.0Hz), 6.98 (2H, d, J=8.8Hz), 7.56 (2H, d, J=8.8Hz), 7.62 (2H, d, J=8.6Hz), 8.07 (2H, d, J-8.6HZ) MASS (m/z) : 257 (M + +l) Preparation 273 IR (KBr) : 2947, 2875, 1722, 1603, 1527, 1495, 1435 cm "1 17 6 NMR (CDCI3, δ) : 1.88-2.18 (4H, m) , 3.51 (2H, m) , 3.93 (3H, s), 4.05 (2H, m) , 6.98 (2H, d, J=8.6Hz) ,7.50-7.70 (4H, m) , 8.08 (2H, d, J=8.2Hz) MASS (m/z) : 363 (M + +l), 365 (M + +3) Preparation 274 NMR (CDCI3, δ) : 3.40 (3H, s) , 3.60 (2H, m) , 3.73 (2H, m) , 3.89 (2H, m) , 3.93 (3H, s) , 4.20 (2H, m) , 7.01 (2H, d, J=8.8Hz), 7.56 (2H, d, J=8.8Hz), 7.62 (2H, d, J=8.6Hz), 8.08 (2H, d, J=8.6Hz) MASS (m/z) : 331 (M + +l) Preparation 275 NMR (CDCI3, δ) : 1.26 (3H, t, J=7.0Hz), 3.62 (2H, q, J=7.0Hz), 3.76-3.87 (2H, m) , 3.93 (3H, s) , 4.12- 4.24 (2H, m) , 6.96-7.08 (2H, m) , 7.52-7.70 (4H, m) , 8.02-8.14 (2H, m) MASS (m/z) : 301 (M + +l) Preparation 276 IR (KBr) : 2949, 2877, 1722, 1695, 1603, 1529, 1497, 1435 cm "1 NMR (CDCI3, δ) : 3.47 (3H, s) , 3.78 (2H, m) , 3.93 (3H, s), 4.18 (2H, ) , 6.95-7.08 (2H, m) , 7.48-7.68 (4H, m) , 8.00-8.12 (2H, m) MASS (m/z) : 287 (M + +l) Preparation 277 IR (KBr) : 2954, 2873, 1718, 1610, 1544, 1494, 1471, 1280, 1249, 1110 cm "1 MASS (m/z) : 408 ( (M-TFA) +H + ) Preparation 278 IR (KBr) : 2935, 2867, 1720, 1610, 1544, 1494, 1471, 1436, 1405, 1332, 1280, 1249, 1176, 1110 cm "1 MASS (m/z) : 436 (M+H + ) Preparation 279 IR (KBr) : 2950, 2867, 1708, 1608, 1525, 1471, 1409, 1305, 1259, 1274, 1176, 1103 cπT 1 MASS (m/z) : 450 (M+H + ) 177 The following compounds [Preparations 280 to 3091 were obtained in a manner similar to that of Preparation 47. Preparation 280 IR (KBr) : 1653, 1626, 1574, 1524 cm "1 NMR (DMS0-d 6 , δ) : 0.85 (3H, m) , 1.1-1.6 (10H, m) , 3.44 (2H, t, J=6.4Hz), 4.42 (2H, brs) , 4.48 (2H, s), 7.44 (2H, d, J=8.6Hz) , 7.82 (2H, d, J=8.6Hz) , 8.12 (lH,s) , 8.88 (IH, s), 9.48 (IH, brs) MASS (m/z) : 331 (M + +l) Preparation 281 IR (KBr) : 1657, 1603, 1570, 1516, 1313 cm "1 NMR (DMSO-d 6 , δ) : 2.4-2.6 (4H, m) , 3.0-3.2 (4H, m) , 3.57 (2H, s), 4.41 (2H, d, J=4.3Hz), 6.76 (IH, t, J=7.8Hz), 6.92 (2H, d, J=7.8Hz), 7.20 (2H, t, J=7.8Hz), 7.47 (2H, t, J=8.5Hz), 7.81 (2H, d, J=8.5Hz), 8.12 (IH, s) , 8.88 (IH, s),9.48 (IH, t, J=4.3Hz) MASS (m/z) : 377 (M + +l) Preparation 282 IR (KBr) : 1632, 1562, 1516 cm "1 NMR (DMSO-d 6 , δ) : 1.5-1.8 (6H, m) , 3.0-3.3 (4H, m) , 4.38 (2H, d, J=3.9Hz), 7.03 (2H, d, J=9.1Hz), 8.04 (IH, s), 8.70 (IH, s), 9.41 (IH, brs) MASS (m/z) : 286 (M + +l) Preparation 283 IR (KBr) : 1649, 1623, 1522 cm "1 NMR (DMSO-d 6 , δ) : 0.8-1.0 (3H, m) , 1.2-1.8 (8H, m) , 4.00 (2H, t, J=4.0Hz), 4.39 (2H, d, J=4.0Hz) , 7.05 (2H, d, J=9.0Hz), 7.72 (2H, d, J=9.0Hz) , 8.07 (IH, s) , 8.76 (IH, s), 9.44 (IH, t, J=4.0Hz) MASS (m/z) : 303 (M + +l) Preparation 284 IR (KBr) : 1618, 1560, 1525 cm -1 NMR (DMSO-d 6 , δ) : 1.9-2.1 (4H, ) , 3.1-3.3 (4H, m) , 4.38 (2H, brs), 6.62 (2H, d, J=9.0Hz), 7.58 (2H, d, 178 J=9.0Hz), 8.02 (IH, s), 8.64 (IH, s),9.40 (IH, brs) MASS (m/z) : 294 (M + +23) Preparation 285 NMR (CDC1 3 , δ) : 1.10-1.40 (5H, m) , 1.40-2.10 (10H, m) , 2.90-3.15 (2H, m) , 3.25-3.50 (IH, m) , 3.50-3.75 (3H, m) , 4.05 (2H, d, J=3.9Hz), 6.88 (2H, d, J=9.0Hz), 7.63 (2H, dd, J=9.0 and 2.0Hz) APCI MASS (positive) : 318.3 (M + +l) Preparation 286 NMR (CDCI3, δ) : 1.70-2.10 (4H, m) , 2.60-2.85 (IH, m) , 2.85-3.05 (2H, m) , 3.05-3.50 (2H, m) , 3.85-4.10 (2H, m) , 6.85-7.00 (2H, m), 7.10-7.40 (5H, m) , 7.68 (2H, d, J=8.8Hz) APCI MASS : 296 (M + +l) Preparation 287 NMR (CDCI3, δ) : 1.20-2.10 (10H, m) , 4.10 (2H, brs), 4.20-4.40 (IH, m) , 6.91 (2H, d, J=8.9Hz), 7.49 (IH, brs), 7.78 (2H, d, J=8.9Hz) ESI MASS : 257.3 (M + +Na) Preparation 288 NMR (CDCI3, δ) : 1.10-1.55 (5H, m) , 1.60-2.00 (5H, m) , 2.40-2.65 (IH, m) , 7.25 (2H, d, J=8.2Hz), 7.67 (2H, d, J=8.2Hz) APCI MASS : 219 (M + +l) Preparati n 289 IR (KBr) : 2958, 2929, 2850, 2821, 1651, 1628, 1603, 1529, 1487, 1443 cm "1 NMR (DMSO-d 6 , δ) : 1.00-1.36 (5H, m) , 1.50-1.92 (5H, m) , 2.16-2.38 (IH, m) , 2.57-2.64 (4H, m) , 3.10-3.28 (4H, m) , 4.48 (2H, s) , 7.01 (2H, d, J=8.9Hz), 7.59 (2H, d, J=8.8Hz), 7.67 (2H, d, J=8.5Hz), 7.86 (2H, d, J=8.4Hz), 9.76 (IH, s) MASS (m/z) : 379 (M + +l) Preparation 290 NMR (DMSO-d 6 , δ) : 3.13-3.54 (8H, m) , 4.38 (2H, s), 6.81 179 (IH, t, J=7.2Hz) , 7.00 (2H, d, J=6.9Hz), 7.01 (2H, d, J=8.8Hz), 7.24 (2H, t, J=7.9Hz), 7.74 (2H, d, J=8.8Hz) , 9.51 (IH, s) MASS (m/z) : 297 (M + +l) Preparation 291 NMR (DMSO-d 6 , δ) : 0.87 (3H, t, J=7.4Hz), 1.37-1.60 (4H, m) , 1.80-1.98 (2H, m) , 2.90-3.10 (2H, m) , 3.38 (2H, t, J=6.6Hz), 3.38-3.70 (3H, m) , 4.34 and 4.35 (2H, s), 6.92 (2H, d, J=9.0Hz), 7.68 (2H, d, J=8.9Hz), 9.45 (IH, brs) MASS (m/z) : 278 (M + +l) Preparation 292 IR (KBr) : 1666, 1605, 1545, 1495, 1448 cm "1 NMR (DMSO-d 6 , δ) : 1.17 (6H, d, J=6.1Hz), 2.20-2.38 (2H, m) , 3.59-3.78 (4H, m) , 4.49 (2H, s) , 7.03 (2H, d, J=8.9Hz), 7.61 (2H, d, J=8.8Hz), 7.69 (2H, d, J=8.5Hz), 7.87 (2H, d, J=8.4Hz), 9.77 (lH, ~ s) MASS (m/z) : 326 (M + +l) Preparation 293 NMR (DMSO-d 6 , δ) : 0.88 (6H, s) , 1.05-1.52 (6H, m) , 1.52-1.73 (2H, m) , 2.08-2.26 (IH, m) , 2.52-2.72 (4H, m) , 3.10-3.31 (4H, m) , 4.36 (2H, s) , 6.91 (2H, d, J=8.9Hz), 7.69 (2H, d, J=8.8Hz), 9.46 (IH, s) MASS (m/z) : 331 (M + +l) Preparation 294 IR (KBr) : 1637, 1606, 1554, 1508, 1456 cm "1 NMR (DMSO-d 6 , δ) : 1.46-1.70 (2H, m) , 1.87-2.06 (2H, m) , 2.92-3.12 (2H, m) , 3.52-3.73 (3H, m) , 4.35 (2H, s) , 4.54 (2H, s), 6.94 (2H, d, J=8.9Hz), 7.20-7.42 (5H, m) , 7.69 (2H, d, J=8.8Hz), 9.45 (IH, s) MASS (m/z) : 326 (M + +l) Preparation 295 NMR (DMSO-d 6 , δ) : 1.16-2.04 (10H, m) , 4.29-4.51 (IH, m) , 4.51 (2H, s), 7.03 (2H, d, J=8.8Hz), 7.64 (2H, d, J=8.8Hz), 7.69 (2H, d, J=8.4Hz), 7.88 (2H, d, 180 J=8.4Hz), 9.79 (IH, s) MASS (m/z) : 311 (M + +l) Preparation 296 IR (KBr) : 2912, 2870, 2846, 1608, 1597, 1533, 1493, 1423 cm "1 NMR (CDC1 3 , δ) : 1.74 (2H, m) , 1.97 (2H, m) , 2.70-3.12 (3H, m) , 3.31 (2H, brs), 4.58 (2H, m) , 6.69 (IH, d, J=9.0Hz) , 7.05-7.55 (6H, m) , 7.88 (IH, dd, J=9.0 and 2.3Hz), 8.56 (IH, d, J=2.3Hz) MASS (m/z) : 297 (M + +l) Preparation 297 NMR (DMSO-d 6 , δ) : 1.35 (3H, t, J=7.0Hz), 4.07 (2H, q, J=7.0Hz), 4.50 (2H, s), 7.02 (2H, d, J=8.8Hz), 7.66(2H, d, J=8.7Hz), 7.70 (2H, d, J=8.4Hz), 7.89 (2H, d, J=8.4Hz), 9.79 (IH, s) MASS (m/z) : 257 (M + +l) Preparation 298 IR (KBr) : 2956, 2916, 2870, 1612, 1535, 1514, 1493 cm "1 NMR (DMSO-d 6 , δ) : 1.55-1.87 (4H, m) , 3.24 (3H, s) , 3.38 (2H, t, J=6.2Hz), 4.03 (2H, t,- J=6.1Hz), 4.57 (2H, brs), 7.03 (2H, d, J=8.7 Hz), 7.58-7.78 (4H, m) , 7.89 (2H, d, J=8.3Hz), 9.79 (IH, s) MASS (m/z) : 315 (M + +l) Preparation 299 IR (KBr) : 1626, 1606, 1566, 1524, 1498, 1454 cm "1 NMR (DMSO-d 6 , δ) : 1.00-1.35 (5H, m) , 1.35-1.90 (5H, m) , 2.16-2.36 (IH, m) , 2.54-2.69 (4H, ) , 3.12-3.28 (4H, m) , 4.35 (2H, s) , 6.91 (2H, d, J=8.9Hz), 7.69 (2H, d, J=8.8Hz), 9.46 (IH, s) MASS (m/z) : 303 (M + +l) Preparation 300 IR (KBr) : 1659, 1626, 1606, 1531, 1498, 1446 cm "1 NMR (DMSO-d 6 , δ) : 0.89 (3H, d, J=6.8Hz), 1.32-1.80 (9H, m) , 2.10-2.26 (IH, m) , 2.50-2.65 (4H, m) , 181 3.15-3.30 (4H, m) , 4.36 (2H, s) , 6.92 (2H, d, J=9.0Hz), 7.69 (2H, d, J=8.8Hz), 9.46 (IH, s) MASS (m/z) : 317 (M + +l) Preparation 301 IR (KBr) : 1660, 1606, 1549, 1506, 1446 cm "1 NMR (DMSO-d 6 , δ) : 0.86 (3H, d, J=6.4Hz), 0.84-1.05 (2H, m) , 1.05-1.54 (3H, m) , 1.60-1.90 (4H, m) , 2.12-2.33 (IH, m) , 2.54-2.65 (4H, m) , 3.11-3.27 (4H, m) , 4.36 (2H, s) , 6.91 (2H, d, J=8.9Hz) , 7.69 (2H, d, J=8.8Hz) , 9.46 (IH, s) MASS (m/z) : 317 (M + +l) Preparation 302 NMR (DMSO-d 6 , δ) : 1.17 (3H, t, J=7.0Hz), 3.51 (2H, q, J=7.0Hz), 4.50 (2H, m) , 4.52 (2H, s), 7.42 (2H, d, J=8.2Hz), 7.66-7.80 (4H, m) , 7.92 (2H, d, J=8.9Hz), 9.83 (IH, s) MASS (m/z) : 271 (M + +l) Preparation 303 NMR (DMSO-d 6 , δ) : 3.27 (3H, m) , 3.45-3.68 (4H, ) , 4.54 (4H, s), 7.43 (2H, d, J=8.2Hz), 7.66-7.81 (4H, m) , 7.92 (2H, d, J=8.4Hz), 9.83 (IH, s) MASS (m/z) : 301 (M + +l) Preparation 304 NMR (DMSO-d 6 , δ) : 3.25 (3H, s) , 3.44-3.55 (2H, m) , 3.55-3.65 (2H, m) , 3.73-3.86 (2H, m) , 4.08-4.20 (2H, m) , 4.52 (2H, s) , 7.05 (2H, d, J=8.8Hz), 7.67 (2H, d, J=8.7Hz), 7.70 (2H, d, J=8.4Hz), 7.89 (2H, d, J=8.5Hz), 9.80 (IH, s) MASS (m/z) : 331 (M + +l) Preparation 305 NMR (DMSO-d 6 , δ) : 1.11 (3H, t, J=7.0Hz), 1.96 (2H, m) , 3.43 (2H, q, J=7.0Hz), 3.52 (2H, t, J=6.4Hz), 4.07 (2H, t, J-6.4HZ) , 4.50 (2H, s) , 7.03 (2H, d, J=8.8Hz) , 7.66 (2H, d, J=8.7Hz), 7.70 (2H, d, J=8.5Hz), 7.89 (2H, d, J=8.4Hz), 9.79 (IH, s) 182 MASS (m/z) : 315 (M + +l) Preparation 306 NMR (DMSO-d 6 , δ) : 1.14 (3H, t, J=7.0Hz), 3.51 (2H, q, J=7.0Hz) , 3.66-3.80 (2H, m) , 4.07-4.20 (2H, m) , 4.51 (2H, s) , 7.05 (2H, d, J=8.8Hz) , 7.67 (2H, d, J=8.8Hz) , 7.70 (2H, d, J=8.4Hz), 7.89 (2H, d, J=8.4Hz), 9.79 (IH, s) MASS (m/z) : 301 (M + +l) Preparation 307 IR (KBr) : 2933, 2873, 1608, 1531, 1491 cm "1 NMR (DMSO-d 6 , δ) : 1.97 (2H, m) , 3.26 (3H, s) , 3.49 (2H, t, J=6.3Hz), 4.07 (2H, t, J=6.4Hz), 4.50 (2H, brs), 7.03 (2H, d, J=8.8Hz), 7.66 (2H, d, J=8.7Hz), 7.70 (2H, d, J=8.5Hz), 7.88 (2H, d, J=8.4Hz), 9.79 (IH, s) MASS (m/z) : 301 (M + +l) Preparation 308 IR (KBr) : 2927, 2881, 1630, 1606, 1533, 1489 cm "1 NMR (DMSO-d 6 , δ) : 3.32 (3H, s), 3.67 (2H, m) , 4.14 (3H, s), 4.52 (2H, s) , 7.05 (2H, d, J=8.8Hz), 7.67 (2H, d, J=8.8Hz), 7.70 (2H, d, J=8.6Hz), 7.89 (2H, d, J=8.4Hz), 9.79 (IH, s) MASS (m/z) : 287 (M + +l) Preparation 309 IR (Nujol) : 3292, 1603 cm "1 NMR (DMSO-d 6 , δ) : 1.8-2.2 (4H, ) , 2.92 (3H, s) , 3.0-3.2 (2H, m) , 3.6-3.8 (2H, m) , 4.36 (2H, s), 6.98 (2H, d, J=8.8Hz), 7.44 (4H, s) , 7.71 (2H, d, J=8.8Hz), 9.46 (IH, s) (+)APCI MASS : 360 (M+H) + The following compounds [Preparations 310 to 3451 were obtained in a manner similar to that of Preparation 7. Preparation 310 IR (KBr) : 1724, 1282 cm "1 NMR (DMSO-d 6 , δ) : 0.86 (3H, t, J=6.9Hz), 1.1-1.6 (10H, 183 m) , 3.45 (2H, t, J=6.4Hz), 3.90 (3H, s) , 4.50 (2H, s), 7.48 (2H, d, J=8.6Hz), 7.86 (2H, d, J=8.6Hz), 8.04 (2H, d, J=8.7Hz), 8.11 (2H, d, J=8.7Hz), 8.26 (IH, s), 9.02 (IH, s), 10.37 (IH, s), 10.70 (IH, s) MASS (m/z) : 493 (M + +l) Preparation 31 IR (KBr) : 1718, 1614, 1279 cm "1 NMR (DMSO-dg, δ) : 2.4-2.6 (4H, m) , 3.0-3.2 (4H, m) , 3.59 (2H, s), 3.90 (3H, s) , 6.77 (IH, t, J=7.7Hz), 6.92 (2H, d, J=7.7Hz), 7.20 (2H, t, J=7.7Hz), 7.50 (2H, t, J=8.5Hz), 7.86 (2H, d, J=8.5Hz), 8.04 (2H, t, J=8.6Hz), 8.11 (2H, d, J=8.6Hz), 8.26 (IH, s) , 9.02 (IH, s), 10.37 (IH, s), 10.70 (IH, s) MASS (m/z) : 539 (M + +l) Preparation 312 NMR (DMSO-dg, δ) : 1.10-2.00 (14H, m) , 2.95-3.15 (2H, m) , 3.40-3.75 (4H, ) , 3.90 (3H, s) , 7.00 (2HA d, J=8.9Hz), 7.80 (2H, d, J=8.8Hz), 8.03 (2H, d, J=8.7Hz), 8.10 (2H, d, J=8.7Hz), 10.25 (IH, s) , 10.58 (IH, s) APCI MASS (positive) : 480.3 (M + +l) Preparation 313 IR (KBr) : 1724, 1635, 1570, 1520, 1279 cm -1 NMR (DMSO-dg, δ) : 1.5-1.7 (6H, m) , 3.1-3.3 (4H, m) , 3.90 (3H, s), 7.05 (2H, d, J=9.1Hz), 7.66 (2H, d, J=9.1Hz), 8.04 (2H, d, J=8.7Hz), 8.11 (2H, d, J=8.7Hz), 8.85 (IH, s) , 10.30 (IH, s) , 10.68 (IH, s) MASS (m/z) : 448 (M + +l) Preparation 314 IR (KBr) : 1716, 1603, 1552, 1521, 1470, 1284, 1257 cm "1 NMR (DMSO-dg, δ) : 0.89 (3H, t, J=6.8Hz), 1.2-1.8 (8H, m) , 3.90 (3H, s), 4.02 (2H, t, J=6.4Hz), 7.08 (2H, d, J=9.0Hz), 7.77 (2H, d, J=9.0Hz), 8.04 (2H, d, 184 J=8.7Hz), 8.11 (2H, d, J=8.7Hz), 8.91 (IH, s) , 10.33 (IH, s), 10.69 (IH, s) MASS (m/z) : 465 (M + +l) Preparation 315 NMR (DMSO-dg, δ) : 1.60-1.95 (4H, m) , 2.65-3.00 (3H, m) , 3.90 (3H, s), 4.04 (2H, m) , 7.05 (2H, d, J=8.9Hz), 7.10-7.40 (5H, m) , 7.83 (2H, d, J=8.9Hz), 8.00-8.15 (4H, m) , 10.27 (IH, s) , 10.59 (IH, s) APCI MASS : 458 (M + ) Preparation 316 IR (KBr) : 1720, 1645, 1560, 1525, 1281 cm "1 NMR (DMSO-dg, δ) : 1.9-2.1 (4H, m) , 3.2-3.4 (4H, m) , 3.90 (3H, s) , 6.64 (2H, d, J=9.0Hz), 7.63 (2H, d, J=9.0Hz), 8.04 (2H, d, J=8.7Hz), 8.11 (2H, d, J=8.7Hz), 8.15 (IH, s) , 8.78 (IH, s) , 10.28 (IH, s) , 10.67 (IH, s) MASS (m/z) : 456 (M + +23) Preparation 317 NMR (DMSO-dg, δ) : 1.10-2.10 (10H, m) , 3.90 (3H, s) , 4.35-4.55 (IH, m) , 7.04 (2H, d, J=8.8Hz), 7.88 (2H, d, J=8.8Hz) , 8.00-8.15 (4H, m) , 10.41 (IH, s) , 10.64 (IH, s) APCI MASS (m/z) : 397 (M + +l) Preparation 318 NMR (DMSO-dg, δ) : 1.15-1.60 (5H, m) , 1.60-1.90 (5H, m) , 2.50-2.70 (IH, m) , 3.90 (3H, s) , 7.37 (2H, d, J=8.3Hz), 7.85 (2H, d, J=8.2Hz), 8.00-8.15 (4H, m) , 10.48 (IH, s), 10.68 (IH, s) APCI MASS : 381 (M + +l) Preparation 319 IR (KBr) : 2927, 2852, 1722, 1684, 1645, 1603, 1495, 1446 cm "1 NMR (DMSO-dg, δ) : 1.00-1.36 (5H, m) , 1.51-1.91 (5H, m) , 2.20-2.38 (IH, ) , 2.56-2.72 (4H, m) , 3.12-3.28 (4H, m) , 3.90 (3H, s) , 7.03 (2H, d, J=8.9Hz), 7.64 185 (2H, d, J=8.7Hz), 7.77 (2H, d, J=8.5Hz), 7.97 (2H, d, J=8.4Hz), 8.00-8.16 (4H, m) , 10.57 (IH, s) , 10.71 (IH, s) MASS (m/z) : 541 (M + +l) Preparation 320 NMR (DMSO-dg, δ) : 3.21-3.54 (8H, m) , 3.90 (3H, s) , 6.82 (IH, t, J=7.2Hz), 7.01 (2H, d, J=7.9Hz), 7.08 (2H, d, J=8.9Hz), 7.25 (2H, t, J=7.9Hz), 7.85 (2H, d, J=8.8Hz), 8.04 (2H, d, J=8.6Hz), 8.09 (2H, d, J=8.6Hz), 10.31 (IH, s), 10.60 (IH, s) MASS (m/z) : 459 (M + +l) Preparation 321 NMR (DMSO-dg, δ) : 0.88 (3H, t, J=7.4Hz), 1.41-1.63 (4H, m) , 1.84-2.01 (2H, m) , 2.96-3.16 (2H, m) , 3.40 (2H, t, J=6.6Hz), 3.40-3.76 (3H, m) , 3.90 (3H, s) , 7.00 (2H, d, J=8.9Hz), 7.80 (2H, d, J=8.8Hz), 8.00-8.16 (4H, m) , 10.25 (IH, s) , 10.58 (IH, s) MASS (m/z) : 440 (M + +l) Preparation 322 NMR (DMSO-dg, δ) : 1.18 (6H, d, J=6.1Hz), 2.18-2.43 (2H, m) , 3.51-3.83 (4H, m) , 3.90 (3H, s) , 7.06 (2H, d, J=8.9Hz), 7.66 (2H, d, J=8.7Hz), 7.78 (2H, d, J=8.4Hz), 7.98 (2H, d, J=8.4Hz), 7.98-8.16 (4H, m) , 10.58 (IH, s), 10.71 (IH, s) MASS (m/z) : 488 (M + +l) Preparation 323 NMR (DMSO-dg, δ) : 0.89 (6H, s) , 1.05-1.72 (8H, m) , 2.09-2.30 (IH, m) , 2.54-2.73 (4H, m) , 3.14-3.37 (4H, m) , 3.90 (3H, s) , 6.99 (2H, d, J=8.9Hz), 7.81 (2H, d, J=8.8Hz), 8.03 (2H, d, J=8.6Hz), 8.09 (2H, d, J=8.7Hz), 10.26 (IH, s) , 10.58 (IH, s) MASS (m/z) : 493 (M + +l) Preparation 324 IR (KBr) : 1714, 1687, 1653, 1605, 1560, 1522, 1460, 1439 cm "1 186 NMR (DMSO-dg, δ) : 1.45-1.70 (2H, m) , 1.87-2.10 (2H, m) , 2.98-3.20 (2H, m) , 3.56-3.78 (3H, m) , 3.90 (3H, s) , 4.56 (2H, s) , 7.01 (2H, d, J=9.0Hz), 7.21-7.46 (5H, m) , 7.80 (2H, d, J=8.8Hz), 8.04 (2H, d, J=8.7Hz), 8.09 (2H, d, J=8.7Hz), 10.26 (IH, s) , 10.58 (IH, s) MASS (m/z) : 488 (M + +l) Preparation 325 NMR (DMSO-dg, δ) : 1.18-2.05 (10H, m) , 3.90 (3H, s) , 4.34-4.50 (IH, m) , 7.05 (2H, d, J=8.8Hz), 7.69 (2H, d, J=8.7Hz), 7.78 (2H, d, J=8.4Hz), 8.00 (2H, d, J=8.4Hz), 8.06 (2H, d, J=8.6Hz), 8.11 (2H, d, J=8.6Hz), 10.60 (IH, s), 10.72 (IH, s) MASS (m/z) : 473 (M + +l) Preparation 326 IR (KBr) : 2945, 2852, 1720, 1693, 1645, 1601, 1524, 1485 cm "1 NMR (DMSO-dg, δ) : 1.61 (2H, m) , 1.87 (2H, m) , 2.78-3.14 (3H, m) , 3.90 (3H, s) , 4.61 (2H, m) , 6.96 (IH, d, J=9.2Hz), 7.27 (5H, m) , 7.98-8.10 (IH, m) , 8.03 (2H, d, J=8.7Hz), 8.10 (2H, d, J=8.6Hz), 8.70 (IH, d, J=2.3Hz), 10.34 (IH, s) , 10.62 (IH, s) MASS (m/z) : 459 (M + +l) Preparation 327 NMR (DMSO-dg, δ) : 1.36 (3H, t, J=7.0Hz), 3.90 (3H, s) , 4.09 (2H, q, J=6.9Hz), 7.04 (2H, d, J=8.8Hz), 7.71 (2H, d, J=8.8Hz), 7.79 (2H, d, J=8.4Hz), 8.00 (2H, d, J=8.5Hz), 8.06 (2H, d, J=8.8Hz), 8.10 (2H, d, J=8.7Hz), 10.60 (IH, s) , 10.72 (IH, s) MASS (m/z) : 419 (M + +l) Preparat n 328 IR (KBr) : 2951, 2872, 1724, 1680, 1651, 1605, 1554, 1497, 1439 cm "1 NMR (DMSO-dg, δ) : 1.57-1.89 (4H, m) , 3.25 (3H, s) , 3.39 (2H, t, J=6.2Hz), 3.91 (3H, s) , 4.05 (2H, t, J=6.1Hz), 7.05 (2H, d, J=8.8Hz), 7.71 (2H, d, J=8.7Hz), 7.79 187 (2H, d, J=8.4Hz), 8.00 (2H, d, J=8.5Hz), 8.06 (2H, d, J=8.7Hz), 8.10 (2H, d, J=8.7Hz), 10.61 (IH, s) , 10.73 (IH, s) MASS (m/z) : 477 (M + +l) Preparation 329 IR (KBr) : 1720, 1678, 1643, 1608, 1564, 1525, 1502 cm "1 NMR (DMSO-dg, δ) : 0.96-1.36 (5H, m) , 1.49-1.91 (5H, m) , 2.16-2.35 (IH, m) , 2.52-2.75 (4H, m) , 3.10-3.35 (4H, m) , 3.90 (3H, s), 6.99 (2H, d, J=8.9Hz), 7.81 (2H, d, J=8.8Hz), 8.04 (2H, d, J=8.6Hz), 8.09 (2H, d, J=8.7Hz), 10.27 (IH, s) , 10.59 (IH, s) MASS (m/z) : 465 (M + +l) Preparation 330 IR (KBr) : 1722, 1676, 1641, 1608, 1500, 1446 cm -1 NMR (DMSO-dg, δ) : 0.90 (3H, d, J=6.8Hz), 1.30-1.85 (9H, m) , 2.11-2.30 (IH, m) , 2.63-2.69 (4H, m) , 3.1.8-3.38 (4H, m) , 3.90 (3H, s) , 6.99 (2H, d, J=9.0Hz), 7.81 (2H, d, J=8.8Hz), 8.04 (2H, d, J=9.1Hz), 8.09 (2H, d, J=8.7Hz), 10.27 (IH, s) , 10.58 (IH, s) MASS (m/z) : 479 (M + +l) Preparation 331 IR (KBr) : 1722, 1678, 1643, 1608, 1500, 1446 cm "1 NMR (DMSO-dg, δ) : 0.86 (3H, d, J=6.4Hz), 0.88-1.08 (2H, m) , 1.08-1.51 (3H, m) , 1.60-1.90 (4H, m) , 2.14-2.35 (IH, m) , 2.54-2.66 (4H, m) , 3.13-3.36 (4H, m) , 3.90 (3H, s) , 6.98 (2H, d, J=8.9Hz) , 7.81 (2H, d, J=8.8Hz) , 8.03 (2H, d, J=8.7Hz), 8.09 (2H, d, J=8.6Hz), 10.26 (IH, s), 10.58 (IH, s) MASS (m/z) : 479 (M + +l) Preparation 332 NMR (DMSO-dg, δ) : 1.18 (3H, t, J=7.0Hz), 3.52 (2H, q, J=7.0Hz), 3.90 (3H, m) , 4.52 (2H, s) , 7.45 (2H, d, J=8.2Hz), 7.75 (2H, d, J=8.2Hz), 7.84 (2H, d, J=8.4Hz), 8.03 (2H, d, J=8.4Hz), 8.00-8.17 (4H, m) , 188 10.64 (IH, s), 10.74 (IH, s) MASS (m/z) : 433 (M + +l) Preparation 333 NMR (DMSO-dg, δ) : 3.28 (3H, m) , 3.47-3.66 (4H, m) , 3.91 (3H, s), 4.56 (2H, s) , 7.46 (2H, d, J=8.3Hz), 7.76 (2H, d, J=8.2Hz), 7.85 (2H, d, J=8.4Hz), 7.98-8.16 (6H, m) , 10.65 (IH, s) , 10.74 (IH, s) MASS (m/z) : 463 (M + +l) Preparation 334 NMR (DMSO-dg, δ) : 3.26 (3H, s) , 3.39-3.55 (2H, m) , 3.55-3.66 (2H, m) , 3.77 (2H, t, J=4.5Hz), 3.90 (3H, s), 4.16 (2H, t, J=4.5Hz), 7.08 (2H, d, J=8.8Hz), 7.72 (2H, d, J=8.8Hz), 7.80 (2H, d, J=8.4Hz), 8.00 (2H, d, J=8.5Hz), 8.06 (2H, d, J=8.7Hz), 8.10 (2H, d, J=8.7Hz), 10.61 (IH, s) , 10.73 (IH, s) MASS (m/z) : 493 (M + +l) Preparation 335 NMR (DMSO-dg, δ) : 1.12 (3H, t, J=7.0Hz), 1.88-2.12 (2H, m) , 3.44 (2H, q, J=7.0Hz), 3.53 (2H, t, J=6.4Hz), 3.91 (3H, s), 4.09 (2H, t, J=6.4Hz), 7.06 (2H, d, J=8.8Hz), 7.71 (2H, d, J=8.8Hz), 7.79 (2H, d, J=8.5Hz), 8.00 (2H, d, J=8.5Hz), 8.06 (2H, d, J=8.7Hz), 8.10 (2H, d, J=8.7Hz), 10.61 (IH, s) , 10.72 (IH, s) MASS (m/z) : 477 (M + +l) Preparation 336 NMR (DMSO-dg, δ) : 1.14 (3H, t, J=7.0Hz), 3.52 (2H, q, J=7.0Hz), 3.68-3.78 (2H, m) , 3.90 (3H, s) , 4.14- 4.22 (2H, m) , 7.08 (2H, d, J=8.8Hz), 7.72 (2H, d, J=8.8Hz), 7.80 (2H, d, J=8.4Hz), 8.00 (2H, d, J=8.4Hz), 8.06 (2H, d, J=8.7Hz), 8.10 (2H, d, J-8.7HZ), 10.61 (IH, s) , 10.73 (IH, s) MASS (m/z) : 463 (M + +l) Preparation 337 IR (KBr) : 1724, 1680, 1655, 1605, 1495, 1437 cm "1 189 NMR (DMSO-dg, δ) : 1.98 (2H, m) , 3.26 (3H, s) , 3.49 (2H, t, J=6.3Hz), 3.90 (3H, s) , 4.09 (2H, t, J=6.4Hz), 7.06 (2H, d, J=8.8Hz), 7.71 (2H, d, J=8.8Hz), 7.79 (2H, d, J=8.5Hz), 8.00 (2H, d, J=8.5Hz), 8.06 (2H, d, J=8.7Hz), 8.10 (2H, d, J=8.7Hz), 10.60 (IH, s) , 10.72 (IH, s) MASS (m/z) : 463 (M + +l) Preparation 338 IR (KBr) : 1724, 1682, 1645, 1605, 1495, 1439, 1404 cm -1 NMR (DMSO-dg, δ) : 3.33 (3H, s) , 3.69 (2H, m) , 3.90 (3H, s), 4.16 (2H, m) , 7.07 (2H, d, J=8.9Hz), 7.72 (2H, d, J=8.7Hz), 7.72 (2H, d, J=8.7Hz), 7.80 (2H, d, J=8.6Hz), 9.79 (IH, s) MASS (m/z) : 287 (M + +l) Preparation 339 IR (Nujol) : 3259, 1724, 1672, 1626, 1605 cm "1 NMR (DMSO-dg, δ) : 1.9-2.2 (4H, m) , 2.93 (3H, s) , 3.0-3.4 (2H, m) , 3.7-3.8 (2H, m) , 3.90 (3H, s) , 7.06 (2H, d, J=8.9Hz), 7.45 (4H, s) , 7.82 (2H, d, J=8.9Hz), 8.0-8.2 (4H, m) , 10.27 (IH, s) , 10.59 (IH, s) (+)APCI MASS : 522 (M+H) + Preparation 340 IR (KBr) : 3247.5, 1727.9, 1687.4, 1255.4 cm "1 NMR (DMSO-dg, δ) : 1.23-1.99 (16H, m) , 2.15-2.45 (2H, m) , 3.21 (3H, s), 3.27-3.35 (2H, m) , 3.60 (3H, s) , 4.02 (2H, t, J=6.4Hz), 7.00 (2H, d, J=8.6Hz), 7.83 (2H, d, J=8.6Hz), 9.74 (IH, s) , 10.12 (IH, s) MASS (m/z) : 435 (M+l) Preparation 341 IR (KBr) : 3236.0, 1724.0, 1677.8, 1255.4 cm "1 NMR (DMSO-dg, δ) : 0.91 (3H, t, J=7.0Hz), 1.30-1.50 (4H, m) , 1.70-1.80 (2H, m) , 3.87 (3H, s) , 4.03 (2H, t, J=6.4Hz), 7.03-7.07 (2H, m) , 7.68-8.00 (8H,m), 10.50-11.00 (2H, ) 190 MASS (m/z) : 467 (M+l) Preparation 342 IR (KBr) : 3201.3, 1714.4, 1594.8, 1253.5 cm "1 NMR (DMSO-dg, δ) : 1.30-1.80 (8H, m) , 2.42 (3H, s) , 3.21 (3H, s), 3.28-3.34 (2H, m) , 3.34 (3H, s) , 3.85 (3H, s), 4.04 (2H, t, J=6.4Hz), 7.04 (2H, d, J=8.8Hz), 7.36 (IH, s), 7.73 (IH, s) , 7.95 (2H, d, J=9Hz) , 10.22 (IH, s), 10.39 (IH, s) MASS (m/z) : 457 (M+l) Preparation 343 IR (KBr) : 3199.3, 1716.3, 1608.3, 1253.5 cm "1 NMR (DMSO-dg, δ) : 1.37-1.80 (8H, m) , 3.21 (3H, s) , 3.28-3.33 (2H, m) , 3.71 (3H, s), 4.03 (2H, t, J=6.4Hz), 6.39-6.59 (2H, m) , 7.00-7.04 (2H, m) , 7.24-7.47 (2H, m) , 7.83-7.88 (2H, m) , 10.35 (2H, d, J=6.9Hz) MASS (m/z) : 405 (M+l) Preparation 344 IR (KBr) : 3193.5, 1718.3, 1606.4, 1249.6 cm "1 NMR (DMSO-dg, δ) : 1.00 (3H, t, J=7.4Hz), 1.75-1.85 (2H, m) , 3.97-4.03 (5H, m) , 7.06-8.78 (12H, m) , 10.64 (IH, s), 10.72 (IH, s) MASS (m/z) : 483 (M+l) Preparation 345 IR (KBr) : 3220.5, 1720.2, 1685.5, 1290.1, 1251.6 cm -1 NMR (DMSO-dg, δ) : 1.30-1.80 (8H, m) , 3.22 (3H, s) , 3.28-3.34 (2H, m) , 3.94 (3H, s), 4.05 (2H, t, J=6.3Hz), 7.04-7.08 (2H, m) , 7.91-8.71 (8H, m) , 10.47 (IH, bs), 10.70 (IH, bs) MASS (m/z) : 479 (M+l) The following compounds [Preparations 346 to 3551 were obtained in a manner similar to that of Preparation 41. Preparation 346 IR (KBr) : 1726, 1284 cm "1 191 NMR (CDCI3, δ) : 0.89 (3H, t, J=6.8Hz), 1.2-1.8 (10H, m) , 3.51 (2H, t, J=6.6Hz) , 3.97 (3H, s) , 4.56 (2H, s) , 7.48 (2H, d, J=8.6Hz), 7.74 (2H, d, J=8.6Hz), 8.07 (2H, d, J=8.6Hz), 8.17 (2H, d, J=8.6Hz), 8.18 (IH, s), 8.55 (IH, s) MASS (m/z) : 491 (M + +l) Preparation 347 NMR (CDCI3-CD3OD, δ) : 1.15-1.40 (6H, m) , 1.40-2.30 (12H, m) , 2.80-3.55 (4H, m) , 3.65-3.80 (4H, m) , 3.97 (3H, s), 4.00-4.25 (IH, m) , 7.20 (2H, d, J=8.6Hz), 7.93 (2H, d, J=8.6Hz), 8.06 (2H, d, J=8.6Hz), 8.16 (2H, d, J=8.6Hz) ESI MASS (positive) : 478 (M + +l) Preparation 348 NMR (CDCI3+CD3OD, δ) : 1.20-1.60 (5H, m) , 1.65-2.05 (5H, ) , 2.50-2.70 (IH, m) , 3.97 (3H, s) , 7.36 (2H, d, J=8.2Hz), 7.92 (2H, d, J=8.3Hz), 8.05-8.20 t4H, m) APCI MASS (positive) : 379.2 (M + +l) Preparation 349 NMR (CDCI3, δ) : 1.20-2.15 (10H, m) , 3.97 (3H, s) , 4.30-4.50 (IH, m) , 7.01 (2H, d, J=8.9Hz), 7.92 (2H, d, J=8.9Hz), 8.00-8.30 (4H, m) APCI MASS (positive) : 395.2 (M + +l) Preparation 350 IR (KBr) : 1722, 1651, 1574, 1522, 1279 cm "1 NMR (CDCI3, δ) : 0.92 (3H, t, J=6.7Hz), 1.2-1.9 (8H, m) , 3.97 (3H, s), 4.01 (2H, t, J=6.5Hz), 7.01 (2H, d, J=9.0Hz), 7.64 (2H, d, J=9.0Hz), 8.07 (2H, d, J=8.6Hz), 8.15 (IH, s), 8.17 (2H, d, J=8.6Hz), 8.46 (IH, s) MASS (m/z) : 465 (M + +l) Preparation 351 IR (KBr) : 1727.9, 1249.6, 1180.2 cm "1 NMR (DMSO-dg, δ) : 1.30-2.30 (18H, m) , 3.21 (3H, s) , 3.28-3.35 (2H, m) , 3.62 (3H, s), 4.04 (2H, t, 192 J=6.4Hz), 7.07 (2H, d, J=8.7Hz), 7.85 (2H, d, J=8.7Hz) MASS (m/z) : 433 (M+l) Preparation 352 IR (KBr) : 1724.0, 1604.5, 1261.2, 1182.2 cm "1 NMR (DMSO-dg, δ) : 1.23-1.80 (8H, m) , 2.48 (3H, s) , 3.22 (3H, s), 3.22-3.33 (2H, m) , 3.33 (3H, s) , 3.87 (3H, s) , 4.07 (2H, t, J=6.4Hz), 7.13 (2H, d, J=8.9Hz), 7.76-8.00 (4H, m) MASS (m/z) : 455 (M+l) Preparation 353 IR (KBr) : 1718.3, 1629.6, 1257.4, 1226.5 cm "1 NMR (DMSO-dg, δ) : 1.25-1.75 (8H, m) , 3.21 (3H, s), 3.28-3.34 (2H, m) , 3.72 (3H, s), 4.06 (2H, t, J=6.4Hz), 6.33-6.41 (2H, m) , 7.09-7.13 (2H, m) , 7.27-7.60 (2H, m) , 7.90-7.95 (2H, m) MASS (m/z) : 403 (M+l) Preparation 354 IR (KBr) : 1716.3, 1297.9, 1255.4 cm "1 NMR (DMSO-dg, δ) : 1.20-1.80 (8H, m) , 3.22 (3H, s) , 3.28-3.33 (2H, m) , 3.95 (3H, s) , 4.08 (2H, t, J=6.4Hz), 7.12-7.17 (2H, m) , 7.97-8.73 (8H, m) MASS (m/z) : 477 (M+l) Preparation 355 IR (KBr) : 2935.1, 2854.1, 1257.4, 827.3 cm "1 NMR (CDC1 3 , δ) : 0.80-1.10 (3H, m) , 1.20-1.60 (8H, m) , 1.70-2.00 (2H, m) , 4.01 (2H, t, J=6.5Hz), 6.96 (2H, d, J=8.8Hz), 7.44 (2H, d, J=8.7Hz), 7.54 (2H, d, J=8.7Hz), 7.89 (2H, d, J=8.8Hz), 7.95 (IH, s) APCI MASS (m/z) : 430, 432 The following compounds [Preparations 356 to 3821 were obtained in a manner similar to that of Preparation 48. Preparation 356 IR (KBr) : 1714, 1514, 1277 cm "1 NMR (CDCI3, δ) : 2.66 (4H, brs), 3.23 (4H, brs), 3.64 (2H, 193 s), 3.90 (3H, s), 6.92 (3H, m) , 7.26 (2H, m) , 7.52 (2H, d, J=8.0Hz), 7.73 (2H, d, J=8.0Hz), 8.0-8.3 (5H, m) , 8.56 (IH, s) MASS (m/z) : 537 (M + +l) Preparation 357 IR (KBr) : 1718, 1520, 1275, 1242 cm "1 NMR (CDC1 3 , δ) : 1.5-1.8 (6H, m) , 3.24 (4H, t, J=5.3Hz), 3.97 (3H, s), 7.02 (2H, d, J=9.1Hz), 7.59 (2H, d, J=9.1Hz), 8.07 (2H, d, J=8.7Hz), 8.14 (IH, s) , 8.17 (2H, d, J=8.7Hz), 8.44 (IH, s) MASS (m/z) : 446 (M + +l) Preparation 358 NMR (DMSO-dg, δ) : 1.50-1.95 (4H, m) , 2.60-3.05 (3H, m) , 3.90 (3H, s), 3.95-4.10 (2H, m) , 6.90-7.35 (7H, m) , 7.65-8.15 (6H, m) APCI MASS (m/z) : 456 (M + ) Preparation 359 NMR (CDCI3, δ) : 2.0-2.2 (4H, m) , 3.2-3.4 (4H, m) , 3.97 (3H, s) , 6.62 (2H, d, J=8.8Hz) , 7.56 (2H, d, J=8.8Hz) , 8.07 (2H, d, J=8.4Hz), 8.13 (IH, s) , 8.17 (2H, d, J=8.4Hz), 8.40 (IH, s) MASS (m/z) : 432 (M + +l) Preparation 360 NMR (CDCI3, δ) : 0.95 (3H, t, J=6.6Hz), 1.33-1.94 (6H, m) , 3.99 (3H, s) , 4.05 (2H, t, J=6.5Hz), 7.02 (2H, d, J=8.8Hz), 7.98 (2H, d, J=8.7Hz), 8.05-8.33 (8H, m) MASS (m/z) : 543 (M + +l) Preparation 361 IR (KBr) : 1722, 1603, 1500, 1439, 1417 cm "1 NMR (CDCI3, δ) : 3.30-3.69 (8H, m) , 3.93 (3H, s) , 6.88-7.17 (3H, m) , 7.03 (2H, d, J=9.0Hz) , 7.34 (2H, t, J=7.7Hz) , 7.94 (2H, d, J=8.8Hz), 8.08 (2H, d, J=8.6Hz), 8.16 (2H, d, J=8.6Hz) MASS (m/z) : 457 (M + +l) 1 94 Preparation 362 NMR (CDC1 3 , δ) : 0.95 (3H, t, J=7.4Hz), 1.40-2.16 (6H, m) , 3.03-3.30 (2H, m) , 3.45 (2H, t, J=6.7Hz), 3.44-3.95 (3H, m) , 3.96 (3H, s) , 6.85-7.12 (2H, m) , 7.80-7.97 (2H, m) , 8.07 (2H, d, J=8.6Hz), 8.15 (2H, d, J=8.6Hz) MASS (m/z) : 438 (M + +l) Preparation 363 IR (KBr) : 1722, 1605, 1520, 1439, 1414 cm "1 NMR (CDCI3, δ) : 0.92 (6H, s) , 1.12-1.90 (8H, m) , 2.18-2.24 (IH, m) , 2.68-2.86 (4H, m) , 3.27-3.46 (4H, m) , 3.96 (3H, s), 6.97 (2H, d, J=9.0Hz), 7.90 (2H, d, J=8.9Hz), 8.07 (2H, d, J=8.6Hz), 8.15 (2H, d, J=8.6Hz) MASS (m/z) : 491 (M + +l) Preparation 364 IR (KBr) : 1716, 1606, 1520, 1441, 1417 cm "1 NMR (CDCI3, δ) : 1.70-2.26 (4H, m) , 3.10-3.31 (2H, m) , 3.60-3.84 (3H, m) , 3.96 (3H, s) , 4.60 (2H, s) , 6.90-7.20 (2H, m) , 7.26-7.46 (5H, m) , 7.91 (2H, d, J=8.8Hz), 8.09 (2H, d, J=8.7Hz), 8.15 (2H, d, J=8.7Hz) MASS (m/z) : 486 (M + +l) Preparation 365 IR (KBr) : 2941, 2845, 1713, 1601, 1549, 1504, 1431, 1404 cm "1 NMR (CDCI3, δ) : 1.79 (2H, m) , 2.01 (2H, m) , 2.84 (IH, m) , 3.08 (2H, m) , 3.96 (3H, s) , 4.64 (2H, m) , 6.80 (IH, d, J=9.1Hz), 7.18-7.40 (5H, m) , 8.03-8.23 (5H, m) , 8.73 (IH, d, J=2.3Hz) MASS (m/z) : 457 (M + +l) Preparation 366 IR (KBr) : 2949, 2870, 1722, 1605, 1504, 1437 cm "1 NMR (CDCI3, δ) : 1.66-2.00 (4H, m) , 3.27 (3H, s) , 3.47 (2H, t, J=6.0Hz), 3.97 (3H, s) , 4.05 (2H, t, J=6.1Hz), 7.00 (2H, d, J=8.6Hz), 7.59 (2H, d, J=8.6Hz), 7.70 195 (2H, d, J=8.2Hz), 8.00-8.14 (4H, m) , 8.17 (2H, d, J=8.5Hz) MASS (m/z) : 475 (M + +l) Preparation 367 IR (KBr) : 1720, 1605, 1522, 1439, 1416 cm -1 NMR (CDC1 3 , δ) : 1.00-1.41 (5H, m) , 1.56-2.14 (5H, m) , 2.24-2.41 (IH, m) , 2.66-2.82 (4H, m) , 3.27-3.43 (4H, m) , 3.96 (3H, s) , 6.96 (2H, d, J=9.0Hz), 7.89 (2H, d, J=8.9Hz), 8.06 (2H, d, J=8.6Hz), 8.14 (2H, d, J=8.6Hz) MASS (m/z) : 463 (M + +l) Preparation 368 IR (KBr) : 1718, 1605, 1520, 1439, 1414 cm "1 NMR (CDCI3, δ) : 0.95 (3H, d, J=6.9Hz), 1.38-1.90 (9H, m) , 2.24-2.47 (IH, m) , 2.66-2.92 (4H, m) , 3.28-3.53 (4H, m) , 3.96 (3H, s) , 6.97 (2H, d, J=9.0Hz), 7.90 (2H, d, J=8.9Hz), 8.07 (2H, d, J=8.7Hz), 8.15 (2H, d, J=8.7Hz) MASS (m/z) : 477 (M + +l) Preparation 369 IR (KBr) : 1724, 1605, 1520, 1437, 1412 cm "1 NMR (CDCI3, δ) : 0.89 (3H, d, J=6.4Hz), 0.89-1.13 (2H, m) , 1.13-2.07 (7H, m) , 2.24-2.50 (IH, m) , 2.68-2.93 (4H, m) , 3.30-3.52 (4H, ) , 3.96 (3H, s) , 6.97 (2H, d, J=8.9Hz), 7.90 (2H, d, J=8.9Hz), 8.07 (2H, d, J=8.6Hz), 8.15 (2H, d, J=8.6Hz) MASS (m/z) : 477 (M + +l) Preparation 370 IR (KBr) : 2976, 1716, 1601, 1531, 1500, 1479, 1437 cm "1 NMR (CDCI3, δ) : 1.46 (3H, t, J=7.0Hz), 3.97 (3H, s) , 4.10 (2H, q, J=7.0Hz), 7.00 (2H, d, J=8.7Hz), 7.59 (2H, d, J=8.7Hz), 7.70 (2H, d, J=8.4Hz), 8.07 (2H, d, J=8.3Hz), 8.10-8.30 (4H, m) MASS (m/z) : 417 (M + +l) 196 Preparation 371 IR (KBr) : 2926, 2852, 1722, 1599, 1529, 1498, 1437 cm "1 NMR (CDC1 3 , δ) : 1.00-1.41 (5H, m) , 1.51-2.05 (5H, m) , 2.24-2.43 (IH, m) , 2.69-2.84 (4H, m) , 3.22-3.36 (4H, m) , 3.97 (3H, s) , 7.02 (2H, d, J=8.8Hz), 7.59 (2H, d, J=8.7Hz), 7.70 (2H, d, J=8.4Hz), 8.06 (2H, d, J=8.5Hz), 8.09-8.15 (4H, ) MASS (m/z) : 539 (M + +l) Preparation 372 IR (KBr) : 1718, 1601, 1429 cm "1 NMR (CDCI3, δ) : 1.29 (6H, d, J=6.3Hz), 2.36-2.56 (2H, m) , 3.44-3.63 (2H, m) , 3.74-3.93 (2H, m) , 3.96 (3H, s), 6.99 (2H, d, J=8.9Hz), 7.58 (2H, d, J=8.8Hz), 7.69 (2H, d, J=8.5Hz), 8.05 (2H, d, J=8.4Hz), 8.09 (2H, d, J=8.6Hz), 8.16 (2H, d, J=8.6Hz) MASS (m/z) : 486 (M + +l) Preparation 373 IR (KBr) : 1707, 1603, 1529, 1498, 1433, 1414 cm "1 NMR (CDCI3, δ) : 1.23-2.12 (10H, m) , 3.97 (3H, s) , 4.18-4.38 (IH, m) , 7.00 (2H, d, J=8.8Hz), 7.57 (2H, d, J=8.8Hz), 7.69 (2H, d, J=8.4Hz), 8.10 (2H, d, J=8.5Hz), 8.06-8.25 (4H, m) MASS (m/z) : 471 (M + +l) Preparation 374 IR (KBr) : 2956, 2933, 2872, 1722, 1605, 1502, 1435 cm "1 NMR (CDCI3, δ) : 1.00 (3H, t, J=7.2Hz), 1.52 (2H, m) , 1.79 (2H, m) , 3.97 (3H, s) , 4.03 (2H, ) , 7.00 (2H, m) , 7.45-7.78 (4H, m) , 7.96-8.29 (6H, ) MASS (m/z) : 445 (M + +l) Preparation 375 IR (KBr) : 1716, 1435 crn -1 NMR (CDCI3, δ) : 1.28 (3H, t, J=7.0Hz), 3.60 (2H, q, J=7.0Hz), 3.97 (3H, m) , 4.58 (2H, s) , 7.47 (2H, d. 197 J=8 . 3Hz ) , 7 . 56-7 . 78 ( 4H, m) , 8 . 04- 8 . 29 ( 6H, m) MASS (m/ z ) : 431 (M + + l ) Preparation 376 IR (KBr) : 1720, 1651, 1606, 1560, 1504, 1435 cm "1 NMR (CDC1 3 , δ) : 3.42 (3H, m) , 3.55-3.71 (4H, m) , 3.97 (3H, s), 4.64 (2H, s) , 7.47 (2H, d, J=8.2Hz), 7.64 (2H, d, J=8.2Hz), 7.68-7.80 (2H, m) , 8.04-8.26 (6H, m) MASS (m/z) : 461 (M + +l) Preparation 377 IR (KBr) : 2926, 2877, 1720, 1605, 1504, 1437 cm "1 NMR (CDCI3, δ) : 3.41 (3H, s) , 3.54-3.64 (2H, m) , 3.69-3.78 (2H, m) , 3.86-3.96 (2H, m) , 3.97 (3H, s) , 4.14-4.28 (2H, m) , 6.95-7.18 (2H, m) , 7.51-5.64 (2H, m) , 5.64-6.77 (2H, m) , 8.00-8.26 ( 6H ,m) MASS (m/z) : 491 (M + +l) Preparation 378 NMR (CDCI3, δ) : 1.22 (3H, t, J=7.0Hz), 2.09 (2H, m) , 3.52 (2H, q, J=7.0Hz), 3.63 (2H, t, J=6.2Hz), 3.97 (3H, s), 4.13 (2H, t, J=6.2Hz), 7.02 (2H, d, J=8.8Hz), 7.59 (2H, d, J=8.8Hz), 7.70 (2H, d, J=8.5Hz), 8.07 (2H, d, J=8.4Hz), 8.08-8.26 (4H, m) MASS (m/z) : 475 (M + +l) Preparation 379 NMR (CDCI3, δ) : 1.27 (3H, t, J=7.0Hz), 3.63 (2H, q, J=7.0Hz), 3.74-3.90 (2H, m) , 3.97 (3H, s) , 4.14- 4.28 (2H, m) , 7.04 (2H, d, J=8.7Hz), 7.59 (2H, d, J=8.7Hz), 7.69 (2H, d, J=8.3Hz), 8.06 (2H, d, J=8.2Hz), 8.10 (2H, d, J=8.5Hz), 8.16 (2H, d, J=8.5Hz) MASS (m/z) : 461 (M + +l) Preparation 380 IR (KBr) : 1722, 1605, 1531, 1500, 1435 cm "1 NMR (CDCI3, δ) : 2.09 (2H, m) , 3.38 (3H, s) , 3.59 (2H, t, J=6.1Hz), 3.97 (3H, s) , 4.13 (2H, t, J=6.3Hz), 198 7.02 (2H, d, J=8.8Hz), 7.50-7.64 (2H, m) , 7.70 (2H, d, J=8.5Hz), 8.07 (2H, d, J=8.4Hz), 8.08-8.25 (4H, m) MASS (m/z) : 461 (M + +l) Preparation 381 IR (KBr) : 1720, 1643, 1603, 1531, 1500, 1435 cm "1 NMR (CDC1 3 , δ) : 3.48 (3H, s), 3.80 (2H, m) , 3.97 (3H, s), 4.18 (2H, m) , 7.04 (2H, d, J=8.8Hz), 7.51-7.77 (4H, m) , 8.03-8.23 (6H, m) MASS (m/z) : 447 (M + +l) Preparation 382 IR (Nujol) : 1714, 1601 cm "1 NMR (CDCI3, δ) : 1.7-2.0 (4H, m) , 2.75 (3H, s) , 3.0-3.2 (2H, m) , 3.4-3.6 (2H, m) , 3.69 (3H, s) , 6.77 (2H, d, J=8.8Hz), 7.08 (4H, s) , 7.60 (2H, d, J=8.8Hz), 7.7-8.0 (4H, m) (+)APCI MASS : 520 (M+H) + The following compounds [Preparations 383 to 3881 were obtained in a manner similar to that of Preparation 33. Preparation 383 IR (KBr) : 1699, 1684 cm "1 NMR (DMSO-dg, δ) : 0.86 (3H, t, J=6.6Hz), 1.2-1.7 (10H, m) , 3.46 (2H, t, J=6.6Hz), 4.51 (2H, s) , 7.50 (2H, d, J=8.6Hz), 7.95 (2H, d, J=8.6Hz), 8.13 (4H, s) , 8.42 (IH, s), 9.36 (IH, s) MASS (m/z) : 477 (M + +l) Preparation 384 IR (KBr) : 1583, 1543, 1516, 1396 cm "1 NMR (DMSO-dg, δ) : 2.4-2.6 (4H, m) , 3.1-3.3 (4H, m) , 3.60 (2H, s), 6.77 (IH, t, J=7.4Hz), 6.93 (2H, d, J=7.4Hz), 7.20 (2H, t, J=7.4Hz), 7.9-8.1 (6H, m) , 8.39 (IH, s), 9.32 (IH, s) MASS (m/z) : 523 (M + +l) Preparation 385 IR (KBr) : 1716, 1520, 1277, 1109 cm "1 199 MASS (m/z) : 432 (M + +l) Preparation 386 IR (KBr) : 1684, 1518, 1252 cm -1 Preparation 387 NMR (DMSO-dg, δ) : 1.60-2.10 (4H, m) , 2.70-3.10 (3H, m) , 4.08 (2H, m) , 7.10-7.40 (7H, m) , 7.95 (2H, d, J=8.5Hz), 8.18 (4H, AB-q, J=8.3Hz, J=16.1Hz) APCI MASS : 426 (M + +l) Preparation 388 IR (KBr) : 1687, 1610, 1568, 1527 cm "1 MASS (m/z) : 418 (M + +l) The following compounds [Preparations 389 to 3931 were obtained in a manner similar to that of Preparation 57. Preparation 389 NMR (CDCI3-CD3OD, δ) : 2.10-2.25 (2H, m) , 2.65-3.15 (3H, m) , 3.45-3.70 (2H, m) , 3.99 (3H, s) , 7.30-7.40 (5H, m) , 7.90-8.40 (8H, m) APCI MASS : 440 (M + ) Preparation 390 NMR (DMSO-dg, δ) : 1.10-2.10 (10H, m) , 3.91 (3H, s) , 4.40-4.60 (IH, m) , 7.17 (2H, d, J=8.9Hz), 8.00-8.30 (6H, m) APCI MASS (positive) : 379.2 (M + +l) Preparation 391 NMR (DMSO-dg, δ) : 1.20-1.60 (5H, m) , 1.60-1.95 (5H, m) , 2.50-2.75 (IH, m) , 3.92 (3H ,s), 7.50 (2H, d, J=8.3Hz), 8.07 (2H, d, J=8.3Hz), 8.18 (2H, d, J=8.7Hz), 8.28 (2H, d, J=8.7Hz) APCI MASS (positive) : 363.3 (M + +l) Preparation 392 IR (KBr) : 1724.0, 1253.5, 1199.5 cm "1 NMR (CDCI3, δ) : 0.95 (3H, t, J=7.0Hz), 1.35-1.60 (4H, m) , 1.70-1.95 (2H, m) , 3.88-4.05 (5H, m) , 6.98-7.03 (2H, m) , 7.57-8.17 (8H, m) MASS (m/z) : 449 (M+l) 200 Preparation 393 IR (KBr) : 1718.3, 1602.6, 1249.6 cm "1 NMR (CDC1 3 , δ) : 1.01 (3H, t, J-7.4Hz), 1.50-1.80 (2H, m) , 3.97-4.05 (5H, m) , 7.06-7.10 (2H, m) , 7.70-9.35 (12H, m) MASS (m/z) : 465 (M+l) The following compounds [Preparations 394 to 4571 were obtained in a manner similar to that of Preparation 49. Preparation 394 NMR (DMSO-dg, δ) : 1.10-1.95 (12H, m) , 3.55-3.80 (4H, m) , 7.08 (2H, d, J=8.9Hz), 7.83 (2H, d, J=8.8Hz), 8.07 (4H, s) APCI MASS : 464 (M + ) Preparation 395 NMR (DMSO-dg, δ) : 1.10-1.60 (5H, m) , 1.60-1.95 (5H, m) , 2.50-2.70 (IH, m) , 7.45 (2H, d, J=8.3Hz), 7.96 (2H, d, J=8.3Hz), 8.14 (4H, s) Preparation 396 NMR (DMSO-dg, δ) : 1.20-2.10 (10H, m) , 4.35-4.60 (IH, m) , 7.13 (2H, d, J=8.9Hz), 7.95 (2H, d, J=8.9Hz), 8.12 (4H, s) APCI MASS (negative) : 379.2 (M + -l) Preparation 397 NMR (DMSO-dg, δ) : 1.50-2.00 (4H, m) , 2.65-3.10 (3H, m) , 3.95-4.15 (2H, m) , 6.90-7.35 (7H, m) , 7.70-8.30 (6H ,m) APCI MASS : 442 (M + ) Preparation 398 NMR (DMSO-dg, δ) : 1.20-2.10 (10H, m) , 4.40-4.60 (IH, m) , 7.17 (2H, d, J=8.9Hz), 7.95-8.30 (6H, m) , 13.0-13.5 (IH, ) APCI MASS (positive) : 365.2 (M + +l) Preparation 399 NMR (CDCI3, δ) : 1.15-1.60 (5H, m) , 1.65-2.05 (5H, m) , 2.50-2.70 (IH, ) , 7.41 (2H, d, J=8.3Hz), 8.05 (2H, 201 d, J=8.4Hz), 8.23 (4H, s) APCI MASS (positive) : 349.2 (M + +l) Preparation 400 IR (KBr) : 2935, 2858, 1705, 1649, 1601, 1531, 1500, 1441, 1400 cm "1 MASS (m/z) : 523 (M + -l) Preparation 401 MASS (m/z) : 527 (M + -l) Preparation 402 NMR (DMSO-dg, δ) : 3.30-3.64 (8H, m) , 6.75-7.33 (7H, m) , 7.70-8.29 (6H, m) MASS (m/z) : 443 (M + -2HC1+1) Preparation 403 NMR (DMSO-dg, δ) : 0.88 (3H, t, J=7.4Hz), 1.35-1.63 (4H ,m) , 1.82-2.03 (2H, m) , 2.99-3.20 (2H ,m), 3.40 (2H, t, J=6.6Hz), 3.40-3.80 (3H, m) , 7.09 (2H, d, J=9.0Hz), 7.84 (2H, d, J=8.9Hz), 8.11 (4H, s), 13.22 (IH, brs) MASS (m/z) : 424 (M + -HC1+1) Preparation 404 IR (KBr) : 1686, 1601, 1531, 1500, 1421 cm "1 NMR (DMSO-dg, δ) : 1.18 (6H, d, J=6.1Hz), 2.24-2.45 (2H, m) , 3.63-3.82 (4H, m) , 7.08 (2H, d, J=8.6Hz), 7.68 (2H, d, J=8.8Hz), 7.90 (2H, d, J=8.5Hz), 8.08 (2H, d, J=8.3Hz), 8.13 (2H, d, J=8.7Hz), 8.16 (2H, d, J=8.7Hz) MASS (m/z) : 472 (M + +l) Preparation 405 IR (KBr) : 1705, 1606, 1524, 1441, 1412 cm "1 MASS (m/z) : 477 (M + +l) Preparation 406 IR (KBr) : 1686, 1603, 1568, 1520, 1416 cm "1 NMR (DMSO-dg, δ) : 1.49-1.71 (2H, m) , 1.90-2.10 (2H, m) , 3.06-3.24 (2H, m) , 3.58-3.80 (3H, m) , 4.56 (2H, s) , 7.10 (2H, d, J=9.0Hz), 7.23-7.46 (5H, m) , 7.85 (2H, 202 d, J=8.9Hz), 8.10 (4H, m) MASS (m/z) : 472 (M + +l) Preparation 407 IR (KBr) : 1682, 1606, 1572, 1524, 1498, 1427 cm "1 NMR (DMSO-dg, δ) : 1.25-2.05 (10H, m) , 4.35-4.50 (IH, m) , 7.07 (2H, d, J=8.8Hz), 7.64-7.94 (4H, m) , 7.99-8.26 (6H, m) MASS (m/z) : 457 (M + +l) Preparation 408 IR (KBr) : 2933, 2846, 1686, 1599, 1552, 1500, 1429 crn -1 NMR (DMSO-dg, δ) : 1.56-2.00 (4H, m) , 2.74-3.18 (3H, m) , 4.62 (2H, m) , 7.00-7.40 (6H, m) , 7.99-8.26 (5H, m) , 8.74 (IH, s), 13.20 (IH, brs) MASS (m/z) : 443 (M + +l) Preparation 409 IR (KBr) : 1686, 1603, 1574, 1527, 1500, 1427 cm "1 NMR (DMSO-dg, δ) : 1.36 (3H, t, J=7.0Hz), 4.10 (2H, q, J=7.1Hz), 7.00-7.13 (2H, m) , 7.65-8.25 (10H, m) MASS (m/z) : 403 (M + +l) Preparation 410 IR (KBr) : 1693, 1603, 1572, 1527, 1500, 1471, 1425 cm "1 NMR (DMSO-dg, δ) : 1.60-1.84 (4H, m) , 3.25 (3H, s), 3.30-3.50 (2H, m) , 4.00-4.16 (2H, m) , 7.07 (2H, d, J=8.8Hz), 7.73 (2H, d, J=8.6Hz), 7.87 (2H, d, J=8.5Hz), 8.04-8.20 (6H, m) MASS (m/z) : 461 (M + +l) Preparation 411 IR (KBr) : 1705, 1606, 1524, 1441, 1412 cm "1 NMR (DMSO-dg, δ) : 1.00-2.20 (10H, m) , 3.00-3.35 (9H, m) , 7.18 (2H, d, J=9.1Hz), 7.92 (2H, d, J=8.7Hz), 8.11 (4H, s) MASS (m/z) : 447 (M + -l) 203 Preparation 412 IR (KBr) : 1703, 1605, 1524, 1441, 1412 cm "1 NMR (DMSO-dg, δ) : 0.95 (3H, d, J=6.8Hz), 1.43-2.00 (9H, m) , 3.16-3.48 (9H, m) , 7.17 (2H, d, J=8.4Hz), 7.92 (2H, d, J=8.3Hz), 8.12 (4H, s) Preparation 413 IR (KBr) : 1705, 1605, 1524, 1443, 1414 cm "1 NMR (DMSO-dg, δ) : 0.88 (3H, d, J=6.4Hz), 0.86-1.60 (5H, m) , 1.74-1.92 (2H, m) , 2.00-2.20 (2H, m) , 2.97-3.35 (9H, m) , 7.18 (2H, d, J=8.9Hz) , 7.92 (2H, d, J=8.8Hz) , 8.12 (4H, s) Preparation 414 IR (KBr) : 2956, 2935, 2872, 1686, 1605, 1500, 1427 cm "1 NMR (DMSO-dg, δ) : 0.95 (3H, t, J=7.2Hz), 1.44 (2H, m) , 1.74 (2H, m) , 4.05 (2H, m) , 1 . 02-1 . 14 (2H, m) , 7.66-8.30 (10H, m) MASS (m/z) : 431 (M + +l) Preparation 415 IR (KBr) : 1686, 1606, 1425 cm "1 NMR (DMSO-dg, δ) : 1.18 (3H, t, J=7.0Hz), 3.52 (2H, q, J=6.9Hz), 4.53 (2H, s), 7.46 (2H, d, J=8.5Hz), 7.77 (2H, d, J=8.3Hz), 7.92 (2H, d, J=8.4Hz), 8.10-8.24 (6H, m) MASS (m/z) : 417 (M + +l) Preparation 416 IR (KBr) : 1682, 1605, 1566, 1425 cm "1 NMR (DMSO-dg, δ) : 3.28 (3H, m) , 3.46-3.64 (4H, m) , 4.56 (2H, s), 7.47 (2H, d, J=8.2Hz), 7.78 (2H, d, J=8.2Hz), 7.92 (2H, d, J=8.4Hz), 8.07-8.25 (6H, m) MASS (m/z) : 447 (M + +l) Preparation 417 IR (KBr) : 1684, 1603, 1500, 1423 cm -1 NMR (DMSO-dg, δ) : 3.26 (3H, s) , 3.35-3.54 (2H, m) , 3.54-3.68 (2H, m) , 3.77 (2H, t, J=4.5Hz), 4.17 (2H, 204 t, J=4.5Hz), 7.09 (2H, d, J=8.8Hz), 7.74 (2H, d, J=8.8Hz), 7.87 (2H, d, J=8.5Hz) , 8.10 (2H, d, J=8.4Hz) , 8.09-8.20 (4H, m) MASS (m/z) : 477 (M + +l) Preparation 418 NMR (DMSO-dg, δ) : 1.12 (3H, t, J=7.0Hz), 1.97 (2H, m) , 3.39 (2H, q, J=7.0Hz), 3.53 (2H, t, J=6.3Hz), 4.09 (2H, t, J=6.3Hz), 7.07 (2H, d, J=8.8Hz), 7.73 (2H, d, J=8.7Hz), 7.87 (2H, d, J=8.5Hz), 8.10 (2H, d, J=8.4Hz), 8.10-8.25 (4H, m) Preparation 419 IR (KBr) : 1686, 1603, 1529, 1498, 1470, 1427 cm "1 NMR (DMSO-dg, δ) : 1.15 (3H, t, J=7.0Hz), 3.52 (2H, q, J=7.0Hz) , 3.68-3.80 (2H, m) , 4.13-4.24 (2H, m) , 7.08 (2H, d, J=8.8Hz), 7.73 (2H, d, J=8.8Hz), 7.86 (2H, d, J=8.5Hz), 8.09 (2H, d, J=8.4Hz), 8.10-8.21 (4H, m) MASS (m/z) : 447 (M + +l) Preparation 420 IR (KBr) : 1686, 1603, 1529, 1498, 1470, 1427 cm "1 NMR (DMSO-dg, δ) : 1.98 (2H, m) , 3.27 (3H, s) , 3.50 (2H, t, J=6.2Hz), 4.09 (2H, m) , 7.07 (2H, d, J=8.8Hz), 7.73 (2H, d, J=8.8Hz), 7.87 (2H, d, J=8.5Hz), 8.10 (2H, d, J=8.5Hz), 8.10-8.21 (4H, m) MASS (m/z) : 447 (M + +l) Preparation 421 IR (KBr) : 1684, 1603, 1525, 1500, 1421 cm "1 NMR (DMSO-dg, δ) : 3.32 (3H, s) , 3.69 (2H, m) , 4.17 (2H, m) , 7.09 (2H, d, J=8.9Hz), 7.73 (2H, d, J=8.8Hz), 7.87 (2H, d, J=8.6Hz), 8.03-8.20 (6H, ) MASS (m/z) : 433 (M + +l) Preparation 422 IR (Nujol) : 1684, 1601 cm "1 NMR (DMSO-dg, δ) : 1.8-2.2 (4H, m) , 2.94 (3H, s) , 3.1-3.3 (2H, m) , 3.7-3.9 (2H, m) , 7.14 (2H, d, J=8.9Hz) , 7.45 205 (4H, s), 7.86 (2H, d, J=8.9Hz), 8.0-8.2 (4H, m) (+)APCI MASS : 506 (M+H) + Preparation 423 IR (KBr) : 1664.3, 1602.6, 1230.4 cm "1 Preparation 424 IR (KBr) : 1685.5, 1608.3, 1238.1 cm "1 NMR (DMSO-dg, δ) : 2.79-4.42 (13H, m) , 6.92-7.14 (2H, m) , 7.21-7.30 (4H, m) , 7.81-7.96 (2H, m) , 11.60 (IH, bs) , 12.55 (IH, bs) MASS (m/z) : 323 (M+l) Preparation 425 IR (KBr) : 1726.0, 1251.6, 1180.2 cm "1 NMR (DMSO-dg, δ) : 1.30-2.40 (18H, m) , 3.21 (3H, s) , 3.28-3.35 (2H, ) , 4.04 (2H, t, J=6.4Hz), 7.07 (2H, d, J=8.8Hz), 7.86 (2H, d, J=8.8Hz), 12.14 (IH, s) MASS (m/z) : 419 (M+l) Preparation 426 IR (KBr) : 1683.6, 1251.6, 825.4 cm "1 NMR (DMSO-dg, δ) : 0.91 (3H, t, J=6.9Hz), 1.24-1.55 (4H, m) , 1.60-1.90 (2H, m) , 4.00-4.10 (2H, m) , 7.02-7.08 (2H, m) , 7.63-8.36 (8H, m) MASS (m/z) : 435 (M+l) Preparation 427 IR (KBr) : 1693.2, 1305.6, 1259.3, 1178.3 cm "1 NMR (DMSO-dg, δ) : 1.38-1.80 (8H, m) , 2.56 (3H, s) , 3.22 (3H, s), 3.28-3.34 (5H, m) , 4.06 (2H, t, J=6.4Hz), 7.12 (2H, d, J=8.9Hz), 7.72 (IH, s) , 7.86 (IH, s) , 7.97 (2H, d, J=8.8Hz), 13.12 (IH, bs) MASS (m/z) : 441 (M+l) Preparati n 428 IR (KBr) : 1675.8, 1606.4, 1259.3 cm -1 NMR (DMSO-dg, δ) : 1.40-2.00 (8H, m) , 3.35 (3H, s) , 3.40 (2H, t, J=6.3Hz), 4.03 (2H, t, J=6.3Hz), 6.13-6.20 (2H, m) , 6.96-7.94 (6H, m) MASS (m/z) : 389 (M+l) 206 Preparation 429 IR (KBr) : 1699.0, 1604.5, 1249.6, 1193.7 cm "1 NMR (DMSO-dg, δ) : 1.00 (3H, t, J=7.4Hz), 1.67-1.85 (2H, m) , 3.99 (2H, t, J=6.5Hz), 7.04-7.09 (2H, m) , 7.65-9.32 (12H, m) MASS (m/z) : 451 (M+l) Preparation 430 IR (KBr) : 1685.5, 1253.5, 1174.4 cm "1 NMR (DMSO-dg, δ) : 1.20-1.80 (8H, m) , 3.22 (3H, s) , 3.29-3.35 (2H, m) , 4.00-4.15 (2H, m) , 7.12-7.17 (2H, m) , 7.97-8.68 (8H, m) MASS (m/z) : 463 (M+l) Preparation 431 IR (KBr) : 2950.6, 1708.6, 1608.3, 1473.3, 1419.4, 1367.3, 1259.3, 1211.1, 1174.4 cm "1 MASS (m/z) : 477 (M+H + ) Preparation 432 IR (KBr) : 2946, 1710, 1608, 1469, 1413, 1369, 1307, 1263, 1218, 1176 cm "1 MASS (m/z) : 491 (M+H + ) Preparation 433 IR (KBr) : 2944, 1706, 1606, 1469, 1417, 1375, 1259, 1176 cm "1 MASS (m/z) : 505 (M+H + ) Preparation 434 IR (KBr) : 3396, 2948, 2871, 1608, 1542, 1471, 1382, 1263, 1180, 1110 crn -1 MASS (m/z) : 493 (M+H + ) Preparation 435 IR (KBr) : 2942, 1687, 1608, 1471, 1309, 1261, 1176 cm "1 MASS (m/z) : 521 (M+H + ) Preparation 436 IR (KBr) : 2937, 1706, 1683, 1606, 1469, 1417, 1307, 1255, 1174, 1110 cm "1 207 MASS (m/ z ) : 535 (M+H + ) Preparation 437 IR (KBr) : 2946, 2570, 1706, 1608, 1469, 1415, 1371, 1309, 1259, 1216, 1174, 1108 cm "1 MASS (m/z) : 509 (M+H + ) Preparation 438 IR (KBr) : 2940, 2867, 2665, 2547, 1681, 1606, 1469, 1421, 1311, 1290, 1255, 1176, 1116 cm "1 MASS (m/z) : 438 (M+H + ) Preparation 439 IR (KBr) : 2939, 2861, 1681, 1606, 1469, 1421, 1311, 1253, 1174, 1114, 1016, 833 cm "1 MASS (m/z) : 452 (M+H + ) Preparation 440 IR (KBr) : 2935, 2858, 1681, 1606, 1571, 1467, 1419, 1311, 1253, 1174, 1112 cm "1 MASS (m/z) : 466 (M+H + ) Preparation 441 IR (KBr) : 2931, 2854, 2663, 1679, 1606, 1467, 1421, 1311, 1290, 1253, 1174, 1116 cm "1 MASS (m/z) : 480 (M+H + ) Preparation 442 IR (KBr) : 2935, 2850, 2819, 1608, 1589, 1537, 1473, 1417, 1240 cm "1 MASS (m/z) : 405 (M+H + ) Preparation 443 IR (KBr) : 3361, 2969, 2848, 1606, 1585, 1535, 1475, 1402, 1238, 1180, 1114, 927 cm "1 Preparation 444 IR (KBr) : 2975, 2873, 2829, 2665, 1681, 1606, 1469, 1423, 1315, 1288, 1240, 1176 cm "1 MASS (m/z) : 435 (M+H + ) Preparation 445 IR (KBr) : 2969, 2530, 1672, 1604, 1467, 1423, 1288, 1267, 1228, 1191 cm "1 208 MASS (m/ z ) : 423 (M+H + ) Preparation 446 IR (KBr) : 2937, 1702, 1606, 1473, 1405, 1369, 1268, 1241, 1176 cm "1 MASS (m/z) : 434 (M+H + ) Preparation 447 MASS (m/z) : 488 (M+H + ) reparation 448 IR (KBr) : 2956, 2869, 2665, 2543, 1681, 1608, 1544, 1492, 1469, 1423, 1332, 1292, 1245, 1172 cm "1 MASS (m/z) : 394 (M+H + ) Preparation 449 IR (KBr) : 2954, 2865, 2665, 2545, 1681, 1608, 1544, 1492, 1423, 1332, 1292, 1247, 1172 cm "1 NMR (DMSO-dg, δ) : 0.91 (3H, t, J=6.8Hz), 1.3-1.5 (4H, m) , 1.6-1.8 (2H, m) , 4.00 (2H, t, J=6.8Hz) , 6.99 (2H, d, J=8.8Hz), 7.82 (2H, d, J=8.8Hz), 8.11 (4H, s) , 8.69 (IH, s) MASS (m/z) : 408 (M+H + ) Preparation 450 IR (KBr) : 2933, 2865, 2667, 2545, 1681, 1608, 1544, 1492, 1469, 1423, 1332 cm "1 MASS (m/z) : 422 (M+H + ) Preparation 451 IR (KBr) : 2933, 2863, 1677, 1606, 1469, 1421, 1313, 1292, 1255, 1174 cm "1 MASS (m/z) : 422 (M+H + ) Preparation 452 IR (KBr) : 2935, 2871, 2667, 2545, 1683, 1608, 1542, 1525, 1461, 1421, 1319, 1294, 1257, 1176 cm "1 NMR (DMSO-dg, δ) : 0.91 (3H, t, J=7.0Hz), 1.2-1.5 (4H, m) , 1.6-1.9 (2H, m) , 4.05 (2H, t, J=6.5Hz) , 7.09 (2H, d, J=8.8Hz), 7.91 (2H, d, J=8.8Hz), 8.09 (2H, d, J=8.5Hz), 8.22 (2H, d, J=8.5Hz), 13.3 (IH, s) MASS (m/z) : 412 (M+H + ) 209 Preparation 453 IR (KBr) : 1726.0, 1687.4, 1259.3, 1176.4 cm "1 NMR (DMSO-dg, δ) : 1.23-1.44 (4H, m) , 1.85-1.96 (4H, m) , 2.10-2.40 (2H, m) , 3.58 (3H, s) , 12.08 (IH, s) MASS (m/z) : 187 (M+l) Preparation 454 IR (KBr) : 1724.0, 1702.8, 1309.4, 1265.1 cm "1 NMR (DMSO-dg, δ) : 2.49 (6H, s) , 3.84 (3H, s) , 7.70-7.72 (2H, m) , 13.14 (IH, bs) Preparation 455 IR (KBr) : 1727.9, 1675.8, 1232.3 cm "1 NMR (DMSO-dg, δ) : 3.70 (3H, s) , 6.24-6.51 (2H, m) , 7.24-7.46 (2H, m) , 12.66 (IH, bs) MASS (m/z) : 157 (M+l) Preparation 456 IR (KBr) : 1726.0, 1685.5, 1286.3, 1251.6 cm "1 NMR (DMSO-dg, δ) : 3.98 (3H, s) , 7.68-7.77 (2H, m) , 8.11 (2H, s), 8.64-8.82 (2H, m) , 13.58 (IH, bs) MASS (m/z) : 231 (M+l) Preparation 457 IR (KBr) : 1724.0, 1697.1, 1290.1 cm "1 NMR (DMSO-dg, δ) : 3.95 (3H, s) , 8.04-8.08 (2H, m) , 8.20-8.27 (2H, m) , 8.68-8.71 (2H, m) MASS (m/z) : 231 (M+l) Preparation 458 To a solution of 1-hydroxybenzotriazole (244 mg) and 4- [5- (4-pentyloxyphenyl) isoxazol-3-yl] benzoic acid (528 mg) in dichloromethane (10 ml) was added l-ethyl-3- (3' - dimethylaminopropyl) carbodiimide hydrochloride (WSCD-HC1) (430 mg) and the mixture was stirred for 4.5 hours at ambient temperature. The reaction mixture was added to water. The organic layer was taken and dried over magnesium sulfate. Magnesium sulfate was filtered off, and the filtrate was evaporated under reduced pressure to give 4- [5- (4- pentyloxyphenyl) isooxazol-3-yl]benzoic acid benzotriazol- 210 1-yl ester (640 mg) . IR (KBr) : 1776.1, 1253.5, 1234.2, 1002.8 cm "1 NMR (CDC1 3 , δ) : 0.95 (3H, t, J=7.0Hz), 1.2-1.6 (4H, m) , 1.6-1.9 (2H, ) , 4.03 (2H, t, J=6.5Hz) , 6.81 (IH, s) , 7.01 (2H, d, J=8.3Hz) , 7.3-7.6 (3H, m) , 7.79 (2H, d, J=8.3Hz), 8.11 (2H, d, J=8.0Hz), 8.12 (IH, d, J=8.2Hz), 8.39 (2H, d, J=8.0Hz) The Starting Compounds (459) to (461) used and the Object Compounds (459) to (461) obtained in the following Preparations 459 to 461 are given in the table as below, in which the formula of the starting compounds are in the upper column and the formula of the object compounds are in the lower column, respectively. 211 Preparation No. Formula OHO __^ H3C/ „^ NH ^ \(CH2)]4CH3 H 2 N ^-N ^o o ^ ^ = ° « H ( NH 0=< CH 3 0= \ H N~ \ H ^ N ^ ' 0 H £— %H 0 Na0 3 SO J HO 459 OHO P *H J 0 HSC/Λ^ -NH ^N-^^(CH 2 ) 14 CH 3 H 2 N ^N 0 H<? NH 0= CH 3 0β \ /^l NH \ " λ'θH Na0 3 SO — ^ HO 212 Preparation No. Formula Hα m HO^S 460 HO, OH o H,N O HN -OH o H<X NH 0=< CH 3 H 0= H p-Λ -t N γ ^ ' 0H OH O NaO^SO" 213 Preparation No. Formula « ρH OHO _^ H 2 N N _ 0 o H *-f NH° 0 = J CH H 3 0= T H ?- Na0 3 SO FT ~ ^ ^ H ° HO 461 OH 0 OHO ^ H 2 N o 1 o^ HO * ^ ^NH° 0 V=< CH 3 ^— ( %H 0 Na0 3 SO — 7 HO 214 Preparation 459 To a suspension of Starting Compound (459) (5.0 g) and triethylsilane (6.67 ml) in dichloromethane (125 ml) was dropwise added trifluoroacetic acid (32.2 ml) with stirring under ice-cooling. The mixture was stirred at ambient temperature for 2 hours. The reaction mixture was slowly poured into pH6.86 standard buffer solution (1.2 L) with stirring under ice-cooling adjusting pH to 8.5-10 with IN sodium hydroxide. The mixture was evaporated in vacuo to remove the organic solvent and chromatographed on nonionic adsorption resin, Diaion SP-205 (Trademark, prepared by Mitsubishi Chemical Industries) (400 ml) eluting in turn with water (2 L) , 10% aqueous methanol (2 L) , 20% aqueous methanol (2 L) , 30% aqueous methanol (2 L) , 50% aqueous methanol (2 L) , 60% aqueous methanol (2 L) and 90% aqueous methanol (2 L) . The fractions containing the desired compound were collected and evaporated in vacuo. The resulting residue was lyophilized to give Object Compound (459) (3.13 g) . NMR (DMSO-dg, δ) : 0.85 (3H, t, J=7.0Hz), 0.96 (3H, d, J=6.7Hz), 1.02 (3H, d, J=6.1Hz), 1.24 (26H, m) , 1.35-1.50 (2H, m) , 1.55-2.50 (11H, m) , 2.80-3.30 (2H, m) , 3.60-5.40 (20H, m) , 6.60-6.80 (3H, m) , 6.85- 7.75 (5H, m) , 8.00-8.15 (2H, m) , 8.71 (IH, broad S) APCI MASS (m/z) : 1141.1 (M + -Na) Preparation 460 A solution of Starting Compound (460) (100 g) in a mixture of tetrahydrofuran (1 L) and pH6.86 standard buffer solution (1 L) was dropwise added benzyloxycarbonyl chloride (16.8 ml) at 5-10°C adjusting pH to 7.0-8.0 with saturated aqueous sodium hydrogen carbonate. The solution was stirred at the same conditions for 3 hours and adjusted pH to 6.0 with IN hydrochloride. The mixture was evaporated in vacuo to remove organic solvent. The residue was passed ion exchange resin, DO EX 50 X4 Na + type (prepared by Dow Chemical) (1 L) and washed with water (3 L) . The eluate was chromatographed on reversed 215 phase silica gel (ODS SP-120, prepared by Daiso Co. , Ltd.) (2.5 L) with water (12L), 10% aqueous methanol (12 L) and 20% aqueous methanol (12 L) successively. The fractions containing the object compound were collected, concentrated by evaporation in vacuo and lyophilized to give Object Compound (460) (76 g, yield 65%) NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.7Hz), 1.05 (3H, d, J=5.7Hz), 1.60-2.50 (7H, m) , 3.10-5.20 (29H, m) , 6.73 (IH, d, J=8.2Hz), 6.75-6.90 (2H, m) , 6.90-7.10 (2H, m) , 7.20-7.40 (7H, m) , 7.63 (IH, d, J=7.8Hz), 8.00-8.15 (2H, m) ESI MASS (Negative) : 1069.3 (M + -Na) Preparation 461 To a solution of Starting Compound (461) (30 g) and sodium cyanoborohydride (3.45 g) in dichloromethane (300 ml) was dropwise added trifluoroacetic acid (150 ml) with stirring under in ice-cooling. The mixture was stirred at the same condition for 3 hours. The reaction mixture was slowly poured into pH6.86 standard buffer solution (1.2 L) with stirring on ice-sodium chloride bath adjusting pH to 8.5-10 with IN sodium hydroxide. An aqueous layer was separated and cooled at refrigerator overnight. The aqueous solution was evaporated in vacuo to remove organic solvent and chromatographed on reversed phase silica gel (ODS SP-120, prepared by Daiso Co., Ltd.) (700 ml) eluting with water (5 L) and 5% aqueous methanol (6 L) successively. The fractions containing the object compound were collected, concentrated by evaporation in vacuo and lyophilized to give Object Compound (461) (17.3 g) NMR (DMSO-dg, δ) : 0.95 (3H, d, J=6.7Hz), 1.07 (3H, d, J=5.7Hz), 1.40-2.45 (7H, m) , 2.85-3.30 (2H, m) , 3.60-4.50 (13H, m) , 4.60-5.35 (10H, m) , 6.65-7.10 (5H, m) , 7.20-7.75 (8H, m) , 7.92 (IH, broad d, J=8.4Hz), 8.84 (IH, s) ESI MASS (Negative) : 1053.3 (M + -Na) 21 6 The Starting Compounds (1) to (169) used and the Object Compounds (1) to (169) obtained in the following Examples 1 to 169 are given in the table as below, in which the formulas of the starting compounds are in the upper column and the formulas of the object compounds are in the lower column, respectively. 217 Example Formula No. HO OH O o H 3 C ».- y!-«,«Λ. H 3 H 2 N HN t (CH 2 ) 6 C o OH > H<5 NH 0= CH- ' "OH OH \---Q_0(CH 2 ) 6 CH 3 218 Example Formula No. HO OH H •N* '"OH OH OH 219 Example Formula No. HO OH o ^ — NH \ "OH Na0 3 S OH HO ~ \ o a 11 H 3 C. — N " j, Na0 3 S 220 Example Formula No. HO OH OH 0 o H 3 G". \ -CH 2 =0 OH HO IH 0= Λ CH- HO IT o » 221 Example Formula No. OH OH 222 Example Formula No . HO OH CH ' / \ OH CH- / \ HO NH O CH N "OH OH . 223 Example Formula No. OH OH 224 Example Formula No . OH OH HO -NH H 3 C, £ \ Naθ 3 S 225 Example Formula No. OH O H 3 C N Γ H 2 N 0 0 HN OH ■ / ^s HO 0 : CH- H HO. "OH OH NaO 3 / HO OH HO O g-\ o _ _ Ktf H HO NH 0=/ CH 3 Naθ 3 S 226 Example Formula No. OH NaOo 10 OH H ΪOO / \ o H,C. 0(CH 2 ) 4 CH 3 H N Hi/ OH HO NH CH- Na0 3 S 227 Example Formula No . OH 11 OH N o. OH Na0 3 S r- 228 Example Formula No. HO OH 12 OH ζ 0CU 3 Na0 3 S 229 Example Formula No. OH 0 HO -N: H 3 G ΓΛ H 2 N - -Nxr -y HN t .N-H 2 O 0 OH HO NH ' CH- "OH OH O NaOoS / HO 13 OH gOCH 3 H 3 C - SW H 2 N \ — N =0 -v>° H VA HO H ' CH, OH Na0 3 S 230 Example Formula No. OH 14 OH HO o H 3 C... (CH 2 ) 7 OCH 3 HO 231 Example Formula No. OH 15 OH HO o H 3 C. (CH 2 )gOCH 3 NaQ 3 S 232 Example Formula No. OH 0 H 3 C _NH- H 2 N. =o > HN OH 0 ■r o " \ HO NH 0 CH- .N ""OH OH Na0 3 S 16 OH 0 \ 0 N _N H 3 C H 2 N -N r --0 r o HN ' „> .OH " \ HO " NH O CH- 0: O OH OH HO 233 Example Formula No. OH 0 » H 3 G .NH- H 2 N \=0 ' y 0 HN OH HO " NH CH- 0 H HO. OH ==< OH NaO / 17 OH HO O N / ~ \ O N H H 3 , C c.. . . . . /\γ/ NH ^N' JL ^ N - s ^r o ( CH 2 ) 3 CH 3 Na0 3 S 234 Example Formula No. HO OH Na0 3 S OH 0 {c}i 2H c}i 3 Na0 3 S w X so 2 P> so o 3 o • 9 Ό O 00 CD o tt O hi tsj a o 3 CO C Cπ o a o o 0J a ω n n a so o in o J a 00 10 236 Example Formula No. HO OH ,τ-N H 3 C... HO N Λ ^ψ - (CH 2 ) CH-J _ 20 OH HO o -N • N- J H 3 C. Γ: \ 0(CH 2 ) 4 CH 3 N-^-S ' H 2 N . -N Na0 3 S 237 Example Formula No. HO OH o HoC, .NH' -C— f ~ \- ~ -fΛ-0 (CH 2 ) 7 CH 3 ? "OH 21 238 Example Formula No. :CH- 22 OH 6 CH 3 HO 239 Example Formula No. HO OH H . o NH-C (CH 2 ) 4 CH 3 HN X OH Λ C.H 3 y "OH Na0 3 S 23 OH 0 H C H λNH-G II (CH 2 ) 4 CH 3 Na0 3 S 240 Example Formula No. HO OH 0 N H C„. H r\ o NH-C- -(CH 2 ) 5 CH 3 HoN -N =0 Na0 3 S 24 .OH 0 0 H 3 C " H , H- ( U-HQ -<Q^(CH 2 )5CH 3 H 2 N =0 Na0 3 SO 241 Example Formula No. ^Q O(CH 2 ) 5 CH 3 25 0(CH 2 ) 5CH3 242 Example Formula No. HO OH CH 2^6 CH- 26 (CH 2 ) 6 CH 3 243 Example Formula No. HO OH / O -M N H C H ΛNH-C- H 2 N O (CH 2 ) 5 CH 3 0 r HN OH Λ HO NH 0 y CH- HO ""OH OH 0 NaO iSoO- \ / HO 27 OH 0 O H C„. H „NH-( H 2 N =0 HN y°OH (CH 2 ) 5 CH 3 0 f Λ HO NH 0= CH- HO "OH OH O Na0 3 SO- \ / HO 244 Example Formula No. HO OH (CH 2 ) 8 OCH 3 28 -/ ~ Vθ(CH 2 ) QOCH 245 Example Formula No. HO OH HO O H C, A \ H .NH-C— ~ -N^ - ~ \-0(CH 2 ) 7 OCH; Na0 3 SO 29 OH HO O / \ 0 H 3 C, H ,NH-C— -^ ~(^- 0 (CH 2 ^ θCH ; HoN 0 HN ° OH HO NH 0=y ~ \ CH 3 "'OH Na0 3 SO' 246 Example Formula No. 30 247 Example Formula No. 31 0(CH 2 ) 5 CH 3 248 Example Formula No. OH HO 0 / 32 OH r. ■ - ° HO / \ II N. N H 3 C H n ^H N-^0(CH 2 )7CH 3 H 2 N — V=0 \ HN OH O HO * NH CH 3 ■Ns. \.. "OH Na0 3 SO 249 Example Formula No. OH HO ^ 0 / " H C. .NH- HoN O 33 OH O O N 0(CH 2 ) 5 CH 3 HO 250 Example Formula No. .OH 0 N r H 3 C„„ H ** . wNHn 2 - HoN O 34 OH o X CH 2 ) 8 0CH 3 w^ ^X oϊ y 0( NaO SO' 251 Example Formula No. H C„. HoN =0 H OH O f HO NH O: CH- HO "OH OH 0 NaO SO- \ HO 35 .OH 0 O HO 252 Example Formula No. OH 0 / -T NJ H 3 C„„ H ^ .iNHn 2 ' H 2 N 0 0 HN OH O r HO " NH 0=^ CH 3 0= HO X ) * ""OH OH Na0 3 SO- \ HO 36 OCH, 253 Example Formula No. 37 OH HO H 3 C, Λ 0(CH 2 ) 2 CH 3 a 0 H->N 254 Example Formula No. 38 0(CH 2 ) 3 CH 3 255 Example Formula No. 39 Na0 3 SO' 256 Example Formula No. HO "OH O 40 θ(CH 2 ) 5 CH 3 257 Example Formula No. 41 0(CH 2 ) 6 CH 3 258 Example Formula No. 42 ,P H HO N-N H 3 C.„. S~ s H irv) ~ V -0(CH 2 )^ ^ HoN V. -J =0 y-\ \ — o HN OH ° HO ^ ""~ NH 0=^-\ CH 3 o= HO. T-^γO'-oH Na0 3 SO — ( /.= " OH ° > HO 259 Example Formula No. .OH HO 0 -N r H C,.. H -NH- 43 » N-N /=-N Ό' " N ^ CH 2 ) 9 CH 3 260 Example Formula No. 44 (CH 2 ) 9 CH 3 Na0 3 SO- 261 Example Formula No. OH NaO 45 ^-QHH ^O ( CH 2 ) 3 -OHQ> 262 Example Formula No. 46 263 Example Formula No. NaO SO 47 264 Example Formula No. .OH O H 3 C. ΓΛ „NH- HoN 0 HN OH 0 f = HO " NH 0= CH- =\ HO "OH OH O Na0 3 SO- \ // HO 48 (CH 2 > 8 ° CH3 NaOoS 265 Example Formula No. OH -N r H^C... H y - H 2 H 2 N \ =0 HN OH 0 f 0 HO " NH 0= CH- 0= H HO ■ "OH " OH O NaO^SO- \ / HO 49 OH HO Λ H 3 C„. ~ \ - (CH 2 ) 3 →Ϊ ^ O H 2 N \ ^ Hi/ OH HO " NH C. OH Na0 3 S 266 Example Formula No. OH -N H^C, HΛ .NH' HoN =0 HN OH o f HO " NH O CH- 0= HO "OH OH 0 Na0 3 SO- \ / HO 50 N-N —4 r - 267 Example Formula No. OH O - TNS Λ H 3 C H V.N NIH 2 HoN O =0 HN OH O f HO H O CH- HO ""OH " OH Na0 3 SO- \ / HO 51 OH 5-0 \ 268 Example Formula No. OH HO 52 OH HO n °. \ / \ " " O II H 3 ^ y^f H ζK Hs-^-0 ( CH 2 ) 3 -Oχ2> H 2 N o ° H C oH HO " \lH 0= CH 3 0= \- "OH NaO SO' 269 Example Formula No. OH HO 0 / -N N H 3 C,.„ H H 2 N f O HN X OH o HO NH 0= Λ CH- HO "OH " OH O Na0 3 SO- \ / HO 53 - N-N / -^ ^^^( >- - >-o (CH2) 5 ° CH3 HN OH 270 Example Formula No. OH 54 H^C„, H 2 N -N \ 1o HN OH Na0 3 S 271 Example Formula No. OH O N H 3 C„„ H r\^ .Ni H 2 - H o N o NaO^SO 55 272 Example Formula No. 56 OH O 273 Example Formula No. HO OH HO O 57 CH 2 ) 7 CH 3 274 Example Formula No. 58 CH 2 ) 6 CH 3 275 Example Formula No. HO .OH HO 0 -N H H 3 C.., H '/ \\_y/ w (CH 2> 4 CH- H 2 N =0 HN y OH O HO " 0= Λ CH- "OH Na0 3 SO 59 OH HO O -, J \ H 3 C - s l^ ^_yχx>- 2 ) 4 CH 3 H 2 N > — N V=0 \ HN OH O 276 Example Formula No. HO OH 60 OH H 3 C„ K )^ (CH 2 ) 5 CH 3 277 Example Formula No. OH 0 H 3 C„. H Λ -NH- H 2 N „κ O HI OH HO 0= Λ CH- 0= OH ΌH Na0 3 S 61 278 Example Formula No. OH 0 62 OH HO H 3 C. H 2 N 2o)'α 9C^H n 3 279 Example Formula No. OH 63 OH H 3 C„. * ^ ^^ > 3-°o H 2 N " V > \ * HO "' NH CH, - " OH 280 Example Formula No. 64 OH 0 H 3 C„, ΪT > ^O- 0 ^ H 2 N ■ κ =0 HN OH HO NH 0= λ CH, 0= V H "OH OH A Na0 3 SO / 281 Example Formula No. OH 0 H^C,. H H 2 N „> O OH ^\ HO O Λ C.H- 0 H V "OH OH , 65 OH \ — N V==0 "OH Na0 3 S 282 Example No. Formula -OH OH O N H 3 C//„. H ^NH 2 HoN ■ N o HN -OH HO NH O ""/OH Na0 3 SO HO 66 ^OH 0 -ς sXς ^ o-Q HN y „= ^°H NH 0 )==<^. cCH 3 0=^ N— \ * oΗ O Na0 3 SO- HO 283 Example Formula No. OH HO 0 H 3 C„ H m 2 H 2 N =o HN OH 0 ? - HO " O Λ C.H- H N "OH NaO / 67 OH H s c < χ y n ( CH^-OO ,N ^ — N 0= Cl OH 284 Example Formula No. OH 0 H 3 C„ H H 2 N - o HN OH HO NH 0=( CH 0= H V .N- "OH OH 6 68 OH N-N — — / /// >- (CH 2 ) 3 -0HQ 285 Example Formula No. OH 0 HoC,,. H H 2 N OH >- HO 0= λ CH- 0= H ""OH OH I NaOoS / 69 OH H °v_κ Λ ϊ ,- N - N H 3 C ' . . ^ O° (CH 2'5 0CH 3 ,N \ — N \=0 HN OH HO TϊH 0= CH 3 286 Example Formula No. OH HO 0 70 OH 0 N-N Na0 3 S 287 Example Formula No. OH 0 H Q H ■ HoN HN OH \ HO 0 CH- 0: H ιN OH NaO 3S< - / HO 71 OH N-N 2 CH 3 HoN — N =0 Na0 3 SO 288 Example Formula No. 72 OH O H 2 ^ H-J N —yNX * (CH2 ) 4C =0 \ HN OH 289 Example Fo mula No. OH 0 H 3 C„ H _-NH 2 H 2 N - HN OH HO 0 Λ C.H- O: H ""OH NaO / 73 OH O O(CH 2 ) 4 CH 3 H 3 C, Na0 3 S 290 Example Formula No. OH 74 OH O H 3-oC, H^ Η ^ \ ^=>_ ^ N >-Q,o^) H 2 N HI OH ^ V HO " NH ■ =( OH ^ 2 9 1 Example No . Formula O HN. £>H H& NH O CH, o= H "'/OH O Na0 3 SO 75 Ma0 3 SO HO 2 9 2 Example No . Formula "'/OH HO„SO 76 Naθ 3 SO HO 2 9 3 Example No . Formula NaOoS 77 J3H N HN ^H o= c CH 3 ''/θH OH O Na0 3 SO ■ 294 Example No. Formula OH NaO S .OH HO *- NH o^ CH 3 H JH Naθ 3 Sθ 295 Example No. Formula Na0 3 SO HO 79 ,-OH r *^ ^^l HN „OH^x N °y N θ > « o 4==^H c CH, • ΌH Naθ 3 SC 2 9 6 Example No . Formula ' » /< '/OH NaOoSO 80 0(0-2)400.3 Naθ 3 Sθ 297 Example No. Formula ""/OH NaOoSO ^OH OH O ■ N^λ θ(CH 2 ) 4 θCH 3 "V CH " °=SA ' 3 '//OH O 298 Example No. Formula OH N H 3 C//„. H *NH 2 — N O O HN =°H HO ,NH O CH 0= N- H N, ""/OH O NaOoS HO 82 «£>H + ^H HO" o= r α CH 3 N"N 'VOH O HO 299 Example No. Formula £>H N H 3 C/,„. H ^ ^.NH 2 O HN HO NH O '"/OH NaO,S PH : 0 H HNN. ,POHH N-N θ=- CH 3 O^ N— \ OH O Naθ 3 SC HO 300 Example No. Formula OH NaOoS 84 ^OH e 1 S^ow o .OEt HO* 0= C C)H> Na0 3 SO 8 Y°' 3 0 1 Example No . Formula ^ OH N H 3 C//,.. H £NH 2 — N =0 O HN OH HO NH O N" '"/OH O Na0 3 SO OMe Na0 3 SO HO 302 Example No. Formula CH H '"/OH O HO^SO 86 ^OH 5* H 2 N \-N 0 |I HN M ^^ θ= CH 3 A '/ 0H 0(CH 2 ) 5 0CH 3 O 303 Example No. Formula XM H0 3 SO 87 ,OH OHO o -N^\ H 2 N HHNN T -PO τ H τ ^^ O -:H CH, N- €L S(CH 2 ) 7 OCH 3 O NaOjSO 304 Example No. Formula -OH H 3 c,,,,/- §H --H/ ~ ^ H 2 N ^-N ^o H ( ^ NH 0= CH 3 0= \ N — \ / ^ N ^ ^""QH —L OH 0 H0 3 SO ζ HO 88 ^OH = MΓ ° H 2 N \-N ≤ 0 |l 0 HCTH N>H 0 _=<}- CH 3 ^ N r 1^ι 1 -- O=3 H ^ I Naθ 3 Sθ— ζ' y HO 305 Example No. Formula H0 3 SO HO 89 » OH "θ H HNN C" NH CH 3 O (012)4013 ^'/θH O o. HO 306 Example No. Formula HO NH O CHo O N- H N, '"/OH HO SO 90 .OH * ^~ " HN „OH ^"^ 0=»^ CH 3 s -1 " ^' /OH XX • ΌH O Naθ,SC x> 307 Example No. Formula H0 3 SO HO 91 -OH * — ^"~ " HN pH ^^ CH, ''/θH 'OH Naθ 3 SC 3 0 8 Example No . Formula 5 OH H 3 C//„. H 5? NHo ) = 0 y HN -OH H(J>y N NHH ° O ""/OH Na0 3 SO 92 θ(CH 2 ) 6 θCH 3 Naθ 3 Sθ 3 0 9 Example No . Formula NaOoS 93 -OH OH O. 0(CH 2 ) 4 CH 3 Naθ 3 Sθ 310 Example No. Formula ""/OH NaO S HO 94 Naθ 3 SO HO 31 1 Example No. Formula HO " NH O '"/OH NaOoS 95 ,OH / o H3 C/„. γ . * 1 N »— N . 0 x HCχT NH° θ=^i < 0(CH2) 6 OCH 3 HQ, Naθ 3 Sθ ■ 312 Example No. Formula -OH N H 3 C//„ H ^ NNHl 2 HoN O P HN -PH H NH P CHo 0=f N — HP •y~y ° '"/PH PH P NaP.S 96 ^H OHO Na0 3 SO HO 313 Example No. Formula PH P ^ N H 3 C//„, H ^*NH 2 ^ 0 P HN HP NH CH 3 0=^ N— H r \ A. X""ion O NaP S 97 ( CH^ β OCHs Naθ 3 Sθ HO 314 Example No. Formula ""/OH NaO S 98 θ(CH2)4CH 3 Naθ 3 Sθ 315 Example No. Formula NaOoS 99 „OH HO* NH θ=^ C θ(CH2) 5 CH 3 CH, 5 *O-H=A3 Naθ 3 Sθ- 316 Example No. Formula -PH ;-> NaP S 100 θ(CH 2 ) 6 CH 3 Naθ 3 Sθ 317 Example No. Formula NaP S 101 OH O w 5.> O 0(CH2)2CH 3 Naθ 3 Sθ 318 Example No. Formula NaP,S HP 102 Hc„.^y- Ns^ ' H<T NH ( CH, 0(CH 2 ) 4 CH 3 'OH Naθ 3 Sθ- 319 Example No. Formula P^ N — v '"/PH PH P NaP,S HP 103 -OH OH O. o H 3 C/ Λ H 2 N HcJ* NH θ= C CH, OCCH 2 ) 5 CH 3 = N — » \ _H ψ \ OH O Naθ 3 Sθ ■ 320 Example No. Formula CH 3 N — ,N \ /\/""/OH O NaOS 104 OH O. H 3 C/,,./\/ H ■■ IT X. 0(CH2)5CH3 Naθ 3 Sθ 3 2 1 Example No . Formula ""/OH OH O H0 3 SO / \ HO 105 .OH O Na0 3 SC HO 322 Example No. Formula -PH HP 3 SP 106 θ(CH 2 ) 2 θ(CH2)2 Me 323 Example No. Formula -PH '"/OH NaOoS 107 „pH o N^~\ H 3 C/./\ ~H N ' — N X OH HCyTt NH ° 0= Υ - ^ ( x o Na0 3 SO> HO 324 Example No. Formula -PH NaP,S 108 .OH OH O. O ■N^ H 3 C//,/\ H LNH *— -N V =tt CL o O Naθ 3 Sθ o 325 Example No. Formula HP 3 SP 109 HO 326 Example No. Formula OH HP 3 SP HP 110 DH OH O H 3 C/,,^ " H H,N V N 327 Example No. Formula • Ϊ P?H HP 3 SP 111 JDH OHO NaC^SO HO 328 Example No. Formula OH HP 3 SP 112 NaQ 3 S HO 3 2 9 Example No . Formula -PH N Ho 3C^/"/,ι. H i*NH P P HN HP NH P CH 3 H ^ s * "/PH PH P HP 3 SP HP 113 . )~ θC6Hl3 Naθ 3 S' HO 330 Example No. Formula HP 3 SP HO 114 Naθ 3 SO HO 331 Example No. Formula H0 3 SO 115 332 Example No. Formula HP 3 SP 116 Naθ3S< HO 333 Example No. Formula HP 3 SP 117 3H HO 334 Example No. Formula OH J PH P H y 3 C ^ /i/i,u H i i*NJNHH 22 HoN >= 0 P HN HP" NH CH 3 o=X H '"/PH P HP 3 SP HP 118 ^OH HN „OHi V f,y OOO CH, O 335 Example No. Formula HP 3 SP 119 PH o' ^ ^— n HN -C" HO * .NH o= CH 3 O: NaQ 3 SC H γ° ■ ' OH OH O HO 336 Example No. Formula HP 3 SP HP 120 ^ OH r H ά^ s fi^ A»H N _y N oo-^ C CH 3 H r N -\ 'VOH 337 Example No. Formula « PrH HP 3 SP HO 121 CH 3 - -O* 1 CH, HO,SO 338 Example No. Formula CH 3 N — v O H0 3 SO 122 3H N- y N °<X 339 Example No. Formula HO NH O ""/OH HP,S HO 123 <OH OHO \ O ΓH OCH 2 CH 3 H 2 N *-N \-_ 0 N-N X HN -OH O _tt CH 3 0=^ R N^ — i N ^ 'V0H "OH O Naθ 3 Sθ- 3 4 0 Example No . Formula 0= N- H "N. OH 1 o HO,S HO 124 DH O H 2 N \-N ^= 0 N_N " HN .OH 0 -=tt ( CH 3 oH 'OH O Naθ,Sθ 341 Example No. Formula HO,S 125 ΫO * v_v HO 342 Example No. Formula -PH PH N H 3 C//„. H λ *NH 2 — N P HN. >H HP NH P ""/OH HP,S 126 N N|l o HO 343 Example No. Formula HP 3 SP 127 CH 2 OEt 344 Example No. Formula 5 O>H HP,S HO 128 CH 2 θ(CH 2 ) 2 θ e 345 Example No. Formula H0 3 SO 129 C CH^OH Naθ 3 Sθ 3 4 6 Example No . Formula -PH HP 3 SP 130 θ(CH 2 ) 3 θMe HO 3 4 7 Example No . Formula P CH, N- H N, ""/OH I oI Na0 3 SO HO 131 Na0 3 SO HO 3 4 8 Example No . Formula '"/OH NaO,S HO 132 Na0 3 SO HO 349 Example No. Formula -PH OHO ζ H 3 C/„..A ^S HO NH 0=< CH 3 0= N — i H \_ ^ " N / .,, /0H / I Na0 3 SO ζ ~ J 0H ° HO 133 ^OH OH O ^ H-.N »■— N \ 0 ^ Hι ^ NH ° 0= "Vf CH 3 0= Λ N — V Na0 3 SO - — — ^τ\y~ o HO 350 Example No. Formula )H HP NH P CH, 0=S N- NaO,S HP 134 ^OH „ ; c/, ' H ^=κ<L HN , >H χ χ ™--o HO^ NH o : 0^γ /o on o Na0 3 SO ■ HO 351 Example No. Formula -PH NaO,S HO 135 -OH OH O. H 3 C/,, H,N ^=o 0 HN OH -tt C=H 3 O Na0 3 SO HO 352 Example No. Formula £>H NaO,S 136 OH O NH H 3 C ( r\ 8 /= " ■ X Na0 3 SO HO 353 Example No. Formula £>H NaP,S 137 .OH OH O, . — NH \ / — > ■ 0(CH 2 ) 5 -N V=o HN .OH , c C:H, O NaO,SO HO 354 Example No. Formula Na0 3 SO HO 138 ^H OH O. - . — NH \ == A .tt HO-i 0= " V^C CH 3 Na0 3 SO HO 355 Example No. Formula NaO,S 139 .3H r ~ \ II /=\ ^ /=\ 0(CH 2 ) 6 — N r- ^=0 X HOf NH° -.OH , 0= "X^ c C.H. 3 , /^" 'Vo Na0 3 S0 ■ HO 3 5 6 Example No . Formula .PH NaP,S HP 140 »pH _OH O IH ' \ Λ M / / \ 0(0^) 5 — N S HN ^OH -tt 5«- "OH Na0 3 SO • HO 357 Example No. Formula -PH N H 3 C/„.. H ^* NNHI 2 O O HN HP NH P CH, H '/PH P NaP,S HP 141 .OH θ(CH 2 ) 5 θMe HO 358 Example No. Formula NaP,S 142 .OH rύr / — ^ \ x >XCH^) 5 OUe HCT NH 0=^ C CH, "ΌH NaO,Sθ- 359 Example No. Formula J O5 > H P N H 3 C//„, H ^NHo HoN o HN HP NH O '"/OH Na0 3 SO 143 PH C^CH j ^Me H 2 N ' — N V— 0 HCT O^ ( CH, O Naθ 3 Sθ' 360 Example No. Formula -PH N H 3 C//„. H i ^ ^*NNNHHI 22 HoN •I ' — N P HN HP NH P CH, N * A '"/OH P NaP,S HO 144 ^OH θ(CH 2 ) 7 θ e H 9 N \ — N L 0 HN, .OH o=tt< O 361 Example No. Formula -PH H 3 3C////,,, i*NH 2 P HN HP NH P ""/OH NaP 3 SP HO 145 .OH H,N -" • _y N \_ o :θ G' HN k, .OH HX > θ(CH 2 ) 8 θMe HT NH 0= o=tt N— ». ΌH O Naθ 3 Sθ- 362 Example No. Formula ^ -PH NaP 3 SP HO 146 -pH OH O. 363 Example No. Formula P CH, 0=^ N- H N, ""/OH NaO,S 147 ^OH z. y— NH \ I o H,N \ γ_ s= 0 X HCyTt NH ° 0= c CH 3 •s- 'OH o Na0 3 SO ■ HO 364 Example No. Formula NaP,S HP 148 OH — H °\ / — \ o ^ X^ X XX >- "i O — N 365 Example No. Formula -PH NaO,S HP 149 OH O • > Q A HO* NH θ= CH 3 /^^ N ^'ZOH 'OH O Naθ 3 Sθ- 366 Example No. Formula -OH NaP 3 SP 150 ,OH OH Q -*-δ •I k Λ /^^H* X Xy Na0 3 SO 367 Example No. Formula NaP,SP HP 151 Naθ 3 Sθ 368 Example No. Formula -PH ^ NaP 3 SP HO 152 .OH •N^Λ S =N H,N — N _ 0 HN -ΛH HO^ NH 0 = =^tt C CH, 0= N— i "OH O Naθ 3 Sθ- 3 6 9 Example No . Formula NaO,SO 153 .OH OH O. i H 3 C/, Naθ 3 Sθ' 370 Example No. Formula X>H ^ NaP 3 SP 154 -OH HSP Λ θ(CH 2 )3CH3 H-.N \Y^ < o > Naθ 3 Sθ HO 371 Example No. Formula o CH, 0=^ H , , , /OH O NaP 3 SP 155 .OH ■ N ^ θ(CH2) 4 CH 3 H 2 N ^-N ^ 0 S N — ' HO" 0=ζ CH 3 O Naθ 3 Sθ 3 7 2 Example No . Formula -PH NaP 3 SP 156 ^H \ ?, θ(CH2)5CH 3 H2 \ N ^ ==° „PH HCT NH 0=^ ( CH, θ= N — i OH Naθ 3 SC HO 3 7 3 Example No . Formula -PH P y \ i* hL 2 = 0 o yy r HN -OH H( NH 0= CH, ""/OH Na0 3 SO HO 157 .OH .^ θ(CH 2 ) 5 CH 3 H,N »— N HO 3 7 4 Example No . Formula OH Na0 3 SO 158 .OH ' \ n /=\ H2 \ Y_ = 0 „OH 0(CH2) 4 CH3 HCT NH o=^ c CH, A>H NaQ 3 SO- 375 Example No. Formula OH ""/OH NaP,S 159 H ■ 0(CH 2 ) 4 CH 3 H 2 N «— N =0 " N-N N-N Hθ" NH 0=^ CH 3 — * ^' //oH 'OH NaO,SO ■ HO 376 Example No. Formula OH PH Ho 3C^/'/",« *NH 2 HoN )= 0 P HN OH HP NH CH 3 0= \ M N — \, /0H o HP,S HO 160 f N-vNo f -o > f 377 Example No. Formula -PH HP,S 161 ^OH N V_N ^=0 N-N ^^ DH HO" ^NH o= C CH, <M O Naθ,SC 378 Example No. Formula ""/OH HP 3 SP 162 379 Example No. Formula -OH OHO N-N H3C/,, γ " H II θ(CH2) 7 θMe HoN *— N V NaQ 3 SO HO 163 ..OH Q(CH 2 ) 7 OMe H- ^OH CH, »AD cm. o HO 380 Example No. Formula 3H θ(CH2) 7 θMe Na0 3 SO HO 164 -OH H, \-N ^j 0 ^- S ~ H * NH o= ( CH 3 N— '//OH O HO 3H H 3 C//,^\ " H 0(CH 2 )7θMe H 2 N N O HCΓ NH o= c CH 3 OH°y o> ^' OH ' MeO 381 Example No. Formula HO, -OH OHP O H 3 C/,.^γ^ H (CH 2 ) 14 CH NaO,SO HO 165 ■ 5 P-rH ψ PHP _ / — v o H 3 C/,,./\ H ≤ £* V NJ- ( CH 2)l4 CH 3 HON \ H N NaP 3 SP 382 Example No. Formula -PH P ≡H P / Λ ^ \ ° H3C/ „.^ ^N N X (CH2)I4CH3 O ) >=P HN -PH HP-f NH 0 J=- CH 3 0=\ \ N— v H r \ ^ NA^"' /OH π—i OΑ o Na0 3 SO X HO 166 - H OHO , H 3 C / „.^ X/--ιH^ * H 2 N \-N \-- 0 > s =0 HN .OH HO * NH p= CH 3 0=\ \ _H f— \v -/ N V A ^ , '' / 0H — ^ OH 0 Na0 3 SO ^ HO 383 Example No. Formula -PH HO,SO 167 _)H OHO W/.^ XV/-H \ θ(CH : ) 7 θCH 3 H0 3 S0' 384 Example No. Formula HQ, )H PHP. H 3 C//„^ g i ^ H; HoN i — - TNVT HP 3 SP 168 HQ, ,OH O O OHH Q U H 3 C / ,,^ -{j * 0(CH 2 ) 4 CH 3 NH \ f N-0 Hσ NH o= ( CH, '"/OH O H0 3 SO 3 8 5 Example No . Formula (CH 2 ) 14 CH 3 NaP 3 SP 169 ,OH OH O H0 3 SO HO 386 Example 1 To a suspension of Starting Compound (1) (0.6 g) and sodium cyanoborohydride (0.076 g) in dichloromethane (6 ml) was gradually added trifluoroacetic acid (3 ml) at 4°C. The mixture was stirred for an hour at 4°C. The reaction mixture was evaporated under reduced pressure. The residue was added to water and adjusted to pH 8.5 with IN NaOH aq. The solution was subjected to column chromatography on ODS (YMC-gel ODS-7AM S- 50) and eluted with 30% acetonitrile aqueous solution. The fractions containing the object compound were combined and evaporated under reduced pressure to remove acetonitrile. The residue was lyophilized to give Object Compound (1) (0.417 g) . IR (KBr) : 3350, 1668.1, 1629.6, 1241.9 cm "1 NMR (DMSO-d 6 , δ) : 0.87 (3H, t, J=6.7Hz), 0.96 (3H, d, J=6.7Hz), 1.11 (3H, d, J=5.7Hz), 1.2-1.55 (8H, m) , 1.55-2.1 (5H, m) , 2.1-2.5 (4H, m) , 3.01 (IH, m) , 3.19 (IH, m) , 3.46 (IH, m) , 3.6-3.87 (3H, m) , 3.87-4.55 (13H, m) , 4.6-5.5 (8H, m) , 6.52 (IH, d, J=8.1Hz), 6.73 (IH, d, J=8.2Hz), 6.83 (IH, d, J=8.2Hz), 6.85 (IH, s), 7.0-7.15 (3H, m) , 7.19 (IH, s) , 7.27-7.55 (3H, m) , 7.55-7.78 (3H, m) , 7.8-8.0 (2H, m) , 8.76 (IH, s), 8.85 (IH, s) MASS (m/z) : 1248 (M+Na + ) Elemental Analysis Calcd. for C 5 3H 7 2N g Na0 21 S • 7H 2 0 : C 47.07, H 6.41, N 9.32 Found : C 46.82, H 6.54, N 9.25 The following compounds (Examples 2 and _3) were obtained in a manner similar to that of Example 1. Exampl 2 IR (KBr) : 3349.7, 1666.2, 1631.5, 1267.0 cm -1 NMR (DMSO-d 6 , δ) : 0.96 (3H, d, J=6.7Hz), 1.11 (3H, d, J=5.9Hz), 1.7-2.0 (2H, m) , 2.0-2.6 (4H, m) , 2.6-2.8 (IH, m) , 3.1-3.3 (IH, m) , 3.3-3.5 (IH, m) , 3.5-4.5 (16H, m) , 4.6-4.9 (2H, m) , 5.1-5.5 (5H, m) , 6.72 (IH, d, J=8.2Hz), 6.81 (IH, dd, J=8.2 and 1.9Hz), 387 6.9-7.5 (4H, m) , 7.05 (IH, d, J=1.9Hz), 7.4-7.9 (3H, m) , 8.84 (IH, s) MASS (m/z) : 965 (M+Na + ) Elemental 7nalysis Calcd. for C35H 51 Ng0 19 SNa- 5.5H 0 : C 40.35, H 6.00, N 10.75 Found : C 40.33, H 5.92, N 10.63 Example 3 IR (KBr) : 3350, 1648.8, 1276.6 cm -1 MASS (m/z) : 1266 (M-Na + ) Exampl 4 To a suspension of Starting Compound (4) (46.1 g) and NaBH 3 CN (7.7 g) in dichloromethane (600 ml) was added dropwise trifluoroacetic acid (240 ml) for 15 minutes below 5°C. The reaction mixture was stirred for 3 hours at the same temperature. The lower layer (trifluoroacetic acid layer) of the reaction mixture was poured into a large volume of an ice cooled aqueous NaHC0 3 solution (pH=8.5). The upper layer (dichloromethane layer) was also poured into a large volume of an ice cooled aqueous NaHCO solution. The aqueous layer was combined together and was purified by column chromatography on ODS to afford Object Compound (4) . NMR (DMSO-d 6 , δ) : 0.95 (3H, d, J=6.7Hz), 1.04-1.12 (3H, m) , 1.48-2.00 (3H, m) , 2.07-2.50 (4H, m) , 2.90-3.34 (2H, m) , 3.60-4.48 (18H, m) , 4.60-5.40 (9H, m) , 6.72 (IH, d, J=8.2Hz), 6.81 (IH, dd, J=8.2 and 1.6Hz), 6.84 (IH, m) , 6.98 (IH, m) , 7.04 (IH, d, J=1.6Hz), 7.28-7.50 (6H, m) , 7.58 (2H, m) , 7.73 (2H, d, J=7.4Hz), 7.84 (IH, m) , 7.88 (2H, d, J=7.6Hz), 8.84 (IH, s) MASS (m/z) : 1141 (M + ) Example 5 To a solution of Starting Compound (5) (38.7 g) in dimethylformamide (250 ml) was added piperidine (17 ml) at room temperature. The solution was stirred for 2.5 hours at the same temperature. Ethyl acetate (2.5 L) was added to the reaction 388 mixture and the mixture was stirred for 30 minutes. The powder was collected by filtration to give Object Compound (5) (34.6 g ) • Example 6 To a solution of Starting Compound (6) (0.3 g) and triethylsilane (0.44 ml) in methylene chloride (7 ml) at 10°C, was added dropwise trifluoroacetic acid (2 ml) . The mixture was stirred at room temperature for 4 hours. The reaction mixture was added in lN-sodium hydroxide (31 ml) at 10°C. The aqueous layer was subjected to column chromatography on ODS (YMC-gel ODS-AM S-50 (Trademark: prepared by Yamamura Chemical Lab.)) eluting with water. The fractions containing the object compound were combined, and evaporated under reduced pressure. The residue was lyophilized to give Object Compound (6) (0.13 g) . IR (KBr) : 3361.3, 1668.1, 1631.5, 1268.9 cm -1 NMR (DMSO-d 6 , δ) : 0.96 (3H, d, J=6.7Hz), 1.06 (3H, d, J=5.5Hz), 1.60-2.50 (9H, m) , 2.90-2.97 (IH, m) , 3.16-3.50 (2H, m) , 3.69-4.50 (13H, m) , 4.74-5.31 (10H, m) , 6.72-7.65 (14H, m) , 7.93-7.97 (IH, m) , 8.71 (IH, s) Example 7 To a solution of Starting Compound (7) (110 mg) in water (5 ml) was added 10% palladium on carbon (11 mg) , and hydrogen gas at atmosphere pressure for 7 hours. The reaction mixture was filtered through celite and lyophilized to give Object Compound (7) (70 mg) . IR (KBr) : 3394, 3327, 1676, 1633, 1439 cm "1 NMR (DMSO-d 6 , δ) : 0.96 (3H, d, J=6.8Hz), 1.08 (3H, d, J=6.0Hz), 1.88-5.83 (35H, m) , 6.68-8.71 (10H, m) MASS (m/z) : 903.17 (M-Na + ) Example 8 To a solution of Starting Compound (8) (350 mg) in N,N- dimethy1formamide (6 ml) was added 4- [4- (4-cyclohexylphenyl) - piperazin-l-yl]benzoic acid benzotriazol-1-yl ester (230 mg) , 389 and the mixture was stirred for 2 hours at ambient temperature. The reaction mixture was pulverized with ethyl acetate. The precipitate was collected by filtration, and dried under reduced pressure. The powder was dissolved in water, and subjected to column chromatography on ion exchange resin (DOWEX-50WX4 (Trademark: prepared by Dow Chemical) ) eluting with water. The fractions containing the object compound were combined, and subjected to column chromatography on ODS (YMC-gel • ODS-AM- S- 50 (Trademark: prepared by Yamamura Chemical Lab. ) ) eluting with 30% acetonitrile in water. The fractions containing the object compound were combined, and evaporated under reduced pressure to remove acetonitrile. The residue was lyophilized to give Object Compound (8) (160 mg) . IR (KBr) : 1666.2, 1633.4, 1608.3, 1511.9, 1230.4 cm "1 NMR (DMSO-d 6 , δ) : 0.95 (3H, d, J=6.7Hz), 1.09 (3H, d, J=5.4Hz), 1.2-1.5 (6H, m) , 1.6-2.1 (7H, m) , 2.1-2.6 (5H, m) , 3.02 (IH, m) , 3.1-3.5 (10H, m) , 3.6-4.5 (14H, m) , 4.6-5.3 (9H, m) , 6.73 (IH, d, J=8.2Hz), 6.77 (IH, d, J=8.2Hz), 6.80 (IH, s), 6.91 (2H, d, J=8.7Hz), 6.9-7.1 (5H, m) , 7.26 (IH, s) , 7.3-7.5 (2H, m) , 7.66 (IH, br s) , 7.78 (2H, d, J=8.6Hz) , 8.04 (IH, d, J=7.3Hz) , 8.31 (IH, d, J=7.3Hz), 8.84 (IH, s) MASS (m/z) : 1311 (M+Na + ) Elemental Analysis Calcd. for C5gH-7γN-j_o°20 s ' ^ H 2° : C 49.85, H 6.42, N 10.02 Found : C 50.06, H 6.36, N 10.07 The following compounds (Examples 9 to 1_1) were obtained in a manner similar to that of Example 8. Example 9 IR (KBr) : 3350, 1648.8, 1276.6 cm "1 NMR (DMSO-d 6 , δ) : 0.95 (3H, d, J=6.8Hz), 1.11 (3H, d, J=5.2Hz), 1.5-1.7 (6H, m) , 1.7-2.6 (7H, m) , 2.94 (IH, m) , 3.1-3.5 (6H, m) , 3.6-4.6 (14H, m) , 4.7-5.3 (9H, m) , 6.73 (IH, d, J=8.2Hz), 6.82 (IH, d, J=8.2Hz), 6.84 (IH, s), 7.04 (IH, s) , 7.06 (2H, d, J=8.7Hz), 7.18 (IH, 390 s), 7.3-7.5 (2H, m) , 7.66 (IH, br s), 7.83 (2H, d, J=8.7Hz), 8.0-8.2 (5H, m) , 8.75 (IH, d, J=7.1Hz), 8.84 (IH, s) MASS (m/z) : 1266 (M-Na + ) Example 10 IR (KBr) : 3361.3, 1646.9, 1517.7, 1257.4 cm "1 NMR (DMSO-d 6 , δ) : 0.91 (3H, t, J=7.3Hz), 0.96 (3H, d, J=6.5Hz), 1.11 (3H, d, J=5.7Hz), 1.3-1.6 (4H, m) , 1.6-2.6 (9H, m) , 2.95 (IH, m) , 3.1-3.5 (2H, m) , 3.6-4.6 (16H, m) , 4.7-5.4 (9H, m) , 6.73 (IH, d, J=8.2Hz), 6.82 (IH, d, J=8.2Hz), 6.90 (IH, s), 7.06 (IH, s) , 7.14 (2H, d, J=8.9Hz), 7.23 (IH, s) , 7.3-7.5 (2H, m) , 7.68 (IH, br s), 7.90 (2H, d, J=8.9Hz), 7.8-8.2 (5H, m) , 8.60 (IH, d, J=6.7Hz), 8.85 (2H, s) MASS (m/z) : 1308 (M-Na + ) Elemental Analysis Calcd. for C5 7 H 7 oN 11 θ2 1 S 2 Na- 10H O : C 45.26, H 6.00, N_10.19 Found : C 45.05, H 5.83, N 10.19 Example 11 NMR (DMSO-d 6 , δ) : 0.95 (3H, d, J=6.7Hz), 1.12 (3H, d, J=6.0Hz), 1.2-1.6 (8H, m) , 1.6-2.6 (9H, m) , 2.9-3.1 (IH, m) , 3.1-3.5 (7H, m) , 3.6-4.6 (16H, m) , 4.6-5.4 (9H, m) , 6.74 (IH, d, J=8.2Hz), 6.83 (IH, d, J=8.2Hz), 6.89 (IH, s), 7.05 (IH, s) , 7.13 (2H, d, J=8.8Hz), 7.16 (IH, m) , 7.3-7.6 (2H, m) , 7.67 (IH, br) , 7.97 (2H, d, J=8.8Hz), 7.9-8.2 (5H, m) , 8.7-9.0 (2H, m) MASS (m/z) : 1327.07 (M-Na + ) Elemental Analysis Calcd. for C5 8 H 7 5N 1Q Naθ22 s 2.5H 0 . C 48.33, H 5.94, N 9.72 Found : C 48.27, H 6.05, N 9.69 Example 12 To a solution of Starting Compound (12) (60.0 g) and diethylisopropylamine (16.6 ml) in diethylformamide (340 ml) was added 4- [5- [4- ( 6-methoxy-n-hexyloxy) phenyl] -1, 3, 4- 391 thiadiazol-2-yl]benzoic acid benzotriazol-1-yl ester (37.4 g) at room temperature. The solution was stirred for 17 hours at the same temperature. Ethyl acetate (3.4 L) was added to the reaction mixture and the mixture was stirred for 30 minutes. The powder was collected by filtration and washed with ethyl acetate (3.5 L) to give crude N-acylated Starting Compound (12) (93.0 g) . This material was used without further purification. To a suspension of crude N-acylated Starting Compound (12) (93.0 g) and NaBH 3 CN (9.0 g) in dichloromethane (900 ml), was added trifluoroacetic acid (450 ml) at 0°C over 30 minutes. The solution was stirred for 2 hours at the same temperature. The reaction mixture was slowly poured into an ice cooled aqueous NaOH solution (8<pH<ll, Temperature<7°C) . The separated organic layer was extracted with water twice. The combined aqueous solution was subjected to column chromatography on SP20 (7 L) , washing with water, and eluting with 60% aqueous CH3CN. The eluent was concentrated to remove CH3CN and chromatographed by reverse-phase (ODS) flash chromatography eluting with 17% CH 3 CN/water, followed by lyophilization of the appropriate fractions to provide 28.3 g of Object Compound (12). NMR (DMSO-d 6 , δ) : 0.96 (3H, d, J=6.7Hz), 1.12 (3H, d, J=5.9Hz), 1.30-1.60 (6H, m) , 1.65-2.60 (9H, m) , 2.80-3.50 (5H, m) , 3.22 (3H, s) , 3.60-4.60 (14H, m) , 4.07 (2H, t, J=6.7Hz), 4.60-5.30 (9H, m) , 6.73 (IH, d, J=8.2Hz), 6.83 (IH, d, J=8.2Hz), 6.89 (IH, s) , 7.05 (IH, s), 7.13 (2H, d, J=8.9Hz), 7.16 (IH, s) , 7.42-7.46 (2H, m) , 7.66 (IH, br) , 7.97 (2H, d, J=8.8Hz), 8.07-8.13 (5H, ) , 8.77 (IH, d, J=6.8Hz), 8.84 (IH, s) MASS (m/z) : 1313.25 (M-Na + ) Elemental Analysis Calcd. for C5 7 H 73 N 10 θ22 s 2 Na ' 7H 2° : C 46.78, H 5.99, N 9.57 Found : C 46.56, H 5.94, N 9.45 Example 13 A solution of Starting Compound (13) (400 mg) in N,N- 392 dimethylformamide (4 ml) was treated with 4- [5- [4- (6- methoxy-n-hexyloxy) phenyl] -1,3, -thiadiazol-2-yl] benzoic acid benzotriazol-1-yl ester (343 mg) then stirred 15 hours at room temperature. Ethyl acetate was added to the reaction mixture and the resulting precipitate were collected by filtration, washed thoroughly with ethyl acetate and dried. The powder was dissolved in saturated sodium hydrogen carbonate solution, filtered then purified by ODS column chromatography (YMC-gel ODS-AM S-50) eluting with 19-21% aqueous acetonitrile. Product-containing fractions were pooled, evaporated to remove acetonitrile, and lyophilized to give Object Compound (13) (306.4 mg) as an amorphous white powder. IR (KBr) : 1675.8, 1650.8, 1631.5, 1540.8, 1513.8, 1452.1, 1257.4 cm "1 NMR (DMSO-d 6 , δ) : 0.97 (3H, d, J=6.6Hz), 1.09 (3H, d, J=5.4Hz), 1.30-1.60 (6H, m) , 1.65-2.60 (10H, m) , 2.80-4.60 (17H, m) , 3.22 (3H, s) , 3.32 (2H, t, J=6.3Hz) , 4.07 (2H, t, J=6.5Hz), 4.68-5.80 (8H, m) , 6.68 (IH, d, J=8Hz), 6.76 (IH, d, J=8Hz) , 6.86 (IH, s), 6.98 (IH, s), 7.13 (2H, d, J=8.8Hz), 7.16 (IH, s) , 7.30-7.50 (3H, m) , 7.97 (2H, d, J=8.8Hz) , 8.03-8.13 (4H, m) , 8.76-8.79 (2H, m) MASS (m/z) : 1343.13 (M+Na + ) Elemental Analysis Calcd. for C 57 H 7 3N 10 O2iS2Na- 8H 2 0 : C 46.72, H 6.12, N 9.56 Found : C 46.66, H 5.97, N 9.53 The following compound was obtained in a manner similar to that of Example 13. Example 14 IR (KBr) : 1675.8, 1650.8, 1631.5, 1540.8, 1513.8, 1450.2 cm _1 NMR (DMSO-d 6 , δ) : 0.97 (3H, d, J=6.7Hz), 1.10 (3H, d, J=5.9Hz), 1.12-1.80 (8H, m) , 1.80-2.60 (10H, m) , 2.90-3.05 (IH, m) , 3.21 (3H, s) , 3.27 (2H, t, J=6.3Hz), 3.30-3.50 (2H, m) , 3.68-4.60 (14H, m) , 4.07 (2H, t, 393 J=6Hz), 4.70-5.45 (8H, m) , 6.71 (IH, d, J=8.2Hz), 6.79 (IH, d, J=8.2Hz), 6.87 (IH, s) , 6.97 (IH, s), 7.13 (2H, d, J=8.9Hz), 7.15 (IH, s), 7.42-7.71 (3H, m) , 7.97 (2H, d, J=8.7Hz), 8.03-8.12 (4H, m) , 8.73-8.81 (3H, m) MASS (m/z) : 1311.32 (M-Na + ) Elemental Analysis Calcd. for C5gH 7 N 10 °21 s 2 Na ' 7H 2° : C 47.67, H 6.14, N 9.58 Found : C 47.49, H 6.09, N 9.47 Example 15 A solution of Starting Compound (15) (508 mg) in N, N-dimethylformamide (10 ml) was treated with 4- [5- [4- ( 6- methoxy-n-hexyloxy) phenyl] -1,3, 4-thiadiazol-2-yl] benzoic acid benzotriazol-1-yl ester (428 mg) and the mixture was stirred 18 hours at room temperature. Ethyl acetate was added to the reaction mixture and the resulting precipitate was collected by filtration, washed thoroughly with ethyl acetate and dried. The powder was dissolved in saturated sodium hydrogen carbonate solution (100 ml), treated with water (100 ml), then purified by ODS column chromatography (YMC-gel ODS-AM S-50) eluting with 16-17% aqueous acetonitrile. Fractions containing the object compound were combined, evaporated to remove acetonitrile, and lyophilized to give Object Compound (15) (400 mg) as an amorphous white powder. IR (KBr) : 1668.1, 1650.8, 1631.5, 1538.9, 1513.8, 1450.2, 1259.3 cm "1 NMR (DMSO-d 6 , δ) : 0.96 (3H, d, J=6.7Hz), 1.12 (3H, d, J=5.9Hz), 1.30-1.60 (6H, m) , 1.65-2.60 (9H, m) , 2.80-3.50 (5H, m) , 3.22 (3H, s) , 3.60-4.60 (14H, m) , 4.07 (2H, t, J=6.7Hz), 4.60-5.30 (9H, m) , 6.73 (IH, d, J=8.2Hz), 6.83 (IH, d, J=8.2Hz), 6.89 (IH, s) , 7.05 (IH, s), 7.13 (2H, d, J=8.9Hz), 7.16 (IH, s) , 7.42-7.46 (2H, m) , 7.66 (IH, br) , 7.97 (2H, d, J=8.8Hz), 8.07-8.13 (5H, m) , 8.77 (IH, d, J=6.8Hz), 8.84 (IH, s) MASS (m/z) : 1313.25 (M-Na + ) 394 Elemental Analysis Calcd. for C 7 H 7 3N 10 O22S2Na- 7^0 : C 46.78, H 5.99, N 9.57 Found : C 46.56, H 5.94, N 9.45 Example 16 To a solution of Starting Compound (16) (200 mg) and 4- [5- (4-piperidin-l-yl-phenyl) -1, 3, 4-thiadiazol-2-yl] benzoic acid benzotriazol-1-yl ester in N, N-dimethylformamide (3 ml) was added dimethylaminopyridine (0.034 g) , and the mixture was stirred for 6.5 hours at ambient temperature. The reaction mixture was pulverized with ethyl acetate. The precipitate was collected by filtration, and dried under reduced pressure. The solid was dissolved in water, and subjected to column chromatography on ion exchange resin (DOWEX-50WX4 (Trademark: prepared by Dow Chemical)) eluting with water. The fractions containing the object compound were combined, and subjected to column chromatography on ODS (YMC-gel ODS-AM S-50 (Trademark: prepared by Yamamura Chemical Lab.)) eluting with 50% nethyl alcohol aqueous solution. The fractions containing the object compound were combined, and evaporated under reduced pressure to remove methanol. The residue was lyophilized to give Object Compound (16) (190 mg) . IR (KBr) : 3367, 1651, 1539, 1443 cm "1 NMR (DMSO-d 6 , δ) : 0.95-5.30 (49H, m) , 6.63-8.72 (19H, m) MASS (m/z) : 1250.22 (M-Na + ) Elemental Analysis Calcd. for C55H 68 N 11 Na0 19 S 2 • 12H 0 : C 44.05, H 6.25, N 10.27 Found : C 43.94, H 5.76, N 10.14 Example 17 To a solution of 1-hydroxybenzotriazole (64 mg) and 4- [2- (4-butyloxyphenyl) imidazo [2, 1-b] [1, 3, 4] thiadiazol-6-yl] benzoic acid (125 mg) in N, N-dimethylformamide (4 ml) was added l-ethyl-3- (3 ' -dimethylaminopropyl) carbodiimide hydrochloride (73 mg) and the mixture was stirred for 4 hours at ambient temperature. Then to the reaction mixture was added Starting Compound (17) (200 mg) and the mixture was stirred for 4 hours 395 at ambient temperature. The reaction mixture was pulverized with ethyl acetate. The precipitate was collected by filtration and dried over reduced pressure. The powder was added to saturated sodium bicarbonate aqueous solution and subjected to column chromatography on ODS (YMC-gel ODS-AM S-50) and eluted with 30% acetonitrile in water. The fractions containing the object compound were combined and evaporated under reduced pressure to remove acetonitrile. The residue was lyophilized to give Object Compound (17) (123 mg) . NMR (DMSO-d 6 , δ) : 0.91 (3H, t, J=7.3Hz), 0.96 (3H, d, J=7.2Hz), 1.11 (3H, d, J=5.5Hz), 1.3-1.6 (2H, m) , 1.6-2.6 (9H, m) , 2.95 (IH, m) , 3.1-3.5 (2H, m) , 3.6-4.6 (16H, m) , 4.7-5.5 (9H, m) , 6.73 (IH, d, J=8.2Hz), 6.82 (IH, d, J=8.2Hz), 6.89 (IH, s) , 7.05 (IH, s) , 7.14 (2H, d, J=8.9Hz), 7.24 (IH, s), 7.3-7.5 (2H, m) , 7.68 (IH, br s), 7.90 (2H, d, J=8.9Hz), 7.8-8.1 (5H, m) , 8.56 (IH, d, J=6.7Hz), 8.85 (2H, s) MASS (m/z) : 1341 (M+Na + ) Example 1 To a suspension of Starting Compound (18) (1.70 g) and triethylsilane (1.58 g) in dichloromethane (15 ml) was added trifluoroacetic acid (15 ml) dropwise, and the mixture was stirred for 30 minutes under nitrogen atmosphere. The reaction mixture was evaporated under reduced pressure. The residue was dissolved in pH 6.86 phosphate-buffer, and adjusted to pH 9.5 with IN sodium hydroxide aqueous solution. The solution was subjected to column-chromatography on ODS (YMC-gel ODS-AM S- 50) and eluted with 30% acetonitrile aqueous solution (v/v) . The fractions containing the object compound were combined and evaporated under reduced pressure to remove acetonitrile. The residue was lyophilized to give Object Compound (18) (136 mg) . IR (KBr) : 3350, 2933, 1668, 1635, 1540, 1471, 1249, 1045 cm "1 NMR (DMSO-d 6 , δ) : 0.88 (3H, t, J=6.7Hz), 0.96 (3H, d, J=6.7Hz), 1.08 (3H, d, J=5.8Hz), 1.2-1.6 (8H, m) , 396 1.6-2.4 (10H, m) , 2.8-4.1 (16H, m) , 4.1-5.3 (11H, m) , 6.6-7.2 (9H, m) , 7.3-7.7 (3H, m) , 7.9-8.3 (4H, m) , 8.7-8.9 (IH, d, J=6.0Hz), 9.04 (IH, s) MASS (m/z) : 1244.5 (M+Na + ) Elemental Analysis Calcd. for C5 4 H 7 2N 9 θ2o N aS • 6H 2 0 : C 48.75, H 6.36, N 9.48 Found : C 48.53, H 6.24, N 9.40 The following compounds rExamples 19 and 2_0] were obtained in a manner similar to that of Example 18. Example 19 NMR (DMSO-d 6 , δ) : 0.95 (3H, t, J=7.3Hz), 0.96 (3H, d, J=7.1Hz), 1.10 (3H, d, J=5.8Hz), 1.3-1.6 (2H, m) , 1.6-2.6 (10H, m) , 2.95 (IH, m) , 3.1-3.5 (2H, m) , 3.6-4.6 (16H, m) , 4.7-5.4 (8H, ) , 6.71 (IH, d, J=8.1Hz), 6.78 (IH, d, J=8.1Hz), 6.87 (IH, s) , 6.97 (IH, s), 7.14 (2H, d, J=8.9Hz), 7.24 (IH, s) , 7.44 (IH, d, J=7.9Hz), 7.5-7.8 (2H, m) , 7.89 (2H, d, J=8.9Hz), 7.9-8.0 (6H, m) , 8.12 (IH, d, J=7.7Hz), 8.60 (IH, d, J=7.2Hz), 8.72 (IH, s) , 8.85 (IH, s) MASS (m/z) : 1278 (M-Na + ) Example 20 NMR (DMSO-d 6 , δ) : 0.91 (3H, t, J=7.3Hz), 0.96 (3H, d, J=7.1Hz), 1.09 (3H, d, J=5.8Hz), 1.3-1.6 (4H, m) , 1.6-2.6 (10H, m) , 2.95 (IH, m) , 3.1-3.5 (2H, m) , 3.6-4.6 (16H, m) , 4.7-5.4 (8H, m) , 6.71 (IH, d, J=8.1Hz), 6.78 (IH, d, J=8.1Hz), 6.87 (IH, s) , 6.97 (IH, s), 7.14 (2H, d, J=8.9Hz), 7.24 (IH, s) , 7.44 (IH, d, J=7.9Hz), 7.5-7.8 (2H, m) , 7.89 (2H, d, J=8.9Hz), 7.9-8.0 (6H, m) , 8.12 (IH, d, J=7.7Hz), 8.60 (IH, d, J=7.2Hz), 8.72 (IH, s) , 8.85 (IH, s) MASS (m/z) : 1338 (M+Na + ) The following compounds rExamples 21 to 23.] were obtained according to similar manner to that of Example 1. Example 21 IR (KBr) : 3353, 1666.2, 1631.5, 1510, 1236 cm "1 397 NMR (DMSO-d 6 , δ) : 0.86 (3H, t, J=6.8Hz), 0.95 (3H, d, J=6.7Hz), 1.09 (3H, d, J=5.8Hz), 1.2-1.5 (10H, m) , 1.55-2.6 (9H, m) , 2.95 (IH, m) , 3.0-3.5 (10H, m) , 3.6-4.5 (15H, m) , 4.6-5.4 (10H, m) , 6.6-7.1 (10H, m) , 7.27 (IH, s), 7.35-7.5 (2H, m) , 7.65 (IH, br s) , 7.78 (2H, d, J=8.8Hz), 8.03 (IH, d, J=8.7Hz), 8.30 (IH, d, J=8.7Hz), 8.83 (IH, s) MASS (m/z) : 1357 (M+Na) + Elemental Analysis Calcd. for Cg 0 H 83 N 10°21 SNa ' 5H 2° : C 50.55, H 6.58, N 9.83 Found : C 50.56, H 6.59, N 9.76 Example 22 IR (KBr) : 3350, 1658.5, 1633, 1278 cm -1 NMR (DMSO-d 6 , δ) : 0.86 (3H, t, J=6.7Hz), 0.96 (3H, d, J=6.7Hz), 1.11 (3H, d, J=5.7Hz), 1.2-1.4 (8H, m) , 1.45-2.45 (9H, m) , 2.62 (2H, t, J=7.4Hz), 2.98 (IH, m) , 3.2 (IH, m) , 3.25-3.5 (IH, m) , 3.6-5.4 (23H, m) , 6.73 (IH, d, J=8.2Hz), 6.83 (IH, dd, J=l .5 and 8.2Hz) , 6.88 (IH, s), 7.05 (IH, d, J=1.5Hz), 7.31 (2H, d, J=8.2Hz), 7.1-7.5 (4H, m) , 7.64 (2H, d, J=8.2Hz), 7.74 (2H, d, J=8.4Hz), 7.6-7.8 (IH, m) , 7.95 (2H, d, J=8.4Hz), 8.0-8.2 (IH, m) , 8.61 (IH, d, J=6.7Hz), 8.84 (IH, s) MASS (m/z) : 1243 (M+Na) + Elemental Analysis Calcd. for C55H 73 N 8 Na0 2 oS • 6H 2 0 : C 49.69, H 6.44, N 8.43 Found : C 49.99, H 6.53, N 8.40 Example 23 IR (Nujol) : 1668.1, 1629.6, 1540.8, 1515.8 cm -1 NMR (DMSO-d 6 , δ) : 0.87 (3H, t, J=6.7Hz), 0.95 (3H, d, J=6.7Hz), 1.07 (3H, d, J=5.9Hz), 1.25-1.48 (4H, m) , 1.49-2.05 (5H, m) , 2.05-2.70 (8H, m) , 2.70-3.05 (3H, m) , 3.08-3.45 (2H, m) , 3.55-3.86 (2H, m) , 3.88-4.50 (11H, m) , 4.65-5.36 (10H, m) , 6.67-6.90 (3H, m) , 7.04 (IH, d, J=1.0Hz), 7.10-7.80 (12H, m) , 8.00 (IH, d, 398 J=8.4Hz), 8.13 (IH, d, J=7.7Hz), 8.84 (IH, s) MASS (m/z) : 1227.5 (M+Na) + Elemental Analysis Calcd. for C55H 73 N 8 Na0 2 oS • 5H 0 : C 50.38, H 6.38, N 8.54 Found : C 50.07, H 6.60, N 8.58 Example 24 IR (KBr) : 3350, 2929, 1664, 1635, 1515, 1440, 1278, 1245, 1085, 1047 cm "1 NMR (DMSO-d 6 , δ) : 0.86 (3H, m) , 0.96 (3H, d, J=7.7Hz), 1.11 (3H, d, J=5.7Hz), 1.30 (6H, m) , 1.5-2.4 (9H, m) , 2.6-2.8 (2H, t, J=7.2Hz) , 2.9-3.1 (IH, m) , 3.1-3.3 (IH, m) , 3.4-3.6 (IH, m) , 3.7-4.6 (14H, m) , 4.6-5.3 (9H, m) , 6.7-7.0 (3H, m) , 7.04 (IH, s) , 7.21 (IH, s), 7.30 (2H, d, J=8.2Hz), 7.4-7.5 (IH, m) , 7.6-7.8 (5H, m) , 7.95 (2H, d, J=8.4Hz), 8.10 (IH, d, J=8.4Hz), 8.60 (IH, d, J=8.4Hz), 8.84 (IH, s) MASS (m/z) : 1230 (M+Na) + Elemental Analysis Calcd. for C 54 H 71 N 8 Naθ2oS • 4.5H 0 : C 50.34, H 6.26, N 8.70 Found : C 50.43, H 6.19, N 8.59 Example 25 IR (KBr) : 3350, 1666.2, 1631.5, 1510.0, 1236.1 cm "1 NMR (DMSO-d 6 , δ) : 0.88 (3H, t, J=6.6Hz), 0.95 (3H, d, J=6.7Hz), 1.08 (3H, d, J=5.7Hz), 1.2-1.5 (6H, m) , 1.6-2.1 (5H, m) , 2.1-2.5 (4H, m) , 2.8-3.0 (IH, m) , 3.1-3.3 (5H, m) , 3.3-3.4 (4H, m) , 3.6-5.4 (23H, m) , 6.73 (IH, d, J=8.1Hz), 6.8-6.9 (4H, m) , 6.94 (2H, d, J=9.3Hz), 7.01 (2H, d, J=8.7Hz), 7.04 (IH, s) , 7.2-7.5 (3H, ) , 7.6-7.7 (IH, ) , 7.78 (2H, d, J=8.7Hz), 8.05 (IH, d, J=8Hz), 8.30 (IH, d, J=6.7Hz), 8.85 (IH, s) MASS (m/z) : 1329 (M+Na) + Elemental Analysis Calcd. for C 58 H 7 9N 10 θ2iS a- 6H 0 : C 49.22, H 6.48, N 9.90 Found : C 49.46, H 6.44, N 9.96 Example 26 399 IR (KBr) : 3347.8, 1670.1, 1652.7, 1635.3 cm "1 NMR (DMSO-d 6 , δ) : 0.85 (3H, t, J=6.6Hz), 0.96 (3H, d, J=6.7Hz), 1.12 (3H, d, J=5.9Hz), 1.18-1.40 (8H, m) , 1.50-2.10 (5H, m) , 2.10-2.60 (4H, m) , 2.76 (2H, t, J=7.6Hz), 2.85-3.50 (3H, m) , 3.60-4.60 (14H, m) , 4.60-5.33 (9H, ) , 6.67-7.00 (3H, m) , 7.05 (IH, d, J=0.4Hz), 7.20-7.50 (4H, m) , 7.60-7.80 (2H, m) , 7.85-8.00 (3H, m) , 8.10 (IH, d, J=8.5Hz), 8.45 (IH, s), 8.68 (IH, d, J=8.4Hz), 8.48 (IH, s) MASS (m/z) : 1217.4 (M+Na-1) Elemental Analysis Calcd. for C 53 H 71 N 8 0 2 χSNa • 4H 2 0 : C 49.61, H 6.20, N 8.73 Found : C 49.62, H 6.38, N 8.68 Example 27 IR (KBr) : 3361.3, 1668.1, 1635.3 cm "1 NMR (DMSO-d 6 , δ) : 0.89 (3H, t, J=6.8Hz), 0.95 (3H, d, J=6.7Hz), 1.10 (3H, d, J=5.9Hz), 1.20-1.48 (6H, m) , 1.55-2.13 (5H, m) , 2.13-2.60 (4H, m) , 2.76 (2H, t, J=7.6Hz), 2.89-3.08 (IH, m) , 3.10-3.50 (3H, m) , 3.60-3.85 (2H, m) , 3.85-4.65 (12H, m) , 4.65-5.50 (8H, m) , 6.62-7.05 (3H, m) , 7.06 (IH, d, J=0.4Hz) , 7.15-7.55 (4H, m) , 7.55-7.80 (2H, m) , 7.80-8.03 (3H, m) , 8.03-8.20 (IH, m) , 8.45 (IH, s) , 8.60-9.05 (2H, m) MASS (m/z) : 1203.4 (M+Na-1) Elemental Analysis Calcd. for C 52 H 69 N 8 Na0 2 oS • 6H 2 0 : C 48.44, H 6.33, N 8.69 Found : C 48.55, H 6.39, N 8.70 Example 28 IR (KBr) : 3359.4, 1664.3, 1631.5, 1510.0, 1230.4, 1045.2 cm "1 NMR (DMS0-d 6 , δ) : 0.95 (3H, d, J=6.5Hz), 1.08 (3H, d, J=5.6Hz), 1.2-1.6 (10H, m) , 1.6-2.1 (5H, m) , 2.1-2.5 (4H, m) , 2.95 (IH, m) , 3.0-3.2 (5H, m) , 3.20 (3H, s) , 3.29 (3H, t, J=6.4Hz), 3.2-3.5 (5H, m) , 3.6-4.5 (16H, m) , 4.6-5.4 (9H, m) , 6.73 (IH, d, J=8.2Hz), 6.8-7.1 400 (10H, ) , 7.2-7.5 (2H, m) , 7.70 (IH, br s) , 7.78 (2H, d, J=8.6Hz), 8.10 (IH, br s) , 8.32 (IH, d, J=7.2Hz), 8.90 (IH, br s) MASS (m/z) : 1387 (M+Na) + Elemental Analysis Calcd. for C 61 H 8 10 O 2 2S a- 8H 2 0 : C 48.53, H 6.74, N 9.28 Found : C 48.38, H 7.18, N 9.18 Example 29 IR (KBr) : 3355.5, 1666.2, 1631.5, 1608.3, 1236.1, 1045.2 cm "1 NMR (DMSO-d 6 , δ) : 0.93 (3H, d, J=6.6Hz), 1.07 (3H, d, J=5.7Hz), 1.2-1.6 (8H, m) , 1.6-2.1 (5H, m) , 2.1-2.6 (4H, m) , 2.96 (IH, m) , 3.1-3.3 (5H, m) , 3.19 (3H, s) , 3.28 (3H, t, J=6.5Hz), 3.3-3.5 (5H, m) , 3.7-4.5 (16H, m) , 4.65-5.3 (9H, ) , 6.71 (IH, d, J=8.1Hz), 6.8-7.1 (9H, m) , 7.26 (IH, s) , 7.3-7.5 (2H, m) , 7.66 (IH, br s), 7.76 (2H, d, J=8.6Hz), 8.07 (IH, d, J=7.7Hz), 8.31 (IH, d, J=6.8Hz), 8.83 (IH, s) MASS (m/z) : 1373 (M+Na) + The following compounds [Examples 30 to 5_4] were obtained in a manner similar to that of Example 8. Example 30 IR (KBr) : 3369, 2935, 1664, 1631, 1444, 1257, 1047 cm "1 NMR (DMSO-d 6 , δ) : 0.89 (3H, d, J=6.9Hz), 0.95 (3H, d, J=6.8Hz), 1.11 (3H, d, J=5.8Hz), 1.2-1.5 (6H, m) , 1.6-2.4 (9H, m) , 2.9-3.4 (2H, m) , 3.6-4.5 (16H, m) , 4.7-5.4 (9H, m) , 6.73 (IH, d, J=8.2Hz), 6.8-7.0 (2H, m) , 7.0-7.2 (4H, m) , 7.3-7.7 (3H, m) , 7.97 (2H, d, J=8.7Hz), 8.1-8.3 (5H, m) , 8.81 (IH, d, J=7.0Hz), 8.85 (IH, s) MASS (m/z) : 1329.8 (M+Na) + Elemental Analysis Calcd. for C 56 H 71 N 10 θ2 S2Na : C 46.93, H 5.98, N 9.77 Found : C 46.72, H 6.11, N 9.72 Exampl 31 401 IR (KBr) : 3353, 2935, 2873, 1658, 1635, 1440, 1257, 1047 cm "1 NMR (DMSO-d 6 , δ) : 0.89 (3H, t, J=6.9Hz), 0.96 (3H, d, J=6.8Hz), 1.12 (3H, d, J=5.8Hz), 1.2-1.5 (6H, m) , 1.6-2.4 (9H, m) , 2.9-3.2 (2H, m) , 3.3-3.4 (IH, m) , 3.8-4.6 (16H, m) , 4.6-5.4 (9H, m) , 6.7-7.0 (3H, m) , 7.0-7.2 (4H, m) , 7.3-7.7 (3H, m) , 7.9-8.3 (7H, m) , 8.7-8.9 (2H, m) MASS (m/z) : 1313.0 (M+Na) + Elemental 7nalysis Calcd. for C5 6 H 71 N 10 θ22 s '• C 48.07, H 5.98, N 10.01 Found : C 48.23, H 6.17, N 10.00 Example 32 IR (KBr) : 3350, 2927, 1668, 1627, 1288, 1047 cm "1 NMR (DMSO-d 6 , δ) : 0.86 (3H, t, J=6.8Hz), 0.95 (3H, d, J=6.8Hz), 1.13 (3H, d, J=6.7Hz), 1.2-1.5 (10H, m) , 1.6-2.4 (8H, m) , 2.9-3.2 (2H, m) , 3.4-4.6 (16H, ) , 4.6-5.3 (9H, m) , 6.5-7.5 (8H, m) , 7.6-8.2 (4H, m) , 8.31 (IH, s), 8.43 (IH, dd, J=8.7 and 2.5Hz) , 8.6-8.8 (IH, d, J=6.3Hz), 8.85 (IH, s), 8.99 (IH, d, J=2.5Hz) MASS (m/z) : 1315.3 (M+Na) + Elemental Analysis Calcd. for C 56 H 7 3N 10 o 22 NaS ' 7H 2° : C 47.39, H 6.18, N 9.87 Found : C 47.11, H 6.29, N 9.72 Example 33 IR (KBr) : 3350, 2925, 1670, 1625, 1259, 1047 cm "1 NMR (DMSO-d 6 , δ) : 0.7-1.0 (6H, m) , 1.1-1.2 (3H, d, J=5.7Hz), 1.2-2.5 (15H, m) , 3.0-3.3 (2H, m) , 3.4-3.6 (IH, m) , 3.6-3.8 (2H, m) , 3.9-4.6 (16H, m) , 4.7-5.4 (9H, m) , 6.6-7.3 (6H, m) , 7.3-8.0 (5H, ) , 8.0-8.3 (5H, m) , 8.6-9.0 (2H, m) MASS (m/z) : 1286.8 (M+Na) + Elemental Analysis Calcd. for C55H 70 N 9 O 2 2NaS • 5.5H 2 0 : C 48.46, H 5.99, N 9.25 Found : C 48.47, H 6.01, N 9.26 402 Example 34 MASS (m/z) : 1387 (M+Na) + Example 35 IR (KBr) : 3363, 1662.3, 1631.5, 1240 cm "1 NMR (DMSO-d 6 , δ) : 0.95 (3H, d, J=6.8Hz), 0.8-1.5 (15H, m) , 1.5-2.6 (16H, m) , 2.8-3.5 (11H, m) , 3.6-4.6 (14H, m) , 4.6-5.3 (9H, m) , 6.73 (IH, d, J=8.2Hz), 6.83 (IH, d, J=8.2Hz), 6.84 (IH, s) , 7.00 (2H, d, J=8.8Hz), 7.04 (IH, s), 7.13 (IH, s) , 7.3-7.5 (2H, m) , 7.63 (IH, br s), 7.79 (2H, d, J=8.8Hz), 8.05 (IH, d, J=7.7Hz), 8.29 (IH, d, J=6.8Hz), 8.83 (IH, s) MASS (m/z) : 1215 (M-S0 3 +Na) Elemental Analysis Calcd. for C5 8 H 84 N 10 θ20 s ' 7H 2° : C 49.78, H 7.06, N 10.01 Found : C 49.93, H 6.92, N 9.98 Example 36 IR (KBr) : 1648, 1631 cm "1 NMR (DMSO-d 6 , δ) : 0.95 (3H, d, J=6.8Hz), 1.12 (3H, d, J=5.7Hz), 1.65-2.50 (7H, m) , 2.84-3.13 (3H, m) , 3.74-5.41 (23H, m) , 3.83 (3H, s) , 6.74 (IH, d, J=8.2Hz) , 6.77 (IH, d, J=10.6Hz), 6.83 (IH, m) , 7.08 (3H, m) , 7.17 (IH, ) , 7.43 (2H, m) , 7.65 (IH, m) , 7.77 (2H, d, J=8.7Hz), 7.92 (2H, d, J=8.5Hz), 8.08 (IH, m) , 8.11 (2H, d, J=8.4Hz), 8.22 (2H, d, J=7.6Hz), 8.25 (2H, d, J=7.6Hz) , 8.85 (2H, m) MASS (m/z) : 1273 Elemental Analysis Calcd. for C 57 H 65 N 10 θ22SNa- 11H 0 : C 45.78, H 5.86, N 9.37 Found : C 45.75, H 5.95, N 9.27 Example 37 IR (KBr) : 2968, 2937, 2879, 1651, 1632 cm "1 NMR (DMSO-d 6 , δ) : 0.95 (3H, d, J=5.5Hz), 1.01 (3H, t, J=7.1Hz), 1.12 (3H, t, J=5.8Hz), 1.75 (2H, q, J=7.1Hz), 1.60-2.48 (7H, m) , 2.75-3.10 (3H, m) , 3.60-5.35 (23H, m) , 4.01 (2H, t, J=7.1Hz), 6.73 (IH, d, J=8.2Hz), 6.78 403 (IH, d, J=9.7Hz), 6.87 (IH, m) , 7.07 (3H, m) , 7.16 (IH, m) , 7.43 (2H, m) , 7.64 (IH, m) , 7.74 (2H, d, J=8.8Hz), 7.91 (2H, d, J=8.5Hz), 8.00 (IH, m) , 8.10 (2H, d, J=8.5Hz) , 8.21 (2H, d, J=7.4Hz) , 8.25 (2H, d, J=8.3Hz) , 8.83 (2H, m) MASS (m/z) : 1301 Elemental Analysis Calcd. for C5 9 H 69 N 10 O22 SNa ' 10H 2° : C 47.07, H 5.96, N 9.30 Found : C 46.88, H 5.70, N 9.14 Example 38 IR (KBr) : 2935, 2873, 1668, 1651, 1632 crn -1 NMR (DMSO-d 6 , δ) : 0.92-0.99 (6H, m) , 1.12 (3H, d, J=6.1Hz), 1.48 (2H, qt, J=5.5 and 5.5Hz), 1.74 (2H, tt, J=5.5 and 5.5Hz) , 1.60-2.40 (7H, m) , 2.80-3.20 (3H, m) , 4.05 (2H, t, J=5.5Hz), 3.74-5.25 (23H, m) , 6.74 (IH, d, J=8.2Hz), 6.78 (IH, d, J=9.5Hz), 6.87 (IH, m) , 7.07 (3H, m) , 7.17 (IH, m) , 7.43 (2H, m) , 7.65 (IH, ) , 7.70 (IH, m) , 7.74 (2H, d, J=8.7Hz), 7.91 (2H, d, J=8.5Hz), 8.00 (IH, m) , 8.10 (2H, d, J=8.6Hz), 8.21 (2H, d, J=7.6Hz), 8.25 (2H, d, J=8.1Hz), 8.88 (2H, m) MASS (m/z) : 1315 Elemental Analysis Calcd. for C 60 H 71 N 10 o 22 SNa ' 9H 2° : C 48.00, H 5.97, N 9.33 Found : C 48.05, H 5.95, N 9.34 Example 39 IR (KBr) : 2943, 2870, 1668, 1651, 1632 cm "1 NMR (DMSO-dg, δ) : 0.95 ( 6H, m) , 1.13 (3H, d, J=5.7Hz), 1.39 (4H, ) , 1.60-2.50 (9H, m) , 2.80-3.20 (3H, m) , 3.74-5.25 (23H, m) , 4.04 (2H, t, J=6.3Hz), 6.74 (IH, d, J=8.2Hz) , 6.78 (IH, d, J=11.2Hz) , 6.88 (IH, m) , 7.07 (3H, m) , 7.17 (IH, m) , 7.45 (2H, m) , 7.67 (IH, m) , 7.74 (2H, d, J=8.8Hz), 7.91 (2H, d, J=8.3Hz), 8.00 (IH, m) , 8.10 (2H, d, J=8.4Hz), 8.21 (2H, d, J=7.9Hz), 8.25 (2H, d, J=7.9Hz), 8.25 (2H, d, J=7.9Hz), 8.80 (IH, m) , 8.85 (IH, s) 404 MASS (m/z) : 1330, 1329 Elemental Analysis Calcd. for C 61 H 73 N 10 θ22SNa- 10H O : C 47.78, H 6.11, N 9.18 Found : C 47.90, H 6.05, N 9.18 Example 40 IR (KBr) : 2933, 2871, 1666, 1650, 1632 cm "1 NMR (DMSO-d 6 , δ) : 0.89 (3H, t, J=6.9Hz), 0.96 (3H, d, J=6.8Hz), 1.12 (3H, d, J=5.7Hz), 1.32-1.43 (6H, m) , 1.60-2.50 (9H, m) , 3.02 (3H, m) , 4.04 (2H, t, J=6.4Hz), 3.74-5.25 (23H, m) , 6.74 (IH, d, J=8.2Hz), 6.78 (IH, d, J=ll.lHz), 6.88 (IH, m) , 7.07 (3H, m) , 7.17 (IH, m) , 7.43 (2H, m) , 7.67 (IH, m) , 7.75 (2H, d, J=8.8Hz), 7.91 (2H, d, J=8.5Hz), 8.00 (IH, m) , 8.11 (2H, d, J=8.5Hz), 8.20 (2H, d, J=7.9Hz), 8.25 (2H, d, J=8.1Hz), 8.84 (2H, m) MASS (m/z) : 1343, 1327 Elemental Analysis Calcd. for C 6 2 H 75 N ιo°22 SNa ' 7I i2° : C 49.86, H 6.01, N 9.38 Found : C 49.87, H 6.01, N 9.30 Example 41 IR (KBr) : 2931, 2858, 1651, 1632 cm -1 NMR (DMSO-d 6 , δ) : 0.88 (3H, t, J=6.6Hz), 0.96 (3H, d, J=6.7Hz), 1.12 (3H, d, J=5.2Hz), 1.30 (8H, m) , 1.60-2.40 (9H, m) , 2.80-3.20 (3H, m) , 4.03 (2H, t, J=6.3Hz), 3.74-5.25 (23H, m) , 6.72 (IH, d, J=8.2Hz), 6.78 (IH, d, J=9.7Hz), 6.87 (IH, m) , 7.06 (3H, m) , 7.16 (IH, m) , 7.44 (2H, m) , 7.70 (IH, m) , 7.74 (2H, d, J=8.8Hz), 7.90 (2H, d, J=8.5Hz), 8.00 (IH, m) , 8.10 (2H, d, J=8.6Hz), 8.20 (2H, d, J=7.8Hz), 8.25 (2H, d, J=8.2Hz), 8.84 (2H, m) MASS (m/z) : 1361, 1357, 1341 Elemental Analysis Calcd. for C 63 H 77 N 10 O22SNa- 6H 2 0 : C 50.80, H 6.02, N 9.40 Found : C 50.79, H 6.28, N 9.48 Example 42 405 IR (KBr) : 2939, 1668, 1651, 1632 cm "1 NMR (DMSO-d 6 , δ) : 0.96 (3H, d, J=5.3Hz), 1.13 (3H, d, J=6.0Hz), 1.35-2.50 (15H, m) , 2.60-3.20 (9H, m) , 3.65-5.40 (25H, m) , 6.73 (IH, d, J=8.5Hz), 6.78 (IH, d, J=11.2Hz), 6.88 (IH, ) , 7.09 (3H, m) , 7.17 (IH, m) , 7.44 (2H, m) , 7.70 (IH, m) , 7.76 (2H, d, J=7.1Hz), 7.91 (2H, d, J=6.6Hz), 8.08 (IH, m) , 8.11 (2H, d, J=7.4Hz), 8.22 (2H, d, J=6.1Hz), 8.25 (2H, d, J=6.3Hz), 8.84 (2H, m) MASS (m/z) : 1388, 1384, 1368 Elemental Analysis Calcd. for Cg 4 H 78 N-L . 0 22 SNa ' 7H 2° : C 50.09, H 6.04, N 10.04 Found : C 50.18, H 6.03, N 9.65 Example 43 IR (KBr) : 1650.8, 1629.6 cm "1 NMR (DMSO-d 6 , δ) : 0.80-0.86 (3H, m) , 0.96 (3H, d, J=6.6Hz), 1.12 (3H, d, J=5.6Hz), 1.23 (14H, br s) , 1.74-2.50 (9H, m) , 2.98 (IH, d, J=13.4Hz), 3.10-3.46 (2H, m) , 3.70-4.60 (16H, m) , 4.64-5.32 (9H, m) , 6.73 (IH, d, J=8.2Hz), 6.83 (IH / d, J=8.4Hz), 6.89 (IH, br s), 7.05 (IH, d, J=1.7Hz), 7.16 (IH, br s), 7.42-7.47 (2H, m) , 7.66 (IH, br s) , 8.06-8.17 (6H, m) , 8.65 (IH, s), 8.80 (IH, d, J=7.5Hz), 8.84 (IH, s) MASS (m/z) : 1297.03 (M-Na) + Elemental Analysis Calcd. for C5 7 H 77 N 1 θ21 SNa- 7H 2° : C 47.30, H 6.34, N 11.61 Found : C 47.33, H 6.16, N 11.54 Example 44 IR (KBr) : 3361.3, 1650.8, 1631.5 cm "1 NMR (DMSO-d 6 , δ) : 0.80-0.90 (3H, m) , 0.96 (3H, d, J=6.7Hz), 1.15 (3H, d, J=6Hz) , 1.23 (14H, br s) , 1.70-2.65 (9H, m) , 2.90-3.10 (IH, m) , 3.20-3.42 (2H, m) , 3.65-4.60 (16H, m) , 4.66-5.40 (9H, m) , 6.73 (IH, d, J=8.3Hz), 6.83 (IH, d, J=8.8Hz), 6.89 (IH, s) , 7.05 (IH, s), 7.18 (IH, s) , 7.42-7.46 (2H, m) , 7.66 (IH, 406 br s), 8.05 (4H, s) , 8.08 (IH, s), 8.57 (IH, s) , 8.57-8.84 (3H, m) MASS (m/z) : 1313.01 (M-Na) + Elemental Analysis Calcd. for C5 7 H 77 N 12 θ2oS 2 Na- 7H 2 0 : C 46.78, H 6.27, N 11.48 Found : C 46.89, H 6.34, N 11.41 Example 45 IR (KBr) : 1650.8, 1631.5 cm "1 NMR (DMSO-d 6 , δ) : 0.96 (3H, d, J=6.7Hz), 1.10 (3H, d, J=6Hz), 1.70-2.60 (9H, m) , 2.80-3.60 (3H, m) , 3.60-4.60 (19H, m) , 4.65-5.40 (8H, m) , 6.73 (IH, d, J=8.2Hz), 6.81-6.99 (6H, m) , 7.05 (IH, s) , 7.11 (2H, d, J=8.8Hz) , 7.34-7.26 (2H, m) , 7.34-7.73 (3H, m) , 7.76 (2H, d, J=8.8Hz), 7.91 (2H, d, J=8.4Hz), 8.11 (2H, d, J=8.4Hz), 8.19-8.30 (4H, m) , 8.70-9.00 (3H, m) MASS (m/z) : 1393.13 (M-Na) + Elemental Analysis Calcd. for C 6 5H 73 N 10 O 2 3SNa- 9H 2 0 : C 49.43, H 5.81, N 8.87 Found : C 49.24, H 5.61, N 8.77 Example 46 IR (KBr) : 3361.3, 1668.1, 1650.8, 1631.5 cm "1 NMR (DMSO-d 6 , δ) : 0.96 (3H, d, J=6.6Hz), 1.12 (3H, d, J-5.6HZ), 1.70-2.60 (7H, m) , 2.80-5.27 (26H, m) , 4.65 (2H, d, J=5.2Hz), 5.27-5.48 (2H, m) , 5.99-6.18 (IH, m) , 6.72 (IH, d, J=8.1Hz), 6.82 (IH, d, J=8.1Hz), 6.89 (IH, s), 7.07 (IH, s), 7.10 (2H, d, J=8.8Hz), 7.12 (IH, s), 7.46 (2H, br s) , 7.68 (IH, br s) , 7.75 (2H, d, J=8.7Hz), 7.91 (2H, d, J=8.4Hz), 8.11 (2H, d, J=8.5Hz), 8.19-8.31 (4H, m) , 8.80-8.83 (2H, m) MASS (m/z) : 1298.97 (M-Na) + Elemental Analysis Calcd. for C5 9 H 67 N 10 O 2 SNa- 9H 0 : C 47.71, H 5.77, N 9.43 Found : C 47.90, H 5.61, N 9.41 Example 47 IR (KBr) : 1650.8, 1631.5, 1540.8, 1513.8 cm "1 407 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.7Hz), 1.12 (3H, d, J=5.7Hz), 1.70-2.60 (11H, m) , 2.80-3.60 (3H, m) , 3.60-4.60 (18H, m) , 4.65-5.40 (9H, m) , 6.73 (IH, d, J=8.1Hz), 6.82 (IH, d, J=9.5Hz), 6.87-6.97 (5H, m) , 7.06 (IH, s), 7.09 (2H, d, J=8.8Hz), 7.25-7.33 (2H, m) , 7.33-7.73 (3H, m) , 7.75 (2H, d, J=8.6Hz) , 7.91 (2H, d, J=8.5Hz), 8.11 (2H, d, J=8.5Hz), 8.19-8.27 (4H, m) , 8.70-8.90 (3H, m) MASS (m/z) : 1407.15 (M-Na) + Elemental Analysis Calcd. for CggH 75 N 10 O 2 3SNa • 7H 2 0 : C 50.90, H 5.76, N 8.99 Found : C 50.80, H 5.90, N 8.90 Example 48 IR (KBr) : 1675.8, 1650.8, 1540.8, 1513.8 cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.9Hz), 1.13 (3H, d, J=5.9Hz), 1.20-1.60 (12H, m) , 1.64-2.68 (7H, m) , 2.80-3.60 (3H, m) , 3.21 (3H, s) , 3.60-5.40 (27H, m) , 6.73 (IH, d, J=8.4Hz), 6.83 (IH, d, J=9.3Hz), 6.89 (IH, s), 7.05 (IH, s), 7.07 (2H, d, J=8.7Hz), 7.17 (IH, s) , 7.30-7.70 (3H, m) , 7.74 (2H, d, J=8.7Hz), 7.91 (2H, d, J=8.4Hz), 8.11 (2H, d, J=8.5Hz), 8.19-8.27 (4H, m) , 8.74-8.90 (3H, m) MASS (m/z) : 1401.12 (M-Na) + Example 49 IR (KBr) : 1675.8, 1650.8, 1540.8 cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.4Hz), 1.03-1.10 (9H, m) , 1.50-2.50 (11H, m) , 2.70-5.50 (34H, m) , 6.71 (IH, d, J=7.3Hz), 6.79-6.90 (2H, m) , 7.00-7.10 (4H, m) , 7.30-7.80 (3H, m) , 7.75 (2H, d, J=8.6Hz) , 7.91 (2H, d, J=8.4Hz), 8.11 (2H, d, J=7.4Hz), 8.19-8.27 (4H, m) , 8.60-8.90 (3H, m) MASS (m/z) : 1414.08 (M-Na) + Elemental Analysis Calcd. for Cg 5 H 8 oN 11 0 3SNa- 11.6H 2 0 : C 47.39, H 6.31, N 9.35 Found : C 47.40, H 6.07, N 9.22 408 Example 50 IR (KBr) : 3353.6, 1650.8, 1631.5, 1538.9, 1515.8, 1442.5, 1114.7 cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.7Hz), 1.12 (3H, d, J=5.7Hz), 1.7-2.6 (11H, m) , 2.9-3.1 (IH, m) , 3.1-3.5 (2H, m) , 3.7-4.6 (18H, m) , 4.7-5.3 (9H, m) , 6.74 (IH, d, J=8.0Hz), 6.83 (IH, d, J=8.0Hz), 6.87-7.02 (4H, m) , 7.05 (IH, s), 7.15 (2H, d, J=8.7Hz), 7.17 (IH, m) , 7.2-7.4 (2H, m) , 7.4-7.6 (2H, m) , 7.67 (IH, br) , 7.98 (2H, d, J=8.7Hz), 7.9-8.2 (5H, m) , 8.77 (IH, d, J=8.5Hz), 8.84 (IH, s) MASS (m/z) : 1346.72 (M-Na) + Elemental Analysis Calcd. for CgoH 71 N 10 Na0 2S • 11H 2 0 : C 45.92, H 5.97, N 8.92 Found : C 46.13, H 5.75, N 8.92 Example 51 IR (KBr) : 3363.2, 1650.8, 1538.9, 1515.8, 1442 ^ 5, 1247.7 cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.7Hz), 1.12 (3H, d, J=5.9Hz), 1.5-2.5 (13H, m) , 2.9-3.1 (IH, m) , 3.1-3.5 (2H, m) , 3.6-5.4 (27H, m) , 6.73 (IH, d, J=8.2Hz), 6.82 (IH, d, J=8.2Hz), 6.87-7.00 (4H, m) , 7.05 (IH, s) , 7.14 (2H, d, J=8.7Hz), 7.16 (IH, s) , 7.27 (2H, m) , 7.42 (2H, m) , 7.66 (IH, br) , 7.97 (2H, d, J=8.7Hz), 7.9-8.2 (5H, m) , 8.7-8.9 (2H, m) MASS (m/z) : 1360.75 (M-Na) + Elemental Analysis Calcd. for C 1 H 73 N 1Q Na0 22 S2 • 9H 0 : C 47.34, H 5.93, N 9.05 Found : C 47.27, H 5.76, N 8.94 Example 52 IR (KBr) : 3365.2, 1650.8, 1631.5, 1538.9, 1515.8, 1442.5, 1245.8 cm -1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.7Hz), 1.12 (3H, d, J=5.6Hz), 1.7-2.7 (9H, ) , 2.9-3.1 (IH, m) , 3.1-3.5 (2H, m) , 3.6-4.6 (18H, m) , 4.6-5.5 (9H, m) , 6.73 (IH, 409 d, J=8.3Hz), 6.83 (IH, d, J=8.3Hz), 6.84-7.00 (4H, m) , 7.05 (IH, s), 7.17 (2H, d, J=8.7Hz), 7.19 (IH, m) , 7.2-7.6 (4H, m) , 7.67 (IH, br) , 7.98 (2H, d, J=8.7Hz), 7.8-8.2 (5H, m) , 8.6-9.0 (2H, ) MASS (m/z) : 1332.97 (M-Na) + Elemental Analysis Calcd. for C5 9 H 9 N 10 NaO 22 s ' 8H 2° : C 47.20, H 5.71, N 9.33 Found : C 47.10, H 5.59, N 9.24 Example 53 IR (KBr) : 3353.6, 1650.8, 1631.5, 1538.9, 1513.8, 1450.2, 1442.5, 1257.4 cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.6Hz), 1.12 (3H, d, J=5.7Hz), 1.3-2.6 (13H, m) , 2.9-3.1 (IH, m) , 3.1-3.6 (7H, m) , 3.6-4.6 (16H, m) , 4.6-5.5 (9H, m) , 6.73 (IH, d, J=8.2Hz), 6.83 (IH, d, J=8.2Hz), 6.89 (IH, s) , 7.05 (IH, s), 7.13 (2H, d, J=8.8Hz), 7.15 (IH, m) , 7.3- 7.8 (3H, m) , 7.97 (2H, d, J=8.8Hz), 7.8-8.2 (5H, m) , 8.6-9.0 (2H, br) MASS (m/z) : 1298.85 (M-Na) + Elemental Analysis Calcd. for C 5 gH 71 N 10 Naθ22S • 10H O : C 44.74, H 6.10, N 9.32 Found : C 44.78, H 5.96, N 9.27 Example 54 IR (KBr) : 3365, 1647, 1541, 1516, 1437, 1248, 1047 cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.7Hz), 1.12 (3H, d, J=5.6Hz), 1.49-1.74 (6H, m) , 1.74-2.55 (7H, m) , 2.90-3.50 (3H, m) , 3.60-3.85 (6H, m) , 3.85-4.59 (13H, m) , 4.70-5.40 (8H, m) , 6.74 (IH, d, J=8.2Hz), 6.81 (IH, s), 6.87 (IH, d, J=8.2Hz), 6.99 (IH, d, J=9.1Hz), 7.06 (IH, s), 7.19 (IH, s) , 7.35-7.50 (2H, m) , 7.68 (IH, m) , 8.05 (IH, m) , 8.06 (4H, s) , 8.08 (IH, dd, J=9.1 and 2.5Hz), 8.71 (IH, d, J=2.5Hz), 8.77 (IH, d, J=7.4Hz) , 8.82 (IH, br s) MASS (m/z) : 1266.93 (M-Na) + Elemental Analysis Calcd. for C5 Hg 7 N 12 NaO 20 S 2 • 10H 2 O : 410 C 44.08, H 5.96, N 11.42 Found : C 44.28, H 5.81, N 11.48 The following compounds [Examples 55 and 5_6] were obtained in a manner similar to that of Example 17. Example 55 IR (KBr) : 3359, 1651, 1539, 1522 cm -1 NMR (DMSO-dg, δ) : 0.8-1.0 (6H, m) , 1.11 (3H, d, J=5.5Hz), 1.3-1.6 (4H, m) , 1.6-2.15 (5H, m) , 2.2-2.5 (4H, m) , 2.97 (IH, m) , 3.20 (IH, m) , 3.74 (2H, m) , 3.8-4.6 (14H, m) , 4.6-5.4 (10H, m) , 6.74 (IH, d, J=8.2Hz), 6.83 (IH, d, J=8.2Hz), 6.89 (IH, s) , 7.05 (IH, s), 7.22 (IH, m) , 7.45 (3H, m) , 7.52 (2H, d, J=4.9Hz), 7.66 (IH, m) , 7.96 (5H, m) , 8.08 (IH, d, J=8.2Hz), 8.59 (IH, d, J=6.4Hz), 8.85 (IH, s) , 8.89 (IH, s) MASS (m/z) : 1307.69 (M-Na) + Elemental Analysis Calcd. for C 57 H 7 oN 11 0 2 ιS2Na- 10H 2 O : C 45.26, H 6.00, N 10.19 Found : C 45.11, H 5.84, N 10.28 Example 56 IR (KBr) : 3359, 1651, 1539, 1524, 1458, 1254 cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.6Hz), 1.12 (3H, d, J=5.5Hz), 1.2-1.6 (6H, m) , 1.6-2.1 (7H, m) , 2.1-2.4 (4H, m) , 2.96 (IH, m) , 3.19 (IH, m) , 3.42 (IH, m) , 3.74 (2H, m) , 3.8-4.6 (12H, m) , 4.73 (IH, m) , 4.8-5.0 (3H, m) , 5.06 (IH, d, J=5.8Hz), 5.1-5.3 (5H, m) , 6.74 (IH, d, J=8.2Hz), 6.83 (IH, d, J=8.2Hz), 6.89 (IH, s) , 7.05 (IH, s), 7.15 (2H, d, J=8.8Hz), 7.23 (IH, s) , 7.3- 7.5 (2H, m) , 7.66 (IH, s) , 7.88 (2H, d, J=8.8Hz), 7.95 (4H, s), 8.07 (IH, d, J=7.8Hz), 8.58 (IH, d, J=7.8Hz), 8.85 (2H, s) MASS (m/z) : 1319.74 (M-Na) + Elemental Analysis Calcd. for C 8 H 70 N 11 θ2iS 2 Na- 10H 2 O : C 45.70, H 5.95, N 10.11 Found : C 45.58, H 5.80, N 10.13 411 The following compounds [Examples 57 to _5_0] were obtained in a manner similar to that of Example 18. Example 57 IR (KBr) : 3350, 2929, 1664, 1629, 1446, 1284, 1047.2 cm -1 NMR (DMSO-dg, δ) : 0.86 (3H, t, J=6.7Hz), 0.96 (3H, d, J=6.7Hz), 1.07 (3H, d, J=5.9Hz), 1.2-1.5 (10H, m) , 1.6-2.5 (9H, m) , 2.9-3.5 (4H, m) , 3.7-4.5 (16H, m) , 4.7-4.8 (IH, m) , 4.87 (IH, d, J=5.9Hz), 5.0-5.4 (5H, m) , 6.7-6.9 (4H, m) , 6.96 (IH, s), 7.17 (IH, s) , 7.40 (IH, d, J=8.4Hz), 7.5-7.8 (2H, m) , 8.0-8.2 (2H, m) , 8.61 (IH, d, J=7.7Hz), 8.68 (IH, d, J=8.9Hz) MASS (m/z) : 1182.4 (M+Na) + Elemental Analysis Calcd. for C4 9 H 70 N g Na0 2 oS • 4H 0 : C 47.76, H 6.38, N 10.23 Found : C 47.81, H 6.73, N 10.12 Example 58 IR (KBr) : 3349, 2929, 1664, 1633, 1535, 1515, 1440, 1272, 1045 cm "1 NMR (DMSO-dg, δ) : 0.86 (3H, t, J=6.8Hz), 0.96 (3H, d, J=6.7Hz), 1.10 (3H, d, J=5.8Hz), 1.2-1.4 (8H, m) , 1.5-2.5 (10H, m) , 2.58 (2H, t, J=7.6Hz), 2.9-3.1 (IH, m) , 3.2-3.6 (3H, m) , 3.7-4.2 (5H, m) , 4.1-4.6 (8H, m) , 4.7-5.2 (7H, m) , 5.3-5.4 (IH, m) , 6.7-7.8 (14H, m) , 7.95 (2H, d, J=8.3Hz), 8.10 (IH, d, J=8.4Hz), 8.63 (IH, d, J=7.7Hz), 8.71 (IH, s) MASS (m/z) : 1227.5 (M+Na) + Elemental Analysis Calcd. for C55H 73 N 8 Na0 19 S • 5H 0 : C 51.00, H 6.46, N 8.65 Found : C 50.90, H 6.54, N 8.81 Example 59 IR (Nujol) : 3353.0, 1668,1, 1629.6, 1540.8, 1515.8 cm "1 NMR (DMSO-dg, δ) : 0.87 (3H, t, J=6.7Hz), 0.96 (3H, d, J=6.7Hz), 1.06 (3H, d, J=6.0Hz), 1.18-1.48 (4H, m) , 1.48-2.06 (5H, m) , 2.06-2.70 (8H, m) , 2.70-3.08 (3H, 412 m) , 3.09-3.50 (2H, m) , 3.60-4.65 (14H, m) , 4.65-5.50 (9H, m) , 6.65-6.90 (3H, m) , 6.90-7.90 (13H, m) , 8.02 (IH, d, J=8.4Hz), 8.15 (IH, d, J=7.7Hz), 8.71 (IH, s) MASS (m/z) : 1227.5 (M+Na) + Elemental Analysis Calcd. for C5 5 H 73 N 8 Na0 19 S • 5H 2 0 : C 50.99, H 6.46, N 8.65 Found : C 50.84, H 6.62, N 8.81 Example 60 IR (KBr) : 3353.6, 1635.3, 1257.4 cm "1 NMR (DMSO-dg, δ) : 0.89 (3H, t, J=6.8Hz), 0.97 (3H, d, J=6.7Hz), 1.09 (3H, d, J=5.7Hz), 1.2-1.5 (6H, m) , 1.65-2.6 (10H, m) , 2.97 (IH, m) , 3.1-3.5 (2H, m) , 3.6-4.6 (16H, m) , 4.7-5.4 (8H, m) , 6.71 (IH, d, J=8.2Hz), 6.79 (IH, d, J=8.2Hz), 6.87 (IH, s) , 6.97 (IH, s), 7.13 (2H, d, J=8.9Hz), 7.16 (IH, s) , 7.4- 7.8 (3H, m) , 7.97 (2H, d, J=8.9Hz), 7.9-8.2 (5H, m) , 8.72 (IH, s), 8.78 (IH, d, J=7.1Hz) MASS (m/z) : 1267 (M-Na) + The following compounds [Examples 61 to 22] were obtained in a manner similar to that of Example 13. Example 61 IR (KBr) : 1650.8, 1631.5 cm "1 NMR (DMSO-dg, δ) : 0.80-0.87 (3H, s) , 0.97 (3H, d, J=6.8Hz), 1.10 (3H, d, J=5.9Hz), 1.23 (14H, br s) , 1.73-2.65 (10H, m) , 2.92-3.50 (3H, m) , 3.60-4.60 (16H, m) , 4.70-5.50 (8H, m) , 6.71 (IH, d, J=8.2Hz) , 6.77-6.81 (IH, m) , 6.86 (IH, s) , 6.97 (IH, s) , 7.07-7.86 (4H, m) , 8.11 (IH, s), 8.06-8.17 (4H, m) , 8.66 (IH, s) , 8.66-8.88 (3H, m) MASS (m/z) : 1326.62 (M+Na) + Elemental Analysis Calcd. for C 57 H 77 N 12 θ20 SNa ' 7H 2° : C 47.83, H 6.41, N 11.74 Found : C 47.77, H 6.45, N 11.62 Example 62 IR (KBr) : 1668.1, 1650.8, 1631.5 cm "1 413 NMR (DMSO-dg, δ) : 0.81-0.90 (3H, m) , 0.97 (3H, d, J=6.7Hz), 1.10 (3H, d, J=6Hz),1.23 (14H, br s) , 1.75-2.70 (10H, m) , 2.95-3.02 (IH, m) , 3.17-3.30 (2H, m) , 3.60-4.60 (16H, m) , 4.70-5.46 (8H, m) , 6.71 (IH, d, J=8.2Hz), 6.79 (IH, d, J=8.5Hz), 6.87 (IH, br s) , 6.98 (IH, s), 7.18 (IH, br s) , 7.40-7.80 (3H, m) , 8.05-8.10 (4H, m) , 8.08 (IH, s), 8.57 (IH, s) , 8.71-8.80 (3H, m) MASS (m/z) : 1297.14 (M-Na) + Elemental Analysis Calcd. for C5 7 H 77 N 12 0 19 S 2 Na- 7H 2 0 : C 47.30, H 6.34, N 11.61 Found : C 47.07, H 6.23, N 11.42 Example 63 IR (KBr) : 1675.8, 1650.8 cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.6Hz), 1.11 (3H, d, J=6.4Hz), 1.70-2.60 (10H, m) , 2.90-3.60 (3H, m) , 3.60-4.60 (18H, m) , 4.68-5.60 (8H, m) , 6.70 (IH, d, J=8.3Hz), 6.78 (IH, d, J=9.7Hz), 6.87 (IH, s) , 6.93-6.99 (4H, m) , 7.11 (2H, d, J=8.8Hz), 7.26-7.34 (2H, m) , 7.09-7.78 (4H, m) , 7.76 (2H, d, J=8.7Hz) , 7.91 (2H, d, J=8.5Hz), 8.12 (2H, d, J=8.6Hz), 8.19-8.27 (4H, m) , 8.60-9.00 (3H, m) MASS (m/z) : 1377.26 (M-Na) + Elemental 7Analysis Calcd. for Cg5H 73 N 10 θ22SNa- 6H 2 0 : C 51.72, H 5.68, N 9.28 Found : C 51.54, H 5.73, N 9.25 Example 64 IR (KBr) : 1675.8, 1650.8, 1631.5 cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.7Hz), 1.11 (3H, d, J=5.6Hz), 1.70-2.60 (8H, m) , 2.80-3.60 (3H, m) , 3.60-5.26 (22H, m) , 4.65 (2H, d, J=5.2Hz), 5.26-5.48 (2H, m) , 5.99-6.18 (IH, m) , 6.70 (IH, d, J=8Hz) , 6.78 (IH, d, J=9.9Hz), 6.87 (IH, s) , 6.97 (IH, s) , 7.00-7.20 (IH, m) , 7.10 (2H, d, J=8.9Hz), 7.30-7.80 (3H, ) , 7.75 (2H, d, J=8.9Hz), 7.92 (2H, d, J=8.5Hz), 8.12 (2H, d, 414 J=8.6Hz), 8.19-8.27 (5H, m) , 8.50-9.00 (2H, m) MASS (m/z) : 1282.84 (M-Na) + Elemental Analysis Calcd. for C5 9 Hg 7 N 10 O χSNa' 7H 2 0 : C 49.44, H 5.70, N 9.77 Found : C 49.33, H 5.64, N 9.74 Example 65 IR (KBr) : 1650.8, 1631.5, 1540.8, 1513.8, 1245.8 cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.7Hz), 1.11 (3H, d, J=5.9Hz), 1.80-2.60 (11H, m) , 2.80-3.60 (3H, m) , 3.65-4.60 (19H, m) , 4.63-5.50 (8H, m) , 6.70 (IH, d, J=8Hz), 6.77 (IH, d, J=7.9Hz), 6.87-6.97 (5H, m) , 7.02-7.22 (IH, m) , 7.09 (2H, d, J=8Hz) , 7.25-7.33 (2H, m) , 7.40-7.80 (3H, m) , 7.75 (2H, d, J=8.9Hz), 7.91 (2H, d, J=8.5Hz), 8.11 (2H, d, J=8.4Hz), 8.23-8.27 (4H, m) , 8.50-9.00 (3H, m) MASS (m/z) : 1391.07 (M-Na) + Elemental Analysis Calcd. for C gH 75 N 10 θ22SNa • 7H 0 : C 51.42, H 5.82, N 9.09 Found : C 51.37, H 5.78, N 9.05 Example 66 IR (KBr) : 3353.6, 2939.0, 1650.8, 1631.5, 1538.9, 1513.8, 1442.5 cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.6Hz), 1.10 (3H, d, J=5.7Hz), 1.7-2.6 (12H, m) , 2.9-3.1 (IH, m) , 3.1-3.7 (2H, m) , 3.7-4.7 (18H, m) , 4.7-5.5 (8H, m) , 6.71 (IH, d, J=8.0Hz), 6.78 (IH, d, J=8.0Hz), 6.83-7.05 (5H, m) , 7.15 (2H, d, J=8.7Hz), 7.17 (IH, m) , 7.2-7.35 (2H, m) , 7.35-7.9 (3H, m) , 7.98 (2H, d, J=8.7Hz), 7.9-8.2 (5H, m) , 8.75 (IH, br) , 8.80 (IH, d, J=7.0Hz) MASS (m/z) : 1331.28 (M-Na) + Elemental Analysis Calcd. for C 0 H 71 N 10 Naθ2iS2 • 9H 2 0 : C 47.49, H 5.91, N 9.23 Found : C 47.41, H 5.71, N 9.17 Example 67 IR (KBr) : 3353.6, 1666.2, 1650.8, 1631.5, 1538.9, 415 1513.8, 1442.5, 1247.7 cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.7Hz), 1.10 (3H, d, J=5.7Hz), 1.4-2.7 (14H, m) , 2.9-3.1 (IH, m) , 3.1-3.5 (2H, m) , 3.6-4.6 (18H, ) , 4.7-5.5 (8H, m) , 6.71 (IH, d, J=8.1Hz), 6.79 (IH, d, J=8.1Hz), 6.84-7.00 (5H, m) , 7.14 (2H, d, J=8.7Hz), 7.16 (IH, m) , 7.27 (2H, m) , 7.44 (IH, d, J=8.6Hz), 7.59 (IH, br) , 7.71 (IH, br) , 7.98 (2H, d, J=8.7Hz), 7.9-8.2 (5H, m) , 8.75 (IH, br) , 8.79 (IH, d, J=7.2Hz) MASS (m/z) : 1345.3 (M-Na) + Elemental Analysis Calcd. for Cg 1 H 73 N 1Q Na0 21 S 2 • 8H 2 0 : C 48.41, H 5.93, N 9.25 Found : C 48.30, H 5.91, N 9.17 Example 68 IR (KBr) : 3353.6, 2937.1, 1650.8, 1540.8, 1513.8, 1452.1, 1243.9 cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.7Hz), 1.11 (3H, d, J=5.7Hz), 1.7-2.7 (10H, m) , 2.9-3.1 (IH, m) , 3.1-3.6 (2H, m) , 3.6-4.7 (18H, m) , 4.7-5.5 (8H, m) , 6.71 (IH, d, J=8.1Hz), 6.79 (IH, d, J=8.1Hz), 6.84-7.10 (5H, m) , 7.17 (2H, d, J=8.7Hz), 7.19 (IH, m) , 7.2-7.4 (2H, m) , 7.44 (IH, d, J=9.2Hz), 7.5-7.9 (2H, m) , 7.98 (2H, d, J=8.7Hz), 7.9-8.2 (5H, m) , 8.6-9.0 (2H, m) MASS (m/z) : 1316.8 (M-Na) + Elemental Analysis Calcd. for C5 9 Hg 9 N 10 NaO 1 S • 9H 2 0 : C 47.13, H 5.83, N 9.32 Found : C 47.40, H 5.67, N 9.30 Example 69 IR (KBr) : 3361.3, 2937.1, 1650.8, 1631.5, 1538.9, 1513.8, 1450.2, 1440.6, 1257.4 cm "1 NMR (DMSO-dg, δ) : 0.99 (3H, m) , 1.11 (3H, m) , 1.3-2.7 (14H, m) , 2.9-3.1 (IH, m) , 3.1-3.6 (7H, m) , 3.6-4.7 (16H, m) , 4.7-5.6 (8H, m) , 6.69 (IH, d, J=8.2Hz), 6.77 (IH, d, J=8.2Hz), 6.86 (IH, s) , 6.98 (IH, s) , 7.13 (2H, d, J=8.7Hz), 7.15 (IH, m) , 7.3-7.9 (3H, m) , 7.97 (2H, 416 d, J=8.7Hz), 7.9-8.2 (5H, m) , 8.6-8.9 (2H, m) MASS (m/z) : 1283.2 (M-Na) + Elemental Analysis Calcd. for C5gH 71 N 10 Naθ2iS2 • 10H O : C 45.22, H 6.17, N 9.42 Found : C 45.30, H 5.90, N 9.38 Example 70 IR (KBr) : 3400, 1651, 1541, 1261 cm -1 NMR (DMSO-dg, δ) : 0.95-5.40 (58H, m) , 6.67-8.77 (19H, m) MASS (m/z) : 1325.29 (M-Na) + Elemental Analysis Calcd. for C5 9 H 77 N 10 N aθ2χS 2 • 37/4H 0 : C 46.74, H 6.35, N 9.24 Found : C 46.74, H 6.10, N 9.15 Example 71 IR (KBr) : 3363, 1648, 1619, 1506, 1257 cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, t, J=3.3Hz), 1.02 (3H, d, J=7.3Hz), 1.11 (3H, d, J=5.5Hz), 1.68-5.40 (38H, m) , 6.69-8.86 (22H, m) MASS (m/z) : 1254 (M-Na) + Elemental Analysis Calcd. for C5 9 Hg 9 N 10 NaO 21 s ' 41/5H 2 0 : C 48.64, H 5.91, N 9.61 Found : C 48.63, H 5.85, N 9.55 Example 72 IR (KBr) : 3300, 1651, 1506, 1437 cm "1 NMR (DMSO-dg, δ) : 0.87-5.30 (50H, m) , 6.66-8.73 (20H, m) MASS (m/z) : 1236.29 (M-Na) + Elemental Analysis Calcd. for C 5 gH 70 N 9 NaO 21 S -23/3H 2 0 : C 48.10, H 6.15, N 9.01 Found : C 48.14, H 6.03, N 8.97 The following compounds fExamples 73 and 2.4] were obtained in a manner similar to that of Example 17. Example 73 IR (KBr) : 3359, 1676, 1651, 1632, 1514 cm "1 NMR (DMSO-dg, δ) : 0.87-1.0 (6H, m) , 1.09 (3H, d, J=5.4Hz), 1.2-1.6 (4H, ) , 1.6-2.1 (5H, m) , 2.1-2.6 (5H, m) , 3.00 (IH, m) , 3.2 (IH, m) , 3.5 (IH, m) , 3.6-4.6 417 (16H, m) , 4.6-5.6 (8H, m) , 6.70 (IH, d, J=8.2Hz), 6.77 (IH, d, J=8.2Hz), 6.87 (IH, s), 6.97 (IH, s) , 7.20 (IH, m) , 7.3-7.8 (6H, m) , 7.8-8.4 (6H, s) , 8.4-8.8 (2H, m) , 8.89 (IH, s) MASS (m/z) : 1292.51 (M-Na) + Elemental Analysis Calcd. for C5 7 H 70 N 11 0 2 oS2Na- 12H 2 0 : C 44.67, H 6.18, N 10.05 Found : C 44.89, H 6.05, N 10.02 Example 74 IR (KBr) : 3359, 1668, 1650, 1631 cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.4Hz), 1.08 (3H, d, J=5.4Hz), 1.2-1.6 (6H, m) , 1.6-2.0 (7H, m) , 2.1-2.4 (4H, m) , 3.01 (IH, m) , 3.20 (IH, m) , 3.67 (IH, m) , 3.7-4.6 (16H, m) , 4.6-5.6 (8H, m) , 6.68 (IH, d, J=8.2Hz), 6.76 (IH, d, J=8.2Hz), 6.85 (IH, s) , 7.15 (2H, d, J=8.9Hz), 7.16 (IH, s) , 7.2-7.8 (4H, m) , 7.88 (2H, d, J=8.9Hz), 7.96 (4H, s) , 8.56 (IH, s) , 8.84 (2H, s) MASS (m/z) : 1304.08 (M-Na) + Elemental Analysis Calcd. for C 58 H 7 oN 11 0 20 S 2 Na- 12H 2 0 : C 45.10, H 6.13, N 9.98 Found : C 45.33, H 5.89, N 9.94 The following compounds [Examples 75 to ]3_5] were obtained according to a similar manner to that of Example 13. Example 75 IR (KBr) : 1668, 1649, 1632, 1541, 1516 cm "1 NMR (DMSO-dg, δ) : 0.86 (3H, m) 0.97 (3H, d, J=6.7Hz), 1.0-1.2 (3H, ) , 1.2-1.4 (8H, m) , 1.45-1.65 (2H, m) , 1.7-2.6 (8H, m) , 2.8-3.5 (3H, m) , 3.46 (2H, t, J=6.4Hz) , 3.6-4.6 (14H, m) , 4.51 (2H, s) , 4.7-5.4 (8H, m) , 6.65-6.85 (2H, m) , 6.88 (IH, s) , 6.97 (IH, s) , 7.18 (IH, s), 7.4-7.8 (3H, m) , 7.50 (2H, d, J=8.6Hz), 8.02 (2H, d, J=8.6Hz), 8.0-8.2 (5H, m) , 8.41 (IH, s) , 8.72 (IH, s), 8.7-8.9 (IH, m) , 9.35 (IH, s) MASS (m/z) : 1407 (M + +23) 418 Elemental Analysis Calcd. for C 61 H 77 N 12 NaO 20 S2 • 7H 0 : C 48.47, H 6.07, N 11.12 Found : C 48.51, H 6.01, N 11.17 Example 76 IR (KBr) : 1632, 1518, 1441, 1250 cm "1 NMR (DMSO-dg, δ) : 0.89 (3H, t, J=6.6Hz), 0.97 (3H, d, J=6.7Hz), 1.10 (3H, d, J=5.3Hz), 1.1-1.5 (6H, m) , 1.6-2.5 (10H, m) , 2.9-3.1 (IH, m) , 3.1-3.5 (2H, m) , 3.6-4.6 (14H, m) , 4.03 (2H, t, J=6.4Hz), 4.7-5.1 (4H, m) , 5.15-5.25 (3H, m) , 5.3-5.45 (IH, m) , 6.7-6.85 (2H, m) , 6.87 (IH, s) , 6.97 (IH, s) , 7.10 (2H, d, J=8.9Hz), 7.18 (IH, s), 7.4-7.8 (3H, m) , 7.85 (2H, d, J=8.9Hz), 8.0-8.2 (5H, m) , 8.06 (IH, s) , 8.72 (IH, s) , 8.75- 8.9 (IH, m) , 9.23 (IH, s) MASS (m/z) : 1333 (M + -23) Elemental Analysis Calcd. for C 59 H 7 3N 1 2 NaO 20 s 2 ' 8H 2 0 : C 47.20, H 5.97, N 11.19 Found : C 47.27, H 6.04, N 11.26 Exampl 77 IR (KBr) : 1633, 1608, 1531, 1444, 1419 cm "1 NMR (DMSO-dg, δ) : 0.88-1.25 (6H, m) 1.49-2.50 (11H, m) , 2.84-5.48 (33H, m) , 6.62-6.98 (3H, m) , 7.00-7.16 (2H, m) , 7.10 (2H, d, J=8.5Hz), 7.25-7.80 (7H, m) , 7.85 (2H, d, J=8.5Hz), 7.91-8.14 (6H, m) , 8.65-8.89 (2H, m) MASS (m/z) : 1371.69 (M-Na + ) Elemental Analysis Calcd. for Cg 2 H 7 N 11 Naθ2χS2 • 8H 2 0 : C 48.34, H 5.89, N 10.00 Found : C 48.39, H 5.65, N 9.95 Example 78 IR (KBr) : 1649, 1605, 1541, 1516, 1448 cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.7Hz), 1.12 (3H, d, J=5.9Hz), 1.40-2.45 (12H, m) , 2.78-3.50 (7H, m) , 3.64-5.34 (23H, m) , 6.47 (IH, d, J=8.2Hz), 6.83 (IH, d, J=8.2Hz), 6.89 (IH, s) , 7.00-7.50 (10H, m) , 7.67 (IH, brs), 7.98-8.20 (6H, m) , 8.74(1H, d, J=2.5Hz), 419 8.65-8.92 (2H, m) MASS (m/z) : 1343.11 (M-Na + ) Elemental Analysis Calcd. for Cg 0 H 7 - ] _N- | _ Na0 2 oS 2 • 7H 0 : C 48.25, H 5.74, N 11.25 Found : C 48.32, H 5.62, N 11.24 Example 7 IR (KBr) : 1637, 1539, 1512, 1443 cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.7Hz), 1.11 (3H, d, J=7.1Hz), 1.36 (3H, t, J=6.9Hz), 1.73-2.52 (8H, m) , 2.79-3.34 (3H, m) , 4.10 (2H, q, J=7.0Hz), 3.66-4.60 (14H, m) , 4.70-5.54 (8H, m) , 6.71 (IH, d, J=8.1Hz), 6.79 (IH, dd, J=8.4 and 1.7Hz), 6.87 (IH, s) , 6.98 (IH, d, J=1.7Hz), 7.06(2H, d, J=8.9Hz), 7.19 (IH, s), 7.45 (IH, d, J=8.8Hz), 7.60 (IH, m) , 7.73 (2H, d, J=8.8Hz), 7.87 (2H, d, J=8.5Hz), 7.96-8.24 (8H, m) , 8.73 (IH, brs), 8.80 (IH, d, J=7.3Hz) MASS (m/z) : 1287.49 (M-Na + ) Elemental Analysis Calcd. for C5 8 H 7 N 10 Na0 2 o s 2 ' 7H 2° : C 48.46, H 5.68, N 9.74 Found : C 48.19, H 5.69, N 9.56 Example 80 IR (KBr) : 1649, 1635, 1510, 1443 cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.8Hz), 1.12 (3H, d, J=5.8Hz), 1.55-2.51 (11H, m) , 2.76-3.64 (3H, m) , 3.25 (3H, s) , 3.64-4.60 (18H, m) , 4.60-5.54 (9H, m) , 6.73 (IH, d, J=8.2Hz), 6.83 (IH, d, J=8.6Hz), 6.89 (IH, s), 7.02-7.15 (3H, m) , 7.36-7.79 (3H, m) , 7.73 (2H, d, J=8.8Hz), 7.87 (2H, d, J=8.4Hz), 8.00-8.26 (8H, m) , 8.70-8.92 (2H, m) MASS (m/z) : 1361.12 (M-Na + ) Elemental Analysis Calcd. for Cg 1 H 73 N 10 NaO 2 S • 7H 2 0 : C 48.47, H 5.80, N 9.27 Found : C 48.63, H 5.71, N 9.19 Example 81 IR (KBr) : 1633, 1533, 1512, 1443 cm "1 420 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.7Hz), 1.10-1.20 (3H, m) , 1.56-2.50 (12H, m) , 2.88-3.28 (3H, m) , 3.25 (3H, s), 3.63-4.56 (18H, m) , 4.70-5.50 (8H, m) , 6.69 (IH, d, J=8.1Hz), 6.77 (IH, d, J=8.1Hz), 6.87 (IH, s) , 6.98 (IH, s), 7.07 (2H, d, J=8.8Hz), 7.28-7.72 (3H, m) , 7.73 (2H, d, J=8.7Hz), 7.87 (2H, d, J=8.4Hz), 7.94-8.20 (8H, m) , 8.64-8.92 (2H, m) MASS (m/z) : 1345.44 (M-Na + ) Elemental Analysis Calcd. for Cg H 7 3N-L Q Naθ2χS2 • 6H 2 0 : C 49.59, H 5.80, N 9.48 Found : C 49.52, H 5.68, N 9.39 Example 82 IR (KBr) : 1635, 1608, 1531, 1444, 1419 cm "1 NMR (DMSO-dg, δ) : 0. 97 (3H, d, J=6.8Hz), 1.10 (3H, d, J=5.7Hz), 1.03-1.20 (5H, m) , 1.50-2.55 (14H,m), 2.55-2.77 (4H, m) , 2.89-3.55 (7H, m) , 3.67-4.63 (14H, m) , 4.68-5.50(8H, m) , 6.71 (IH, d, J=8.2Hz-), 6.78 (IH, d, J=8.2Hz), 6.87 (lH,s), 6.97 (lH,s), 7.08 (2H, d, J=8.7Hz), 7.18 (IH, s) , 7.44 (IH, d, J=7.5Hz), 7.58 (IH, m) , 7.71 (IH, m) , 7.85 (2H, d, J=8.8Hz), 7.94-8.20 (5H, m) , 8.72 (lH,s), 8.78 (IH, d, J=7.0Hz) , MASS (m/z) : 1332.99 (M-Na + ) Elemental T^nalysis Calcd. for C oH 77 N 1 Na0 19 S 2 • 7H 0 : C 48.58, H 6.18, N 11.33 Found : C 48.58, H 6.02, N 11.22 Example 83 IR (KBr) : 1633, 1535, 1512, 1443 cm -1 NMR (DMSO-dg, δ) : 0.95 (3H, t, J=7.4Hz), 0.97 (3H, d, J=7.1Hz), 1.11 (3H, d, J=5.6Hz), 1.35-1.56 (2H, m) , 1.66-2.55(10H, m) , 2.90-3.38 (3H, m) , 3.68-4.62 (16H, m) , 4.75-5.52 (8H, ) , 6.71 (IH, d, J=8.2Hz), 6.79 (IH, d, J=8.2Hz), 6.88 (IH, s) , 6.99 (IH, s) , 7.07 (2H, d, J=8.8Hz), 7. 10-7.68 (3H, m) , 7.73 (2H, d, J=8.7Hz), 7.86 (2H, d, J=8.4Hz), 8.05-8.25 (8H, 421 m) , 8.50-8.92 (2H, m) MASS (m/z) : 1315.58 (M-Na + ) Elemental Analysis Calcd. for CgoH 71 10 Na0 2 oS2 ' 10H 2 O : C 47.43, H 6.04, N 9.22 Found : C 47.60, H 5.66, N 9.24 Example 84 IR (KBr) : 1647, 1539, 1512, 1448 cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.7Hz), 1.16-1.20 (3H, m) , 1.15 (3H, t, J=7.0Hz), 1.73-2.58 (8H, m) , 2.84-3.35 (3H, m) , 3.49 (2H, q, J=7.0Hz), 3.66-4.62 (18H, m) , 4.74-5.50 (8H, m) , 6.71 (IH, d, J=8.2Hz), 6.79 (IH, d, J-8.3 and 1.7Hz), 6.88 (IH, brs), 6.98 (IH, d, J=1.7Hz), 7.09 (2H, d, J=8.8Hz), 7. 19 (IH, brs), 7.36-7.69 (2H,m) , 7.74 (2H, d, J=8.8Hz), 7.87(2H, d, J=8.5Hz), 8.02-8.24 (8H, m) , 8.63-8.90 (2H, m) MASS (m/z) : 1331.2 (M-Na + ) Elemental Analysis Calcd. for CgoH 71 N 10 Naθ2iS 2 • 8H 2 0 : C 48.06, H 5.85, N 9.34 Found : C 47.93, H 5.82, N 9.23 Example 85 IR (KBr) : 1633, 1537, 1513, 1443 cπT 1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.8Hz), 1. 11 (3H, d, J=5.8Hz) 1.74-2.52 (8H, m) , 2.90-3.40 (3H, m) , 3.35 (3H, s), 3.62-4.57 (18H, m) , 4.70-5.49 (8H, m) , 6.70 (IH, d, J=8.1Hz), 6.78 (I H, d, J=8.1Hz), 6.87 (IH, s), 6.97 (IH, s), 7.09 (2H, d, J=8.8Hz), 7.10-7.51 (3H, m) , 7.74 (2H, d, J=8.7Hz) , 7.87 (2H, d, J=8.7Hz) , 7.94-8.28 (8H, ) , 8.56-8.92 (2H, m) MASS (m/z) : 1317.28 (M-Na + ) Elemental Analysis Calcd. for C5 9 Hg 9 N 10 aO 2 χS2 • H 2 0 : C 47.13, H 5.83, N 9.32 Found : C 47.24, H 5.55, N 9.35 Example 86 To a solution of Starting Compound (86) (0.15 g) and 422 4- [4- [4- (5-methoxypentyloxy) biphenyl-4-yl] piperazin-1- yl]benzoic acid benzotriazol-1-yl-ester (0.12 g) in N,N- dimethylformamide (3 ml) was added diaminopyridine (0.024g), and the mixture was stirred for 15 hours at ambient temperature . The reaction mixture was pulverized with ethyl acetate. The precipitate was collected by filtration, and dried under reduced pressure. The solid was dissolved in diluted NaHC03 aq., and subjected to column chromatography on ODS (YMC-gel ODS-AM S-50 (Trademark : prepared by Yamamura Chemical Lab.) ) eluting with 60% methanol aqueous solution. The fractions containing the object compound were combined, and evaporated under reduced pressure to remove methanol. The residue was lyophilized to give Object Compound (86) (0.16 g) . IR (KBr) : 1666.2, 1629.6, 1228.4, 1043.3 cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.4Hz), 1.08 (3H, d, J=5.4Hz), 1.44-5.17 (55H, m) , 6.69-8.72 (22H, m) MASS (m/z) : 1405.4 (M+Na) Elemental Analysis Calcd. for Cg H 8 3N 10 Naθ2χS • 7.5H 2 0 : C 50.62, H 6.50, N 9.32 Found : C 50.52, H 6.42, N 9.16 The following compounds [Examples 87 to 1051 were obtained in a manner similar to that of Example 86. Example 87 IR (KBr) : 1668.1, 1629.6, 1230.4 cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.6Hz), 1.07 (3H, d, J=5.7Hz), 1.24-5.50 (59H,m) , 6.68-8.80 (18H, ) MASS (m/z) : 1327.5 (M-Na) Elemental Analysis Calcd. for C Q H 8 3N 1Q Naθ2oS > 6.5H 2 0 : C 49.07, H 6.59, N 9.54 Found : C 49.05, H 6.64, N 9.44 Example 88 IR (KBr) : 1666.2, 1631.5, 1240.0 cm -1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.7Hz), 1.07 (3H, d, J=5.9Hz), 1.40-5.40 (52H, m) , 6.69-8.71 (19H, m) MASS (m/z) : 1249.3 (M-Na) 423 Elemental Analysis Calcd. for C 58 H 77 N 10 NaO 19 S • 8H 0 : C 49.15, H 6.61, N 9.88 Found : C 48.96, H 6.49, N 9.79 Example 89 IR (KBr) : 1668.1, 1631.5, 1238.1 cm "1 NMR (DMSO-dg, δ) : 0.82-5.38 (69H, m) , 6.69-8.40 (14H, m) MASS (m/z) : 1265.6, 1243.5 (M-Na) Elemental Analysis Calcd. for C5 7 H 83 N- | _ Q Na0 9 S • 7H 2 0 : C 49.13, H 7.02, N 10.05 Found : C 49.19, H 7.02, N 10.00 Example 90 IR (KBr) : 1664.3, 1629.6, 1232.3 cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.7Hz), 1.07 (3H, d, J=5.6Hz), 1.16-5.20 (53H,m) , 6.70-8.30 (18H,m) MASS (m/z) : 1265.4 (M-Na) Elemental Analysis Calcd. for C 58 H 77 N 10 NaO 20 s ' 8 • 5H 2° : C 48.29, H 6.57, N 9.71 Found : C 48.04, H 6.21, N 9.60 Example 91 IR (KBr) : 1666.2, 1631.5, 1232.3, 1045.2cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.7Hz), 1.07 (3H, d, J=5.8Hz), 1.30-5.40 (53H, m) , 6.69-8.71 (18H,m) MASS (m/z) : 1296.3 (M+Na) Elemental Analysis Calcd. for C 58 H 77 N 10 Na0 19 S • 8H 2 0 : C 49.15, H 6.61, N 9.88 Found : C 49.14, H 6.53, N 9.90 Example 92 IR (KBr) : 3330.5, 1666.2, 1631.5, 1255.4cm "1 NMR (DMSO-dg, δ) : 0.94-5.26 (68H, m) , 6.66-8.26 (11H, m) MASS (m/z) : 1319.35 (M-Na) Elemental Analysis Calcd. for C 57 H 79 N 10 N aO 2 2S2 * 4.5H 2 0 : C 48.06, H 6.23, N 9.83 Found : C 48.10, H 6.26, N 9.72 424 Example 93 IR (KBr) : 1660.4, 1631.5, 1442.5, 1249.6 cm "1 NMR (DMSO-dg, δ) : 0.88-1.45 (11H, m) , 1.60-3.40 (18H, m) , 3.75-5.30 (22H, m) , 6.72-9.00 (20H, m) MASS (m/z) : 1334.69 (M-Na) Elemental Analysis Calcd. for C5 9 H 7 ι_N 10 Naθ22 s 2 * 6H 2 0 : C 48.29, H 5.70, N 9.54 Found : C 48.40, H 5.62, N 9.44 Example 94 IR (KBr) : 1666.2, 1631.5, 1515.8, 1257.4, 1178.3cm "1 NMR (DMSO-dg, δ) : 0.94-5.25 (51H,m), 6.67-8.84 (16H,m) MASS (m/z) : 1341.55 (M-Na) Elemental Analysis Calcd. for C5 9 H 77 N-L 0 Naθ22S2 • 6H2O : C 48.09, H 6.09, N 9.51 Found : C 47.98, H 6.01, N 9.49 Example 95 IR (KBr) : 1666.2, 1629.6, 1257.4, 1178.3 cm "1 NMR (DMSO-dg, δ) : 0.94-5.16 (55H,m) , 6.41-8.84 (18H, m) MASS (m/z) : 1289.3 (M-Na) Elemental Analysis Calcd. for C 55 H 7 3N 10 aθ22S2 ' 7H 2° : C 45.89, H 6.09, N 9.73 Found : C 45.67, H 5.91, N 9.74 Example 96 IR (KBr) : 1666.2, 1633.4, 1249.6 cm "1 NMR (DMSO-dg, δ) : 0.96-5.20 (47H, m) ,6.72-9.29 (24H,m) MASS (m/z) : 1351.41 (M-Na) Elemental Analysis Calcd. for Cg 3 H 71 N 10 Naθ22S • 8.5H 2 0 : C 49.51, H 5.80, N 9.16 Found : C 49.64, H 5.49, N 9.13 Example 97 IR (KBr) : 1666.2, 1631.5, 1515.8, 1257.4, 1178.3 cm "1 NMR (DMSO-dg, δ) : 0.94-5.24 (55H, m) ,6.72-8.84 (20H, m) 425 MASS (m/z) : 1363.41 (M-Na) Elemental Analysis Calcd. for Cg 1 H 75 N 10 Naθ22 s 2 ' 7H 2° : C 48.41, H 5.93, N 9.25 Found : C 48.45, H 5.80, N 9.14 Example 98 IR (KBr) : 3355.5, 2935.1, 2873.4, 1633.4, 1521.6, 1438.6, 1255.4 cm "1 NMR (DMSO-dg, δ) : 0.85-1.05 (m, 6H) , 1.10 (d, 3H, J=5.8Hz), 1.25-1.60 ( , 4H) , 1.60-2.60 (m, 9H) , 2.80-3.10(m, IH) , 3.10-3.60 (m, 2H) , 3.60-4.60 (m, 16H), 4.60-5.60 (m, 9H) , 6.71 (d, IH, J=8.2Hz), 6.81 (d, IH, J=8.2Hz), 6.89 (s, IH) , 7.05 (s, IH) , 7.08 (d, 2H, J=8.9Hz), 7.15-7.30 (m, IH) , 7.30-7.55 (m, 2H) , 7.55-7.70 (m, IH) , 7.80 (d, 2H, J=8.3Hz), 7.91 (d, 2H, J=8.9Hz), 7.96 (d, 2H, J=8.3Hz), 8.00-8.20 (m, IH) , 8.38 (s, IH) , 8.65 (d, IH, J=6.8Hz), 8.75-9.00 (m, IH) MASS (m/z) : 1268.40 (M-Na) Elemental Analysis Calcd. for C5 H 70 N 9 NaO 2 ιS2 • 8H 0 : C 46.82, H 6.03, N 8.78 Found : C 47.11, H 5.84, N 8.82 Example 99 IR (KBr) : 3396.0, 2933.2, 2871.5, 1648.8, 1631.5, 1538.9, 1515.8, 1456.0, 1438.6, 1253.5cm "1 NMR (DMSO-dg, δ) : 0.75-0.90 (m, 3H) , 0.96(d, 3H, J=6.7Hz), 1.11 (d, 3H, J=5.8Hz), 1.10-1,60 (m, 6H) , 1.60-2.60(m, 9H) , 2.80-3.10 (m, IH) , 3.10-3.60 (m, 2H) , 3.60-4.65 (m, 16H) , 4.65-5.60 (m, 9H) , 6.73 (d, IH, J=8.2Hz), 6.82 (d, IH, J=8.2Hz), 6.89 (s, IH) , 7.05 (s, IH) , 7.07 (d, 2H, J=8.9Hz), 7.15-7.30 (m, IH) , 7.30-7.55 (m, 2H) , 7.55-7.75 (m, IH) , 7.80 (d, 2H, J=8.3Hz), 7.91 (d, 2H, J=8.9Hz), 7.96 (d, 2H, J=8.3Hz), 8.00-8.20 (m, IH) , 8.38 (s, IH) , 8.65 (d, IH, J=6.8Hz), 8.75-9.00 ( , IH) MASS (m/z) : 1282.09 (M-Na) 42 6 Elemental Analysis Calcd. for C 57 H 72 N g Na0 21 S • 7H 2 0 : C 47.79, H 6.05, N 8.80 Found : C 47.89, H 5.96, N 8.77 Example 100 IR (KBr) : 3430.7, 2931.3, 2858.0, 1668.1, 1648.0, 1631.5, 1515.8, 1456.0, 1438.6, 1255.4 cm "1 NMR (DMSO-dg, δ) : 0.75-0.90 (m, 3H) , 0.96 (d, 3H, J=6.7Hz), l.ll(d, 3H, J=5.6Hz), 1.10-1.55 (m, 8H) , 1.60-2.60 (m, 9H) , 2.80-3.10 (m, IH) , 3.10-3.60 (m, 2H) , 3.60-4.65 (m, 16H) , 4.65-5.40 (m, 9H) , 6.74 (d, IH, J=8.2Hz), 6.83 (d, IH, J=8.2Hz), 6.89 (s, IH) , 7.05 (s, IH) , 7.08 (d, 2H, J=8.8Hz), 7.20(s, IH) , 7.30-7.55 (m, 2H) , 7.60-7.75 (m, IH) , 7.80 (d, 2H, J=8.2Hz), 7.92 (d, 2H, J=8.8Hz), 7.96 (d, 2H, J=8.2Hz), 8.07 (d, IH, J=7.0Hz), 8.38 (s, IH) , 8.66 (d, IH, J=6.8Hz), 8.85 (s, IH) MASS (m/z) : 1296.16 (M-Na) Elemental Analysis Calcd. for C5 8 H 7 4N 9 Naθ2 S2 • 6H2O : C 48.77, H 6.07, N 8.82 Found : C 48.61, H 6.06, N 8.78 Example 101 IR (KBr) : 3425.0, 2969.8, 2937.1, 2881.1, 1633.4, 1517.7, 1438.6, 1247.7cm "1 NMR (DMSO-dg, δ) : 0.80-1.10 (m, 6H) , 1.10 (d, 3H, J=5.7Hz), 1.60-2.60 (m, 10H) , 2.85-3.10 (m, IH) , 3.10-3.60 (m, 2H) , 3.60-4.60 (m, 16H) , 4.65-5.50 (m, 8H) , 6.71 (d, IH, J=8.1Hz), 6.79 (d, IH, J=8.1Hz), 6.88 (s, IH) , 6.98 (s, IH) , 7.06 (d, 2H, J=8.8Hz), 7.20 (m, IH) , 7.30-8.20 (m, 12H) , 7.70 (d, 2H, J=8.8Hz), 8.48 (s, IH) , 8.60-8.85 (m, 2H) MASS (m/z) : 1300.35 (M-Na) Elemental Analysis Calcd. for CgQH 7 oN 9 Na0 2 o s 2 ' 7H 2° : C 49.68, H 5.84, N 8.69 Found : C 49.59, H 5.49, N 8.68 427 Exampl 102 IR (KBr) : 3349.7, 2937.1, 2871.5, 1633.4, 1519.6, 1438.6, 1255.4 cm "1 NMR (DMSO-dg, δ) : 0.70-1.05 (m, 6H) , 1.08 (d, 3H, J=5.9Hz), 1.20-1.55 (m, 4H) , 1.60-2.60 (m, 10H) , 2.80-3.10 (m, IH) , 3.10-3.60 (m, 2H) , 3.60-4.60 (m, 16H), 4.60-5.50 (m, 8H) , 6.70 (d, IH, J=8.1Hz), 6.77 (d, IH, J=8.1Hz), 6.86 (s, IH) , 6.96 (s, IH) , 7.07 (d, 2H, J=8.9Hz), 7.20 (m, IH) , 7.30-7.50 (m, IH) , 7.50-7.80 (m, 2H) , 7.79 (d, 2H, J=8.4Hz), 7.90 (d, 2H, J=8.9Hz), 7.96 (d, 2H, J=8.4Hz), 8.00-8.20 (m, IH) , 8.37 (s, IH) , 8.50-8.80 (m, 2H) MASS (m/z) : 1252.57 (M-Na) Elemental Analysis Calcd. for C 5 gH 70 N 9 Na0 2 oS2 ' 7H 2 0 : C 47.96, H 6.04, N 8.99 Found : C 47.78, H 5.87, N 8.87 Example 103 IR (KBr) : 3432.7, 2935.1, 2869.6, 1633.4, 1535.1, 1438.6, 1251.6 cm "1 NMR (DMSO-dg, δ) : 0.75-0.95 (m, 3H) , 0.97 (d, 3H, J=6.8Hz), 1.10 (d, 3H, J=5.9Hz), 1.20-1.55 (m, 6H) , 1.60-2.60 (m, 10H) , 2.80-3.10 (m, IH) , 3.10-3.60 (m, 2H) , 3.60-4.60 (m, 16H) , 4.65-5.50 (m, 8H) , 6.71 (d, IH, J=8.2Hz), 6.78 (d, IH, J=8.2Hz), 6.87 (s, IH) , 6.97 (s, IH) , 7.04 (d, 2H, J=8.7Hz), 7.20 (m, IH) , 7.30-7.90 (m, 3H) , 7.67 (d, 2H, J=8.7Hz), 8.01 (s, 4H), 8.05-8.20 (m, IH) , 8.26 (s, IH) , 8.60-8.90 (m, 2H) MASS (m/z) : 1266.27 (M-Na) Elemental Analysis Calcd. for C 57 H 72 N 9 Na0 2 oS2 " 6 H 2 0 : C 48.96, H 6.05, N 9.01 Found : C 49.07, H 5.97, N 8.94 Example 104 IR (KBr) : 3353.6, 2931.3, 2861.8, 1631.5, 1519.6, 1438.6, 1253.5 cm "1 428 NMR ( DMSO-dg , δ ) : 0 . 70-0 . 95 (m, 3H) , 0 . 97 ( d, 3H, J=6.8Hz), 1.10 (d, 3H, J=6.0Hz), 1.20-1.60 (m, 6H) , 1.60-2.60 (m, 10H) , 2.80-3.10 (m, IH) , 3.10-3.60 (m, 2H) , 3.60-4.65 (m, 16H) , 4.70-5.50 ( , 8H) , 6.71 (d, IH, J=8.1Hz), 6.79 (d, IH, J=8.1Hz), 6.88 (s, IH) , 6.98 (s, IH) , 7.08 (d, 2H, J=8.9Hz), 7.21 (m, IH) , 7.44 (d, IH, J=7.4Hz), 7.50-7.80 (m, 2H) , 7.80 (d, 2H, J=8.4Hz), 7.91 (d, 2H, J=8.9Hz), 7.97 (d, 2H, J=8.4Hz), 8.12 (d, IH, J=8.1Hz), 8.37 (s, IH) , 8.60-8.80 (m, IH) , 8.72 (s, IH) MASS (m/z) : 1266.27 (M-Na) Elemental Analysis Calcd. for C5 7 H 7 N 9 Na0 2 oS2 " 6H 0 : C 48.96, H 6.05, N 9.01 Found : C 48.75, H 5.98, N 8.91 Example 105 IR (KBr) : 1666.2, 1629.6, 1240.0, 1047.2 cm -1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.6Hz), 1.07 f3H, d, J=5.8Hz), 1.60-5.40 (47H,m) , 6.68-8.80 (18H,m) MASS (m/z) : 1231.3 (M+l) Elemental Analysis Calcd. for C55H 71 N 10 Na0 19 s ' 8H 2° : C 48.03, H 6.38, N 10.18 Found : C 47.84, H 6.46, N 10.12 Example 106 A solution of Starting Compound (106) (200 mg) in N, N-dimethylformamide (4 ml) was treated with 4- [5- [4- [4- [2- (2-methoxyethoxy) ethoxy] phenyl] phenyl] -1, 3, 4- thiadiazol-2-yl]benzoic acid benzotrizol-1-yl ester (144 mg) and diisopropylethylamine (58 μl) , and the mixture was stirred for 19 hours at room temperature. Ethyl acetate was added to the reaction mixture and the resulting precipitate was collected by filtration, washed thoroughly with ethyl acetate and diisopropyl ether and dried. The powder was dissolved in saturated aqueous sodium hydrogen carbonate solution, filtered and purified by ODS column chromatography (YMC-gel ODS-AM S-50) eluting with 17-18% aqueous acetonitrile. 429 Product-containing fractions were pooled, evaporated to remove acetonitrile, and lyophilized to give Object Compound (106) (225 mg) as an amorphous pale yellow powder. IR (KBr) : 1659, 1633, 1533, 1510, 1444 cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.7Hz), 1.10 (3H, d J=5.6Hz) , 1.76-2.47 (8H, m) , 2.83-3.32 (3H, m) , 3.26 (3H, s), 3.40-4.60 (22H, m) , 4.70-5.54 (8H, m) , 6.69 (IH, d, J=8.2 Hz), 6.77 (IH, d, J=8.2Hz), 6.87 (IH, brs), 6.98 (IH, s) , 7.09 (2H, d, J=8.8Hz), 7.34- 7.55 (3H, m) , 7.74 (2H, d, J=8.7Hz), 7.87 (2H, d, J=8.5Hz), 8.00-8.20 (8H, m) , 8.66-8.92 (2H, m) MASS (m/z) : 1361.4 (M-Na + ) Elemental Analysis Calcd. for Cg 1 H 73 N 10 Naθ22S2 * 10H 2 O : C 46.80, H 5.99, N 8.95 Found : C 46.93, H 5.80, N 8.89 The following compounds [Examples 107 to 1321 were obtained in a manner similar to that of Example 106. Example 107 IR (KBr) : 3367, 2925, 1668, 1631, 1538, 1511, 1450, 1265, 1230, 1085, 1047 cm -1 NMR (DMSO-dg, δ) : 0.95 (3H, d, J=6.7Hz), 1.07 (3H, d J=5.9Hz) , 1.2-1.6 (5H, m) , 1.6-2.1 (10H, m) , 2.1-2.5 (8H, ) , 2.63 (4H, m) , 2.79 (2H, ) , 2.98 (2H, m) , 3.06 (4H, m) , 3.20 (IH, m) , 3.71 (2H, m) , 3.8-4.6 (14H, ) , 4.6-5.6 (9H, m) , 6.70 (IH, d, J=8.2 Hz), 6.78 (IH, s), 6.83 (3H, d, J=8.2Hz), 6.94 (2H, d, J=8.7Hz), 7.04 (3H, m) , 7.2-7.7 (3H, m) , 7.74 (2H, d, J=8.7Hz), 8.07 (IH, m) , 8.23 (IH, m) , 8.56 (IH, m) , 8.84 (IH, s) MASS (m/z) : 1348.35 (M-Na + ) Elemental Analysis Calcd. For Cg 3 H 8 gN 11 NaO 20 S 2 • 11H 2 0 : C 48.18, H 6.93, N 9.81 Found : C 48.19, H 6.68, N 9.71 Example 108 IR (KBr) : 1676, 1651, 1622, 1514 cm "1 430 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.6Hz), 1.05-1.1 (3H, m) , 1.7-2.65 (12H, m) , 2.8-3.2 (7H, m) , 3.60 (2H, s), 2.65-4.1 (5H, m) , 4.1-4.6 (9H, m) , 4.7-5.45 (8H, m) , 6.65-7.85 (3H, m) , 7.85-7.05 (4H, m) , 7.15-7.3 (3H, m) , 7.4-7.8 (3H, m) , 7.52 (2H, d, J=8.6Hz) , 7.94 (2H, d, J=8.6Hz), 8.0-8.2 (5H, m) , 8.41 (IH, s) , 8.72 (IH, s), 8.75-8.9 (IH, m) , 9.34 (IH, s) MASS (m/z) : 1407 (M + -23) Elemental Analysis Calcd. For C H 75 N 1 4Na0 19 S 2 • 9H 2 0 : C 48.24, H 5.88, N 12.30 Found : C 48.41, H 5.68, N 12.22 Example 109 IR (KBr) : 1649, 1632, 1541, 1514 cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.6Hz), 1.10 (3H, d, J=5.7Hz), 1.1-1.35 (5H, m) , 1.35-2.5 (17H, m) , 2.85-3.55 (6H, m) , 3.55-4.1 (8H, m) , 4.1-4.6 (9H, m) , 4.7-5.45 (8H, m) , 6.71 (lH,d, J=8.3Hz), 6.78 (lH,d, J=8.3Hz), 6.85-6.9 (IH, m) , 6.9-7.0 (IH, m) , 7.08 (2H, d, J=8.9Hz), 7.1-7.25 (IH, m) , 7.35-7.75 (3H, m) , 7.84 (2H, d, J=8.9Hz), 7.9-8.2 (5H, m) , 8.6-8.85 (2H, m) MASS (m/z) : 1348 (M + -23) Example 110 IR (KBr) : 1651, 1632, 1539, 1514 cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.8Hz), 1.10 (3H, d, J=5.8Hz), 1.2-1.6 (5H, ) , 1.6-2.75 (14H, m) , 2.85-3.1 (IH, m) , 3.1-3.55 (2H, ) , 3.65-4.1 (5H, m) , 4.1-4.6 (9H, m) , 4.6-5.45 (8H, m) , 6.71 (IH, d, J=9.0Hz), 6.78 (IH, d, J=9.0Hz), 6.85-6.95 (IH, m) , 6.95-7.0 (IH, m) , 7.1-7.25 (IH, m) , 7.4-7.8 (3H, m) , 7.46 (2H, d, J=8.3Hz), 7.96 (2H, d, J=8.3Hz), 8.0-8.2 (IH, m) , 8.06 (2H, d, J=8.8Hz), 8.12 (2H, d, J=8.8Hz), 8.72 (IH, s), 8.75-8.85 (IH, m) MASS (m/z) : 1249 (M + -23) Elemental Analysis Calcd. For C 5 gH 69 N 10 NaO ιg S2 • 7H 2 0 : 431 C 46.86, H 6.11, N 9.76 Found : C 47.02, H 6.01, N 9.77 Example 11 IR (KBr) : 1649, 1632, 1541, 1522 cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.6Hz), 1.10 (3H, d, J=6.1Hz), 1.1-1.65 (6H, m) , 1.65-2.5 (12H, m) , 2.85-3.6 (3H, m) , 3.6-4.1 (5H, m) , 4.1-4.6 (10H, m) , 4.75-5.45 (8H, m) , 6.71 (IH, d, J=8.9Hz), 6.78 (IH, d, J=8.9Hz), 6.85-6.9 (IH, m) , 6.9-7.0 (IH, m) , 7.14 (2H, d, J=8.9Hz), 7.15-7.25 (IH, m) , 7.4-7.8 (3H, m) , 7.95 (2H, d, J=8.9Hz) , 8.05 (2H, d, J=8.9Hz) , 8.1-8.2 (IH, m) , 8.11 (2H, d, J=8.9Hz), 8.72 (IH, s), 8.75-8.85 (IH, m) MASS (m/z) : 1265 (M + -23) Elemental Analysis Calcd. For C 5 gHg 9 N 10 Naθ2oS2 ' 9H 2 0 : C 46.34, H 6.04, N 9.65 Found : C 46.24, H 5.95, N 9.58 Example 112 IR (KBr) : 1664, 1628 cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.5Hz), 1.05-1.2 (3H, m) , 1.5-1.75 (6H, m) , 1.75-2.5 (8H, m) , 2.8-3.5 (7H, m) , 3.6-4.1 (5H, m) , 4.1-4.6 (9H, m) , 4.7-5.5 (8H, m) , 6.65-6.85 (2H, m) , 6.87 (IH, s) , 6.97 (IH, s), 7.07 (2H, d, J=9.2Hz), 7.1-7.25 (IH, m) , 7.35-7.8 (3H, ) , 7.75 (2H, d, J=9.2Hz) , 8.0-8.2 (IH, m) , 8.06 (4H, s), 8.32 (IH, s) , 8.6-8.9 (2H, m) , 9.17 (IH, s) MASS (m/z) : 1316 (M + -23) Elemental Analysis Calcd. For C 58 H 7 oN 13 Na0 19 S2 • 10H O : C 45.82, H 5.97, N 11.98 Found : C 45.80, H 5.74, N 11.91 Example 113 IR (KBr) : 1633, 1518, 1250 cm "1 NMR (DMSO-dg, δ) : 0.8-1.05 (6H, ) , 1.12 (3H, d, J=5.4Hz) , ' 1.2-1.55 (6H, m) , 1.65-2.5 (9H, m) , 2.9-3.5 (3H, m) , 432 3.6-4.6 (16H, m) , 4.7-5.35 (9H, m) , 6.73 (IH, d, J=8.3Hz), 6.83 (IH, d, J=8.3Hz), 6.85-6.95 (IH, m) , 7.0-7.25 (2H, m) , 7.10 (2H, d, J=9.1Hz), 7.3-7.55 (2H, ) , 7.6-7.75 (IH, m) , 7.85 (2H, d, J=9.1Hz), 8.0-8.2 (5H, m) , 8.36 (IH, s) , 8.7-8.9 (IH, m) , 8.84 (IH, s), 9.24 (IH, s) MASS (m/z) : 1349(M + -23) Elemental Analysis Calcd. For C5 9 H 7 3N 1 Na0 21 s 2 ' 8H 2° : C 46.70, H 5.91, N 11.08 Found : C 46.64, H 5.88, N 10.90 Example 114 IR (KBr) : 1612, 1497, 1446 cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.7Hz), 1.11 (3H, d, J=6.1Hz), 1.6-2.5 (12H, m) , 2.6-3.1 (4H, m) , 3.1-3.5 (2H, m) , 3.6-4.6 (16H, m) , 4.6-5.45 (8H, m) , 6.71 (IH, d, J=8.9Hz), 6.78 (IH, d, J=8.9Hz), 6.87 (IH, s), 6.98 (IH, d, J=1.8Hz), 7.18 (3H, d, J=8-.9Hz), 7.2-7.35 (5H, m) , 7.4-7.8 (3H, m) , 7.97 (2H, d, J=8.9Hz), 8.0-8.2 (IH, m) , 8.09 (2H, d, J=8.4Hz), 8.20 (2H, d, J=8.4Hz), 8.72 (IH, s) , 8.75-8.9 (IH, m) MASS (m/z) : 1310 (M + -23) Elemental Analysis Calcd. For Cg 1 H 72 N 11 Na0 2 oS ' 9H 2 0 : C 48.67, H 6.06, N 10.30 Found : C 48.67, H 5.89, N 10.15 Example 115 IR (KBr) : 1672, 1628, 1605, 1531, 1444 cm -1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.5Hz), 1.10 (3H, d, J=5.9Hz) , 1.6-2.5 (12H, m) , 2.6-3.1 (4H, m) , 3.1-3.5 (2H, m) , 3.6-4.6 (16H, m) , 4.7-5.45 (8H, m) , 6.71 (IH, d, J=8.1Hz), 6.78 (IH, d, J=8.1Hz), 6.8-6.9 (IH, m) , 6.9-7.0 (IH, m) , 7.18 (3H, d, J=9.2Hz), 7.2- 7.35 (5H, ) , 7.35-7.8 (3H, m) , 7.87 (2H, d, J=9.2Hz) , 8.0-8.2 (5H, m) , 8.72 (IH, s) , 8.75-8.85 (IH, m) MASS (m/z) : 1326 (M + -23) 433 Elemental Analysis Calcd. For Cg 1 H 72 N 11 Na0 19 S 2 • 9H 2 0 : C 48.44, H 6.00, N 10.19 Found : C 48.54, H 5.91, N 10.15 Example 116 IR (KBr) : 1676, 1649, 1541, 1514, 1255 cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.7Hz), 1.10 (3H, d, J=5.6Hz) , 1.2-2.5 (18H, m) , 2.9-3.1 (IH, m) , 2.9-3.6 (2H, m) , 3.65-4.1 (5H, m) , 4.1-4.6 (10H, m) , 4.7-5.45 (8H, m) , 6.72 (IH, d, J=9.3Hz), 6.78 (IH, d, J=9.3Hz), 6.85-6.95 (IH, m) , 6.95-7.0 (IH, m) , 7.1-7.25 (IH, m) , 7.18 (2H, d, J=8.9Hz) , 7.4-7.8 (3H, m) , 8.0-8.15 (5H, m) , 8.21 (2H, d, J=8.6Hz), 8.72 (IH, s), 8.75-8.95 (IH, m) MASS (m/z) : 1249 (M + -23) Elemental Analysis Calcd. For C 5 gHg 9 N 10 NaO 21 s ' 9H 2° : C 46.86, H 6.11, N 9.76 Found : C 47.13, H 5.98, N 9.79 Example 117 IR (KBr) : 1659, 1628 cm "1 NMR (DMSO-dg, δ) : 0.95 (3H, d, J=6.8Hz), 1.09 (3H, d, J=6.0Hz) , 1.2-1.6 (5H, m) , 1.6-2.7 (14H, m) , 2.8-3.6 (3H, m) , 3.6-4.1 (5H, m) , 4.1-4.6 (9H, m) , 4.6-5.4 (8H, m) , 6.7-7.0 (4H, m) , 7.1-7.2 (IH, m) , 7.4-7.8 (3H, m) , 7.49 (2H, d, J=7.2Hz), 8.05-8.2 (5H, m) , 8.21 (2H, d, J=8.4Hz), 8.70 (IH, s) , 8.8-8.9 (IH, m) MASS (m/z) : 1233 (M + -23) Elemental Analysis Calcd. For C 5 gHg 9 N 10 Na0 2 oS • 8H 2 0 : C 48.00, H 6.11, N 9.99 Found : C 47.81, H 6.04, N 9.93 Example 118 IR (KBr) : 1664, 1635, 1605, 1531, 1510, 1444 cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.1Hz), 1.11 (3H, d, J=6.0Hz), 1.07-1.37 (5H, m) , 1.50-2.44 (14H, m) , 2.56-3.50 (11H, m) , 3.65-4.60 (14H, m) , 4.73-5.44 434 (8H, m) , 6.71 (IH, d, J=8.2Hz) , 6.79 (IH, d, J=8.2Hz) , 6.87 (IH, s), 6.97 (IH, s), 7.05 (2H, d, J=8.9Hz), 7.18 (IH, s), 7.35-7.77 (2H, m) , 7.44 (IH, d, J=9.4Hz), 7.66 (2H, d, J=8.8Hz), 7.85 (2H, d, J=8.5Hz), 7.95-8.21 (7H, m) , 8.72 (IH, s) , 8.80 (IH, d, J=7.5Hz) MASS (m/z) : 1409.4 (M-Na + ) Elemental Analysis Calcd. For CggH 81 N 1 Na0 19 S2 • 7H 0 : C 50.83, H 6.14, N 10.78 Found : C 51.17, H 6.03, N 10.42 Example 119 IR (KBr) : 1659, 1633, 1531, 1508, 1443 cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.6Hz), 1.00 (3H, t, J=7.4Hz) , 1.10 (3H, d, J==5.6Hz) , 1.66-2.56 (10H, m) , 2.91-3.36 (3H, m) , 3.65-4.60 (14H, m) , 4.00 (2H, d, J=6.4Hz), 4.72-5.52 (8H, m) , 6.70 (IH, d, J=8.1Hz), 6.77 (IH, d, J=8.1Hz), 6.87 (IH, s) , 6.98 (IH, s) , 7.07 (2H, d, J=8.9Hz), 7.34-7.82 (3H, m) , 7.73 (2H, d, J=8.8Hz), 7.86 (2H, d, J=8.5Hz), 8.04-8.22 (8H, m) , 8.74-8.92 (2H, m) MASS (m/z) : 1301.2 (M-Na) + Elemental Analysis Calcd. For C 59 Hg 9 N 10 Na0 2 oS2 " 10H 2 O : C 47.07, H 5.96, N 9.30 Found : C 46.90, H 5.72, N 9.22 Example 120 IR (KBr) : 1659, 1635, 1533, 1510, 1444 cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.1Hz), 1.11 (3H, d, J=5.8Hz) , 1.18 (6H, d, J=6.1Hz) , 1.74-2.69 (10H, m) , 2.80-3.52 (3H, m) , 3.59-4.59 (18H, m) , 4.72-5.49 (8H, m) , 6.71 (IH, d, J=8.1Hz), 6.79 (IH, dd, J=8.1 and 1.6Hz), 6.87 (IH, s) , 6.98 (IH, d, J=1.6Hz) 7.07 (2H, d, J=9.0Hz), 7.18 (IH, s) , 7.33-7.72 (3H, m) , 7.68 (2H, d, J=8.8Hz), 7.85 (2H, d, J=8.5Hz), 7.96-8.25 (7H, m) , 8.72 (IH, s) , 8.80 (IH, d, J=7.5Hz) MASS (m/z) : 1356.3 (M-Na + ) 435 Elemental Analysis Calcd. For Cg 2 H 7 N 11 Naθ2oS2 ' 9H 2° : C 48.28, H 6.01, N 9.99 Found : C 48.54, H 5.94, N 9.95 Example 121 IR (KBr) : 1659, 1635, 1606, 1529, 1518, 1444, 1419 cm "1 NMR (DMSO-dg, δ) : 0.90 (6H, s) 0.97 (3H, d, J=6.7Hz), 1.10 (3H, d, J=5.8Hz), 1.03-2.66 (21H, m) , 2.66- 3.54 (8H, m) , 3.65-4.58 (14H, m) , 4.68-5.43 (8H, m) , 6.71 (IH, d, J=8.1Hz) , 6.79 (IH, dd, J=8.1 andl.6Hz) , 6.87 (IH, s), 6.98 (IH, d, J=1.6Hz) 7.11 (2H, d, J=8.6Hz), 7.18 (IH, s) , 7.44 (IH, d, J=9.0Hz), 7.48-7.77 (2H, m) , 7.88 (2H, d, J=8.7Hz), 7.95-8.20 (5H, m) , 8.72 (IH, s) , 8.78 (IH, d, J=7.7Hz) MASS (m/z) : 1361.4 (M + -l) Elemental Analysis Calcd. For Cg2H 8 N 1 0 19 S2 • 10H 2 O : C 48.24, H 6.66, N 10.89 Found : C 48.22, H 6.38, N 10.79 Example 122 IR (KBr) : 1659, 1633, 1531, 1510, 1444 cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.7Hz), 1.11 (3H, d, J=5.8Hz), 1.10-2.68 (18H, m) , 2.90-3.55 (3H, m) , 3.66-4.62 (15H, m) , 4.72-5.52 (8H, m) , 6.71 (IH, d, J=8.1Hz), 6.79 (IH, d, J=8.1Hz), 6.87 (IH, s) , 6.98 (IH, s), 7.07 (2H, d, J=8.9Hz), 7.19 (IH, s) , 7.45 (IH, d, J=8.9Hz), 7.47-7.77 (IH, m) , 7.71 (2H, d, J=8.8Hz), 7.86 (2H, d, J=8.5Hz), 7.93-8.28 (8H, ) , 8.54-8.92 (IH, m) , 8.81 (IH, d, J=7.7Hz) MASS (m/z) : 1341.3 (M-Na + ) Elemental Analysis Calcd. For Cg 2 H 73 N 10 Naθ2oS2 ' 8H 2 0 : C 49.33, H 5.94, N 9.28 Found : C 49.40, H 5.87, N 9.23 Example 123 IR (KBr) : 1659, 1633, 1531, 1443 cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.7Hz), 1.12 (3H, d, J=6.1Hz), 1.36 (3H, t, J=6.9Hz), 1.64-2.50 (7H, m) , 436 2.65-3.46 (3H, m) , 4.13 (2H, q, J=7.0Hz), 3.67-4.58 (14H, m) , 4.70- 5.34 (9H, m) , 6.74 (IH, d, J=8.2Hz), 6.83 (IH, d, J=8.2Hz), 6.90 (IH, s) , 6.97-7.13 (3H, m) , 7.19 (IH, s), 7.33 (IH, s), 7.44 (2H, m) , 7.70 (IH, brs), 7.73 (2H, d, J=8.8Hz), 7.87 (2H, d, J=8.5Hz), 8.00-8.22 (6H, m) , 8.80 (IH, d, J=6.9Hz), 8.84 (IH, s) MASS (m/z) : 1303.3 (M-Na + ) Elemental Analysis Calcd. For C 58 Hg 7 N 10 NaO 21 s 2 ' 10H 2° : C 46.21, H 5.82, N 9.29 Found : C 46.47, H 5.65, N 9.29 Example 124 IR (KBr) : 1633, 1608, 1531, 1444, 1419 cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.7Hz), 1.12 (3H, d, J=5.5Hz), 1.05-1.36 (5H, m) , 1.47-2.50 (13H, m) , 2.58-3.46 (11H, m) , 3.64-4.60 (14H, m) , 4.70-5.34 (9H, m) , 6.74 (IH, d, J=8.2Hz) , 6.83 (IH, d, J=-8.2Hz) , 6.89 (IH, s), 7.08 (2H, d, J=8.7Hz), 7.01-7.25 (2H, m) , 7.35-7.74 (3H, m) , 7.86 (2H, d, J=8.8Hz), 7.98-8.26 (5H, m) , 8.53-8.86 (IH, m) , 8.85 (IH, s) MASS (m/z) : 1349.05 (M-Na + ) Elemental Analysis Calcd. For CgoH 77 N 1 Na0 2 oS2 ' 6H 2° : C 48.64, H 6.05, N 11.34 Found : C 48.38, H 6.09, N 11.15 Example 125 IR (KBr) : 1658, 1633, 1606, 1531, 1444, 1419 cm "1 NMR (DMSO-dg, δ) : 0.90 (3H, d, J=6.7Hz), 0.97 (3H, d, J=6.6Hz) , 1.10 (3H, d, J=5.9Hz) , 1.31-2.51 (18H, m) , 2.51-2.70 (4H, m) , 2.88-3.46 (7H, m) , 3.55-4.59 (14H, m) , 4.69-5.56 (8H, m) , 6.70 (IH, d, J=8.1Hz), 6.77 (IH, d, J=8.1Hz), 6.86 (IH, s) , 6.97 (IH, s) 7.08 (2H, d, J=8.7Hz), 7.09-7.78 (3H, m) , 7.86 (2H, d, J=8.7Hz) , 7.96-8.18 (6H, m) , 8.63-8.92 (IH, s) , 8.78 (IH, d, J=6.9Hz) MASS (m/z) : 1347.3 (M-Na + ) 437 Elemental Analysis Calcd. For C 1 H 79 N 12 a0 19 S2 • 11H 2 0 : C 46.68, H 6.49, N 10.71 Found : C 46.67, H 6.19, N 10.64 Example 126 IR (KBr) : 1658, 1633, 1606, 1531, 1518, 1444, 1417 cm "1 NMR (DMSO-dg, δ) : 0.86 (3H, d, J=6.4Hz), 0.87-1.44 (2H, m) , 0.97 (3H, d, J=6.7Hz), 1.10 (3H, d, J=5.9Hz), 1.60-2.55 (16H, m) , 2.55-2.73 (4H, m) , 2.96-3.54 (7H, m) , 3.65-4.60 (14H, m) , 4.70-5.28 (8H, m) , 6.71 (IH, d, J=8.3Hz), 6.79 (IH, dd, J=8.3 and 1.7Hz), 6.87 (IH, s), 6.98 (IH, d, J=1.7Hz), 7.07 (2H, d, J=9.0Hz), 7.18 (IH, s), 7.44 (IH, d, J=8.4Hz), 7.50-7.78 (2H, m) , 7.85 (2H, d, J=8.9Hz), 7.95-8.24 (5H, m) , 8.72 (IH, s), 8.79 (IH, d, J=7.1Hz) MASS (m/z) : 1347.3 (M-Na + ) Elemental Analysis Calcd. For C 61 H 79 N 12 Na0 19 S 2 • 11H 2 0 : C 46.68, H 6.49, N 10.71 Found : C 46.77, H 6.20, N 10.65 Example 127 IR (KBr) : 1633, 1533, 1516, 1443, cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.7Hz), 1.10 (3H, d, J=5.6Hz), 1.18 (3H, t, J=7.0Hz), 1.73-2.52 (8H, m) , 2.86-3.38 (3H, m) , 3.52 (2H, q, J=7.0Hz), 3.63-4.60 (16H, m) , 4.53 (2H, s) , 4.71-5.53 (6H, m) , 6.68 (IH, d, J=8.0Hz), 6.76 (IH, d, J=7.8Hz), 6.87 (IH, s) , 6.98 (lH,s), 7.28-7.83 (3H, ) , 7.47 (2H, d, J=8.5Hz), 7.77 (2H, d, J=8.2Hz), 7.92 (2H, d, J=8.5Hz), 8.00-8.25 (8H, m) , 8.70-8.85 (2H, m) MASS (m/z) : 1301.3 (M-Na + ) Elemental Analysis Calcd. For C5 9 Hg g N 10 NaO 20 S 2 ■ 9H 2 0 : C 47.64, H 5.89, N 9.42 Found : C 47.92, H 5.84, N 9.39 Example 128 IR (KBr) : 1659, 1633, 1533, 1514, 1443, cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.7Hz), 1.10 (3H, d. 438 J=5.9Hz) , 1.75-2.53 (8H, m) , 2.81-3.36 (3H, m) , 3.28 (3H, s), 3.47-4.64 (20H, m) , 4.56 (2H, s) , 4.74- 5.60 (6H, m) , 6.69 (IH, d, J=8.3Hz), 6.77 (IH, d, J=8.3Hz), 6.87 (IH, s) , 6.98 (lH,s), 7.26-7.84 (3H, m) , 7.47 (2H, d, J=8.4Hz), 7.78 (2H, d, J=8.3Hz), 7.92 (2H, d, J=8.5Hz), 8.03-8.28 (8H, m) , 8.74-8.90 (2H, m) MASS (m/z) : 1331.3 (M-Na + ) Elemental Analysis Calcd. For CgoH 71 N 10 Naθ2iS 2 • 9H 2 0 : C 47.49, H 5.91, N 9.23 Found : C 47.36, H 5.81, N 9.16 Example 129 IR (KBr) : 1668, 1651, 1632, 1539, 1512 cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.7Hz), 1.10-1.12 (3H, m) 1.12 (3H, t, J=7.0Hz), 1.70-2.50 (10H, m) , 2.80-3.30 (3H, m) , 3.41 (2H, q, J=7.0Hz), 3.53 (2H, t, J=6.4Hz), 3.66-4.60 (14H, m) , 4.10 (2H, t, J=6.4Hz), 4.70-5.52 (8H, m) , 6.71 (IH, d, J=8.1Hz), 6.79 (IH, dd, J=8.1 and 1.6Hz), 6.87 (IH, s) , 6.98 (IH, d, J=1.6Hz), 7.08 (2H, d, J=8.8Hz), 7.18 (IH, s), 7.32-7.68 (3H, m) , 7.73 (2H, d, J=8.8Hz), 7.87 (2H, d, J=8.5Hz), 8.04-8.24 (7H, ) , 8.56-8.91 (IH, m) , 8.81 (IH, d, J=7.0Hz) MASS (m/z) : 1345.3 (M-Na + ) Elemental Analysis Calcd. For C 1 H 73 N 10 Naθ2iS 2 • 10H 2 O : C 47.28, H 6.05, N 9.04 Found : C 47.44, H 5.91, N 9.02 Example 130 IR (KBr) : 1649, 1537, 1512 1443 cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.6Hz), 1.10 (3H, d, J=5.7Hz), 1.74-2.22 (10H, m) , 2.80-3.30 (3H, ) , 3.27 (3H, s), 3.50 (2H, t, J=6.3Hz), 3.65-4.60 (14H, m) , 4.09 (2H, t, J=6.4Hz), 4.60-5.58 (8H, m) , 6.70 (IH, d, J=8.1Hz), 6.77 (IH, d, J=8.1Hz), 6.87 (IH, s), 6.99 (IH, s) , 7.07 (2H, d, J=8.9Hz), 7.10-7.72 439 (3H, m) , 7.73 (2H, d, J=8.8Hz) , 7.87 (2H, d, J=8.5Hz) , 8.00-8.35 (8H, m) , 8.64-8.96 (2H, m) MASS (m/z) : 1331.3 (M-Na + ) Elemental Analysis Calcd. For Cg 0 H 71 N 10 NaO 21 S 2 • 9H 0 : C 47.49, H 5.91, N 9.23 Found : C 47.39, H 5.75, N 9.16 Example 131 IR (KBr) : 3349.7, 1633.4, 1537.0, 1515.8, 1442.5, 1419.4 cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.8Hz), 1.10 (3H, d, J=5.3Hz), 1.7-2.5 (12H, m) , 2.94 (3H, s) , 2.94-4.6 (21H, m) , 4.7-5.4 (8H, m) , 6.71 (IH, d, J=8Hz) , 6.79 (IH, dd, J=8.4 and 1.7Hz) , 6.88 (IH, brs), 6.97 (IH, brs), 7.15 (2H, d, J=9Hz) , 7.17 (IH, brs), 7.45 (4H, s) , 7.4-7.8 (3H, m) , 7.87 (2H, d, J=8.8Hz), 8.02 (4H, s) , 8.02-8.07 (IH, m) , 8.72 (IH, s) , 8.78 (IH, d, J=7.6Hz) MASS (m/z) : 1390.23 (M-Na) Elemental Analysis Calcd. For Cg 2 H 73 ClN 11 θ2oS2Na- 7H 2 0 : C 48.32, H 5.69, N 10.00 Found : C 48.15, H 5.51, N 9.93 Example 132 IR (KBr) : 1633.4, 1535.1, 1523.5, 1442.5, 1419.4, 1276.6, 1243.9 cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.8Hz), 1.12 (3H, d, J=6Hz) , 1.7-2.5 (10H, m) , 2.94 (3H, s) , 2.9-5.4 (31H, m) , 6.73 (IH, d, J=8.3Hz) , 6.81-6.85 (IH, m) , 6.89 (IH, brs), 7.05 (IH, brs), 7.15 (2H, d, J=8.7Hz), 7.17 (IH, brs), 7.45 (4H, s), 7.3-7.7 (3H, ) , 7.87 (2H, d, J=8.7Hz), 8.06 (4H, s), 8.0-8.15 (IH, m) , 8.7-9.0 (2H, m) MASS (m/z) : 1405.8 (M-Na + ) Elemental Analysis Calcd. For C 62 H 73 ClN 11 θ2 1 S2Na- 6H 2 0 : C 48.39, H 5.57, N 10.01 Found : C 48.39, H 5.52, N 9.90 440 Example 133 To a solution of 4- [2- [4- (4-piperidin-l-yl- butyloxy) phenyl] imidazo [2, 1-b] [1,3,4] thiadiazol-6- yl]benzoic acid (147 mg) , l-ethyl-3- (3' - dimethylaminopropyl) carbodiimide hydrochloride (WSCD-HCl) (74 mg) and 1-hydroxybenzotriazole (66 mg) in N,N- dimethylformamide (4 ml) was added diisopropylethylamine (0.5 ml) . After stirring for 24 hours at ambient temperature, the Starting Compound (133) (200 mg) was added to the solution and the mixture was stirred for 8 hours at ambient temperature. The reaction mixture was pulverized with ethyl acetate. The precipitate was collected by filtration, and dried under reduced pressure. The powder was dissolved in water, and subjected to column chromatography on ion exchange resin (DOWEX-50WX4 (Trademark : prepared by Dow Chemical)) eluting with water. The fractions containing the object compound were combined, and subjected to column chromatography on-ODS (YMC-gel -ODS-AM* S-50 (Trademark : prepared by Yamamura Chemical Lab. ) ) eluting with 20% acetonitrile aqueous solution. The fractions containing the object compound were combined, and evaporated under reduced pressure to remove acetonitrile. The residue was lyophilized to give Object Compound (133) (30 mg) . IR (KBr) : 3326, 2933, 1666, 1631, 1523, 1463, 1367, 1257 cm "1 NMR (DMSO-dg, δ) : 0.95 (3H, d, J=6.7Hz), 1.11 (3H, d, J=5.7Hz) , 1.3-1.6 (8H, m) , 1.6-2.15 (5H, m) , 2.2-2.5 (10H, m) , 2.97 (2H, m) , 3.20 (IH, m) , 3.74 (2H, m) , 3.8-4.6 (14H, m) , 4.6-5.4 (9H, m) , 6.74 (IH, d, J=8.2Hz), 6.83 (IH, d, J=8.2Hz) , 6.88 (IH, s) , 7.04 (IH, s) , 7.14 (2H, d, J=8.8Hz) , 7.23 (IH, m) , 7.3-7.5 (2H, m) , 7.66 (IH, m) , 7.88 (2H, d, J=8.8Hz), 7.95 (4H, s) , 8.07 (IH, d, J=7.8Hz) , 8.58 (IH, d, J=7.8Hz) , 8.85 (IH, s), 8.95 (IH, s) MASS (m/z) : 1377.25 (M-Na + ) 441 The following compounds [Examples 134 to 1591 were obtained in a manner similar to that of Example 133. Exampl 134 IR (KBr) : 3353, 2940, 1666, 1631, 1523, 1465, 1257 cm -1 NMR (DMSO-dg, δ) : 0.95 (3H, d, J=6.7Hz), 1.11 (3H, d, J=5.7Hz), 1.3-1.6 (10H, m) , 1.6-2.15 (5H, m) , 2.2-2.5 (10H, m) , 2.97 (2H, m) , 3.20 (IH, m) 3.74 (2H, m) , 3.8-4.6 (14H, m) , 4.6-5.4 (9H, m) , 6.74 (IH, d, J=8.2Hz), 6.83 (IH, d, J=8.2Hz), 6.89 (IH, s) , 7.05 (IH, s), 7.14 (2H, d, J=8.8Hz), 7.23 (IH, m) , 7.3-7.5 (2H, m) , 7.67 (IH, m) , 7.90 (2H, d, J=8.8Hz) , 7.96 (4H, s), 8.07 (IH, d, J=7.8Hz), 8.57 (IH, d, J=7.8Hz), 8.85 (IH, s), 8.95 (IH, s) MASS (m/z) : 1391.13 (M-Na + ) Example 135 IR (KBr) : 3349, 2939, 1666, 1633, 1523, 1440, 1257 cm "1 NMR (DMSO-dg, δ) : 0.95 (3H, d, J=6.7Hz), 1.11 (3H, d, J=5.7Hz), 1.3-1.6 (12H, m) , 1.6-2.15 (5H, m) , 2.2-2.5 (10H, m) , 2.97 (2H, m) , 3.20 (IH, m) 3.74 (2H, m) , 3.8-4.6 (14H, m) , 4.6-5.4 (9H, m) , 6.74 (IH, d, J=8.2Hz), 6.83 (IH, d, J=8.2Hz), 6.89 (IH, s) , 7.05 (IH, s), 7.14 (2H, d, J=8.8Hz), 7.23 (IH, m) , 7.3-7.5 (2H, m) , 7.67 (IH, m) , 7.90 (2H, d, J-8.8Hz), 7.96 (4H, s), 8.07 (IH, d, J=7.8Hz), 8.60 (IH, d, J=7.8Hz), 8.85 (IH, s) , 8.95 (IH, s) MASS (m/z) : 1405.31 (M-Na + ) Elemental Analysis Calcd. For Cg 3 H 81 N 12 Naθ2χS2 • 8H 2 0 : C 48.09, H 6.21, N 10.68 Found : C 48.04, H 6.15, N 10.49 Example 136 IR (KBr) : 3351, 2939, 1658, 1633, 1527, 1465, 1444, 1257 cm "1 NMR (DMSO-dg, δ) : 0.95 (3H, d, J=6.7Hz), 1.11 (3H, d, J=5.7Hz) , 1.3-1.6 (4H, m) , 1.6-2.15 (5H, m) , 2.2-2.5 (10H, m) , 2.97 (2H, m) , 3.20 (IH, m) 3.56 (4H, t. 442 J=4.6Hz), 3.71 (2H, m) , 3.8-4.6 (14H, m) , 4.6-5.4 (9H, m) , 6.74 (IH, d, J=8.2Hz) , 6.85 (IH, d, J=8.2Hz) , 6.93 (IH, s), 7.04 (IH, s) , 7.14 (2H, d, J=8.8Hz), 7.23 (IH, m) , 7.3-7.5 (2H, m) , 7.67 (IH, m) , 7.90 (2H, d, J=8.8Hz), 7.96 (4H, s) , 8.07 (IH, d, J=7.8Hz), 8.57 (IH, d, J=7.8Hz), 8.85 (IH, s) , 8.95 (IH, s) MASS (m/z) : 1392.65 (M-Na + ) Elemental Analysis Calcd. For Cg 1 H 77 N 12 Na0 2 2S3 • 10H 2 O : C 45.86, H 6.12, N 10.52 Found : C 45.75, H 5.83, N 10.46 Example 137 IR (KBr) : 3347, 2935, 1666, 1631, 1523, 1463, 1255, 1078, 1047 cm "1 NMR (DMSO-dg, δ) : 0.95 (3H, d, J=6.7Hz), 1.03 (6H, d, J=6.3Hz), 1.11 (3H, d, J=5.7Hz), 1.3-1.6 (6H, m) , 1.6-2.15 (5H, m) , 2.2-2.5 (6H, m) , 2.71 (2H, d, J=10.2Hz), 2.97 (2H, m) , 3.20 (IH, m) 3.56 (2H, m) 3.71 (2H, m) , 3.8-4.6 (14H, m) , 4.6-5.4 (9H, m) , 6.74 (IH, d, J=8.2Hz), 6.85 (IH, d, J=8.2Hz), 6.93 (IH, s), 7.04 (IH, s), 7.14 (2H, d, J=8.8Hz), 7.23 (IH, m) , 7.3-7.5 (2H, m) , 7.67 (IH, m) , 7.90 (2H, d, J=8.8Hz), 7.96 (4H, s) , 8.07 (IH, d, J=7.8Hz), 8.57 (IH, d, J=7.8Hz), 8.85 (IH, s) , 8.95 (IH, s) MASS (m/z) : 1420.94 (M-Na + ) Elemental Analysis Calcd. For C 3 H 81 N 12 Na0 2 2S2 ' 8H 2 0 : C 47.60, H 6.15, N 10.57 Found : C 47.84, H 6.06, N 10.50 Example 138 IR (KBr) : 3347, 2937, 1666, 1631, 1521, 1465, 1257, 1074, 1047 cm "1 NMR (DMSO-dg, δ) : 0.95 (3H, d, J=6.7Hz), 1.03 (6H, d, J=6.3Hz), 1.08 (3H, d, J=5.7Hz), 1.3-1.6 (6H, m) , 1.6-2.15 (5H, m) , 2.2-2.5 (6H, m) , 2.45 (2H, m) , 2.71 (2H, d, J=10.2Hz), 2.97 (2H, m) , 3.20 (IH, m) 3.56 (2H, m) 3.71 (2H, m) , 3.8-4.6 (13H, m) , 4.6-5.4 (8H, 443 m) , 6.68 (IH, d, J=8.2Hz), 6.76 (IH, d, J=8.2Hz), 6.86 (IH, s), 6.97 (IH, s) , 7.14 (2H, d, J=8.9Hz), 7.23 (IH, m) , 7.3-7.5 (2H, m) , 7.67 (IH, m) , 7.90 (2H, m) , 7.96 (4H, s) , 8.07 (IH, m) , 8.60 (IH, m) , 8.85 (IH, s), 8.95 (IH, s) MASS (m/z) : 1405.74 (M-Na + ) Elemental Analysis Calcd. For Cg 3 H 81 N 12 Naθ2iS2 • 9H 2 0 : C 47.54, H 6.27, N 10.56 Found : C 47.68, H 6.21, N 10.50 Example 139 MASS (m/z) : 1435.29 (M-Na + ) Example 140 IR (KBr) : 3328, 2939, 1664, 1633, 1525, 1465, 1442, 1257, 1047 cm "1 NMR (DMSO-dg, δ) : 0.95 (3H, d, J=6.7Hz), 1.10 (3H, d, J=5.7Hz) , 1.3-1.6 (6H, m) , 1.6-2.15 (5H, m) , 2.2-2.5 (6H, m) , 2.5-2.7 (2H, m) , 2.59 (4H, s) , 2.97 (2H, m) , 3.20 (IH, m) 3.73 (2H, m) , 3.8-4.6 (14H, m) , 4.6-5.4 (9H, m) , 6.69 (IH, d, J=8.2Hz), 6.80 (IH, d, J=8.2Hz), 6.88 (IH, s) , 7.05 (IH, s) , 7.14 (2H, d, J=8.8Hz) , 7.23 (IH, m) , 7.3-7.5 (2H, m) , 7.67 (IH, m) , 7.90 (2H, d, J=8.8Hz), 7.96 (4H, s) , 8.07 (lH,d, J=7.8Hz), 8.57 (IH, d, J=7.8Hz), 8.85 (IH, s), 8.95 (IH, s) MASS (m/z) : 1408.94 (M-Na + ) Elemental Analysis Calcd. For Cg 1 H 77 N 12 Na0 21 s 3 * 10H 2° : C 45.40, H 6.06, N 10.42 Found : C 45.49, H 5.59, N 10.26 Example 141 IR (KBr) : 3340, 2939, 1631, 1523, 1465, 1442, 1257, 1047 cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.7Hz), 1.10 (3H, d, J=5.7Hz) , 1.3-1.6 (4H, m) , 1.6-2.15 (5H, m) , 2.2-2.5 (4H, ) , 2.97 (2H, m) , 3.20 (IH, m) 3.23 (3H, s) , 3.34 (2H, t J=6.2Hz), 3.73 (2H, m) , 3.8-4.6 (14H, 444 ) , 4.6-5.4 (9H, m) , 6.69 (IH, d, J=8.2Hz) , 6.76 (IH, d, J=8.2Hz), 6.88 (IH, s) , 7.04 (IH, s), 7.14 (2H, d, J=8.8Hz) , 7.23 (IH, m) , 7.3-7.5 (2H, ) , 7.67 (IH, m) , 7.90 (2H, d, J=8.8Hz), 7.95 (4H, s) , 8.07 (lH,m), 8.57 (IH, m) , 8.85 (IH, s) , 8.95 (IH, s) MASS (m/z) : 1338.33 (M-Na + ) Elemental Analysis Calcd. For C 58 H 7 N 11 Na0 2 S 2 • 10H 2 O : C 45.16, H 6.01, N 9.99 Found : C 45.39, H 5.80, N 10.02 Example 142 IR (KBr) : 3340, 2935, 1648, 1631, 1537, 1515, 1456, 1257, 1047 cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.7Hz), 1.10 (3H, d, J=5.7Hz) , 1.3-1.6 (4H, m) , 1.6-2.15 (5H, m) , 2.2-2.5 (6H, m) , 2.97 (2H, m) , 3.20 (IH, m) 3.23 (3H, s) , 3.34 (2H, t J=6.2Hz), 3.74 (2H, m) , 3.8-4.6 (13H, m) , 4.6-5.4 (8H, m) , 6.68 (IH, d, J=8.2Hz) , 6.J 6 (IH, d, J=8.2Hz), 6.86 (IH, s) , 6.97 (IH, s) , 7.14 (2H, d, J=8.9Hz) , 7.23 (IH, m) , 7.3-7.5 (2H, m) , 7.67 (IH, m) , 7.90 (2H, m) , 7.96 (4H, s) , 8.07 (lH,m), 8.60 (IH, m) , 8.85 (IH, s) , 8.95 (IH, s) MASS (m/z) : 1322.3 (M-Na + ) Elemental Analysis Calcd. For C5 8 H 72 N 11 Naθ2χS 2 • 9H 2 0 : C 46.18, H 6.01, N 10.21 Found : C 45.96, H 5.86, N 10.12 Example 143 IR (KBr) : 3349, 2937, 1666, 1631, 1523, 1465, 1257, 1047 cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.7Hz), 1.10 (3H, d, J=5.7Hz) , 1.3-1.6 (6H, m) , 1.6-2.15 (5H, m) , 2.2-2.5 (4H, m) , 2.97 (2H, m) , 3.20 (IH, m) 3.23 (3H, s) , 3.34 (2H, t J=6.2Hz), 3.73 (2H, m) , 3.8-4.6 (14H, m) , 4.6-5.4 (9H, m) , 6.69 (IH, d, J=8.2Hz), 6.76 (IH, d, J=8.2Hz), 6.88 (IH, s) , 7.04 (IH, s) , 7.14 (2H, d, J=8.8Hz) , 7.23 (IH, m) , 7.3-7.5 (2H, m) , 7.67 (IH, 445 m) , 7.90 (2H, d, J=8.8Hz), 7.95 (4H, s) , 8.07 (lH,m) , 8.57 (IH, m) , 8.85 (IH, s) , 8.95 (IH, s) MASS (m/z) : 1352.48 (M-Na + ) Elemental Analysis Calcd. For C 59 H 7 N 11 Na0 2 S • 12H 0 : C 44.50, H 6.20, N 9.67 Found : C 44.74, H 5.71, N 9.70 Example 144 IR (KBr) : 3330, 2931, 1666, 1631, 1523, 1465, 1257, 1047 cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.7Hz), 1.10 (3H, d, J=5.7Hz) , 1.3-1.6 (8H, m) , 1.6-2.15 (5H, m) , 2.2-2.5 (4H, m) , 2.97 (2H, m) , 3.20 (IH, m) 3.23 (3H, s) , 3.34 (2H, t J=6.2Hz), 3.73 (2H, m) , 3.8-4.6 (14H, m) , 4.6-5.4 (9H, m) , 6.69 (IH, d, J=8.2Hz) , 6.76 (IH, d, J=8.2Hz), 6.88 (IH, s) , 7.04 (IH, s) , 7.14 (2H, d, J=8.8Hz) , 7.23 (IH, m) , 7.3-7.5 (2H, m) , 7.67 (IH, m) , 7.90 (2H, d, J=8.8Hz), 7.95 (4H, s) , 8.07 (lH,m), 8.57 (IH, ) , 8.85 (IH, s) , 8.95 (IH, s) MASS (m/z) : 1366.46 (M-Na + ) Elemental Analysis Calcd. For Cg 0 H- 7 gN 11 NaO 22 S 2 • 13H 2 0 : C 44.36, H 6.33, N 9.48 Found : C 44.40, H 5.88, N 9.30 Example 145 IR (KBr) : 3324, 2933, 1666, 1631, 1523, 1465, 1257, 1047 cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.7Hz), 1.10 (3H, d, J=5.7Hz), 1.3-1.6 (10H, m) , 1.6-2.15 (5H, m) , 2.2-2.5 (4H, m) , 2.97 (2H, ) , 3.20 (IH, m) 3.23 (3H, s) , 3.34 (2H, t J=6.2Hz) , 3.73 (2H, m) , 3.8-4.6 (14H, m) , 4.6-5.4 (9H, m) , 6.69 (IH, d, J=8.2Hz) , 6.76 (IH, d, J=8.2Hz), 6.88 (IH, s) , 7.04 (IH, s) , 7.14 (2H, d, J=8.8Hz) , 7.23 (IH, m) , 7.3-7.5 (2H, m) , 7.67 (IH, m) , 7.90 (2H, d, J=8.8Hz), 7.95 (4H, s) , 8.07 (lH,m) , 8.57 (IH, m) , 8.85 (IH, s) , 8.95 (IH, s) 446 MASS (m/z) : 1380.30 (M-Na + ) Elemental Analysis Calcd. For Cg 1 H 78 N 11 Na0 2 2S2 ' 10H 2 O : C 46.24, H 6.23, N 9.72 Found : C 46.29, H 6.02, N 9.71 Example 146 IR (KBr) : 3351, 3330, 2935, 1664, 1633, 1606, 1529, 1465, 1446, 1267, 1238 cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.4Hz), 1.10 (3H, d, J=5.4Hz) , 1.60 (6H, s) , 1.7-2.1 (3H, m) , 2.1-2.6 (4H, m) , 2.98 (2H, m) , 3.20 (IH, m) 3.4 (4H, m) , 3.73 (2H, m) , 3.8-4.6 (12H, m) , 4.6-5.6 (9H, ) , 6.70 (IH, d, J=8.2Hz), 6.81 (IH, d, J=8.2Hz), 6.89 (IH, s) , 7.05 (IH, s) , 7.06 (2H, d, J=8.9Hz) , 7.2-7.7 (4H, m) , 7.74 (2H, d, J=8.9Hz), 7.94 (4H, s) , 8.07 (lH,m), 8.56 (IH, m) , 8.79 (IH, s) , 8.95 (IH, s) MASS (m/z) : 1304.84 (M-Na + ) Elemental Analysis Calcd. For C5 7 H 9 N 12 NaO 20 s 2 ' 7H 2° : C 47.04, H 5.75, N 11.55 Found : C 47.32, H 5.75, N 11.67 Example 147 IR (KBr) : 3351, 3330, 2933, 1668, 1631, 1515, 1454, 1268, 1236 cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.4Hz), 1.11 (3H, d, J=5.4Hz) , 1.6-2.1 (3H, m) , 2.1-2.6 (4H, m) , 2.98 (2H, m) , 3.20 (IH, ) 3.4 (4H, m) , 3.76 (6H, m) , 3.8- 4.6 (12H, m) , 4.6-5.6 (9H, m) , 6.70 (IH, d, J=8.2Hz) , 6.81 (IH, d, J=8.2Hz), 6.89 (IH, s) , 7.05 (IH, s) , 7.06 (2H, d, J=8.9Hz), 7.2-7.7 (4H, m) , 7.74 (2H, d, J=8.9Hz), 7.94 (4H, s) , 8.07 (lH,m), 8.56 (IH, m) , 8.79 (IH, s) , 8.95 (IH, s) MASS (m/z) : 1306.85 (M-Na + ) Example 148 IR (KBr) : 3355, 2975, 2935, 1666, 1631, 1610, 1523, 1465, 1241 cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.7Hz), 1.10 (3H, d. 447 J=5.7Hz), 1.18 (6H, d, J=6.2Hz), 1.6-2.1 (3H, m) , 2.1-2.6 (6H, ) , 2.98 (2H, m) , 3.20 (IH, m) 3.4 (2H, m) , 3.73 (4H, m) , 3.8-4.6 (12H, m) , 4.6-5.6 (9H, m) , 6.70 (IH, d, J=8.2Hz), 6.81 (IH, d, J=8.2Hz), 6.89 (IH, s), 7.04 (IH, s) , 7.11 (2H, d, J=8.9Hz), 7.2-7.7 (4H, m) , 7.78 (2H, d, J=8.9Hz), 7.95 (4H, s) , 8.07 (lH,m), 8.54 (IH, m) , 8.80 (IH, s) , 8.95 (IH, s) MASS (m/z) : 1334.95 (M-Na + ) Elemental Analysis Calcd. For C 5 gH 71 N 12 Na0 21 S 2 • 10H 2 O : C 45.25, H 5.96, N 10.92 Found : C 45.25, H 5.76, N 10.94 Example 149 IR (KBr) : 3355, 2971, 2933, 1668, 1648, 1631, 1610, 1535, 1515, 1463, 1241 cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.7Hz), 1.10 (3H, d, J=5.7Hz), 1.18 (6H, d, J=6.2Hz), 1.6-2.1 (3H, m) , 2.1-2.6 (8H, m) , 2.98 (2H, m) , 3.20 (IH, m) 3.4 (2H, m) , 3.73 (4H, m) , 3.8-4.6 (11H, m) , 4.6-5.6 (8H, m) , 6.70 (IH, d, J=8.2Hz), 6.81 (IH, d, J=8.2Hz), 6.89 (IH, s), 6.96 (IH, s) , 7.12 (2H, d, J=8.9Hz), 7.2-7.7 (4H, m) , 7.78 (2H, d, J=8.9Hz), 7.95 (4H, s) , 8.12 (lH, ), 8.56 (IH, m) , 8.80 (IH, s) , 8.95 (IH, s) MASS (m/z) : 1319.3 (M-Na + ) Elemental Analysis Calcd. For C 58 H 71 N 12 NaO 20 S • 9H 2 0 : C 46.27, H 5.96, N 11.16 Found : C 46.03, H 5.85, N 11.02 Example 150 IR (KBr) : 3353, 2927, 1666, 1631, 1608, 1535, 1465, 1432, 1265, 1193, 1047 cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.7Hz), 1.10 (3H, d, J=5.7Hz) , 1.6-2.1 (3H, m) , 2.1-2.6 (4H, m) , 2.66 (4H, m) , 2.98 (2H, m) , 3.20 (IH, m) , 3.73 (2H, m) , 3.79 (4H, m) , 3.8-4.6 (12H, m) , 4.6-5.6 (9H, m) , 6.72 (IH, d, J=8.2Hz), 6.81 (IH, d, J=8.2Hz), 6.88 (IH, s) , 7.04 (IH, s), 7.11 (2H, d, J=8.9Hz), 7.2-7.7 (4H, 448 m) , 7.77 (2H, d, J=8.9Hz), 7.94 (4H, s) , 8.07 (lH,m), 8.54 (IH, m) , 8.80 (IH, s) , 8.95 (IH, s) MASS (m/z) : 1322.96 (M-Na + ) Example 151 IR (KBr) : 3353, 1666, 1629, 1523, 1454, 1378, 1268, 1238 cm "1 NMR (DMSO-dg, δ) : 0.9-1.4 (9H, m) , 1.4-2.1 (3H, ) , 2.1-2.6 (10H, m) , 2.98 (2H, m) , 3.20 (IH, m) , 3.4 (4H, m) , 3.74 (2H, m) , 3.8-4.6 (12H, m) , 4.6-5.6 (9H, m) , 6.72 (IH, d, J=8.2Hz), 6.81 (IH, d, J=8.2Hz), 6.88 (IH, s), 7.05 (IH, s) , 7.09 (2H, d, J=8.9Hz), 7.2-7.7 (4H, m) , 7.78 (2H, d, J=8.9Hz), 7.94 (4H, s), 8.07 (IH, m) , 8.54 (IH, m) , 8.80 (IH, s), 8.95 (IH, s) MASS (m/z) : 1334.63 (M-Na + ) Example 152 IR (KBr) : 3353, 2927, 1675, 1650, 1538, 1513, 1456-, 1396, 1340, 1238, 1047 cm "1 NMR (DMSO-dg, δ) : 0.95 (3H, d, J=6.7Hz), 1.0-1.4 (8H, m) , 1.58 (IH, m) , 1.78 (4H, ) , 1.8-2.1 (3H, m) , 2.1-2.6 (5H, m) , 2.63 (4H, m) , 2.98 (2H, m) , 3.20 (IH, m) , 3.4 (4H, m) , 3.74 (2H, m) , 3.8-4.6 (12H, m) , 4.6-5.6 (9H, m) , 6.72 (IH, d, J=8.2Hz) , 6.81 (IH, d, J=8.2Hz), 6.88 (IH, s) , 7.04 (IH, s) , 7.08 (2H, d, J=8.9Hz), 7.2-7.7 (4H, m) , 7.77 (2H, d, J=8.9Hz), 7.94 (4H, s), 8.10 (lH,m) , 8.58 (IH, m) , 8.80 (IH, s), 8.95 (IH, s) MASS (m/z) : 1388.3 (M-Na + ) Example 153 IR (KBr) : 3353, 2931, 1668, 1650, 1631, 1537, 1513, 1456, 1396,1270, 1238, 1197 cm -1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.7Hz), 1.0-1.4 (8H, m) , 1.58 (IH, m) , 1.75 (4H, m) , 1.7-2.1 (3H, m) , 2.1-2.6 (7H, m) , 2.63 (4H, m) , 2.98 (2H, m) , 3.20 (IH, m) , 3.4 (4H, m) , 3.74 (2H, m) , 3.8-4.6 (11H, 449 m) , 4.6-5.6 (8H, m) , 6.72 (IH, d, J=8.2Hz) , 6.81 (IH, d, J=8.2Hz), 6.88 (IH, s) , 7.04 (IH, s) , 7.08 (2H, d, J=8.9Hz), 7.2-7.7 (4H, m) , 7.77 (2H, d, J=8.9Hz), 7.94 (4H, s) , 8.11 (lH,m), 8.58 (IH, m) , 8.80 (IH, s) , 8.95 (IH, s) MASS (m/z) : 1372.3 (M-Na + ) Example 154 IR (KBr) : 3353, 2935, 1666, 1633, 1540, 1513, 1461, 1440, 1247 cm "1 NMR (DMSO-dg, δ) : 0.9-1.1 (6H, m) , 1.10 (3H, d, J=5.7Hz), 1.47 (2H, m) , 1.6-2.1 (5H, m) , 2.1-2.6 (4H, m) , 2.98 (2H, m) , 3.20 (IH, m) , 3.71 (2H, m) , 3.8-4.6 (14H, m) , 4.6-5.6 (9H, m) , 6.67 (IH, d, J=8.2Hz) , 6.79 (IH, d, J=8.2Hz), 6.88 (IH, s) , 6.99 (2H, d, J=8.8Hz), 7.05 (IH, s), 7.2-7.7 (4H, m) , 7.82 (2H, d, J=8.8Hz), 7.97 (4H, s), 8.10 (lH,m) , 8.58 (IH, m) , 8.66 (IH, s), 8.78 (IH, s) MASS (m/z) : 1294.53 (M-Na + ) Elemental Analysis Calcd. For C 5 gHg 8 N 11 Naθ2iS 2 • 9H 2 0 : C 45.43, H 5.85, N 10.41 Found : C 45.52, H 5.81, N 10.41 Example 155 IR (KBr) : 3361, 2935, 1650, 1631, 1540, 1515, 1463, 1442, 1247, 1047 cm "1 NMR (DMSO-dg, δ) : 0.9-1.1 (6H, m) , 1.10 (3H, d, J=5.7Hz), 1.2-1.5 (4H, m) , 1.6-2.1 (5H, m) , 2.1-2.6 (4H, m) , 2.98 (2H, m) , 3.20 (IH, m) , 3.71 (2H, m) , 3.8-4.6 (14H, ) , 4.6-5.6 (9H, m) , 6.69 (2H, d, J=8.2Hz), 6.80 (IH, d, J=8.2Hz), 6.87 (IH, s) , 6.99 (2H, d, J=8.8Hz), 7.05 (IH, s) , 7.2-7.7 (4H, m) , 7.82 (2H, d, J=8.8Hz), 8.06 (4H, s) , 8.10 (lH,m), 8.58 (IH, m) , 8.67 (IH, s) , 8.76 (IH, s) MASS (m/z) : 1308.25 (M-Na + ) Elemental Analysis Calcd. For C 57 H 70 N 11 NaO 21 S2 • 8H 2 0 : C 46.37, H 5.87, N 10.44 450 Found : C 46.29, H 5.44, N 10.19 Example 156 IR (KBr) : 3359, 2933, 1666, 1631, 1540, 1513, 1463, 1440, 1295, 1247, 1047 cm "1 NMR (DMSO-dg, δ) : 0.9-1.1 (6H, m) , 1.10 (3H, d, J=5.7Hz), 1.2-1.5 (6H, m) , 1.6-2.1 (5H, m) , 2.1-2.6 (4H, m) , 2.98 (2H, m) , 3.20 (IH, ) , 3.71 (2H, m) , 3.8-4.6 (14H, m) , 4.6-5.6 (9H, m) , 6.69 (IH, d, J=8.2Hz), 6.79 (IH, d, J=8.2Hz), 6.87 (IH, s) , 6.98 (2H, d, J=8.8Hz), 7.04 (IH, s) , 7.2-7.7 (4H, m) , 7.82 (2H, d, J=8.8Hz), 8.06 (4H, s) , 8.10 (lH,m), 8.58 (IH, m) , 8.67 (IH, s) , 8.77 (IH, s) MASS (m/z) : 1322.61 (M-Na + ) Elemental Analysis Calcd. For C5 8 H 7 N 11 Naθ2χS 2 • 11H 2 0 : C 45.10, H 6.13, N 9.98 Found : C 45.31, H 5.81, N 9.84 Example 157 IR (KBr) : 3351, 2933, 1631, 1523, 1465, 1440, 1255, 1178, 1047 c "1 NMR (DMSO-dg, δ) : 0.8-1.0 (6H, m) , 1.10 (3H, d, J=5.7Hz), 1.2-1.6 (6H, m) , 1.6-2.1 (5H, m) , 2.1-2.5 (4H, m) , 2.98 (2H, m) , 3.20 (IH, m) , 3.73 (2H, m) , 3.8-4.6 (14H, m) , 4.6-5.4 (9H, m) , 6.69 (IH, d, J=8.2Hz), 6.79 (IH, d, J=8.2Hz), 6.88 (IH, s) , 7.05 (IH, s) , 7.14 (2H, d, J=8.8Hz), 7.23 (IH, m) , 7.3-7.5 (2H, m) , 7.67 (IH, m) , 7.89 (2H, d, J=8.8Hz), 7.96 (4H, s), 8.07 (IH, ) , 8.54 (IH, m) , 8.85 (IH, s) , 8.95 (IH, s) MASS (m/z) : 1322.12 (M-Na + ) Elemental Analysis Calcd. For C 58 H 7 N 11 Na0 1 S • 8H 0 : C 46.74, H 5.95, N 10.34 Found : C 46.81, H 5.67, N 10.23 Example 158 IR (KBr) : 3359, 2935, 1652, 1631, 1538, 1523, 1429, 1382, 1299, 1253, 1047 cm "1 451 NMR (DMSO-dg, δ) : 0.8-1.0 (6H, m) , 1.10 (3H, d,J=5.7Hz), 1.3-1.5 (4H, m) , 1.6-2.1 (5H, m) , 2.1-2.5 (4H, m) , 2.98 (2H, m) , 3.20 (IH, ) , 3.75 (2H, s) , 3.8-4.6 (14H, m) , 4.6-5.4 (9H, m) , 6.69 (IH, d, J=8.2Hz), 6.77 (IH, d, J=8.2Hz), 6.85 (IH, s) , 7.01 (2H, d, J=8.8Hz), 7.05 (IH, s) , 7.23 (IH, m) , 7.43 (2H, d, J=8.2Hz), 7.69 (IH, m) , 7.77 (2H, d, J=8.8Hz), 7.87 (2H, d, J=8.3Hz), 8.05 (IH, d, J=7.9Hz), 8.19 (2H,d, J=8.3Hz), 8.54 (IH, m) , 8.61 (IH, d, J=6.7Hz), 8.82 (IH, s) MASS (m/z) : 1312.10 (M-Na + ) Elemental Analysis Calcd. For C 56 H 70 N 11 NaO 22 S 2 • 13H 2 0 : C 42.83, H 6.16, N 9.81 Found : C 42.83, H 5.39, N 9.75 Example 159 MASS (m/z) : 1429.04 (M-Na + ) Example 160 To a solution of 1-hydroxybenzotriazole (26 mg) and 4- [5- [4- (4-propoxypiperidin-l-yl) phenyl] -1, 3, 4-thiadiazol- 2-yl] benzoic acid hydrochloride (60 mg) in N,N- dimethylformamide (2.4 ml) was added l-ethyl-3- (3' - dimethylaminopropyl) carbodiimide (48 μl) and the mixture was stirred for 19 hours at ambient temperature. Then to the reaction mixture was added Starting Compound (160) (120 mg) and N,N' -diisopropylethylamine (34 μl) and the mixture was stirred for 24 hours at ambient temperature. The reaction mixture was pulverized with ethyl acetate. The resulting precipitate was collected by filtration, washed with diisopropyl ether and dried under reduced pressure . The solid was added to saturated aqueous sodium hydrogen carbonate solution, subjected to column chromatography on ODS (YMC-gel ODS-AM S-50) and eluted with 20% acetonitrile in water. The fractions containing the object compound were combined and evaporated under reduced pressure to remove acetonitrile . The residue was lyophilized to give Object Compound (160) (48 mg) 452 as a yellow powder. NMR (DMSO-dg, δ) : 0.88 (3H, d, J=7.4Hz), 0.96 (3H, d, J=6.7Hz), 1.10 (3H, d, J=5.6Hz), 1.38-2.47 (16H, m) , 2.80-5.50 (30H, m) , 6.70 (IH, d, J=8.2Hz), 6.81 (IH, d, J=8.2Hz), 6.87 (IH, s) , 7.04 (IH, s) , 7.09 (2H, d, J=9.2Hz), 7.26-7.76 (3H, m) , 7.84 (2H, d, J=8.8Hz), 7.97-8.14 (6H, m) , 8.64-8.95 (2H,m) MASS (m/z) : 1347.44 (M-Na + ) The following compounds [Examples 161 and 1621 were obtained in a manner similar to that of Example 160. Example 161 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.6Hz), 1.10 (3H, d, J=5.6Hz), 1.68-2.50 (7H, m) , 2.80-5.50 (34H, m) , 6.71 (IH, d, J=8.2Hz), 6.80 (IH, d, J=8.2Hz), 6.86 (IH, s), 6.76-6.94 (IH, m) , 6.94-7.09 (3H, m) , 7.09-7.34 (4H, m) , 7.34-7.78 (3H, m) , 7.90 (2H, d, J=8.7Hz), 7.96-8.17 (6H, m) , 8.49-8.88 (2Hm) MASS (m/z) : 1343.23 (M-Na + ) Example 162 IR (KBr) : 1655, 1527 cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.8Hz), 1.10 (3H, d, J=5.7Hz) , 1.8-2.6 (12H, m) , 2.8-3.6 (7H, m) , 3.7-4.6 (14H, m) , 4.7-5.5 (8H, m) , 6.6-6.85 (4H, m) , 6.85-6.95 (IH, m) , 6.97 (IH, s) , 7.15-7.25 (IH, m) , 7.4-7.8 (3H, m) , 7.72 (2H, d, J=8.9Hz), 8.0-8.2 (5H, m) , 8.30 (IH, s), 8.71 (IH, s) , 8.7-8.9 (IH, ) , 9.11 (IH, s) MASS (m/z) : 1302 (M + -23) Elemental Analysis Calcd. For C5 7 H 8 13 Na0 19 S • 9H 0 : C 45.99, H 5.82, N 12.23 Found : C 45.92, H 5.73, N 12.09 Example 163 To a solution of Starting Compound (163) (2.0 g) in trifluoroacetic acid (48 ml) was added IN hydrochloric acid (8 ml) with stirring at ambient temperature. The mixture was 453 stirred at the same temperature overnight. The reaction mixture was evaporated to remove trifluoroacetic acid under reduced pressure . To the residue were added standard solution (pH 6.86) (100 ml) and acetonitrile (50 ml), and the solution was adjusted to pH 3 with IN sodium hydroxide. The solution was chromatographed on reverse phase silica gel, YMC-gel ODS-AM 120-S50 (Trademark, made by YMC) (600 ml) eluting in turn with 20% aqueous acetonitrile (2 L) , 30% aqueous acetonitrile (3 L) , and 40% aqueous acetonitrile (4 L) . The fractions containing the desired compound were collected and evaporated in vacuo to remove organic solvent. The resulting residue was lyophilized to give a white powder. The white powder was washed with ethyl acetate (30 ml) and dried in vacuo at ambient temperature for 3 hours to give Object Compound (163) (1.02 g) . NMR (DMS0-dg+D 2 0 , δ) : 0.96 (3H, d, J=6.7Hz), 1.09 (3H, d,J=6.0Hz), 1.25-1.60 (8H, m) , 1.60-2.45 (10H, m) , 2.80-3.10 (IH, m) , 3.21 (3H, s) , 3.30 (2H, t, J=6.4Hz), 3.60-4.50 (15H, m) , 4.65-4.95 (2H, m) , 6.41 (IH, d, J=8.3Hz), 6.50-6.70 (2H, m) , 7.11 (IH, s), 7.16 (IH, s), 7.25-7.60 (2H, m) , 7.85-8.25 (8H,m) ESI-MASS (m/z) : 1255.08 (M + +Na + ) Elemental Analysis Calcd. For C5gH 7 gN 0 Oi8 s " 4H 2° : C 53.37, H 6.49, N 10.73 Found : C 53.61, H 6.44, N 10.84 Example 164 To a solution of the Starting Compound (164) (6.0 g) in a mixture of tetrahydrofuran (120 ml) and N,N-dimethylamide (30 ml) were added trimethylsilyl chloride (22.8 ml) and triethylamine (37.6 ml) with stirring under ice-cooling and the mixture was stood at ambient temperature overnight. To the reaction mixture was added tetrahydrofuran (50 ml) . The resulting precipitates were filtered off. The filtrate was stood at 2-5°C overnight and evaporated in vacuo. The residue 454 was dissolved in a mixture of hexane (50 ml) and ethyl acetate (50 ml) (1:1, v/v) and the solution was evaporated in vacuo to give a residue. The residue was chromatographed on silica gel (600 ml) eluting in turn with a mixture of hexane and ethyl acetate (3:2, v/v) and a mixture of hexane and ethyl acetate (1:1, v/v). The fractions containing the desired compound were collected and evaporated in vacuo. The resulting residue (5.68 g) was dissolved in a mixture of acetonitrile (30 ml) and methanol (30 ml) . To the solution were added in turn diisopropylethylamine (1.68 ml) and trimethylsilyldiazomethane (4.82 ml) with stirring at ambient temperature and the mixture was allowed to stand at the same temperature overnight. To the reaction mixture were added ethyl acetate (150 ml) and saturated aqueous hydrogen carbonate solution (100 ml) . The organic layer was separated, washed with saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate and evaporated in vacuo to give a residue. The residue was dissolved in a mixture of tetrahydrofuran (30 ml) and acetic acid (3.68 ml). To the solution was added IM solution of tetrabutyl ammonium fluoride in water with stirring under ice-cooling and the mixture was stirred at the same temperature for 4 hours. The reaction mixture was evaporated in vacuo and dissolved in 20% aqueous acetonitrile. The solution was chromatographed on reverse phase silica gel, YMC-gel ODS-AM 120-S50 (Trademark, made by YMC) (700 ml) eluting in turn with 20% aqueous acetonitrile (3.5 L) , 30% aqueous acetonitrile (3.5 L) and 40% aqueous acetonitrile (3.5 L) . The fractions containing the desired compound were collected and evaporated in vacuo to remove organic solvent. The resulting residue was lyophilized to give a white powder. The white powder was purified by liquid chromatography eluting with 38% acetonitrile in pH 6.86 standard buffer solution to give two compounds. The first compound was chromatographed on reverse phase silica gel, YMC-gel ODS-AM 120-S50 (Trademark, made by YMC) 455 (700 ml) eluting in turn with 20% aqueous acetonitrile (3.5 L) and 50% aqueous acetonitrile (3.5 L) . The fractions containing the desired compound were collected and evaporated in vacuo to remove organic solvent. The resulting residue was lyophilized to give Object Compound (164-1) (1.37 g) . The other Object Compound (164-11) was chromatographed on reverse phase silica gel, YMC-gel ODS-AM 120-S50 (Trademark, made by YMC) (700 ml) eluting in turn with 20% aqueous acetonitrile (3.5 L) and 50% aqueous acetonitrile (3.5L). The fractions containing the desired compound were collected and evaporated in vacuo to remove organic solvent. The resulting residue was lyophilized to give Object Compound (164-11) (275 mg) . Object Compound (164-1) NMR (DMSO-dg+D 2 0 , δ) : 0.96 (3H, d, J=6.7Hz), 1.09 (3H, d,J=6.1Hz), 1.25-2.50 (19H, m) , 2.85-3.00 (IH, m) , 3.74 (3H, s), 3.31 (2H, t, J=6.4Hz), 3.75-4.55 (17H, m) , 4.70-5.00 (2H, m) , 6.40-6.70 (3H, m) , 7.14 (2H, d, J=8.9Hz), 7.98 (2H, d, J=8.9Hz), 8.05 (2H, d, J=8.7Hz), 8.12 (2H, d, J=8.7Hz) ESI-MASS (m/z) : 1269.4 (M + +Na + ) (positive) 1246.4 (M + -l) (negative) Elemental Analysis Calcd. For C 9 H 7 N-L Q θ^ S • 3H 2 0 : C 54.45, H 6.51, N 10.76 Found : C 54.11, H 6.74, N 11.18 Object Compound (164-11) NMR (DMS0-dg+D 0 , δ) : 0.96 (3H, d, J=6.7Hz), 1.10 (3H, d, J=6.1Hz), 1.20-2.45 (19H, ) , 3.72 (3H, s) , 3.73 (3H, s), 3.80-5.00 (15H, m) , 6.55-6.90 (3H, m) , 7.13 (2H, d, J=8.9Hz), 7.97 (2H, d, J=8.9Hz), 8.00-8.20 (4H, m) ESI-MASS (m/z) : 1283.4 (M+Na + ) (positive) The following compound was obtained according to a similar manner by using tert-butyldimethylsilane instead of tert-butylsilane of Example 6. 456 Example 165 The following compound was obtained in a manner similar to that of Example 2-3 of W097/32975. Example 166 IR (KBr) : 3394, 3327, 1676, 1633, 1439 cm -1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.8Hz), 1.08 (3H, d, J=6.0Hz), 1.88-5.83 (35H, m) , 6.68-8.71 (10H, m) MASS (m/z) : 903.17 (M-Na + ) Example 167 To a solution of Starting Compound (167) (0.1 g) and 4- [5- [4- (7-methoxyheptyloxy) phenyl] -1, 3, 4-thiadiazol-2- yl]benzoic acid benzotriazol-1-yl ester (66.1 mg) in dimethylformamide (1 ml) was added diisopropylethylamine (0.029 ml) and the mixture was stirred for 5 hours at ambient temperature. The reaction mixture was pulverized with ethyl acetate. The precipitate was collected by filtration and dried under reduced pressure to give Object Compound ( 16J ) (159 mg) . IR (KBr) : 3344, 1648.8, 1637.3, 1513.8, 1257.4, 1043.3 cm "1 NMR (DMSO-dg, δ) : 0.97 (3H, d, J=6.6Hz), 1.10 (3H, d, J=5.6Hz), 1.2-1.6 (23H, m) , 1.6-2.6 (12H, m) , 2.9-4.6 (25H, m) , 4.7-5.5 (9H, m) , 6.71 (IH, d, J=8.2Hz), 6.78 (IH, d, J=8.2Hz), 6.88 (IH, s) , 6.97 (IH, s), 7.13 (2H, d, J=8.8Hz), 7.16 (IH, s) , 7.44 (IH, d, J=8.0Hz), 7.59 (IH, br s) , 7.70 (IH, brs), 7.97 (2H, d, J=8.8Hz), 7.9-8.2 (6H, m) , 8.72 (IH, s), 8.79 (IH, d, J=7.3Hz) MASS (m/z) : 1311 (M-diisopropylamine-1) Elemental Analysis Calcd. For C gH 95 N 11 0 2 χS 2 • 5H 2 0 : C 51.72, H 6.90, N 10.05 Found : C 51.89, H 6.57, N 9.98 The following compound was obtained in a manner similar to that of Example 167. 457 Example 168 IR (KBr) : 3344, 1664.3, 1633.4, 1506.1, 1436.7, 1257.4 cm "1 NMR (DMSO-dg, δ) : 0.91 (3H, t, J=7.0Hz), 0.97 (3H, d, J=6.6Hz), 1.10 (3H, d, J=5.6Hz), 1.0-1.5 (19H, m) , 1.6-2.7 (10H, m) , 3.0-3.3 (3H, m) , 3.7-4.6 (15H, m) , 4.8-5.3 (11H, m) , 5.54 (IH, d, J=5.6Hz), 6.73 (IH, d, J=8.2Hz), 6.83 (IH, dd, J=8.2 and 1.5Hz), 6.85 (IH, s), 7.04 (IH, d, J=1.5Hz), 7.12 (2H, d, J=8.8Hz), 7.2-7.5 (3H, m) , 7.23 (IH, s), 7.56 (IH, s) , 7.58 (IH, m) , 7.85 (2H, d, J=8.8Hz) , 7.9-8.1 (5H, m) , 8.26 (IH, d, J=8.7Hz) , 8.85 (IH, s), 8.87 (IH, d, J=7.3Hz) MASS (m/z) : 1268 (M-diisopropylamine-1) The following compound was obtained in a manner similar to that of Example 2-3 of W097/32975. Example 169 IR (KBr) : 1664, 1627, 1234, 1086, 1043 cm "1 NMR (DMSO-dg, δ) : 0.96 (3H, d, J=6.7Hz), 1.14 (3H, d, J=5.9Hz), 1.3-2.55 (8H, m) , 2.6-3.6 (3H, m) , 3.65-4.5 (15H, m) , 4.7-5.4 (7H, m) , 6.65-7.05 (4H, m) , 7.07 (IH, s), 7.4-8.25 (7H, m) , 8.71 (IH, s) MASS (m/z) : 903 (M-l)

Claims: 458 CLAIMS 1. A polypeptide compound of following the general formula [I] : OH O R H O V=0 OH [I] / -X CH NH wherein R 1 is hydrogen; arylamino (lower) alkanoyl which may have one or more suitable substituent (s) ; aroyl substituted with heterocyclic group which may have one or more suitable substituent (s) ; aroyl substituted with aryl having higher alkyl; aroyl substituted with aryl having lower alkyl; aryl (C 2 -Cg) alkanoyl substituted with aryl having lower alkyl; lower alkanoyl substituted with unsaturated condensed heterocyclic group which may have one or more suitable substituent (s) ; lower alkanoyl substituted with pyridyl which may have one or more suitable substituent (s) ; amino protective group; 459 heptylnaphthoyl ; hexylnaphthoyl ; aroyl substituted with heterocyclic carbamoyl which may have one or more suitable substituent (s) ; lower alkanoyl substituted with cyclo (lower) alkyl which may have one or more suitable substituent (s) ; lower alkanoyl substituted with thienyl having heterocyclic group which may have one or more suitable substituent (s) ; or lower alkenoyl substituted with heterocyclic group which may have one or more suitable substituent (s) , R^ is hydrogen or hydroxy, R 3 is hydroxy, hydroxysulfonyloxy or lower alkoxy, and R 4 is hydroxy or lower alkoxy, or a salt thereof. 2. A compound of claim 1, wherein R 1 is aroyl substituted with heterocyclic group which may have one or more suitable substituent (s) . 3. A compound of claim 2, wherein R 1 is benzoyl substituted with unsaturated 3 to 8- membered heteromonocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s) having phenyl which has a suitable substituent selected from the group consisting of saturated 3 to 8- membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) which may have cyclo (lower) alkyl having di (lower) alkyl, lower alkoxy (lower) alkoxy, lower alkoxy (higher) alkoxy and phenyl substituted with saturated 3 to 8-membered heteromonocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 460 nitrogen atom(s) having di (lower) alkyl; or benzoyl substituted with unsaturated condensed heterocyclic group containing 1 or 2 sulfur atom(s)and 1 to 3 nitrogen atom(s) having phenyl which has lower alkoxy. 4. A compound of claim 3, wherein R 1 is benzoyl substituted with thiadiazolyl which has phenyl having piperidyl, benzoyl substituted with thiadiazolyl which has phenyl having lower alkoxy (lower) alkoxy, benzoyl substituted with thiadiazolyl which has phenyl having lower alkoxy (higher) alkoxy, benzoyl substituted with thiadiazolyl having phenyl which has piperazinyl substituted with cyclohexyl, benzoyl substituted with thiadiazolyl -having phenyl substituted with phenyl which has morpholino having di (lower) alkyl, or benzoyl substituted with imidazothiadiazolyl having phenyl which has lower alkoxy. 5. A compound of claim 4, wherein R 1 is benzoyl substituted with thiadiazolyl which has phenyl having piperidyl, or benzoyl substituted with thiadiazolyl which has phenyl having lower alkoxy (higher) alkoxy, R 3 is hydroxysulfonyloxy, and R 4 is hydroxy. A process for preparing a polypeptide compound [I] of claim 1 or a salt thereof, which comprises, i) reacting a compound [lb] of the formula : 4 61 OH H O χ o χ HN 7 OH [ l b ] / ~/ /NH °= CH 3 NH OH O R wherein R , R 3 and R 4 are as defined in Claim 1 or its reactive derivative at the amino group or a salt thereof, with a compound [III] of the formula : - 0H [III] wherein R 1 is arylamino (lower) alkanoyl which may have one or more suitable substituent (s) ; aroyl substituted with heterocyclic group which may have one or more suitable substituent (s) ; aroyl substituted with aryl having higher alkyl; aroyl substituted with aryl having lower alkyl; aryl (C 2 _ Cg) alkanoyl substituted with aryl having lower alkyl; lower alkanoyl substituted with unsaturated condensed heterocyclic group which may have one or more suitable substituent (s) ; 462 lower alkanoyl substituted with pyridyl which may have one or more suitable substituent (s) ; amino protective group; heptylnaphthoyl ; hexylnaphthoyl ; aroyl substituted with heterocyclic carbamoyl which may have one or more suitable substituent (s) ; lower alkanoyl substituted with cyclo (lower) alkyl which may have one or more suitable substituent (s) ; lower alkanoyl substituted with thienyl having heterocyclic group which may have one or more suitable substituent (s) ; or lower alkenoyl substituted with heterocyclic group which may have one or more suitable substituent (s) , or its reactive derivative at the carboxy group or a salt thereof, to give a compound [Ia] of the formula: OH HO O H,C- -N [la] wherein R 2 , R 3 and R 4 are as defined in Claim 1, and 463 Rd± is as defined above or a salt thereof, or ii) reducing a compound [II] of the formula: HO OH HO O H 3 C \ — R, — N H HOO / = =00 H HNN OH O. I] NH 0= CH, [I wherein R 1 , R 3 and R 4 are as defined above, or a salt thereof, to give a compound [Ia] of the formula: OH HO ~ H-OL X \=0 _ H X N OH- « [la] ° ' ^ ~ NH OH O 464 wherein R , R 3 and R 4 are as defined in Claim 1, and R^ is as defined above, or a salt thereof, or iii) reducing a compound [IV] of the formula HO OH ~ H-Oc Λ \=0 il HNr OH O. [IV] NH 0=^ CH 3 NH wherein R 3 and R 4 are as defined in Claim 1, or a salt thereof, to give a compound [lb] of the formula: OH O HO NH H,C. NH 2 \ — N ^=0 HO >=0 HN OH [lb] / \-J / Ά 0= N — CH 3 4 65 wherein R 2 , R 3 and R 4 are as defined in Claim 1, or a salt thereof. 7. A pharmaceutical composition which comprises, as an active ingredient, a compound of Claim 1 or a pharmaceutically acceptable salt thereof in admixture with pharmaceutically acceptable carrier or excipients. 8. Use of a compound of Claim 1 or a pharmaceutically acceptable salt thereof as a medicament. 9. A compound of Claim 1 or a pharmaceutically acceptable salt thereof for use as a medicament. 10. A method for the prophylactic and/or therapeutic treatment of infectious diseases caused by pathogenic microorganisms, which comprises administering a compound of claim 1 or a pharmaceutically acceptable salt thereof to a human being or an animal.

Inventors: BARRETT DAVID, KAWABATA KOHJI, MATSUDA HIROSHI, MATSUDA KEIJI, MATSUYA TAKAHIRO, MIZUNO HIROAKI, MURANO KENJI, OHKI HIDENORI, SHIRAISHI NOBUYUKI, TOJO TAKASHI, BARRETT, DAVID, KAWABATA, KOHJI, MATSUDA, HIROSHI, MATSUDA, KEIJI, MATSUYA, TAKAHIRO, MIZUNO, HIROAKI, MURANO, KENJI, OHKI, HIDENORI, SHIRAISHI, NOBUYUKI, TOJO, TAKASHI
Applicants: BARRETT DAVID, FUJISAWA PHARMACEUTICAL CO, KAWABATA KOHJI, MATSUDA HIROSHI, MATSUDA KEIJI, MATSUYA TAKAHIRO, MIZUNO HIROAKI, MURANO KENJI, OHKI HIDENORI, SHIRAISHI NOBUYUKI, TOJO TAKASHI, BARRETT, DAVID, FUJISAWA PHARMACEUTICAL CO., LTD., KAWABATA, KOHJI, MATSUDA, HIROSHI, MATSUDA, KEIJI, MATSUYA, TAKAHIRO, MIZUNO, HIROAKI, MURANO, KENJI, OHKI, HIDENORI, SHIRAISHI, NOBUYUKI, TOJO, TAKASHI
Application year: 1999
Main classification: C07K7
IPC codes: A61K38, A61P31, A61P33, A61P43, C07K7